P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
4.704e-14 | -30.69 | nucleoside-triphosphatase regulator activity | molecular function | GO:0060589 | 491 | 16 | 18094 | 47 |
GIT2,ARHGAP27,AKAP13,DOCK10,DOCK1,TBC1D8,RGS14,GMIP,ELMO1,DOCK8,PREX1,ARHGAP15,ARHGAP33,DOCK2,DENND1B,VAV3 |
4.704e-14 | -30.69 | GTPase regulator activity | molecular function | GO:0030695 | 491 | 16 | 18094 | 47 |
ELMO1,GMIP,TBC1D8,RGS14,ARHGAP15,ARHGAP33,DOCK8,PREX1,DOCK2,VAV3,DENND1B,GIT2,ARHGAP27,AKAP13,DOCK1,DOCK10 |
1.909e-13 | -29.29 | PH-like_dom_sf | interpro domains | IPR011993 | 431 | 15 | 18521 | 49 |
ELMO1,PREX1,ARHGAP15,ARHGAP27,DOCK10,IPCEF1,PLCG2,GAB1,VAV3,SKAP1,TBC1D8,AKAP13,CARMIL3,WDFY4,TLN1 |
3.180e-12 | -26.47 | Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB) | gene3d domains | 2.30.29.30 | 431 | 15 | 14470 | 47 |
ARHGAP27,ELMO1,WDFY4,IPCEF1,VAV3,SKAP1,DOCK10,PLCG2,ARHGAP15,PREX1,GAB1,AKAP13,TLN1,CARMIL3,TBC1D8 |
1.924e-11 | -24.67 | signal transduction | biological process | GO:0007165 | 4637 | 35 | 18204 | 49 |
CD74,HIF1A,SKAP1,SPI1,PIK3R5,DOCK8,BLNK,DOCK10,ARHGAP15,CSF1R,ELMO1,ARHGAP33,STAT6,FYB1,IRF5,ADCY7,GMIP,VAV3,PREX1,IL6R,PRKCD,P2RY6,DOCK1,P2RY2,ARHGAP27,DOCK2,PTPN6,RGS14,AKAP13,GAB1,DENND1B,HCK,APOE,PLCG2,TLN1 |
2.697e-11 | -24.34 | regulation of response to stimulus | biological process | GO:0048583 | 4104 | 33 | 18204 | 49 |
GSDME,CSF1R,STAT6,ADCY7,FYB1,GMIP,NEK6,SKAP1,SPI1,HIF1A,CD74,BLNK,PIK3R5,DOCK8,ARHGAP15,SBNO2,HCK,DENND1B,RHBDF2,GIT2,APOE,PLCG2,NRK,PREX1,VAV3,PRKCD,P2RY6,IL6R,DOCK2,ARHGAP27,PTPN6,RGS14,AKAP13 |
3.335e-11 | -24.12 | cell activation | biological process | GO:0001775 | 725 | 16 | 18204 | 49 |
DOCK8,DOCK10,DOCK2,BLNK,PTPN6,PREX1,VAV3,CD74,IL6R,SPI1,PRKCD,WDFY4,TLN1,PLCG2,STAT6,SBNO2 |
4.424e-11 | -23.84 | regulation of intracellular signal transduction | biological process | GO:1902531 | 1832 | 23 | 18204 | 49 |
VAV3,PREX1,P2RY6,PRKCD,DOCK2,ARHGAP27,PTPN6,AKAP13,RGS14,GIT2,APOE,PLCG2,NRK,NEK6,SPI1,CD74,HIF1A,PIK3R5,DOCK8,ARHGAP15,CSF1R,GSDME,GMIP |
7.844e-11 | -23.27 | PH_domain | interpro domains | IPR001849 | 266 | 11 | 18521 | 49 |
GAB1,VAV3,SKAP1,PLCG2,ARHGAP15,ARHGAP27,DOCK10,IPCEF1,ELMO1,AKAP13,PREX1 |
8.123e-11 | -23.23 | GTPase activator activity | molecular function | GO:0005096 | 273 | 11 | 18094 | 47 |
DOCK1,DOCK2,VAV3,GMIP,TBC1D8,GIT2,ARHGAP27,RGS14,ARHGAP15,ARHGAP33,PREX1 |
9.740e-11 | -23.05 | SH3 Domains | gene3d domains | 2.30.30.40 | 223 | 11 | 14470 | 47 |
VAV3,SKAP1,MYO1F,DOCK2,PLCG2,ARHGAP27,ELMO1,HCK,ARHGAP33,FYB1,DOCK1 |
1.556e-10 | -22.58 | signaling | biological process | GO:0023052 | 4968 | 35 | 18204 | 49 |
PIK3R5,DOCK8,BLNK,DOCK10,ARHGAP15,CD74,HIF1A,SPI1,SKAP1,FYB1,IRF5,ADCY7,GMIP,CSF1R,ARHGAP33,ELMO1,STAT6,ARHGAP27,DOCK2,AKAP13,RGS14,PTPN6,VAV3,PREX1,IL6R,PRKCD,P2RY6,P2RY2,DOCK1,APOE,PLCG2,TLN1,GAB1,DENND1B,HCK |
1.703e-10 | -22.49 | regulation of immune system process | biological process | GO:0002682 | 1584 | 21 | 18204 | 49 |
BLNK,DOCK8,PTPN6,VAV3,SPI1,SKAP1,PRKCD,HIF1A,CD74,IL6R,RHBDF2,ADCY7,IRF5,FYB1,APOE,PLCG2,CSF1R,GSDME,HCK,STAT6,DENND1B |
1.739e-10 | -22.47 | SH3-like_dom_sf | interpro domains | IPR036028 | 212 | 10 | 18521 | 49 |
DOCK1,SKAP1,VAV3,FYB1,PLCG2,ARHGAP33,HCK,DOCK2,MYO1F,ARHGAP27 |
1.756e-10 | -22.46 | enzyme regulator activity | molecular function | GO:0030234 | 1305 | 19 | 18094 | 47 |
VAV3,DENND1B,DOCK2,PRKCD,ARHGAP15,ARHGAP33,PREX1,DOCK8,ELMO1,GMIP,TBC1D8,RGS14,PIK3R5,APOE,DOCK1,DOCK10,AKAP13,GIT2,ARHGAP27 |
2.005e-10 | -22.33 | cell communication | biological process | GO:0007154 | 5010 | 35 | 18204 | 49 |
DOCK8,PIK3R5,BLNK,DOCK10,ARHGAP15,CD74,HIF1A,SPI1,SKAP1,FYB1,IRF5,ADCY7,GMIP,CSF1R,ELMO1,ARHGAP33,STAT6,ARHGAP27,DOCK2,PTPN6,AKAP13,RGS14,VAV3,PREX1,IL6R,PRKCD,P2RY6,DOCK1,P2RY2,APOE,TLN1,PLCG2,GAB1,DENND1B,HCK |
2.380e-10 | -22.16 | enzyme binding | molecular function | GO:0019899 | 2086 | 23 | 18094 | 47 |
PRKCD,CSF1R,PTPN6,RGS14,SKAP1,HIF1A,PREX1,NEK6,DOCK10,GIT2,IL6R,BLNK,DOCK2,DENND1B,IRF5,ARHGAP33,PLCG2,DOCK1,APOE,SPI1,CD74,STAT6,AKAP13 |
2.385e-10 | -22.16 | immune system process | biological process | GO:0002376 | 1991 | 23 | 18204 | 49 |
IL6R,PRKCD,PREX1,VAV3,PTPN6,DOCK2,HCK,DENND1B,SBNO2,PLCG2,HIF1A,CD74,SKAP1,SPI1,PIK3R5,DOCK8,DOCK10,BLNK,STAT6,CSF1R,WDFY4,FYB1,IRF5 |
2.527e-10 | -22.10 | lymphocyte activation | biological process | GO:0046649 | 476 | 13 | 18204 | 49 |
PREX1,PRKCD,SPI1,IL6R,CD74,BLNK,DOCK2,DOCK10,DOCK8,PTPN6,STAT6,WDFY4,PLCG2 |
2.731e-10 | -22.02 | SH3_domain | interpro domains | IPR001452 | 222 | 10 | 18521 | 49 |
DOCK1,SKAP1,VAV3,FYB1,PLCG2,ARHGAP33,HCK,DOCK2,MYO1F,ARHGAP27 |
3.257e-10 | -21.85 | positive regulation of immune system process | biological process | GO:0002684 | 986 | 17 | 18204 | 49 |
STAT6,HCK,DENND1B,CSF1R,GSDME,PLCG2,FYB1,IRF5,IL6R,CD74,SPI1,SKAP1,PRKCD,VAV3,PTPN6,DOCK8,BLNK |
3.502e-10 | -21.77 | leukocyte activation | biological process | GO:0045321 | 599 | 14 | 18204 | 49 |
IL6R,CD74,SPI1,PRKCD,PREX1,PTPN6,DOCK8,DOCK2,DOCK10,BLNK,STAT6,SBNO2,PLCG2,WDFY4 |
9.670e-10 | -20.76 | cellular response to stimulus | biological process | GO:0051716 | 6307 | 38 | 18204 | 49 |
SPI1,SKAP1,HIF1A,CD74,IPCEF1,DOCK10,BLNK,PIK3R5,DOCK8,ARHGAP15,ELMO1,ARHGAP33,GSDME,CSF1R,STAT6,ADCY7,IRF5,FYB1,GMIP,PREX1,VAV3,DOCK1,P2RY2,PRKCD,P2RY6,IL6R,DOCK2,ARHGAP27,AKAP13,RGS14,PTPN6,GAB1,SBNO2,HCK,DENND1B,APOE,TLN1,PLCG2 |
1.604e-09 | -20.25 | regulation of immune response | biological process | GO:0050776 | 944 | 16 | 18204 | 49 |
RHBDF2,ADCY7,FYB1,APOE,PLCG2,GSDME,HCK,STAT6,DENND1B,BLNK,PTPN6,VAV3,SPI1,SKAP1,PRKCD,CD74 |
2.520e-09 | -19.80 | enzyme activator activity | molecular function | GO:0008047 | 599 | 13 | 18094 | 47 |
DOCK2,PRKCD,VAV3,GMIP,TBC1D8,RGS14,ARHGAP33,ARHGAP15,PREX1,DOCK1,APOE,GIT2,ARHGAP27 |
3.052e-09 | -19.61 | SRC (SRC proto-oncogene, non-receptor tyrosine kinase) | protein interactions | 6714 | 624 | 13 | 19454 | 49 |
STAT6,PRKCD,DOCK1,IL6R,HCK,CSF1R,P2RY2,GAB1,HIF1A,SKAP1,TLN1,FYB1,PTPN6 |
4.072e-09 | -19.32 | intracellular signal transduction | biological process | GO:0035556 | 1505 | 19 | 18204 | 49 |
PLCG2,GMIP,ADCY7,APOE,HCK,ARHGAP33,ELMO1,AKAP13,PTPN6,BLNK,DOCK2,DOCK10,DOCK8,PIK3R5,PRKCD,DOCK1,HIF1A,VAV3,PREX1 |
4.383e-09 | -19.25 | LCP2 (lymphocyte cytosolic protein 2) | protein interactions | 3937 | 54 | 6 | 19454 | 49 |
FYB1,PTPN6,HCK,VAV3,PLCG2,BLNK |
4.748e-09 | -19.17 | SH3 | prosite domains | PS50002 | 222 | 10 | 12186 | 44 |
ARHGAP27,DOCK1,PLCG2,HCK,MYO1F,FYB1,SKAP1,DOCK2,VAV3,ARHGAP33 |
5.183e-09 | -19.08 | immune effector process | biological process | GO:0002252 | 389 | 11 | 18204 | 49 |
DOCK10,DOCK2,PTPN6,VAV3,PRKCD,CD74,IL6R,PLCG2,SBNO2,HCK,STAT6 |
6.149e-09 | -18.91 | guanyl-nucleotide exchange factor activity | molecular function | GO:0005085 | 228 | 9 | 18094 | 47 |
PREX1,DOCK8,AKAP13,ELMO1,DENND1B,VAV3,DOCK2,DOCK10,DOCK1 |
7.159e-09 | -18.75 | regulation of small GTPase mediated signal transduction | biological process | GO:0051056 | 306 | 10 | 18204 | 49 |
DOCK2,GIT2,DOCK8,ARHGAP27,APOE,AKAP13,GMIP,ARHGAP15,PREX1,VAV3 |
8.611e-09 | -18.57 | immune response-activating cell surface receptor signaling pathway | biological process | GO:0002429 | 228 | 9 | 18204 | 49 |
BLNK,FYB1,PLCG2,PTPN6,VAV3,SKAP1,PRKCD,HCK,DENND1B |
9.091e-09 | -18.52 | positive regulation of immune response | biological process | GO:0050778 | 640 | 13 | 18204 | 49 |
BLNK,PTPN6,VAV3,CD74,PRKCD,SPI1,SKAP1,FYB1,PLCG2,GSDME,DENND1B,STAT6,HCK |
1.117e-08 | -18.31 | cell surface receptor signaling pathway | biological process | GO:0007166 | 1992 | 21 | 18204 | 49 |
SPI1,DOCK1,SKAP1,P2RY2,P2RY6,PRKCD,CD74,IL6R,VAV3,RGS14,PTPN6,BLNK,STAT6,HCK,DENND1B,CSF1R,GAB1,TLN1,PLCG2,IRF5,FYB1 |
1.272e-08 | -18.18 | PH_DOMAIN | prosite domains | PS50003 | 246 | 10 | 12186 | 44 |
VAV3,IPCEF1,SKAP1,AKAP13,GAB1,PLCG2,DOCK10,PREX1,ARHGAP27,ARHGAP15 |
1.295e-08 | -18.16 | leukocyte differentiation | biological process | GO:0002521 | 425 | 11 | 18204 | 49 |
BLNK,DOCK10,DOCK2,PLCG2,PREX1,CSF1R,SBNO2,SPI1,IL6R,CD74,STAT6 |
1.407e-08 | -18.08 | C2_DOCK-type_domain | interpro domains | IPR027007 | 11 | 4 | 18521 | 49 |
DOCK1,DOCK10,DOCK8,DOCK2 |
1.407e-08 | -18.08 | DOCKER_dom | interpro domains | IPR027357 | 11 | 4 | 18521 | 49 |
DOCK2,DOCK8,DOCK10,DOCK1 |
1.407e-08 | -18.08 | DOCK_C_lobe_C | interpro domains | IPR043162 | 11 | 4 | 18521 | 49 |
DOCK2,DOCK1,DOCK10,DOCK8 |
1.407e-08 | -18.08 | DOCK | interpro domains | IPR026791 | 11 | 4 | 18521 | 49 |
DOCK1,DOCK10,DOCK8,DOCK2 |
1.407e-08 | -18.08 | DOCKER_Lobe_B | interpro domains | IPR046770 | 11 | 4 | 18521 | 49 |
DOCK2,DOCK1,DOCK10,DOCK8 |
1.407e-08 | -18.08 | DOCKER_Lobe_C | interpro domains | IPR046773 | 11 | 4 | 18521 | 49 |
DOCK1,DOCK8,DOCK10,DOCK2 |
1.407e-08 | -18.08 | DOCKER_Lobe_A | interpro domains | IPR046769 | 11 | 4 | 18521 | 49 |
DOCK2,DOCK8,DOCK10,DOCK1 |
1.407e-08 | -18.08 | DOCK_C_lobe_A | interpro domains | IPR043161 | 11 | 4 | 18521 | 49 |
DOCK10,DOCK8,DOCK1,DOCK2 |
1.650e-08 | -17.92 | DOCK-C2 | pfam domains | PF14429 | 11 | 4 | 17795 | 49 |
DOCK10,DOCK8,DOCK2,DOCK1 |
1.650e-08 | -17.92 | DHR-2_Lobe_C | pfam domains | PF20421 | 11 | 4 | 17795 | 49 |
DOCK2,DOCK1,DOCK8,DOCK10 |
1.650e-08 | -17.92 | DHR-2_Lobe_B | pfam domains | PF20422 | 11 | 4 | 17795 | 49 |
DOCK2,DOCK1,DOCK8,DOCK10 |
1.650e-08 | -17.92 | DHR-2_Lobe_A | pfam domains | PF06920 | 11 | 4 | 17795 | 49 |
DOCK10,DOCK2,DOCK1,DOCK8 |
1.910e-08 | -17.77 | positive regulation of response to stimulus | biological process | GO:0048584 | 2266 | 22 | 18204 | 49 |
AKAP13,PTPN6,PIK3R5,BLNK,HIF1A,CD74,IL6R,SPI1,SKAP1,P2RY6,PRKCD,NEK6,VAV3,NRK,PLCG2,FYB1,APOE,HCK,STAT6,DENND1B,GSDME,CSF1R |
2.144e-08 | -17.66 | hemopoiesis | biological process | GO:0030097 | 688 | 13 | 18204 | 49 |
CSF1R,STAT6,SBNO2,PLCG2,PREX1,CD74,IL6R,HIF1A,SPI1,BLNK,DOCK2,DOCK10,PTPN6 |
2.871e-08 | -17.37 | immune response-regulating cell surface receptor signaling pathway | biological process | GO:0002768 | 262 | 9 | 18204 | 49 |
SKAP1,PRKCD,HCK,DENND1B,VAV3,PTPN6,PLCG2,BLNK,FYB1 |
2.934e-08 | -17.34 | response to stimulus | biological process | GO:0050896 | 7803 | 40 | 18204 | 49 |
CSF1R,GSDME,ARHGAP33,ELMO1,STAT6,WDFY4,FYB1,ADCY7,IRF5,GMIP,HIF1A,CD74,SKAP1,SPI1,DOCK8,PIK3R5,DOCK10,IPCEF1,BLNK,ARHGAP15,GAB1,HCK,DENND1B,SBNO2,APOE,TLN1,PLCG2,PREX1,VAV3,IL6R,DOCK1,P2RY2,P2RY6,PRKCD,ARHGAP27,TBXAS1,DOCK2,PTPN6,AKAP13,RGS14 |
3.170e-08 | -17.27 | - | gene3d domains | 1.25.40.410 | 11 | 4 | 14470 | 47 |
DOCK2,DOCK1,DOCK10,DOCK8 |
3.170e-08 | -17.27 | - | gene3d domains | 1.20.58.740 | 11 | 4 | 14470 | 47 |
DOCK8,DOCK10,DOCK1,DOCK2 |
3.710e-08 | -17.11 | mononuclear cell differentiation | biological process | GO:1903131 | 364 | 10 | 18204 | 49 |
PLCG2,BLNK,DOCK10,DOCK2,CD74,IL6R,STAT6,SPI1,CSF1R,PREX1 |
4.015e-08 | -17.03 | positive regulation of catalytic activity | biological process | GO:0043085 | 868 | 14 | 18204 | 49 |
GMIP,APOE,TBC1D8,CSF1R,DOCK10,PIK3R5,DOCK8,ARHGAP27,PRKCD,P2RY6,HIF1A,CD74,IL6R,PREX1 |
4.789e-08 | -16.85 | DOCKER | prosite domains | PS51651 | 11 | 4 | 12186 | 44 |
DOCK2,DOCK10,DOCK1,DOCK8 |
4.789e-08 | -16.85 | C2_DOCK | prosite domains | PS51650 | 11 | 4 | 12186 | 44 |
DOCK10,DOCK2,DOCK8,DOCK1 |
4.896e-08 | -16.83 | PH | smart domains | SM00233 | 259 | 10 | 9717 | 39 |
PREX1,ARHGAP15,AKAP13,VAV3,SKAP1,ARHGAP27,GAB1,IPCEF1,DOCK10,PLCG2 |
5.961e-08 | -16.64 | cellular response to chemical stimulus | biological process | GO:0070887 | 2411 | 22 | 18204 | 49 |
HCK,SBNO2,GAB1,PLCG2,APOE,IL6R,PRKCD,P2RY6,P2RY2,VAV3,PREX1,PTPN6,STAT6,GSDME,CSF1R,IRF5,ADCY7,CD74,HIF1A,SPI1,DOCK8,IPCEF1 |
6.027e-08 | -16.62 | regulation of catalytic activity | biological process | GO:0050790 | 1395 | 17 | 18204 | 49 |
ARHGAP27,DOCK8,PIK3R5,DOCK10,ARHGAP15,RGS14,PREX1,VAV3,HIF1A,IL6R,CD74,P2RY6,PRKCD,APOE,GMIP,CSF1R,TBC1D8 |
6.587e-08 | -16.54 | molecular function regulator activity | molecular function | GO:0098772 | 2079 | 20 | 18094 | 47 |
APOE,PIK3R5,DOCK10,DOCK1,AKAP13,ARHGAP27,GIT2,DENND1B,VAV3,PRKCD,DOCK2,DOCK8,PREX1,ARHGAP33,ARHGAP15,RGS14,TBC1D8,HIF1A,ELMO1,GMIP |
6.683e-08 | -16.52 | endocytosis | biological process | GO:0006897 | 499 | 11 | 18204 | 49 |
APOE,ARHGAP27,DOCK2,MYO1F,VAV3,ELMO1,DENND1B,HCK,P2RY6,PRKCD,DOCK1 |
6.863e-08 | -16.49 | lymphocyte differentiation | biological process | GO:0030098 | 290 | 9 | 18204 | 49 |
PREX1,CD74,IL6R,STAT6,SPI1,BLNK,DOCK2,DOCK10,PLCG2 |
7.362e-08 | -16.42 | BLNK (B cell linker) | protein interactions | 29760 | 43 | 5 | 19454 | 49 |
GAB1,PTPN6,PLCG2,TLN1,VAV3 |
7.494e-08 | -16.41 | SH3 | smart domains | SM00326 | 202 | 9 | 9717 | 39 |
ARHGAP33,PLCG2,HCK,DOCK1,MYO1F,DOCK2,VAV3,FYB1,SKAP1 |
7.515e-08 | -16.40 | regulation of molecular function | biological process | GO:0065009 | 2005 | 20 | 18204 | 49 |
PLCG2,GMIP,APOE,TBC1D8,HCK,CSF1R,RGS14,ARHGAP15,DOCK10,DOCK8,PIK3R5,ARHGAP27,SPI1,PRKCD,P2RY6,HIF1A,CD74,IL6R,PREX1,VAV3 |
8.546e-08 | -16.28 | antigen receptor-mediated signaling pathway | biological process | GO:0050851 | 139 | 7 | 18204 | 49 |
FYB1,BLNK,PTPN6,PLCG2,VAV3,DENND1B,SKAP1 |
9.700e-08 | -16.15 | immune response-activating signaling pathway | biological process | GO:0002757 | 302 | 9 | 18204 | 49 |
SKAP1,PRKCD,HCK,DENND1B,VAV3,PTPN6,PLCG2,BLNK,FYB1 |
1.388e-07 | -15.79 | T cell activation | biological process | GO:0042110 | 315 | 9 | 18204 | 49 |
DOCK2,WDFY4,DOCK8,PTPN6,PREX1,SPI1,IL6R,CD74,STAT6 |
1.437e-07 | -15.76 | plasma membrane | cellular component | GO:0005886 | 5538 | 32 | 19108 | 49 |
ADCY7,GMIP,HCK,MYO1F,CARMIL3,PRKCD,ELMO1,PLCG2,PTPN6,BLNK,DOCK8,P2RY6,CSF1R,APOE,PIK3R5,VAV3,DOCK2,PARVG,ARHGAP33,PREX1,TLN1,DOCK1,RHBDF2,FYB1,IL6R,SKAP1,GSDME,IPCEF1,P2RY2,ARHGAP15,RGS14,CD74 |
1.457e-07 | -15.74 | regulation of MAPK cascade | biological process | GO:0043408 | 669 | 12 | 18204 | 49 |
P2RY6,PRKCD,SPI1,CD74,PIK3R5,RGS14,PTPN6,CSF1R,GSDME,APOE,PLCG2,NRK |
2.107e-07 | -15.37 | cellular response to organic substance | biological process | GO:0071310 | 1716 | 18 | 18204 | 49 |
DOCK8,PTPN6,PRKCD,P2RY6,P2RY2,SPI1,CD74,IL6R,HIF1A,IRF5,ADCY7,PLCG2,GAB1,GSDME,CSF1R,SBNO2,STAT6,HCK |
2.432e-07 | -15.23 | immune response | biological process | GO:0006955 | 1349 | 16 | 18204 | 49 |
FYB1,IRF5,PLCG2,CSF1R,STAT6,HCK,SBNO2,PIK3R5,DOCK2,DOCK10,BLNK,PTPN6,CD74,IL6R,SKAP1,PRKCD |
2.687e-07 | -15.13 | cell periphery | cellular component | GO:0071944 | 6020 | 33 | 19108 | 49 |
MYO1F,HCK,ADCY7,GMIP,CARMIL3,PRKCD,ELMO1,AKAP13,PLCG2,PTPN6,DOCK8,BLNK,CSF1R,P2RY6,APOE,VAV3,PIK3R5,PARVG,DOCK2,ARHGAP33,PREX1,DOCK1,RHBDF2,TLN1,FYB1,IL6R,SKAP1,GSDME,ARHGAP15,P2RY2,IPCEF1,CD74,RGS14 |
2.741e-07 | -15.11 | regulation of signal transduction | biological process | GO:0009966 | 3114 | 24 | 18204 | 49 |
ARHGAP27,DOCK2,AKAP13,RGS14,PTPN6,PREX1,VAV3,P2RY6,PRKCD,APOE,RHBDF2,GIT2,NRK,PLCG2,DOCK8,PIK3R5,ARHGAP15,NEK6,HIF1A,CD74,SPI1,GMIP,CSF1R,GSDME |
3.038e-07 | -15.01 | positive regulation of molecular function | biological process | GO:0044093 | 1192 | 15 | 18204 | 49 |
DOCK10,DOCK8,PIK3R5,ARHGAP27,PREX1,PRKCD,P2RY6,IL6R,CD74,HIF1A,APOE,PLCG2,GMIP,CSF1R,TBC1D8 |
3.113e-07 | -14.98 | SH2 | pfam domains | PF00017 | 100 | 6 | 17795 | 49 |
VAV3,BLNK,PLCG2,HCK,STAT6,PTPN6 |
3.268e-07 | -14.93 | KIT (KIT proto-oncogene, receptor tyrosine kinase) | protein interactions | 3815 | 110 | 6 | 19454 | 49 |
HCK,BLNK,PTPN6,CSF1R,VAV3,PLCG2 |
3.829e-07 | -14.78 | Fcgamma receptor (FCGR) dependent phagocytosis | REACTOME pathways | R-HSA-2029480 | 86 | 6 | 10285 | 35 |
ELMO1,HCK,PRKCD,DOCK1,VAV3,PLCG2 |
3.945e-07 | -14.75 | cellular response to cytokine stimulus | biological process | GO:0071345 | 734 | 12 | 18204 | 49 |
CSF1R,GSDME,HCK,STAT6,SBNO2,IRF5,HIF1A,CD74,IL6R,SPI1,DOCK8,PTPN6 |
4.014e-07 | -14.73 | Rho GTPase cycle | REACTOME pathways | R-HSA-194840 | 142 | 7 | 10285 | 35 |
ARHGAP27,VAV3,GMIP,PREX1,ARHGAP33,AKAP13,ARHGAP15 |
4.117e-07 | -14.70 | SH2 | interpro domains | IPR000980 | 109 | 6 | 18521 | 49 |
PLCG2,PTPN6,VAV3,HCK,STAT6,BLNK |
4.880e-07 | -14.53 | cytosol | cellular component | GO:0005829 | 5475 | 31 | 19108 | 49 |
GSDME,SKAP1,FYB1,IRF5,ARHGAP15,DOCK2,NEK6,DOCK1,TLN1,PREX1,ARHGAP33,BLNK,DOCK8,VAV3,ARHGAP27,PIK3R5,NRK,ELMO1,STAT6,DOCK10,PRKCD,HCK,MYO1F,GMIP,TBXAS1,PTPN6,GAB1,DENND1B,HIF1A,PLCG2,AKAP13 |
5.096e-07 | -14.49 | SH2_dom_sf | interpro domains | IPR036860 | 113 | 6 | 18521 | 49 |
HCK,PTPN6,VAV3,BLNK,STAT6,PLCG2 |
5.146e-07 | -14.48 | immune response-regulating signaling pathway | biological process | GO:0002764 | 368 | 9 | 18204 | 49 |
HCK,DENND1B,SKAP1,PRKCD,VAV3,PTPN6,PLCG2,FYB1,BLNK |
5.146e-07 | -14.48 | activation of immune response | biological process | GO:0002253 | 368 | 9 | 18204 | 49 |
FYB1,BLNK,PTPN6,PLCG2,VAV3,HCK,DENND1B,SKAP1,PRKCD |
6.317e-07 | -14.27 | molecular function activator activity | molecular function | GO:0140677 | 1132 | 14 | 18094 | 47 |
ARHGAP27,GIT2,APOE,DOCK1,PREX1,ARHGAP15,ARHGAP33,TBC1D8,RGS14,GMIP,HIF1A,VAV3,DOCK2,PRKCD |
7.012e-07 | -14.17 | regulation of GTPase activity | biological process | GO:0043087 | 278 | 8 | 18204 | 49 |
ARHGAP27,DOCK8,DOCK10,ARHGAP15,GMIP,VAV3,PREX1,TBC1D8 |
7.440e-07 | -14.11 | VAV1 (vav guanine nucleotide exchange factor 1) | protein interactions | 7409 | 204 | 7 | 19454 | 49 |
PTPN6,HCK,PLCG2,GAB1,BLNK,DOCK2,SPI1 |
7.483e-07 | -14.11 | PH | pfam domains | PF00169 | 187 | 7 | 17795 | 49 |
GAB1,IPCEF1,DOCK10,SKAP1,VAV3,ARHGAP15,ARHGAP27 |
7.987e-07 | -14.04 | RAC1 (Rac family small GTPase 1) | protein interactions | 5879 | 1005 | 13 | 19454 | 49 |
GAB1,GIT2,PREX1,ARHGAP27,DOCK8,PRKCD,VAV3,ARHGAP15,DOCK1,DOCK2,ARHGAP33,GMIP,EHBP1L1 |
9.515e-07 | -13.87 | positive regulation of multicellular organismal process | biological process | GO:0051240 | 1691 | 17 | 18204 | 49 |
IRF5,APOE,PLCG2,CSF1R,GAB1,STAT6,DENND1B,TBXAS1,DOCK8,RGS14,PTPN6,VAV3,P2RY2,SPI1,HIF1A,IL6R,CD74 |
1.045e-06 | -13.77 | leukocyte activation involved in immune response | biological process | GO:0002366 | 201 | 7 | 18204 | 49 |
DOCK10,DOCK2,PLCG2,STAT6,CD74,IL6R,SBNO2 |
1.193e-06 | -13.64 | cell activation involved in immune response | biological process | GO:0002263 | 205 | 7 | 18204 | 49 |
SBNO2,CD74,IL6R,STAT6,PLCG2,DOCK10,DOCK2 |
1.478e-06 | -13.42 | SH2 domain | gene3d domains | 3.30.505.10 | 111 | 6 | 14470 | 47 |
PTPN6,STAT6,PLCG2,VAV3,BLNK,HCK |
1.522e-06 | -13.40 | response to cytokine | biological process | GO:0034097 | 834 | 12 | 18204 | 49 |
HIF1A,IL6R,CD74,SPI1,PTPN6,DOCK8,HCK,STAT6,SBNO2,GSDME,CSF1R,IRF5 |
1.580e-06 | -13.36 | intracellular signaling cassette | biological process | GO:0141124 | 837 | 12 | 18204 | 49 |
VAV3,DOCK1,DOCK10,DOCK2,PIK3R5,DOCK8,AKAP13,PTPN6,ELMO1,ARHGAP33,APOE,PLCG2 |
1.606e-06 | -13.34 | import into cell | biological process | GO:0098657 | 687 | 11 | 18204 | 49 |
DOCK1,P2RY6,PRKCD,HCK,DENND1B,ELMO1,VAV3,MYO1F,DOCK2,ARHGAP27,APOE |
1.970e-06 | -13.14 | Signal Transduction | REACTOME pathways | R-HSA-162582 | 2547 | 22 | 10285 | 35 |
AKAP13,STAT6,ADCY7,PREX1,ELMO1,DOCK1,APOE,TLN1,GAB1,VAV3,PIK3R5,IL6R,ARHGAP15,RGS14,ARHGAP27,PTPN6,PRKCD,P2RY2,ARHGAP33,GMIP,P2RY6,HIF1A |
1.998e-06 | -13.12 | Nef and signal transduction | REACTOME pathways | R-HSA-164944 | 8 | 3 | 10285 | 35 |
ELMO1,HCK,DOCK2 |
2.024e-06 | -13.11 | positive T cell selection | biological process | GO:0043368 | 34 | 4 | 18204 | 49 |
DOCK2,STAT6,IL6R,CD74 |
2.126e-06 | -13.06 | response to chemical | biological process | GO:0042221 | 3743 | 25 | 18204 | 49 |
DOCK2,TBXAS1,PTPN6,VAV3,PREX1,IL6R,PRKCD,P2RY6,P2RY2,APOE,PLCG2,GAB1,HCK,SBNO2,DOCK8,IPCEF1,CD74,HIF1A,SPI1,IRF5,ADCY7,CSF1R,GSDME,ARHGAP33,STAT6 |
2.143e-06 | -13.05 | SH2 | prosite domains | PS50001 | 107 | 6 | 12186 | 44 |
PTPN6,BLNK,VAV3,STAT6,HCK,PLCG2 |
2.601e-06 | -12.86 | PLCG2 (phospholipase C gamma 2) | protein interactions | 5336 | 87 | 5 | 19454 | 49 |
PLCG2,GAB1,HCK,PTPN6,BLNK |
2.670e-06 | -12.83 | positive regulation of intracellular signal transduction | biological process | GO:1902533 | 1048 | 13 | 18204 | 49 |
CD74,SPI1,P2RY6,NEK6,VAV3,PTPN6,AKAP13,PIK3R5,GSDME,CSF1R,NRK,PLCG2,APOE |
2.971e-06 | -12.73 | regulation of signaling | biological process | GO:0023051 | 3534 | 24 | 18204 | 49 |
GMIP,CSF1R,GSDME,ARHGAP15,DOCK8,PIK3R5,SPI1,CD74,HIF1A,NEK6,PLCG2,NRK,GIT2,RHBDF2,APOE,RGS14,PTPN6,AKAP13,DOCK2,ARHGAP27,P2RY6,PRKCD,VAV3,PREX1 |
3.010e-06 | -12.71 | SH2 | smart domains | SM00252 | 103 | 6 | 9717 | 39 |
BLNK,VAV3,STAT6,PTPN6,PLCG2,HCK |
3.081e-06 | -12.69 | regulation of cell communication | biological process | GO:0010646 | 3541 | 24 | 18204 | 49 |
RHBDF2,GIT2,APOE,PLCG2,NRK,PREX1,VAV3,P2RY6,PRKCD,DOCK2,ARHGAP27,RGS14,AKAP13,PTPN6,CSF1R,GSDME,GMIP,NEK6,SPI1,HIF1A,CD74,PIK3R5,DOCK8,ARHGAP15 |
3.209e-06 | -12.65 | positive regulation of cell migration | biological process | GO:0030335 | 592 | 10 | 18204 | 49 |
HIF1A,CD74,IL6R,DOCK1,P2RY6,CSF1R,GAB1,PREX1,PLCG2,DOCK8 |
3.249e-06 | -12.64 | SOS1 (SOS Ras/Rac guanine nucleotide exchange factor 1) | protein interactions | 6654 | 91 | 5 | 19454 | 49 |
CSF1R,GAB1,HCK,PTPN6,PRKCD |
3.296e-06 | -12.62 | positive regulation of biological process | biological process | GO:0048518 | 6326 | 33 | 18204 | 49 |
PLCG2,NRK,APOE,SBNO2,TBC1D8,DENND1B,HCK,GAB1,AKAP13,RGS14,PTPN6,DOCK2,TBXAS1,PRKCD,P2RY6,P2RY2,DOCK1,IL6R,VAV3,PREX1,IRF5,FYB1,STAT6,GSDME,CSF1R,BLNK,DOCK8,PIK3R5,SKAP1,SPI1,CD74,HIF1A,NEK6 |
3.552e-06 | -12.55 | PLCG1 (phospholipase C gamma 1) | protein interactions | 5335 | 258 | 7 | 19454 | 49 |
PLCG2,TLN1,VAV3,HCK,PTPN6,GAB1,BLNK |
4.081e-06 | -12.41 | positive regulation of MAPK cascade | biological process | GO:0043410 | 473 | 9 | 18204 | 49 |
P2RY6,SPI1,CD74,GSDME,CSF1R,PLCG2,NRK,APOE,PIK3R5 |
4.141e-06 | -12.39 | phagocytosis | biological process | GO:0006909 | 159 | 6 | 18204 | 49 |
HCK,P2RY6,PRKCD,DOCK1,VAV3,ELMO1 |
4.431e-06 | -12.33 | regulation of body fluid levels | biological process | GO:0050878 | 356 | 8 | 18204 | 49 |
APOE,PTPN6,TLN1,PLCG2,VAV3,PRKCD,P2RY2,HIF1A |
4.641e-06 | -12.28 | Hemostasis | REACTOME pathways | R-HSA-109582 | 632 | 11 | 10285 | 35 |
DOCK8,DOCK1,PRKCD,PTPN6,DOCK2,CD74,PLCG2,DOCK10,PIK3R5,VAV3,TLN1 |
4.764e-06 | -12.25 | SH3DOMAIN | prints domains | PR00452 | 83 | 5 | 5227 | 17 |
MYO1F,HCK,PLCG2,VAV3,SKAP1 |
4.767e-06 | -12.25 | positive regulation of cell motility | biological process | GO:2000147 | 619 | 10 | 18204 | 49 |
CSF1R,GAB1,PREX1,HIF1A,CD74,IL6R,DOCK1,P2RY6,DOCK8,PLCG2 |
5.473e-06 | -12.12 | small GTPase-mediated signal transduction | biological process | GO:0007264 | 258 | 7 | 18204 | 49 |
VAV3,ELMO1,ARHGAP33,DOCK1,DOCK2,DOCK10,DOCK8 |
5.710e-06 | -12.07 | C2_domain_sf | interpro domains | IPR035892 | 171 | 6 | 18521 | 49 |
DOCK2,DOCK8,DOCK10,PRKCD,PLCG2,DOCK1 |
5.807e-06 | -12.06 | positive regulation of locomotion | biological process | GO:0040017 | 633 | 10 | 18204 | 49 |
PLCG2,DOCK8,DOCK1,P2RY6,HIF1A,IL6R,CD74,PREX1,CSF1R,GAB1 |
5.810e-06 | -12.06 | B cell receptor signaling pathway | biological process | GO:0050853 | 44 | 4 | 18204 | 49 |
PLCG2,PTPN6,VAV3,BLNK |
5.827e-06 | -12.05 | integrin-mediated signaling pathway | biological process | GO:0007229 | 96 | 5 | 18204 | 49 |
FYB1,VAV3,HCK,DOCK1,TLN1 |
5.904e-06 | -12.04 | positive regulation of immune effector process | biological process | GO:0002699 | 261 | 7 | 18204 | 49 |
SPI1,DENND1B,CD74,STAT6,IRF5,PTPN6,PLCG2 |
6.324e-06 | -11.97 | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 6023 | 31 | 16828 | 45 |
P2RY2,GAB1,ARHGAP15,RGS14,BLNK,IPCEF1,ELMO1,GMIP,PREX1,PARVG,ARHGAP27,TBXAS1,ADCY7,DOCK2,HCK,TLN1,DOCK8,DOCK1,EHBP1L1,VAV3,HIF1A,IRF5,AKAP13,DOCK10,MYO1F,P2RY6,PLCG2,PRKCD,CSF1R,RHBDF2,TBC1D8 |
7.576e-06 | -11.79 | Chemokine signaling pathway | KEGG pathways | hsa04062 | 182 | 7 | 7161 | 30 |
ELMO1,HCK,VAV3,PREX1,ADCY7,DOCK2,PRKCD |
7.576e-06 | -11.79 | Chemokine signaling pathway | KEGG pathways | ko04062 | 182 | 7 | 7161 | 30 |
PRKCD,ADCY7,DOCK2,VAV3,PREX1,ELMO1,HCK |
7.588e-06 | -11.79 | T cell selection | biological process | GO:0045058 | 47 | 4 | 18204 | 49 |
DOCK2,STAT6,IL6R,CD74 |
7.717e-06 | -11.77 | cytokine-mediated signaling pathway | biological process | GO:0019221 | 384 | 8 | 18204 | 49 |
IRF5,PTPN6,CSF1R,CD74,IL6R,STAT6,HCK,SPI1 |
9.000e-06 | -11.62 | T cell differentiation | biological process | GO:0030217 | 182 | 6 | 18204 | 49 |
DOCK2,PREX1,SPI1,STAT6,IL6R,CD74 |
9.873e-06 | -11.53 | Immune System | REACTOME pathways | R-HSA-168256 | 2101 | 19 | 10285 | 35 |
FYB1,DOCK1,PRKCD,PTPN6,DOCK2,ELMO1,BLNK,HIF1A,PLCG2,GAB1,VAV3,TLN1,HCK,CSF1R,STAT6,ADCY7,IL6R,IRF5,CD74 |
9.913e-06 | -11.52 | T cell receptor signaling pathway | biological process | GO:0050852 | 107 | 5 | 18204 | 49 |
FYB1,PTPN6,SKAP1,PLCG2,DENND1B |
1.009e-05 | -11.50 | protein kinase binding | molecular function | GO:0019901 | 701 | 10 | 18094 | 47 |
PLCG2,BLNK,NEK6,PRKCD,ARHGAP33,HIF1A,SKAP1,PTPN6,RGS14,IRF5 |
1.036e-05 | -11.48 | positive regulation of cell communication | biological process | GO:0010647 | 1792 | 16 | 18204 | 49 |
AKAP13,RGS14,PTPN6,PIK3R5,SPI1,PRKCD,P2RY6,HIF1A,CD74,NEK6,VAV3,PLCG2,NRK,APOE,GSDME,CSF1R |
1.051e-05 | -11.46 | positive regulation of signaling | biological process | GO:0023056 | 1794 | 16 | 18204 | 49 |
GSDME,CSF1R,PLCG2,NRK,APOE,PRKCD,P2RY6,SPI1,CD74,HIF1A,VAV3,NEK6,RGS14,AKAP13,PTPN6,PIK3R5 |
1.063e-05 | -11.45 | C2 domain | gene3d domains | 2.60.40.150 | 156 | 6 | 14470 | 47 |
DOCK8,PRKCD,DOCK2,PLCG2,DOCK1,DOCK10 |
1.139e-05 | -11.38 | positive regulation of signal transduction | biological process | GO:0009967 | 1593 | 15 | 18204 | 49 |
GSDME,CSF1R,APOE,PLCG2,NRK,NEK6,VAV3,SPI1,PRKCD,P2RY6,HIF1A,CD74,PIK3R5,AKAP13,PTPN6 |
1.159e-05 | -11.37 | response to organic substance | biological process | GO:0010033 | 2498 | 19 | 18204 | 49 |
CD74,IL6R,HIF1A,P2RY6,PRKCD,P2RY2,SPI1,PTPN6,DOCK8,TBXAS1,HCK,STAT6,SBNO2,GAB1,GSDME,CSF1R,PLCG2,IRF5,ADCY7 |
1.428e-05 | -11.16 | Fc receptor signaling pathway | biological process | GO:0038093 | 55 | 4 | 18204 | 49 |
PLCG2,PRKCD,HCK,VAV3 |
1.437e-05 | -11.15 | CRKL (CRK like proto-oncogene, adaptor protein) | protein interactions | 1399 | 211 | 6 | 19454 | 49 |
BLNK,DOCK2,HCK,GAB1,ELMO1,DOCK1 |
1.570e-05 | -11.06 | SH3 domain binding | molecular function | GO:0017124 | 122 | 5 | 18094 | 47 |
DOCK1,ELMO1,PTPN6,ARHGAP27,SKAP1 |
1.603e-05 | -11.04 | positive regulation of cellular process | biological process | GO:0048522 | 5719 | 30 | 18204 | 49 |
RGS14,PTPN6,AKAP13,DOCK2,DOCK1,PRKCD,P2RY6,IL6R,PREX1,VAV3,PLCG2,NRK,APOE,TBC1D8,SBNO2,HCK,DENND1B,GAB1,BLNK,PIK3R5,DOCK8,SKAP1,SPI1,HIF1A,CD74,NEK6,IRF5,STAT6,CSF1R,GSDME |
1.788e-05 | -10.93 | regulation of cell migration | biological process | GO:0030334 | 1061 | 12 | 18204 | 49 |
DOCK10,DOCK8,APOE,PLCG2,PREX1,CSF1R,GAB1,DOCK1,P2RY6,HIF1A,IL6R,CD74 |
1.849e-05 | -10.90 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 34 | 16828 | 45 |
AKAP13,VAV3,IRF5,HIF1A,DOCK1,EHBP1L1,HCK,TLN1,DOCK8,RHBDF2,TBC1D8,CSF1R,P2RY6,PLCG2,PRKCD,DOCK10,MYO1F,DENND1B,IPCEF1,ELMO1,GMIP,RGS14,BLNK,GAB1,ARHGAP33,ARHGAP15,P2RY2,ADCY7,DOCK2,TBXAS1,PTPN6,PARVG,ARHGAP27,PREX1 |
1.918e-05 | -10.86 | regulation of hydrolase activity | biological process | GO:0051336 | 726 | 10 | 18204 | 49 |
PREX1,VAV3,TBC1D8,P2RY6,PRKCD,DOCK10,ARHGAP27,DOCK8,GMIP,ARHGAP15 |
1.927e-05 | -10.86 | response to external stimulus | biological process | GO:0009605 | 1882 | 16 | 18204 | 49 |
PREX1,VAV3,PRKCD,HIF1A,IL6R,CD74,DOCK2,PTPN6,CSF1R,GSDME,GAB1,SBNO2,HCK,IRF5,WDFY4,PLCG2 |
1.978e-05 | -10.83 | G protein-coupled UTP receptor activity | molecular function | GO:0045030 | 3 | 2 | 18094 | 47 |
P2RY2,P2RY6 |
2.023e-05 | -10.81 | immune response-regulating cell surface receptor signaling pathway involved in phagocytosis | biological process | GO:0002433 | 20 | 3 | 18204 | 49 |
PRKCD,HCK,VAV3 |
2.023e-05 | -10.81 | Fc-gamma receptor signaling pathway involved in phagocytosis | biological process | GO:0038096 | 20 | 3 | 18204 | 49 |
PRKCD,HCK,VAV3 |
2.084e-05 | -10.78 | positive regulation of GTPase activity | biological process | GO:0043547 | 211 | 6 | 18204 | 49 |
ARHGAP27,DOCK8,DOCK10,PREX1,GMIP,TBC1D8 |
2.359e-05 | -10.65 | SH3_2 | pfam domains | PF07653 | 61 | 4 | 17795 | 49 |
VAV3,FYB1,ARHGAP33,DOCK2 |
2.365e-05 | -10.65 | regulation of B cell activation | biological process | GO:0050864 | 128 | 5 | 18204 | 49 |
VAV3,CD74,STAT6,PTPN6,SPI1 |
2.541e-05 | -10.58 | kinase binding | molecular function | GO:0019900 | 780 | 10 | 18094 | 47 |
PRKCD,NEK6,BLNK,PLCG2,ARHGAP33,HIF1A,RGS14,PTPN6,IRF5,SKAP1 |
2.562e-05 | -10.57 | membrane | cellular component | GO:0016020 | 9220 | 38 | 19108 | 49 |
CD74,RGS14,ARHGAP15,IPCEF1,P2RY2,GSDME,SKAP1,IL6R,FYB1,DOCK1,RHBDF2,TLN1,PREX1,ARHGAP33,PARVG,DOCK2,ARHGAP27,VAV3,TBC1D8,PIK3R5,APOE,CSF1R,P2RY6,DOCK8,BLNK,PTPN6,PLCG2,AKAP13,ELMO1,PRKCD,DOCK10,CARMIL3,MYO1F,HCK,EHBP1L1,ADCY7,TBXAS1,GMIP |
2.578e-05 | -10.57 | SHC1 (SHC adaptor protein 1) | protein interactions | 6464 | 350 | 7 | 19454 | 49 |
GAB1,HIF1A,PTPN6,CSF1R,PRKCD,VAV3,PLCG2 |
2.583e-05 | -10.56 | cell motility | biological process | GO:0048870 | 1101 | 12 | 18204 | 49 |
HIF1A,HCK,IL6R,DOCK1,PRKCD,CARMIL3,GAB1,PREX1,ELMO1,VAV3,DOCK8,DOCK2 |
2.599e-05 | -10.56 | cell migration | biological process | GO:0016477 | 921 | 11 | 18204 | 49 |
DOCK8,DOCK2,CARMIL3,GAB1,PREX1,VAV3,HIF1A,HCK,IL6R,DOCK1,PRKCD |
2.600e-05 | -10.56 | RhoGAP_dom | interpro domains | IPR000198 | 65 | 4 | 18521 | 49 |
ARHGAP27,GMIP,ARHGAP15,ARHGAP33 |
2.637e-05 | -10.54 | regulation of peptidyl-tyrosine phosphorylation | biological process | GO:0050730 | 220 | 6 | 18204 | 49 |
CSF1R,PRKCD,CD74,IL6R,PTPN6,PLCG2 |
2.723e-05 | -10.51 | Fc receptor mediated stimulatory signaling pathway | biological process | GO:0002431 | 22 | 3 | 18204 | 49 |
VAV3,HCK,PRKCD |
2.762e-05 | -10.50 | PE/DAG-bd | interpro domains | IPR002219 | 66 | 4 | 18521 | 49 |
AKAP13,PRKCD,VAV3,GMIP |
2.882e-05 | -10.45 | IL6ST (interleukin 6 cytokine family signal transducer) | protein interactions | 3572 | 70 | 4 | 19454 | 49 |
PRKCD,PTPN6,HCK,IL6R |
2.882e-05 | -10.45 | INPP5D (inositol polyphosphate-5-phosphatase D) | protein interactions | 3635 | 70 | 4 | 19454 | 49 |
HCK,GAB1,CSF1R,PRKCD |
3.036e-05 | -10.40 | RhoGAP | pfam domains | PF00620 | 65 | 4 | 17795 | 49 |
ARHGAP15,ARHGAP27,ARHGAP33,GMIP |
3.056e-05 | -10.40 | positive regulation of production of molecular mediator of immune response | biological process | GO:0002702 | 135 | 5 | 18204 | 49 |
PLCG2,STAT6,CD74,DENND1B,IRF5 |
3.113e-05 | -10.38 | regulation of cell motility | biological process | GO:2000145 | 1122 | 12 | 18204 | 49 |
APOE,DOCK8,DOCK10,PLCG2,GAB1,CSF1R,PREX1,CD74,IL6R,HIF1A,P2RY6,DOCK1 |
3.115e-05 | -10.38 | positive regulation of hydrolase activity | biological process | GO:0051345 | 466 | 8 | 18204 | 49 |
TBC1D8,P2RY6,PRKCD,PREX1,GMIP,DOCK8,ARHGAP27,DOCK10 |
3.118e-05 | -10.38 | Fc gamma R-mediated phagocytosis | KEGG pathways | hsa04666 | 90 | 5 | 7161 | 30 |
HCK,DOCK2,PRKCD,PLCG2,VAV3 |
3.118e-05 | -10.38 | Fc gamma R-mediated phagocytosis | KEGG pathways | ko04666 | 90 | 5 | 7161 | 30 |
PLCG2,PRKCD,VAV3,HCK,DOCK2 |
3.150e-05 | -10.37 | GPVI-mediated activation cascade | REACTOME pathways | R-HSA-114604 | 54 | 4 | 10285 | 35 |
PLCG2,PIK3R5,VAV3,PTPN6 |
3.279e-05 | -10.33 | lymphocyte activation involved in immune response | biological process | GO:0002285 | 137 | 5 | 18204 | 49 |
DOCK10,IL6R,CD74,STAT6,PLCG2 |
3.801e-05 | -10.18 | NHLRC2 (NHL repeat containing 2) | protein interactions | 374354 | 372 | 7 | 19454 | 49 |
DOCK10,MYO1F,PRKCD,TBXAS1,TLN1,AKAP13,ARHGAP15 |
3.949e-05 | -10.14 | G protein-coupled pyrimidinergic nucleotide receptor activity | molecular function | GO:0071553 | 4 | 2 | 18094 | 47 |
P2RY2,P2RY6 |
4.166e-05 | -10.09 | positive regulation of chemokine production | biological process | GO:0032722 | 72 | 4 | 18204 | 49 |
HIF1A,CD74,IL6R,CSF1R |
4.465e-05 | -10.02 | regulation of locomotion | biological process | GO:0040012 | 1164 | 12 | 18204 | 49 |
DOCK10,DOCK8,PREX1,DOCK1,P2RY6,HIF1A,IL6R,CD74,APOE,PLCG2,CSF1R,GAB1 |
4.727e-05 | -9.96 | regulation of cell adhesion | biological process | GO:0030155 | 807 | 10 | 18204 | 49 |
DOCK8,PTPN6,TLN1,PREX1,VAV3,CD74,DOCK1,SKAP1,SPI1,PRKCD |
5.219e-05 | -9.86 | Regulation of RAC1 activity | Pathway Interaction DB | rac1_reg_pathway | 39 | 5 | 2226 | 25 |
PREX1,DOCK1,ELMO1,VAV3,DOCK2 |
5.381e-05 | -9.83 | - | gene3d domains | 3.30.60.20 | 64 | 4 | 14470 | 47 |
VAV3,AKAP13,PRKCD,GMIP |
5.411e-05 | -9.82 | bone | COSMIC cancer mutations | bone | 8157 | 35 | 16828 | 45 |
PREX1,PARVG,PTPN6,ARHGAP27,TBXAS1,DOCK2,ADCY7,P2RY2,ARHGAP33,GAB1,ARHGAP15,BLNK,RGS14,ELMO1,GMIP,IPCEF1,DENND1B,MYO1F,DOCK10,P2RY6,PRKCD,PLCG2,CSF1R,WDFY4,TBC1D8,RHBDF2,HCK,TLN1,DOCK8,DOCK1,EHBP1L1,IRF5,HIF1A,VAV3,AKAP13 |
5.442e-05 | -9.82 | ZF_DAG_PE_1 | prosite domains | PS00479 | 58 | 4 | 12186 | 44 |
VAV3,AKAP13,PRKCD,GMIP |
5.559e-05 | -9.80 | leukocyte proliferation | biological process | GO:0070661 | 153 | 5 | 18204 | 49 |
DOCK2,DOCK8,CSF1R,PTPN6,PRKCD |
5.570e-05 | -9.80 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 23 | 16828 | 45 |
TBXAS1,CSF1R,GIT2,RHBDF2,DOCK2,PIK3R5,PREX1,MYO1F,PLCG2,PTPN6,BLNK,VAV3,HIF1A,IRF5,IPCEF1,ELMO1,GMIP,AKAP13,DOCK8,TLN1,STAT6,EHBP1L1,DOCK1 |
5.594e-05 | -9.79 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 23 | 16828 | 45 |
DOCK8,TLN1,STAT6,EHBP1L1,DOCK1,BLNK,VAV3,IRF5,HIF1A,IPCEF1,GMIP,ELMO1,AKAP13,PIK3R5,PREX1,MYO1F,PLCG2,PTPN6,CSF1R,TBXAS1,GIT2,RHBDF2,DOCK2 |
5.913e-05 | -9.74 | myeloid leukocyte activation | biological process | GO:0002274 | 155 | 5 | 18204 | 49 |
PRKCD,SBNO2,PLCG2,PREX1,DOCK2 |
6.075e-05 | -9.71 | Rho GTPase activation protein | gene3d domains | 1.10.555.10 | 66 | 4 | 14470 | 47 |
ARHGAP15,ARHGAP27,GMIP,ARHGAP33 |
6.257e-05 | -9.68 | LYN (LYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 4067 | 713 | 9 | 19454 | 49 |
GAB1,BLNK,PLCG2,SKAP1,PRKCD,CSF1R,TBC1D8,HCK,PTPN6 |
6.307e-05 | -9.67 | response to biotic stimulus | biological process | GO:0009607 | 1408 | 13 | 18204 | 49 |
PTPN6,CD74,IL6R,HIF1A,PRKCD,SPI1,WDFY4,IRF5,PLCG2,GSDME,CSF1R,HCK,SBNO2 |
6.346e-05 | -9.67 | GAB1 (GRB2 associated binding protein 1) | protein interactions | 2549 | 168 | 5 | 19454 | 49 |
GAB1,HCK,BLNK,PLCG2,VAV3 |
6.375e-05 | -9.66 | cellular response to interleukin-6 | biological process | GO:0071354 | 29 | 3 | 18204 | 49 |
SBNO2,SPI1,IL6R |
6.450e-05 | -9.65 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 23 | 16828 | 45 |
DOCK2,TBXAS1,PTPN6,PREX1,PIK3R5,GMIP,ELMO1,IPCEF1,BLNK,RHBDF2,CSF1R,GIT2,PLCG2,MYO1F,AKAP13,HIF1A,IRF5,VAV3,DOCK1,EHBP1L1,STAT6,TLN1,DOCK8 |
6.618e-05 | -9.62 | positive regulation of cytokine production involved in immune response | biological process | GO:0002720 | 81 | 4 | 18204 | 49 |
PLCG2,CD74,DENND1B,IRF5 |
6.822e-05 | -9.59 | DOCK_N | interpro domains | IPR032376 | 5 | 2 | 18521 | 49 |
DOCK1,DOCK2 |
6.822e-05 | -9.59 | DOCK_N_sub1 | interpro domains | IPR042455 | 5 | 2 | 18521 | 49 |
DOCK2,DOCK1 |
6.880e-05 | -9.58 | SH2DOMAIN | prints domains | PR00401 | 72 | 4 | 5227 | 17 |
PTPN6,VAV3,PLCG2,HCK |
7.281e-05 | -9.53 | positive regulation of B cell activation | biological process | GO:0050871 | 83 | 4 | 18204 | 49 |
VAV3,SPI1,CD74,STAT6 |
7.389e-05 | -9.51 | DOCK_N | pfam domains | PF16172 | 5 | 2 | 17795 | 49 |
DOCK1,DOCK2 |
7.494e-05 | -9.50 | NME2 (NME/NM23 nucleoside diphosphate kinase 2) | protein interactions | 4831 | 174 | 5 | 19454 | 49 |
DOCK8,GIT2,PREX1,PLCG2,AKAP13 |
7.541e-05 | -9.49 | ZF_DAG_PE_2 | prosite domains | PS50081 | 63 | 4 | 12186 | 44 |
GMIP,PRKCD,AKAP13,VAV3 |
7.577e-05 | -9.49 | regulation of multicellular organismal process | biological process | GO:0051239 | 3113 | 20 | 18204 | 49 |
DENND1B,STAT6,GAB1,CSF1R,PLCG2,APOE,IRF5,ADCY7,CD74,IL6R,HIF1A,PRKCD,DOCK1,SPI1,P2RY2,VAV3,RGS14,PTPN6,DOCK8,TBXAS1 |
7.763e-05 | -9.46 | regulation of immune effector process | biological process | GO:0002697 | 390 | 7 | 18204 | 49 |
PTPN6,PLCG2,IRF5,DENND1B,CD74,STAT6,SPI1 |
8.505e-05 | -9.37 | ELMO1 (engulfment and cell motility 1) | protein interactions | 9844 | 34 | 3 | 19454 | 49 |
HCK,DOCK2,DOCK1 |
8.526e-05 | -9.37 | RHOGAP | prosite domains | PS50238 | 65 | 4 | 12186 | 44 |
ARHGAP15,GMIP,ARHGAP27,ARHGAP33 |
8.604e-05 | -9.36 | Fc-gamma receptor signaling pathway | biological process | GO:0038094 | 32 | 3 | 18204 | 49 |
HCK,PRKCD,VAV3 |
8.699e-05 | -9.35 | small GTPase binding | molecular function | GO:0031267 | 283 | 6 | 18094 | 47 |
AKAP13,DENND1B,DOCK1,DOCK2,DOCK10,GIT2 |
8.699e-05 | -9.35 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 24 | 16828 | 45 |
PIK3R5,MYO1F,PREX1,DOCK10,P2RY6,PARVG,WDFY4,TBC1D8,RHBDF2,DOCK2,ADCY7,DOCK8,STAT6,TLN1,EHBP1L1,SBNO2,ARHGAP15,DOCK1,BLNK,IRF5,GMIP,ELMO1,IPCEF1,AKAP13 |
8.699e-05 | -9.35 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 24 | 16828 | 45 |
STAT6,TLN1,DOCK8,DOCK1,SBNO2,EHBP1L1,IRF5,AKAP13,DOCK10,MYO1F,P2RY6,WDFY4,TBC1D8,RHBDF2,ARHGAP15,BLNK,GMIP,ELMO1,IPCEF1,PREX1,PIK3R5,PARVG,DOCK2,ADCY7 |
8.750e-05 | -9.34 | cellular response to virus | biological process | GO:0098586 | 87 | 4 | 18204 | 49 |
WDFY4,GSDME,IRF5,HIF1A |
8.770e-05 | -9.34 | IL-6 signaling pathway | WikiPathways | WP364 | 43 | 4 | 5310 | 30 |
PRKCD,GAB1,IL6R,HCK |
9.346e-05 | -9.28 | Rho_GTPase_activation_prot | interpro domains | IPR008936 | 90 | 4 | 18521 | 49 |
ARHGAP33,ARHGAP15,GMIP,ARHGAP27 |
1.022e-04 | -9.19 | DOCK_C/D_N | interpro domains | IPR021816 | 6 | 2 | 18521 | 49 |
DOCK8,DOCK10 |
1.026e-04 | -9.18 | Dedicator of cytokinesis N-terminal subdomain | gene3d domains | 1.20.1270.350 | 5 | 2 | 14470 | 47 |
DOCK1,DOCK2 |
1.034e-04 | -9.18 | response to interleukin-6 | biological process | GO:0070741 | 34 | 3 | 18204 | 49 |
SBNO2,SPI1,IL6R |
1.034e-04 | -9.18 | regulation of type 2 immune response | biological process | GO:0002828 | 34 | 3 | 18204 | 49 |
STAT6,DENND1B,CD74 |
1.036e-04 | -9.17 | CBLB (Cbl proto-oncogene B) | protein interactions | 868 | 97 | 4 | 19454 | 49 |
VAV3,PLCG2,FYB1,BLNK |
1.063e-04 | -9.15 | regulation of cellular process | biological process | GO:0050794 | 11468 | 43 | 18204 | 49 |
SBNO2,TBC1D8,DENND1B,HCK,GAB1,CARMIL3,TLN1,PLCG2,NRK,GIT2,RHBDF2,APOE,PRKCD,P2RY6,P2RY2,DOCK1,IL6R,VAV3,PREX1,RGS14,AKAP13,PTPN6,DOCK2,ARHGAP27,STAT6,ELMO1,ARHGAP33,GSDME,CSF1R,GMIP,IRF5,ADCY7,FYB1,SPI1,SKAP1,CD74,HIF1A,NEK6,ARHGAP15,BLNK,DOCK10,DOCK8,PIK3R5 |
1.106e-04 | -9.11 | DOCK_C-D_N | pfam domains | PF11878 | 6 | 2 | 17795 | 49 |
DOCK10,DOCK8 |
1.142e-04 | -9.08 | vesicle-mediated transport | biological process | GO:0016192 | 1283 | 12 | 18204 | 49 |
MYO1F,DOCK2,GIT2,APOE,ARHGAP27,PRKCD,P2RY6,DOCK1,DENND1B,HCK,VAV3,ELMO1 |
1.184e-04 | -9.04 | RhoGAP | smart domains | SM00324 | 64 | 4 | 9717 | 39 |
ARHGAP15,ARHGAP33,ARHGAP27,GMIP |
1.229e-04 | -9.00 | cell-cell fusion | biological process | GO:0140253 | 36 | 3 | 18204 | 49 |
SBNO2,DOCK1,DOCK2 |
1.229e-04 | -9.00 | syncytium formation by plasma membrane fusion | biological process | GO:0000768 | 36 | 3 | 18204 | 49 |
DOCK2,SBNO2,DOCK1 |
1.242e-04 | -8.99 | The role of Nef in HIV-1 replication and disease pathogenesis | REACTOME pathways | R-HSA-164952 | 29 | 3 | 10285 | 35 |
ELMO1,HCK,DOCK2 |
1.258e-04 | -8.98 | C1 | smart domains | SM00109 | 65 | 4 | 9717 | 39 |
AKAP13,VAV3,GMIP,PRKCD |
1.335e-04 | -8.92 | negative regulation of lymphocyte apoptotic process | biological process | GO:0070229 | 37 | 3 | 18204 | 49 |
HIF1A,CD74,DOCK8 |
1.340e-04 | -8.92 | regulation of ERK1 and ERK2 cascade | biological process | GO:0070372 | 295 | 6 | 18204 | 49 |
PTPN6,RGS14,APOE,CD74,P2RY6,CSF1R |
1.343e-04 | -8.92 | LCK (LCK proto-oncogene, Src family tyrosine kinase) | protein interactions | 3932 | 455 | 7 | 19454 | 49 |
PLCG2,SKAP1,PRKCD,HCK,IL6R,PTPN6,GAB1 |
1.384e-04 | -8.89 | regulation of inflammatory response | biological process | GO:0050727 | 428 | 7 | 18204 | 49 |
HCK,PRKCD,SBNO2,PLCG2,PTPN6,APOE,RHBDF2 |
1.392e-04 | -8.88 | Platelet activation | KEGG pathways | hsa04611 | 123 | 5 | 7161 | 30 |
TBXAS1,ADCY7,PIK3R5,PLCG2,TLN1 |
1.468e-04 | -8.83 | Cytokine Signaling in Immune system | REACTOME pathways | R-HSA-1280215 | 756 | 10 | 10285 | 35 |
CSF1R,IRF5,HIF1A,IL6R,STAT6,PRKCD,BLNK,PTPN6,TLN1,HCK |
1.474e-04 | -8.82 | regulation of response to external stimulus | biological process | GO:0032101 | 1116 | 11 | 18204 | 49 |
HCK,SBNO2,CSF1R,PLCG2,APOE,RHBDF2,IL6R,CD74,SPI1,PRKCD,PTPN6 |
1.478e-04 | -8.82 | vascular endothelial growth factor production | biological process | GO:0010573 | 7 | 2 | 18204 | 49 |
HIF1A,IL6R |
1.483e-04 | -8.82 | regulation of biological process | biological process | GO:0050789 | 12079 | 44 | 18204 | 49 |
NEK6,SPI1,DOCK8,DOCK10,ARHGAP15,ARHGAP33,FYB1,ADCY7,IRF5,GMIP,VAV3,TBXAS1,PTPN6,AKAP13,RGS14,CARMIL3,GAB1,GIT2,PLCG2,HIF1A,CD74,SKAP1,PIK3R5,BLNK,CSF1R,GSDME,ELMO1,STAT6,PREX1,IL6R,DOCK1,P2RY2,PRKCD,P2RY6,ARHGAP27,DOCK2,HCK,DENND1B,TBC1D8,SBNO2,APOE,RHBDF2,NRK,TLN1 |
1.506e-04 | -8.80 | regulation of production of molecular mediator of immune response | biological process | GO:0002700 | 189 | 5 | 18204 | 49 |
IRF5,PLCG2,STAT6,DENND1B,CD74 |
1.506e-04 | -8.80 | B cell activation | biological process | GO:0042113 | 189 | 5 | 18204 | 49 |
BLNK,DOCK10,PRKCD,PLCG2,STAT6 |
1.561e-04 | -8.76 | platelet activation | biological process | GO:0030168 | 101 | 4 | 18204 | 49 |
VAV3,PTPN6,TLN1,PLCG2 |
1.563e-04 | -8.76 | GTPase binding | molecular function | GO:0051020 | 315 | 6 | 18094 | 47 |
DOCK1,DOCK2,DOCK10,GIT2,AKAP13,DENND1B |
1.565e-04 | -8.76 | syncytium formation | biological process | GO:0006949 | 39 | 3 | 18204 | 49 |
DOCK2,DOCK1,SBNO2 |
1.570e-04 | -8.76 | biological process involved in interspecies interaction between organisms | biological process | GO:0044419 | 1540 | 13 | 18204 | 49 |
PTPN6,PRKCD,HIF1A,CD74,IL6R,IRF5,WDFY4,APOE,PLCG2,CSF1R,GSDME,SBNO2,HCK |
1.609e-04 | -8.73 | PRAM1 (PML-RARA regulated adaptor molecule 1) | protein interactions | 84106 | 42 | 3 | 19454 | 49 |
NEK6,SKAP1,APOE |
1.622e-04 | -8.73 | alpha-beta T cell activation | biological process | GO:0046631 | 102 | 4 | 18204 | 49 |
STAT6,IL6R,DOCK2,WDFY4 |
1.633e-04 | -8.72 | response to oxygen-containing compound | biological process | GO:1901700 | 1546 | 13 | 18204 | 49 |
TBXAS1,HIF1A,PRKCD,P2RY6,P2RY2,PLCG2,APOE,IRF5,ADCY7,STAT6,HCK,SBNO2,GAB1 |
1.748e-04 | -8.65 | regulation of chemokine production | biological process | GO:0032642 | 104 | 4 | 18204 | 49 |
CSF1R,HIF1A,IL6R,CD74 |
1.756e-04 | -8.65 | SH2 domain binding | molecular function | GO:0042169 | 42 | 3 | 18094 | 47 |
PTPN6,SKAP1,BLNK |
1.828e-04 | -8.61 | negative regulation of immune response | biological process | GO:0050777 | 197 | 5 | 18204 | 49 |
STAT6,HCK,PTPN6,SPI1,RHBDF2 |
1.831e-04 | -8.61 | phosphorylation-dependent protein binding | molecular function | GO:0140031 | 8 | 2 | 18094 | 47 |
PTPN6,PLCG2 |
1.875e-04 | -8.58 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 33 | 16828 | 45 |
DOCK2,ADCY7,PIK3R5,PREX1,ARHGAP27,PARVG,BLNK,ELMO1,GMIP,IPCEF1,SKAP1,ARHGAP15,ARHGAP33,GAB1,WDFY4,CSF1R,GIT2,TBC1D8,DENND1B,DOCK10,MYO1F,PRKCD,APOE,HIF1A,NEK6,VAV3,AKAP13,DOCK8,STAT6,HCK,TLN1,SBNO2,DOCK1 |
1.894e-04 | -8.57 | B cell receptor signaling pathway | KEGG pathways | ko04662 | 70 | 4 | 7161 | 30 |
PTPN6,PLCG2,VAV3,BLNK |
1.894e-04 | -8.57 | B cell receptor signaling pathway | KEGG pathways | hsa04662 | 70 | 4 | 7161 | 30 |
PTPN6,PLCG2,VAV3,BLNK |
1.910e-04 | -8.56 | B Cell Receptor Signaling Pathway | WikiPathways | WP23 | 98 | 5 | 5310 | 30 |
GAB1,PRKCD,PTPN6,PLCG2,BLNK |
1.950e-04 | -8.54 | Rap1 signaling pathway | KEGG pathways | ko04015 | 210 | 6 | 7161 | 30 |
TLN1,CSF1R,SKAP1,FYB1,RGS14,ADCY7 |
1.950e-04 | -8.54 | Rap1 signaling pathway | KEGG pathways | hsa04015 | 210 | 6 | 7161 | 30 |
ADCY7,RGS14,FYB1,SKAP1,TLN1,CSF1R |
1.961e-04 | -8.54 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 45 | 16828 | 45 |
PRKCD,APOE,DOCK10,TBC1D8,RHBDF2,WDFY4,CSF1R,GIT2,EHBP1L1,SBNO2,DOCK1,STAT6,HCK,AKAP13,IRF5,NEK6,HIF1A,ARHGAP27,PARVG,CD74,PIK3R5,DOCK2,ADCY7,TBXAS1,ARHGAP15,P2RY2,GMIP,PLCG2,P2RY6,IL6R,DENND1B,MYO1F,DOCK8,TLN1,SPI1,VAV3,PTPN6,PREX1,SKAP1,ARHGAP33,GAB1,ELMO1,IPCEF1,BLNK,RGS14 |
1.961e-04 | -8.54 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 45 | 16828 | 45 |
PREX1,PTPN6,SKAP1,GAB1,ARHGAP33,RGS14,BLNK,IPCEF1,ELMO1,IL6R,MYO1F,DENND1B,PLCG2,P2RY6,DOCK8,TLN1,VAV3,SPI1,PIK3R5,ARHGAP27,PARVG,CD74,TBXAS1,ADCY7,DOCK2,P2RY2,ARHGAP15,GMIP,DOCK10,APOE,PRKCD,WDFY4,GIT2,CSF1R,RHBDF2,TBC1D8,HCK,STAT6,EHBP1L1,SBNO2,DOCK1,IRF5,NEK6,HIF1A,AKAP13 |
1.978e-04 | -8.53 | SKAP2 (src kinase associated phosphoprotein 2) | protein interactions | 8935 | 45 | 3 | 19454 | 49 |
HCK,FYB1,SKAP1 |
1.978e-04 | -8.53 | EPOR (erythropoietin receptor) | protein interactions | 2057 | 45 | 3 | 19454 | 49 |
PTPN6,GAB1,PLCG2 |
1.978e-04 | -8.53 | SH3BP2 (SH3 domain binding protein 2) | protein interactions | 6452 | 45 | 3 | 19454 | 49 |
VAV3,PLCG2,MYO1F |
1.979e-04 | -8.53 | regulation of phosphate metabolic process | biological process | GO:0019220 | 1154 | 11 | 18204 | 49 |
APOE,PLCG2,CSF1R,PIK3R5,PTPN6,RGS14,CD74,IL6R,HIF1A,P2RY6,PRKCD |
1.994e-04 | -8.52 | regulation of phosphorus metabolic process | biological process | GO:0051174 | 1155 | 11 | 18204 | 49 |
P2RY6,PRKCD,CD74,IL6R,HIF1A,CSF1R,PTPN6,RGS14,PLCG2,APOE,PIK3R5 |
2.007e-04 | -8.51 | negative regulation of inflammatory response | biological process | GO:0050728 | 201 | 5 | 18204 | 49 |
HCK,PTPN6,PRKCD,APOE,RHBDF2 |
2.022e-04 | -8.51 | response to other organism | biological process | GO:0051707 | 1363 | 12 | 18204 | 49 |
IRF5,WDFY4,PLCG2,CSF1R,GSDME,SBNO2,HCK,PTPN6,PRKCD,IL6R,CD74,HIF1A |
2.050e-04 | -8.49 | SH3_1 | pfam domains | PF00018 | 106 | 4 | 17795 | 49 |
HCK,DOCK1,PLCG2,MYO1F |
2.064e-04 | -8.49 | response to external biotic stimulus | biological process | GO:0043207 | 1366 | 12 | 18204 | 49 |
GSDME,CSF1R,HCK,SBNO2,WDFY4,IRF5,PLCG2,HIF1A,IL6R,CD74,PRKCD,PTPN6 |
2.091e-04 | -8.47 | signaling adaptor activity | molecular function | GO:0035591 | 113 | 4 | 18094 | 47 |
AKAP13,GAB1,BLNK,RGS14 |
2.255e-04 | -8.40 | kidney-carcinoma | COSMIC cancer mutations | kidney-carcinoma | 3720 | 21 | 16828 | 45 |
CSF1R,GIT2,PRKCD,PLCG2,PTPN6,IL6R,PIK3R5,PREX1,AKAP13,SPI1,RGS14,HIF1A,IRF5,NEK6,VAV3,ARHGAP15,DOCK1,ARHGAP33,GAB1,STAT6,HCK |
2.344e-04 | -8.36 | PDGFRB (platelet derived growth factor receptor beta) | protein interactions | 5159 | 222 | 5 | 19454 | 49 |
HIF1A,CSF1R,GAB1,PTPN6,VAV3 |
2.380e-04 | -8.34 | positive regulation of lymphocyte activation | biological process | GO:0051251 | 328 | 6 | 18204 | 49 |
STAT6,CD74,SPI1,PTPN6,DOCK8,VAV3 |
2.405e-04 | -8.33 | regulation of adaptive immune response | biological process | GO:0002819 | 209 | 5 | 18204 | 49 |
STAT6,DENND1B,PTPN6,SKAP1,ADCY7 |
2.444e-04 | -8.32 | protein domain specific binding | molecular function | GO:0019904 | 651 | 8 | 18094 | 47 |
BLNK,DOCK1,TLN1,ARHGAP27,PTPN6,SKAP1,HIF1A,ELMO1 |
2.458e-04 | -8.31 | phosphotyrosine residue binding | molecular function | GO:0001784 | 47 | 3 | 18094 | 47 |
HCK,PTPN6,PLCG2 |
2.532e-04 | -8.28 | regulation of cell activation | biological process | GO:0050865 | 630 | 8 | 18204 | 49 |
STAT6,CD74,SPI1,PTPN6,PRKCD,DOCK8,APOE,VAV3 |
2.641e-04 | -8.24 | PH_12 | pfam domains | PF16457 | 9 | 2 | 17795 | 49 |
PLCG2,ELMO1 |
2.708e-04 | -8.21 | DOK1 (docking protein 1) | protein interactions | 1796 | 50 | 3 | 19454 | 49 |
HCK,PTPN6,TLN1 |
2.734e-04 | -8.20 | negative regulation of MAP kinase activity | biological process | GO:0043407 | 47 | 3 | 18204 | 49 |
APOE,RGS14,PRKCD |
2.800e-04 | -8.18 | cell chemotaxis | biological process | GO:0060326 | 216 | 5 | 18204 | 49 |
PREX1,VAV3,GAB1,PRKCD,IL6R |
2.872e-04 | -8.16 | IL4R (interleukin 4 receptor) | protein interactions | 3566 | 51 | 3 | 19454 | 49 |
STAT6,RHBDF2,PTPN6 |
2.978e-04 | -8.12 | regulation of actin cytoskeleton organization | biological process | GO:0032956 | 342 | 6 | 18204 | 49 |
AKAP13,CSF1R,CARMIL3,PREX1,HCK,PRKCD |
3.013e-04 | -8.11 | BTK (Bruton tyrosine kinase) | protein interactions | 695 | 128 | 4 | 19454 | 49 |
GAB1,BLNK,HCK,PLCG2 |
3.013e-04 | -8.11 | positive regulation of cell adhesion | biological process | GO:0045785 | 486 | 7 | 18204 | 49 |
CD74,SKAP1,PTPN6,DOCK1,DOCK8,VAV3,PREX1 |
3.025e-04 | -8.10 | Signaling by Interleukins | REACTOME pathways | R-HSA-449147 | 525 | 8 | 10285 | 35 |
HIF1A,IL6R,STAT6,CSF1R,BLNK,PTPN6,HCK,TLN1 |
3.026e-04 | -8.10 | regulation of cytokine production involved in immune response | biological process | GO:0002718 | 120 | 4 | 18204 | 49 |
IRF5,DENND1B,CD74,PLCG2 |
3.034e-04 | -8.10 | Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | REACTOME pathways | R-HSA-983695 | 39 | 3 | 10285 | 35 |
PLCG2,BLNK,PTPN6 |
3.121e-04 | -8.07 | chemotaxis | biological process | GO:0006935 | 345 | 6 | 18204 | 49 |
GAB1,VAV3,DOCK2,PREX1,IL6R,PRKCD |
3.177e-04 | -8.05 | defense response | biological process | GO:0006952 | 1431 | 12 | 18204 | 49 |
PLCG2,IRF5,HCK,STAT6,CSF1R,PTPN6,BLNK,PRKCD,SPI1,CD74,IL6R,HIF1A |
3.200e-04 | -8.05 | lipid binding | molecular function | GO:0008289 | 861 | 9 | 18094 | 47 |
TLN1,APOE,DENND1B,BLNK,PREX1,HCK,ARHGAP33,GSDME,FYB1 |
3.219e-04 | -8.04 | taxis | biological process | GO:0042330 | 347 | 6 | 18204 | 49 |
GAB1,VAV3,PREX1,DOCK2,IL6R,PRKCD |
3.220e-04 | -8.04 | ELMO2 (engulfment and cell motility 2) | protein interactions | 63916 | 53 | 3 | 19454 | 49 |
DOCK2,DOCK1,ELMO1 |
3.346e-04 | -8.00 | Platelet activation, signaling and aggregation | REACTOME pathways | R-HSA-76002 | 282 | 6 | 10285 | 35 |
PRKCD,PLCG2,VAV3,PIK3R5,PTPN6,TLN1 |
3.369e-04 | -8.00 | LAT2 (linker for activation of T cells family member 2) | protein interactions | 7462 | 11 | 2 | 19454 | 49 |
PLCG2,GAB1 |
3.430e-04 | -7.98 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 21 | 16828 | 45 |
DENND1B,DOCK10,PTPN6,PRKCD,PLCG2,GIT2,CSF1R,WDFY4,DOCK2,TBC1D8,ARHGAP33,DOCK1,GAB1,SKAP1,SBNO2,ARHGAP15,BLNK,AKAP13,ELMO1,GMIP,IPCEF1 |
3.430e-04 | -7.98 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 21 | 16828 | 45 |
BLNK,AKAP13,ELMO1,GMIP,IPCEF1,DOCK1,ARHGAP33,GAB1,SKAP1,SBNO2,ARHGAP15,GIT2,CSF1R,WDFY4,DOCK2,TBC1D8,DENND1B,DOCK10,PTPN6,PRKCD,PLCG2 |
3.491e-04 | -7.96 | regulation of anatomical structure size | biological process | GO:0090066 | 498 | 7 | 18204 | 49 |
P2RY2,PRKCD,HCK,PREX1,TBXAS1,VAV3,APOE |
3.577e-04 | -7.94 | positive regulation of cytokine production | biological process | GO:0001819 | 500 | 7 | 18204 | 49 |
PLCG2,IRF5,HIF1A,CD74,IL6R,DENND1B,CSF1R |
3.658e-04 | -7.91 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 13 | 16828 | 45 |
BLNK,HIF1A,ELMO1,SPI1,AKAP13,HCK,STAT6,DOCK1,CSF1R,DOCK2,DOCK10,PLCG2,CD74 |
3.993e-04 | -7.83 | ITK (IL2 inducible T cell kinase) | protein interactions | 3702 | 57 | 3 | 19454 | 49 |
GAB1,BLNK,PLCG2 |
3.997e-04 | -7.82 | cellular response to oxygen-containing compound | biological process | GO:1901701 | 1047 | 10 | 18204 | 49 |
PRKCD,SBNO2,P2RY6,P2RY2,HCK,STAT6,HIF1A,GAB1,PLCG2,ADCY7 |
4.032e-04 | -7.82 | positive regulation of leukocyte activation | biological process | GO:0002696 | 362 | 6 | 18204 | 49 |
DOCK8,PTPN6,VAV3,STAT6,CD74,SPI1 |
4.036e-04 | -7.81 | RWDD1 (RWD domain containing 1) | protein interactions | 51389 | 12 | 2 | 19454 | 49 |
CD74,P2RY6 |
4.102e-04 | -7.80 | lymphocyte proliferation | biological process | GO:0046651 | 130 | 4 | 18204 | 49 |
DOCK8,DOCK2,PTPN6,PRKCD |
4.185e-04 | -7.78 | anchoring junction | cellular component | GO:0070161 | 902 | 9 | 19108 | 49 |
HCK,FYB1,SKAP1,PARVG,PRKCD,GIT2,GAB1,PTPN6,TLN1 |
4.198e-04 | -7.78 | NCK2 (NCK adaptor protein 2) | protein interactions | 8440 | 252 | 5 | 19454 | 49 |
BLNK,FYB1,GAB1,GIT2,DOCK1 |
4.212e-04 | -7.77 | response to oxidative stress | biological process | GO:0006979 | 365 | 6 | 18204 | 49 |
APOE,IPCEF1,STAT6,HIF1A,PRKCD,RGS14 |
4.248e-04 | -7.76 | pleura-mesothelioma | COSMIC cancer mutations | pleura-mesothelioma | 4189 | 22 | 16828 | 45 |
VAV3,NEK6,HIF1A,IRF5,SPI1,AKAP13,TLN1,HCK,STAT6,DOCK1,CSF1R,GIT2,IL6R,PLCG2,PRKCD,RGS14,ARHGAP15,GAB1,ARHGAP33,PIK3R5,PREX1,PTPN6 |
4.312e-04 | -7.75 | regulation of cytokine production | biological process | GO:0001817 | 863 | 9 | 18204 | 49 |
PTPN6,PLCG2,IRF5,ADCY7,DENND1B,CD74,IL6R,HIF1A,CSF1R |
4.336e-04 | -7.74 | locomotion | biological process | GO:0040011 | 367 | 6 | 18204 | 49 |
IL6R,PRKCD,GAB1,DOCK2,PREX1,VAV3 |
4.451e-04 | -7.72 | PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) | protein interactions | 5295 | 394 | 6 | 19454 | 49 |
GAB1,CSF1R,PTPN6,HCK,PLCG2,VAV3 |
4.595e-04 | -7.69 | negative regulation of leukocyte apoptotic process | biological process | GO:2000107 | 56 | 3 | 18204 | 49 |
HIF1A,CD74,DOCK8 |
4.595e-04 | -7.69 | B cell activation involved in immune response | biological process | GO:0002312 | 56 | 3 | 18204 | 49 |
PLCG2,STAT6,DOCK10 |
4.601e-04 | -7.68 | mononuclear cell proliferation | biological process | GO:0032943 | 134 | 4 | 18204 | 49 |
PTPN6,PRKCD,DOCK8,DOCK2 |
4.605e-04 | -7.68 | positive thymic T cell selection | biological process | GO:0045059 | 12 | 2 | 18204 | 49 |
CD74,DOCK2 |
4.605e-04 | -7.68 | negative thymic T cell selection | biological process | GO:0045060 | 12 | 2 | 18204 | 49 |
DOCK2,CD74 |
4.790e-04 | -7.64 | kidney-carcinoma-renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-renal_cell_carcinoma | 4535 | 23 | 16828 | 45 |
PTPN6,PRKCD,PLCG2,PREX1,IL6R,PIK3R5,DOCK2,CSF1R,GIT2,ARHGAP33,DOCK1,GAB1,ARHGAP15,STAT6,HCK,TLN1,SPI1,AKAP13,NEK6,HIF1A,IRF5,VAV3,RGS14 |
4.790e-04 | -7.64 | renal_cell_carcinoma | COSMIC cancer mutations | renal_cell_carcinoma | 4535 | 23 | 16828 | 45 |
ARHGAP15,GAB1,ARHGAP33,RGS14,PTPN6,PIK3R5,PREX1,DOCK2,DOCK1,TLN1,HCK,STAT6,SPI1,AKAP13,VAV3,IRF5,HIF1A,NEK6,PLCG2,PRKCD,IL6R,CSF1R,GIT2 |
4.841e-04 | -7.63 | PTPN6 (protein tyrosine phosphatase non-receptor type 6) | protein interactions | 5777 | 260 | 5 | 19454 | 49 |
PLCG2,PRKCD,STAT6,PTPN6,BLNK |
4.842e-04 | -7.63 | regulation of lymphocyte apoptotic process | biological process | GO:0070228 | 57 | 3 | 18204 | 49 |
HIF1A,CD74,DOCK8 |
4.845e-04 | -7.63 | biological regulation | biological process | GO:0065007 | 12501 | 44 | 18204 | 49 |
PREX1,DOCK1,P2RY2,PRKCD,P2RY6,IL6R,DOCK2,ARHGAP27,TBC1D8,SBNO2,HCK,DENND1B,RHBDF2,APOE,TLN1,NRK,SKAP1,HIF1A,CD74,BLNK,PIK3R5,ELMO1,CSF1R,GSDME,STAT6,VAV3,TBXAS1,PTPN6,RGS14,AKAP13,CARMIL3,GAB1,GIT2,PLCG2,NEK6,SPI1,DOCK10,DOCK8,ARHGAP15,ARHGAP33,ADCY7,IRF5,FYB1,GMIP |
4.866e-04 | -7.63 | regulation of MAP kinase activity | biological process | GO:0043405 | 136 | 4 | 18204 | 49 |
PIK3R5,APOE,RGS14,PRKCD |
4.887e-04 | -7.62 | Signaling by Rho GTPases | REACTOME pathways | R-HSA-194315 | 426 | 7 | 10285 | 35 |
ARHGAP15,ARHGAP33,GMIP,ARHGAP27,AKAP13,PREX1,VAV3 |
4.987e-04 | -7.60 | leukocyte migration | biological process | GO:0050900 | 245 | 5 | 18204 | 49 |
HCK,IL6R,DOCK8,PREX1,VAV3 |
5.058e-04 | -7.59 | G protein-coupled purinergic nucleotide receptor activity | molecular function | GO:0045028 | 13 | 2 | 18094 | 47 |
P2RY6,P2RY2 |
5.067e-04 | -7.59 | protein phosphorylated amino acid binding | molecular function | GO:0045309 | 60 | 3 | 18094 | 47 |
HCK,PLCG2,PTPN6 |
5.096e-04 | -7.58 | mammary gland epithelium development | biological process | GO:0061180 | 58 | 3 | 18204 | 49 |
HIF1A,STAT6,CSF1R |
5.129e-04 | -7.58 | regulation of kinase activity | biological process | GO:0043549 | 531 | 7 | 18204 | 49 |
APOE,PIK3R5,RGS14,CSF1R,IL6R,CD74,PRKCD |
5.175e-04 | -7.57 | regulation of leukocyte mediated immunity | biological process | GO:0002703 | 247 | 5 | 18204 | 49 |
DENND1B,STAT6,SPI1,PTPN6,PLCG2 |
5.176e-04 | -7.57 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 30 | 16828 | 45 |
RGS14,ELMO1,GMIP,P2RY2,GAB1,ARHGAP33,TBXAS1,DOCK2,PREX1,PTPN6,PARVG,VAV3,NEK6,IRF5,AKAP13,TLN1,HCK,DOCK1,SBNO2,EHBP1L1,CSF1R,GIT2,WDFY4,RHBDF2,TBC1D8,DOCK10,MYO1F,DENND1B,PLCG2,PRKCD |
5.284e-04 | -7.55 | positive regulation of transferase activity | biological process | GO:0051347 | 381 | 6 | 18204 | 49 |
APOE,PIK3R5,PRKCD,IL6R,CD74,CSF1R |
5.284e-04 | -7.55 | positive regulation of cell activation | biological process | GO:0050867 | 381 | 6 | 18204 | 49 |
PTPN6,DOCK8,SPI1,STAT6,CD74,VAV3 |
5.367e-04 | -7.53 | lung-carcinoma | COSMIC cancer mutations | lung-carcinoma | 4255 | 22 | 16828 | 45 |
IL6R,PIK3R5,PREX1,PRKCD,PLCG2,PTPN6,CSF1R,GIT2,STAT6,HCK,TLN1,ARHGAP15,ARHGAP33,DOCK1,GAB1,RGS14,IRF5,NEK6,HIF1A,VAV3,SPI1,AKAP13 |
5.432e-04 | -7.52 | negative T cell selection | biological process | GO:0043383 | 13 | 2 | 18204 | 49 |
CD74,DOCK2 |
5.432e-04 | -7.52 | G protein-coupled purinergic nucleotide receptor signaling pathway | biological process | GO:0035589 | 13 | 2 | 18204 | 49 |
P2RY6,P2RY2 |
5.507e-04 | -7.50 | regulation of actin filament-based process | biological process | GO:0032970 | 384 | 6 | 18204 | 49 |
AKAP13,PRKCD,HCK,PREX1,CSF1R,CARMIL3 |
5.547e-04 | -7.50 | LYSMD2 (LysM domain containing 2) | protein interactions | 256586 | 14 | 2 | 19454 | 49 |
PRKCD,HIF1A |
5.547e-04 | -7.50 | MS4A2 (membrane spanning 4-domains A2) | protein interactions | 2206 | 14 | 2 | 19454 | 49 |
PRKCD,PTPN6 |
5.623e-04 | -7.48 | C1-like_sf | interpro domains | IPR046349 | 61 | 3 | 18521 | 49 |
PRKCD,AKAP13,GMIP |
5.778e-04 | -7.46 | FYN (FYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 2534 | 414 | 6 | 19454 | 49 |
FYB1,CSF1R,ARHGAP33,PRKCD,PLCG2,SKAP1 |
5.815e-04 | -7.45 | regulation of supramolecular fiber organization | biological process | GO:1902903 | 388 | 6 | 18204 | 49 |
CARMIL3,APOE,PREX1,HCK,AKAP13,PRKCD |
6.032e-04 | -7.41 | ERBB2 (erb-b2 receptor tyrosine kinase 2) | protein interactions | 2064 | 583 | 7 | 19454 | 49 |
GAB1,BLNK,HCK,PTPN6,TLN1,PLCG2,VAV3 |
6.144e-04 | -7.39 | transport | biological process | GO:0006810 | 3615 | 20 | 18204 | 49 |
VAV3,HIF1A,CD74,DOCK1,PRKCD,P2RY6,ARHGAP27,DOCK2,IPCEF1,MYO1F,RGS14,GSDME,ELMO1,ARHGAP33,HCK,DENND1B,APOE,GIT2,RHBDF2,PLCG2 |
6.159e-04 | -7.39 | GRB2 (growth factor receptor bound protein 2) | protein interactions | 2885 | 769 | 8 | 19454 | 49 |
SKAP1,DOCK1,VAV3,CSF1R,PTPN6,GAB1,BLNK,IRF5 |
6.327e-04 | -7.37 | immunological synapse formation | biological process | GO:0001771 | 14 | 2 | 18204 | 49 |
DOCK2,DOCK8 |
6.327e-04 | -7.37 | T-helper cell lineage commitment | biological process | GO:0002295 | 14 | 2 | 18204 | 49 |
IL6R,STAT6 |
6.327e-04 | -7.37 | interleukin-6-mediated signaling pathway | biological process | GO:0070102 | 14 | 2 | 18204 | 49 |
IL6R,SPI1 |
6.361e-04 | -7.36 | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning | COSMIC cancer mutations | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning | 1803 | 13 | 16828 | 45 |
RGS14,BLNK,WDFY4,CSF1R,IPCEF1,ELMO1,ADCY7,DOCK2,DOCK8,SKAP1,SBNO2,PTPN6,DOCK1 |
6.361e-04 | -7.36 | functioning | COSMIC cancer mutations | functioning | 1803 | 13 | 16828 | 45 |
ELMO1,IPCEF1,DOCK2,ADCY7,WDFY4,BLNK,RGS14,CSF1R,SBNO2,SKAP1,DOCK1,PTPN6,DOCK8 |
6.617e-04 | -7.32 | Inflammatory mediator regulation of TRP channels | KEGG pathways | hsa04750 | 97 | 4 | 7161 | 30 |
ADCY7,P2RY2,PLCG2,PRKCD |
6.617e-04 | -7.32 | Inflammatory mediator regulation of TRP channels | KEGG pathways | ko04750 | 97 | 4 | 7161 | 30 |
PLCG2,PRKCD,ADCY7,P2RY2 |
6.691e-04 | -7.31 | regulation of protein phosphorylation | biological process | GO:0001932 | 917 | 9 | 18204 | 49 |
CSF1R,IL6R,CD74,PRKCD,APOE,PIK3R5,PTPN6,PLCG2,RGS14 |
6.711e-04 | -7.31 | TRAF6 (TNF receptor associated factor 6) | protein interactions | 7189 | 426 | 6 | 19454 | 49 |
STAT6,PRKCD,VAV3,HIF1A,PTPN6,IRF5 |
6.860e-04 | -7.28 | positive regulation of leukocyte migration | biological process | GO:0002687 | 149 | 4 | 18204 | 49 |
DOCK8,CSF1R,CD74,IL6R |
7.136e-04 | -7.25 | multicellular organismal process | biological process | GO:0032501 | 6177 | 28 | 18204 | 49 |
SBNO2,TBC1D8,GAB1,TLN1,PLCG2,APOE,GIT2,IL6R,PRKCD,P2RY2,VAV3,PREX1,PTPN6,RGS14,AKAP13,TBXAS1,DOCK2,STAT6,CSF1R,GSDME,WDFY4,ADCY7,CD74,HIF1A,SPI1,DOCK8,BLNK,DOCK10 |
7.212e-04 | -7.23 | positive regulation of leukocyte mediated immunity | biological process | GO:0002705 | 151 | 4 | 18204 | 49 |
SPI1,PLCG2,DENND1B,STAT6 |
7.242e-04 | -7.23 | Innate Immune System | REACTOME pathways | R-HSA-168249 | 1285 | 12 | 10285 | 35 |
STAT6,ADCY7,GAB1,PLCG2,VAV3,HCK,TLN1,DOCK1,PRKCD,DOCK2,PTPN6,ELMO1 |
7.268e-04 | -7.23 | P2Y receptors | REACTOME pathways | R-HSA-417957 | 12 | 2 | 10285 | 35 |
P2RY2,P2RY6 |
7.286e-04 | -7.22 | angioimmunoblastic_T_cell_lymphoma | COSMIC cancer mutations | angioimmunoblastic_T_cell_lymphoma | 269 | 5 | 16828 | 45 |
PLCG2,STAT6,CSF1R,HCK,BLNK |
7.288e-04 | -7.22 | regulation of phospholipid transport | biological process | GO:2001138 | 15 | 2 | 18204 | 49 |
APOE,PRKCD |
7.444e-04 | -7.20 | myeloid cell activation involved in immune response | biological process | GO:0002275 | 66 | 3 | 18204 | 49 |
SBNO2,PLCG2,DOCK2 |
7.444e-04 | -7.20 | peptidyl-tyrosine phosphorylation | biological process | GO:0018108 | 66 | 3 | 18204 | 49 |
CSF1R,PTPN6,HCK |
7.484e-04 | -7.20 | regulation of leukocyte proliferation | biological process | GO:0070663 | 268 | 5 | 18204 | 49 |
VAV3,CSF1R,PTPN6,STAT6,CD74 |
7.555e-04 | -7.19 | T cell receptor complex | cellular component | GO:0042101 | 16 | 2 | 19108 | 49 |
SKAP1,PTPN6 |
7.848e-04 | -7.15 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 38 | 16828 | 45 |
DOCK8,STAT6,TLN1,HCK,SBNO2,DOCK1,IRF5,VAV3,AKAP13,DENND1B,MYO1F,DOCK10,PRKCD,PLCG2,APOE,P2RY6,GIT2,CSF1R,TBC1D8,RHBDF2,P2RY2,SKAP1,ARHGAP15,ARHGAP33,GAB1,BLNK,RGS14,ELMO1,GMIP,IPCEF1,PIK3R5,PREX1,ARHGAP27,PARVG,PTPN6,TBXAS1,DOCK2,ADCY7 |
7.848e-04 | -7.15 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 38 | 16828 | 45 |
DOCK2,ADCY7,TBXAS1,ARHGAP27,PARVG,PTPN6,PIK3R5,PREX1,GMIP,ELMO1,IPCEF1,BLNK,RGS14,SKAP1,ARHGAP15,ARHGAP33,GAB1,P2RY2,TBC1D8,RHBDF2,CSF1R,GIT2,PRKCD,PLCG2,APOE,P2RY6,DENND1B,MYO1F,DOCK10,AKAP13,IRF5,VAV3,SBNO2,DOCK1,DOCK8,STAT6,HCK,TLN1 |
8.122e-04 | -7.12 | peptidyl-tyrosine modification | biological process | GO:0018212 | 68 | 3 | 18204 | 49 |
CSF1R,HCK,PTPN6 |
8.251e-04 | -7.10 | ARL4A (ADP ribosylation factor like GTPase 4A) | protein interactions | 10124 | 17 | 2 | 19454 | 49 |
DOCK1,ELMO1 |
8.410e-04 | -7.08 | DH-domain | interpro domains | IPR000219 | 70 | 3 | 18521 | 49 |
VAV3,AKAP13,PREX1 |
8.571e-04 | -7.06 | Signal regulatory protein (SIRP) family interactions | REACTOME pathways | R-HSA-391160 | 13 | 2 | 10285 | 35 |
PTPN6,FYB1 |
8.686e-04 | -7.05 | regulation of protein-containing complex assembly | biological process | GO:0043254 | 419 | 6 | 18204 | 49 |
PREX1,HCK,PRKCD,SKAP1,APOE,PLCG2 |
8.765e-04 | -7.04 | DBL_dom_sf | interpro domains | IPR035899 | 71 | 3 | 18521 | 49 |
AKAP13,PREX1,VAV3 |
8.776e-04 | -7.04 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | 10418 | 38 | 16828 | 45 |
BLNK,GMIP,ELMO1,IPCEF1,P2RY2,SKAP1,ARHGAP15,ARHGAP33,GAB1,TBXAS1,DOCK2,ADCY7,PIK3R5,PREX1,PARVG,CD74,PTPN6,HIF1A,NEK6,IRF5,VAV3,AKAP13,SPI1,DOCK8,STAT6,TLN1,EHBP1L1,DOCK1,WDFY4,CSF1R,GIT2,TBC1D8,RHBDF2,DOCK10,MYO1F,PRKCD,PLCG2,P2RY6 |
8.776e-04 | -7.04 | acute_myeloid_leukaemia | COSMIC cancer mutations | acute_myeloid_leukaemia | 10418 | 38 | 16828 | 45 |
PREX1,PIK3R5,CD74,PARVG,PTPN6,TBXAS1,DOCK2,ADCY7,P2RY2,ARHGAP33,GAB1,SKAP1,ARHGAP15,BLNK,ELMO1,GMIP,IPCEF1,MYO1F,DOCK10,P2RY6,PRKCD,PLCG2,GIT2,CSF1R,WDFY4,TBC1D8,RHBDF2,STAT6,TLN1,DOCK8,DOCK1,EHBP1L1,HIF1A,IRF5,NEK6,VAV3,AKAP13,SPI1 |
8.972e-04 | -7.02 | PLSCR1 (phospholipid scramblase 1) | protein interactions | 5359 | 171 | 4 | 19454 | 49 |
P2RY6,PRKCD,DOCK2,ADCY7 |
9.162e-04 | -7.00 | positive regulation of peptidyl-tyrosine phosphorylation | biological process | GO:0050731 | 161 | 4 | 18204 | 49 |
CSF1R,CD74,IL6R,PLCG2 |
9.407e-04 | -6.97 | CD4-positive, alpha-beta T cell lineage commitment | biological process | GO:0043373 | 17 | 2 | 18204 | 49 |
IL6R,STAT6 |
9.434e-04 | -6.97 | RhoGEF | pfam domains | PF00621 | 70 | 3 | 17795 | 49 |
PREX1,VAV3,AKAP13 |
9.514e-04 | -6.96 | breast-carcinoma-ER-PR-positive_carcinoma | COSMIC cancer mutations | breast-carcinoma-ER-PR-positive_carcinoma | 1881 | 13 | 16828 | 45 |
PLCG2,PRKCD,PTPN6,P2RY6,PIK3R5,DOCK10,CSF1R,GAB1,P2RY2,TLN1,STAT6,ELMO1,VAV3 |
9.514e-04 | -6.96 | ER-PR-positive_carcinoma | COSMIC cancer mutations | ER-PR-positive_carcinoma | 1881 | 13 | 16828 | 45 |
PTPN6,P2RY6,PLCG2,PRKCD,DOCK10,PIK3R5,CSF1R,GAB1,TLN1,STAT6,P2RY2,ELMO1,VAV3 |
9.577e-04 | -6.95 | Signalling by NGF | REACTOME pathways | R-HSA-166520 | 477 | 7 | 10285 | 35 |
PRKCD,GAB1,VAV3,PREX1,AKAP13,TLN1,ADCY7 |
9.586e-04 | -6.95 | lung-carcinoma-undifferentiated_carcinoma | COSMIC cancer mutations | lung-carcinoma-undifferentiated_carcinoma | 1408 | 11 | 16828 | 45 |
VAV3,GAB1,P2RY2,TLN1,STAT6,CSF1R,PLCG2,PRKCD,PTPN6,P2RY6,PIK3R5 |
9.696e-04 | -6.94 | cell surface receptor protein tyrosine kinase signaling pathway | biological process | GO:0007169 | 428 | 6 | 18204 | 49 |
GAB1,CSF1R,STAT6,HCK,BLNK,RGS14 |
9.772e-04 | -6.93 | regulation of transport | biological process | GO:0051049 | 1621 | 12 | 18204 | 49 |
CD74,HIF1A,PRKCD,P2RY6,SPI1,P2RY2,PTPN6,DOCK2,HCK,PLCG2,APOE,RHBDF2 |
1.016e-03 | -6.89 | undifferentiated_carcinoma | COSMIC cancer mutations | undifferentiated_carcinoma | 1418 | 11 | 16828 | 45 |
STAT6,TLN1,PIK3R5,P2RY2,P2RY6,GAB1,PTPN6,PRKCD,PLCG2,VAV3,CSF1R |
1.026e-03 | -6.88 | lymphocyte mediated immunity | biological process | GO:0002449 | 166 | 4 | 18204 | 49 |
STAT6,CD74,PTPN6,PRKCD |
1.041e-03 | -6.87 | ERBB4 (erb-b2 receptor tyrosine kinase 4) | protein interactions | 2066 | 178 | 4 | 19454 | 49 |
HCK,PTPN6,VAV3,PLCG2 |
1.043e-03 | -6.87 | negative regulation of intracellular signal transduction | biological process | GO:1902532 | 599 | 7 | 18204 | 49 |
APOE,RGS14,PTPN6,PRKCD,SPI1,CD74,HIF1A |
1.051e-03 | -6.86 | env (Envelope surface glycoprotein gp160, precursor) | protein interactions | 155971 | 1501 | 11 | 19454 | 49 |
SPI1,CD74,APOE,ADCY7,HIF1A,VAV3,PRKCD,SKAP1,PLCG2,HCK,IL6R |
1.056e-03 | -6.85 | positive regulation of type 2 immune response | biological process | GO:0002830 | 18 | 2 | 18204 | 49 |
DENND1B,CD74 |
1.056e-03 | -6.85 | negative regulation of platelet activation | biological process | GO:0010544 | 18 | 2 | 18204 | 49 |
APOE,PRKCD |
1.082e-03 | -6.83 | NRAGE signals death through JNK | REACTOME pathways | R-HSA-193648 | 60 | 3 | 10285 | 35 |
AKAP13,PREX1,VAV3 |
1.115e-03 | -6.80 | negative regulation of defense response | biological process | GO:0031348 | 293 | 5 | 18204 | 49 |
HCK,PTPN6,PRKCD,APOE,RHBDF2 |
1.121e-03 | -6.79 | negative regulation of MAPK cascade | biological process | GO:0043409 | 170 | 4 | 18204 | 49 |
PRKCD,PTPN6,RGS14,APOE |
1.122e-03 | -6.79 | T cell proliferation | biological process | GO:0042098 | 76 | 3 | 18204 | 49 |
DOCK8,DOCK2,PTPN6 |
1.130e-03 | -6.79 | mesothelioma | COSMIC cancer mutations | mesothelioma | 4477 | 22 | 16828 | 45 |
PIK3R5,PREX1,PTPN6,RGS14,ARHGAP15,ARHGAP33,GAB1,GIT2,CSF1R,IL6R,PRKCD,PLCG2,IRF5,NEK6,HIF1A,VAV3,SPI1,AKAP13,STAT6,TLN1,HCK,DOCK1 |
1.135e-03 | -6.78 | Regulation of actin dynamics for phagocytic cup formation | REACTOME pathways | R-HSA-2029482 | 61 | 3 | 10285 | 35 |
ELMO1,DOCK1,VAV3 |
1.139e-03 | -6.78 | CDC42 (cell division cycle 42) | protein interactions | 998 | 1280 | 10 | 19454 | 49 |
TBC1D8,DOCK8,EHBP1L1,PLCG2,NEK6,GMIP,ARHGAP27,DOCK10,PREX1,GIT2 |
1.143e-03 | -6.77 | DAP12 signaling | REACTOME pathways | R-HSA-2424491 | 356 | 6 | 10285 | 35 |
PRKCD,GAB1,PLCG2,VAV3,TLN1,ADCY7 |
1.154e-03 | -6.76 | HCK (HCK proto-oncogene, Src family tyrosine kinase) | protein interactions | 3055 | 183 | 4 | 19454 | 49 |
ELMO1,PLCG2,GAB1,HCK |
1.169e-03 | -6.75 | positive regulation of cell population proliferation | biological process | GO:0008284 | 992 | 9 | 18204 | 49 |
PTPN6,CSF1R,VAV3,CD74,IL6R,HCK,HIF1A,P2RY6,TBC1D8 |
1.171e-03 | -6.75 | negative regulation of secretion | biological process | GO:0051048 | 172 | 4 | 18204 | 49 |
RHBDF2,APOE,SPI1,CD74 |
1.179e-03 | -6.74 | macrophage activation involved in immune response | biological process | GO:0002281 | 19 | 2 | 18204 | 49 |
SBNO2,PLCG2 |
1.179e-03 | -6.74 | alpha-beta T cell lineage commitment | biological process | GO:0002363 | 19 | 2 | 18204 | 49 |
IL6R,STAT6 |
1.186e-03 | -6.74 | regulation of phosphorylation | biological process | GO:0042325 | 994 | 9 | 18204 | 49 |
PRKCD,IL6R,CD74,CSF1R,RGS14,PLCG2,PTPN6,APOE,PIK3R5 |
1.218e-03 | -6.71 | nucleotide receptor activity | molecular function | GO:0016502 | 20 | 2 | 18094 | 47 |
P2RY6,P2RY2 |
1.218e-03 | -6.71 | purinergic nucleotide receptor activity | molecular function | GO:0001614 | 20 | 2 | 18094 | 47 |
P2RY2,P2RY6 |
1.239e-03 | -6.69 | regulation of epithelial cell migration | biological process | GO:0010632 | 300 | 5 | 18204 | 49 |
GAB1,APOE,PLCG2,DOCK1,HIF1A |
1.245e-03 | -6.69 | positive regulation of gene expression | biological process | GO:0010628 | 1212 | 10 | 18204 | 49 |
IRF5,BLNK,PLCG2,CSF1R,HIF1A,STAT6,IL6R,DENND1B,CD74,SPI1 |
1.248e-03 | -6.69 | regulation of interleukin-6 production | biological process | GO:0032675 | 175 | 4 | 18204 | 49 |
CD74,IL6R,PTPN6,PLCG2 |
1.252e-03 | -6.68 | angiosarcoma | COSMIC cancer mutations | angiosarcoma | 2192 | 14 | 16828 | 45 |
AKAP13,ELMO1,VAV3,BLNK,DOCK1,GAB1,SBNO2,SKAP1,ARHGAP15,STAT6,TLN1,DOCK2,WDFY4,DOCK10 |
1.252e-03 | -6.68 | soft_tissue-blood_vessel-angiosarcoma | COSMIC cancer mutations | soft_tissue-blood_vessel-angiosarcoma | 2192 | 14 | 16828 | 45 |
GAB1,DOCK1,ARHGAP15,SKAP1,SBNO2,TLN1,STAT6,AKAP13,ELMO1,VAV3,BLNK,DOCK10,DOCK2,WDFY4 |
1.274e-03 | -6.67 | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | biological process | GO:0002460 | 176 | 4 | 18204 | 49 |
PRKCD,STAT6,IL6R,CD74 |
1.274e-03 | -6.67 | blood coagulation | biological process | GO:0007596 | 176 | 4 | 18204 | 49 |
VAV3,PLCG2,TLN1,PTPN6 |
1.276e-03 | -6.66 | positive regulation of kinase activity | biological process | GO:0033674 | 302 | 5 | 18204 | 49 |
CD74,IL6R,PRKCD,PIK3R5,CSF1R |
1.284e-03 | -6.66 | CH_dom | interpro domains | IPR001715 | 81 | 3 | 18521 | 49 |
PARVG,EHBP1L1,VAV3 |
1.310e-03 | -6.64 | Nucleotide-like (purinergic) receptors | REACTOME pathways | R-HSA-418038 | 16 | 2 | 10285 | 35 |
P2RY2,P2RY6 |
1.327e-03 | -6.62 | WAS (WASP actin nucleation promoting factor) | protein interactions | 7454 | 86 | 3 | 19454 | 49 |
FYB1,HCK,RGS14 |
1.329e-03 | -6.62 | coagulation | biological process | GO:0050817 | 178 | 4 | 18204 | 49 |
PTPN6,TLN1,PLCG2,VAV3 |
1.331e-03 | -6.62 | CH_dom_sf | interpro domains | IPR036872 | 82 | 3 | 18521 | 49 |
PARVG,VAV3,EHBP1L1 |
1.356e-03 | -6.60 | positive regulation of epithelial cell migration | biological process | GO:0010634 | 179 | 4 | 18204 | 49 |
HIF1A,PLCG2,DOCK1,GAB1 |
1.363e-03 | -6.60 | blood_vessel | COSMIC cancer mutations | blood_vessel | 2211 | 14 | 16828 | 45 |
AKAP13,ELMO1,VAV3,BLNK,GAB1,DOCK1,ARHGAP15,SKAP1,SBNO2,TLN1,STAT6,DOCK2,WDFY4,DOCK10 |
1.390e-03 | -6.58 | FCGR2B (Fc gamma receptor IIb) | protein interactions | 2213 | 22 | 2 | 19454 | 49 |
PTPN6,GAB1 |
1.394e-03 | -6.58 | GDS_CDC24_CS | interpro domains | IPR001331 | 21 | 2 | 18521 | 49 |
PREX1,VAV3 |
1.398e-03 | -6.57 | T cell activation involved in immune response | biological process | GO:0002286 | 82 | 3 | 18204 | 49 |
IL6R,CD74,STAT6 |
1.412e-03 | -6.56 | lung-carcinoma-non_small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-non_small_cell_carcinoma | 5198 | 24 | 16828 | 45 |
DOCK1,STAT6,TLN1,HCK,SPI1,AKAP13,NEK6,IRF5,HIF1A,VAV3,PRKCD,PLCG2,DOCK10,IL6R,CSF1R,GIT2,WDFY4,ARHGAP33,GAB1,ARHGAP15,RGS14,PTPN6,PREX1,PIK3R5 |
1.412e-03 | -6.56 | non_small_cell_carcinoma | COSMIC cancer mutations | non_small_cell_carcinoma | 5198 | 24 | 16828 | 45 |
PRKCD,PLCG2,DOCK10,IL6R,GIT2,CSF1R,WDFY4,DOCK1,STAT6,TLN1,HCK,AKAP13,SPI1,IRF5,NEK6,HIF1A,VAV3,PTPN6,PREX1,PIK3R5,ARHGAP33,GAB1,ARHGAP15,RGS14 |
1.413e-03 | -6.56 | response to reactive oxygen species | biological process | GO:0000302 | 181 | 4 | 18204 | 49 |
HIF1A,STAT6,PRKCD,APOE |
1.414e-03 | -6.56 | DAP12 interactions | REACTOME pathways | R-HSA-2172127 | 371 | 6 | 10285 | 35 |
VAV3,GAB1,PLCG2,PRKCD,ADCY7,TLN1 |
1.442e-03 | -6.54 | hemostasis | biological process | GO:0007599 | 182 | 4 | 18204 | 49 |
VAV3,PTPN6,TLN1,PLCG2 |
1.443e-03 | -6.54 | prostanoid biosynthetic process | biological process | GO:0046457 | 21 | 2 | 18204 | 49 |
CD74,TBXAS1 |
1.443e-03 | -6.54 | thymic T cell selection | biological process | GO:0045061 | 21 | 2 | 18204 | 49 |
CD74,DOCK2 |
1.443e-03 | -6.54 | positive regulation by host of viral process | biological process | GO:0044794 | 21 | 2 | 18204 | 49 |
APOE,CSF1R |
1.443e-03 | -6.54 | CD4-positive or CD8-positive, alpha-beta T cell lineage commitment | biological process | GO:0043369 | 21 | 2 | 18204 | 49 |
STAT6,IL6R |
1.443e-03 | -6.54 | prostaglandin biosynthetic process | biological process | GO:0001516 | 21 | 2 | 18204 | 49 |
TBXAS1,CD74 |
1.468e-03 | -6.52 | regulation of cellular component organization | biological process | GO:0051128 | 2455 | 15 | 18204 | 49 |
NEK6,PREX1,PRKCD,SKAP1,HIF1A,DOCK2,AKAP13,ARHGAP33,CARMIL3,CSF1R,TBC1D8,HCK,APOE,TLN1,PLCG2 |
1.472e-03 | -6.52 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 39 | 16828 | 45 |
WDFY4,GIT2,CSF1R,RHBDF2,TBC1D8,DOCK10,MYO1F,PLCG2,PRKCD,P2RY6,VAV3,NEK6,IRF5,HIF1A,SPI1,AKAP13,DOCK8,HCK,TLN1,STAT6,EHBP1L1,DOCK1,TBXAS1,ADCY7,DOCK2,PIK3R5,PREX1,PTPN6,CD74,PARVG,BLNK,IPCEF1,GMIP,ELMO1,P2RY2,ARHGAP15,SKAP1,GAB1,ARHGAP33 |
1.487e-03 | -6.51 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 43 | 16828 | 45 |
DOCK1,SBNO2,EHBP1L1,STAT6,TLN1,HCK,DOCK8,SPI1,AKAP13,NEK6,IRF5,HIF1A,VAV3,P2RY6,PRKCD,APOE,PLCG2,DENND1B,DOCK10,MYO1F,IL6R,TBC1D8,RHBDF2,GIT2,CSF1R,WDFY4,ARHGAP33,GAB1,SKAP1,ARHGAP15,P2RY2,ELMO1,GMIP,BLNK,RGS14,CD74,PARVG,PTPN6,PREX1,PIK3R5,DOCK2,ADCY7,TBXAS1 |
1.489e-03 | -6.51 | localization | biological process | GO:0051179 | 4474 | 22 | 18204 | 49 |
RGS14,DOCK2,ARHGAP27,P2RY6,PRKCD,DOCK1,VAV3,PLCG2,GIT2,RHBDF2,APOE,DENND1B,HCK,MYO1F,IPCEF1,SKAP1,CD74,HIF1A,FYB1,ELMO1,ARHGAP33,GSDME |
1.490e-03 | -6.51 | Signaling by PTK6 | REACTOME pathways | R-HSA-8848021 | 67 | 3 | 10285 | 35 |
DOCK1,HIF1A,ELMO1 |
1.498e-03 | -6.50 | regulation of protein modification process | biological process | GO:0031399 | 1242 | 10 | 18204 | 49 |
CSF1R,PRKCD,IL6R,CD74,HIF1A,APOE,PIK3R5,PLCG2,PTPN6,RGS14 |
1.506e-03 | -6.50 | MTOR (mechanistic target of rapamycin kinase) | protein interactions | 2475 | 335 | 5 | 19454 | 49 |
PRKCD,PREX1,P2RY6,CD74,HIF1A |
1.514e-03 | -6.49 | PIK3R3 (phosphoinositide-3-kinase regulatory subunit 3) | protein interactions | 8503 | 197 | 4 | 19454 | 49 |
IL6R,HCK,GAB1,SKAP1 |
1.517e-03 | -6.49 | CBL (Cbl proto-oncogene) | protein interactions | 867 | 499 | 6 | 19454 | 49 |
HCK,FYB1,PTPN6,CSF1R,BLNK,HIF1A |
1.518e-03 | -6.49 | NRAS (NRAS proto-oncogene, GTPase) | protein interactions | 4893 | 683 | 7 | 19454 | 49 |
GAB1,PREX1,FYB1,DOCK8,PRKCD,EHBP1L1,RHBDF2 |
1.531e-03 | -6.48 | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction | biological process | GO:0051897 | 185 | 4 | 18204 | 49 |
PIK3R5,CSF1R,VAV3,PTPN6 |
1.550e-03 | -6.47 | regulation of protein kinase activity | biological process | GO:0045859 | 469 | 6 | 18204 | 49 |
APOE,CSF1R,PIK3R5,PRKCD,RGS14,IL6R |
1.566e-03 | -6.46 | ERBB3 (erb-b2 receptor tyrosine kinase 3) | protein interactions | 2065 | 338 | 5 | 19454 | 49 |
BLNK,PTPN6,HCK,VAV3,PLCG2 |
1.573e-03 | -6.46 | Dbl homology (DH) domain | gene3d domains | 1.20.900.10 | 71 | 3 | 14470 | 47 |
VAV3,PREX1,AKAP13 |
1.573e-03 | -6.45 | T-Cell antigen Receptor (TCR) Signaling Pathway | WikiPathways | WP69 | 91 | 4 | 5310 | 30 |
SKAP1,PRKCD,VAV3,FYB1 |
1.575e-03 | -6.45 | guanyl-nucleotide exchange factor complex | cellular component | GO:0032045 | 23 | 2 | 19108 | 49 |
DOCK1,ELMO1 |
1.584e-03 | -6.45 | positive regulation of cell adhesion mediated by integrin | biological process | GO:0033630 | 22 | 2 | 18204 | 49 |
PTPN6,SKAP1 |
1.586e-03 | -6.45 | phospholipid binding | molecular function | GO:0005543 | 489 | 6 | 18094 | 47 |
GSDME,ARHGAP33,PREX1,TLN1,DENND1B,APOE |
1.595e-03 | -6.44 | establishment of localization | biological process | GO:0051234 | 3887 | 20 | 18204 | 49 |
RHBDF2,GIT2,APOE,PLCG2,ARHGAP33,ELMO1,GSDME,DENND1B,HCK,DOCK2,IPCEF1,ARHGAP27,RGS14,MYO1F,VAV3,PRKCD,P2RY6,DOCK1,CD74,HIF1A |
1.598e-03 | -6.44 | regulation of transferase activity | biological process | GO:0051338 | 645 | 7 | 18204 | 49 |
RGS14,PIK3R5,APOE,PRKCD,CD74,IL6R,CSF1R |
1.644e-03 | -6.41 | Nucleotide GPCRs | WikiPathways | WP80 | 11 | 2 | 5310 | 30 |
P2RY2,P2RY6 |
1.656e-03 | -6.40 | Crebbp (CREB binding protein) | protein interactions | 12914 | 24 | 2 | 19454 | 49 |
HIF1A,SPI1 |
1.663e-03 | -6.40 | Regulation of signaling by CBL | REACTOME pathways | R-HSA-912631 | 18 | 2 | 10285 | 35 |
HCK,BLNK |
1.669e-03 | -6.40 | wound healing | biological process | GO:0042060 | 321 | 5 | 18204 | 49 |
VAV3,HIF1A,PTPN6,TLN1,PLCG2 |
1.707e-03 | -6.37 | regulation of defense response | biological process | GO:0031347 | 843 | 8 | 18204 | 49 |
PTPN6,PLCG2,RHBDF2,APOE,SBNO2,PRKCD,SPI1,HCK |
1.758e-03 | -6.34 | cell development | biological process | GO:0048468 | 2236 | 14 | 18204 | 49 |
PTPN6,BLNK,DOCK10,DOCK2,CD74,IL6R,HIF1A,SPI1,PREX1,PLCG2,APOE,STAT6,SBNO2,CSF1R |
1.769e-03 | -6.34 | positive regulation of lipid biosynthetic process | biological process | GO:0046889 | 89 | 3 | 18204 | 49 |
CD74,PRKCD,APOE |
1.769e-03 | -6.34 | regulation of leukocyte apoptotic process | biological process | GO:2000106 | 89 | 3 | 18204 | 49 |
CD74,HIF1A,DOCK8 |
1.810e-03 | -6.31 | phosphoprotein binding | molecular function | GO:0051219 | 93 | 3 | 18094 | 47 |
PLCG2,PTPN6,HCK |
1.820e-03 | -6.31 | acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | acute_myeloid_leukaemia_therapy_related | 1523 | 11 | 16828 | 45 |
ARHGAP15,SKAP1,DOCK1,DOCK10,PREX1,IPCEF1,ELMO1,AKAP13,DOCK2,WDFY4,VAV3 |
1.820e-03 | -6.31 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | 1523 | 11 | 16828 | 45 |
DOCK1,ARHGAP15,SKAP1,VAV3,AKAP13,IPCEF1,ELMO1,DOCK10,PREX1,WDFY4,DOCK2 |
1.849e-03 | -6.29 | Factors involved in megakaryocyte development and platelet production | REACTOME pathways | R-HSA-983231 | 156 | 4 | 10285 | 35 |
DOCK8,DOCK2,DOCK1,DOCK10 |
1.875e-03 | -6.28 | human chr7p14.2-p14.1 | chromosome location | human chr7p14.2-p14.1 | 1 | 1 | 26134 | 49 |
ELMO1 |
1.875e-03 | -6.28 | human chr2q22.2-q22.3 | chromosome location | human chr2q22.2-q22.3 | 1 | 1 | 26134 | 49 |
ARHGAP15 |
1.886e-03 | -6.27 | negative regulation of T cell apoptotic process | biological process | GO:0070233 | 24 | 2 | 18204 | 49 |
HIF1A,DOCK8 |
1.886e-03 | -6.27 | positive regulation of macrophage cytokine production | biological process | GO:0060907 | 24 | 2 | 18204 | 49 |
PLCG2,CD74 |
1.916e-03 | -6.26 | Osteoclast differentiation | KEGG pathways | ko04380 | 129 | 4 | 7161 | 30 |
CSF1R,PLCG2,BLNK,SPI1 |
1.916e-03 | -6.26 | Osteoclast differentiation | KEGG pathways | hsa04380 | 129 | 4 | 7161 | 30 |
SPI1,BLNK,CSF1R,PLCG2 |
1.931e-03 | -6.25 | PTK2B (protein tyrosine kinase 2 beta) | protein interactions | 2185 | 98 | 3 | 19454 | 49 |
PRKCD,TLN1,PTPN6 |
1.941e-03 | -6.24 | ARM-type_fold | interpro domains | IPR016024 | 338 | 5 | 18521 | 49 |
ELMO1,WDFY4,DOCK1,DOCK8,DOCK2 |
1.945e-03 | -6.24 | positive regulation of leukocyte chemotaxis | biological process | GO:0002690 | 92 | 3 | 18204 | 49 |
CSF1R,IL6R,CD74 |
1.950e-03 | -6.24 | mouth | COSMIC cancer mutations | mouth | 9004 | 34 | 16828 | 45 |
DOCK2,ADCY7,TBXAS1,PARVG,CD74,PTPN6,PREX1,ELMO1,GMIP,RGS14,ARHGAP33,GAB1,P2RY2,TBC1D8,RHBDF2,GIT2,CSF1R,WDFY4,PRKCD,APOE,PLCG2,DENND1B,MYO1F,DOCK10,AKAP13,IRF5,NEK6,VAV3,DOCK1,SBNO2,EHBP1L1,TLN1,HCK,DOCK8 |
1.999e-03 | -6.22 | positive regulation of ERK1 and ERK2 cascade | biological process | GO:0070374 | 199 | 4 | 18204 | 49 |
CD74,P2RY6,CSF1R,APOE |
2.031e-03 | -6.20 | DH_2 | prosite domains | PS50010 | 70 | 3 | 12186 | 44 |
VAV3,PREX1,AKAP13 |
2.045e-03 | -6.19 | actin cytoskeleton | cellular component | GO:0015629 | 520 | 6 | 19108 | 49 |
PARVG,HCK,MYO1F,FYB1,AKAP13,ARHGAP33 |
2.047e-03 | -6.19 | Fc-epsilon receptor signaling pathway | biological process | GO:0038095 | 25 | 2 | 18204 | 49 |
PLCG2,VAV3 |
2.066e-03 | -6.18 | kidney-carcinoma-papillary_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-papillary_renal_cell_carcinoma | 6364 | 27 | 16828 | 45 |
P2RY2,ARHGAP33,SKAP1,ARHGAP15,RGS14,ELMO1,IPCEF1,PREX1,PARVG,DOCK2,ADCY7,STAT6,TLN1,HCK,DOCK8,DOCK1,IRF5,NEK6,AKAP13,DOCK10,MYO1F,P2RY6,PRKCD,PLCG2,CSF1R,WDFY4,TBC1D8 |
2.066e-03 | -6.18 | papillary_renal_cell_carcinoma | COSMIC cancer mutations | papillary_renal_cell_carcinoma | 6364 | 27 | 16828 | 45 |
DOCK8,TLN1,HCK,STAT6,DOCK1,NEK6,IRF5,AKAP13,DOCK10,MYO1F,PLCG2,PRKCD,P2RY6,WDFY4,CSF1R,TBC1D8,P2RY2,ARHGAP15,SKAP1,ARHGAP33,RGS14,IPCEF1,ELMO1,PREX1,PARVG,ADCY7,DOCK2 |
2.069e-03 | -6.18 | negative regulation of protein serine/threonine kinase activity | biological process | GO:0071901 | 94 | 3 | 18204 | 49 |
RGS14,PRKCD,APOE |
2.095e-03 | -6.17 | OLIG1 (oligodendrocyte transcription factor 1) | protein interactions | 116448 | 27 | 2 | 19454 | 49 |
HCK,PTPN6 |
2.095e-03 | -6.17 | CD72 (CD72 molecule) | protein interactions | 971 | 27 | 2 | 19454 | 49 |
BLNK,PTPN6 |
2.137e-03 | -6.15 | Calponin-like domain | gene3d domains | 1.10.418.10 | 79 | 3 | 14470 | 47 |
VAV3,PARVG,EHBP1L1 |
2.141e-03 | -6.15 | regulation of cell-cell adhesion | biological process | GO:0022407 | 500 | 6 | 18204 | 49 |
CD74,PRKCD,SKAP1,SPI1,PTPN6,DOCK8 |
2.141e-03 | -6.15 | Cell death signalling via NRAGE, NRIF and NADE | REACTOME pathways | R-HSA-204998 | 76 | 3 | 10285 | 35 |
VAV3,AKAP13,PREX1 |
2.149e-03 | -6.14 | negative regulation of cell-cell adhesion | biological process | GO:0022408 | 203 | 4 | 18204 | 49 |
SPI1,PTPN6,PRKCD,CD74 |
2.164e-03 | -6.14 | GRAP2 (GRB2 related adaptor protein 2) | protein interactions | 9402 | 102 | 3 | 19454 | 49 |
BLNK,CSF1R,GAB1 |
2.164e-03 | -6.14 | DOCK5 (dedicator of cytokinesis 5) | protein interactions | 80005 | 102 | 3 | 19454 | 49 |
ELMO1,DOCK1,GIT2 |
2.197e-03 | -6.12 | negative regulation of response to wounding | biological process | GO:1903035 | 96 | 3 | 18204 | 49 |
PTPN6,PRKCD,APOE |
2.197e-03 | -6.12 | immunoglobulin mediated immune response | biological process | GO:0016064 | 96 | 3 | 18204 | 49 |
CD74,STAT6,PRKCD |
2.203e-03 | -6.12 | programmed cell death | biological process | GO:0012501 | 1087 | 9 | 18204 | 49 |
PLCG2,HIF1A,IL6R,SPI1,DOCK1,PRKCD,GSDME,ELMO1,NEK6 |
2.250e-03 | -6.10 | regulation of lymphocyte activation | biological process | GO:0051249 | 505 | 6 | 18204 | 49 |
CD74,STAT6,SPI1,PTPN6,DOCK8,VAV3 |
2.259e-03 | -6.09 | cell death | biological process | GO:0008219 | 1091 | 9 | 18204 | 49 |
GSDME,NEK6,ELMO1,IL6R,HIF1A,PRKCD,DOCK1,SPI1,PLCG2 |
2.291e-03 | -6.08 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 36 | 16828 | 45 |
P2RY2,ARHGAP15,SKAP1,GAB1,ARHGAP33,RGS14,ELMO1,PIK3R5,PREX1,PTPN6,PARVG,ADCY7,DOCK2,DOCK8,TLN1,HCK,STAT6,DOCK1,VAV3,HIF1A,IRF5,NEK6,SPI1,AKAP13,IL6R,MYO1F,DOCK10,DENND1B,PLCG2,PRKCD,P2RY6,WDFY4,CSF1R,GIT2,RHBDF2,TBC1D8 |
2.297e-03 | -6.08 | CH | smart domains | SM00033 | 66 | 3 | 9717 | 39 |
EHBP1L1,VAV3,PARVG |
2.300e-03 | -6.07 | regulation of cell population proliferation | biological process | GO:0042127 | 1790 | 12 | 18204 | 49 |
CSF1R,GSDME,TBC1D8,HCK,STAT6,APOE,VAV3,P2RY6,HIF1A,IL6R,CD74,PTPN6 |
2.319e-03 | -6.07 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 36 | 16828 | 45 |
PIK3R5,PREX1,PTPN6,PARVG,ADCY7,DOCK2,P2RY2,ARHGAP15,SKAP1,GAB1,ARHGAP33,RGS14,ELMO1,IL6R,DOCK10,MYO1F,DENND1B,PLCG2,PRKCD,P2RY6,WDFY4,GIT2,CSF1R,RHBDF2,TBC1D8,DOCK8,HCK,TLN1,STAT6,DOCK1,VAV3,IRF5,HIF1A,NEK6,AKAP13,SPI1 |
2.387e-03 | -6.04 | cytokine production | biological process | GO:0001816 | 27 | 2 | 18204 | 49 |
HIF1A,IL6R |
2.387e-03 | -6.04 | mature B cell differentiation involved in immune response | biological process | GO:0002313 | 27 | 2 | 18204 | 49 |
DOCK10,PLCG2 |
2.387e-03 | -6.04 | T cell lineage commitment | biological process | GO:0002360 | 27 | 2 | 18204 | 49 |
STAT6,IL6R |
2.416e-03 | -6.03 | CNTF (ciliary neurotrophic factor) | protein interactions | 1270 | 29 | 2 | 19454 | 49 |
APOE,IL6R |
2.435e-03 | -6.02 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 27 | 16828 | 45 |
TLN1,HCK,DOCK8,SBNO2,NEK6,IRF5,AKAP13,DOCK10,MYO1F,PLCG2,APOE,PRKCD,GIT2,WDFY4,RHBDF2,TBC1D8,P2RY2,ARHGAP33,RGS14,GMIP,ELMO1,PREX1,PTPN6,CD74,TBXAS1,ADCY7,DOCK2 |
2.447e-03 | -6.01 | EGF receptor (ErbB1) signaling pathway | Pathway Interaction DB | erbb1_receptor_proximal_pathway | 25 | 3 | 2226 | 25 |
PTPN6,GAB1,TLN1 |
2.456e-03 | -6.01 | JPH1 (junctophilin 1) | protein interactions | 56704 | 225 | 4 | 19454 | 49 |
RHBDF2,SKAP1,CSF1R,TBC1D8 |
2.467e-03 | -6.00 | positive regulation of interleukin-6 production | biological process | GO:0032755 | 100 | 3 | 18204 | 49 |
PLCG2,IL6R,CD74 |
2.479e-03 | -6.00 | positive regulation of phosphorus metabolic process | biological process | GO:0010562 | 697 | 7 | 18204 | 49 |
CSF1R,CD74,IL6R,PRKCD,P2RY6,PIK3R5,PLCG2 |
2.479e-03 | -6.00 | positive regulation of phosphate metabolic process | biological process | GO:0045937 | 697 | 7 | 18204 | 49 |
CSF1R,PRKCD,P2RY6,CD74,IL6R,PIK3R5,PLCG2 |
2.483e-03 | -6.00 | Integrin-mediated Cell Adhesion | WikiPathways | WP185 | 103 | 4 | 5310 | 30 |
TLN1,VAV3,GIT2,DOCK1 |
2.494e-03 | -5.99 | regulation of cellular component size | biological process | GO:0032535 | 352 | 5 | 18204 | 49 |
PREX1,VAV3,APOE,PRKCD,HCK |
2.495e-03 | -5.99 | PIK3R2 (phosphoinositide-3-kinase regulatory subunit 2) | protein interactions | 5296 | 226 | 4 | 19454 | 49 |
HCK,GAB1,CSF1R,SKAP1 |
2.502e-03 | -5.99 | RhoGEF | smart domains | SM00325 | 68 | 3 | 9717 | 39 |
AKAP13,VAV3,PREX1 |
2.519e-03 | -5.98 | Prkch (protein kinase C, eta) | protein interactions | 81749 | 1 | 1 | 19454 | 49 |
AKAP13 |
2.519e-03 | -5.98 | Bmal1 (basic helix-loop-helix ARNT like 1) | protein interactions | 11865 | 1 | 1 | 19454 | 49 |
HIF1A |
2.519e-03 | -5.98 | NTA1 (amidase) | protein interactions | 853525 | 1 | 1 | 19454 | 49 |
DOCK8 |
2.519e-03 | -5.98 | EUC1 (Euc1p) | protein interactions | 855138 | 1 | 1 | 19454 | 49 |
DOCK8 |
2.538e-03 | -5.98 | B cell mediated immunity | biological process | GO:0019724 | 101 | 3 | 18204 | 49 |
CD74,STAT6,PRKCD |
2.562e-03 | -5.97 | DH_1 | prosite domains | PS00741 | 21 | 2 | 12186 | 44 |
PREX1,VAV3 |
2.564e-03 | -5.97 | NOS2-CD74 complex | cellular component | GO:0035693 | 1 | 1 | 19108 | 49 |
CD74 |
2.566e-03 | -5.97 | purinergic nucleotide receptor signaling pathway | biological process | GO:0035590 | 28 | 2 | 18204 | 49 |
P2RY2,P2RY6 |
2.584e-03 | -5.96 | PECAM1 (platelet and endothelial cell adhesion molecule 1) | protein interactions | 5175 | 30 | 2 | 19454 | 49 |
PTPN6,HCK |
2.584e-03 | -5.96 | CSF3R (colony stimulating factor 3 receptor) | protein interactions | 1441 | 30 | 2 | 19454 | 49 |
PRKCD,HCK |
2.598e-03 | -5.95 | MHC class II protein binding, via antigen binding groove | molecular function | GO:0042658 | 1 | 1 | 18094 | 47 |
CD74 |
2.598e-03 | -5.95 | metal chelating activity | molecular function | GO:0046911 | 1 | 1 | 18094 | 47 |
APOE |
2.598e-03 | -5.95 | ciliary neurotrophic factor binding | molecular function | GO:0070119 | 1 | 1 | 18094 | 47 |
IL6R |
2.601e-03 | -5.95 | negative regulation of cell activation | biological process | GO:0050866 | 214 | 4 | 18204 | 49 |
APOE,PRKCD,PTPN6,CD74 |
2.610e-03 | -5.95 | regulation of phagocytosis | biological process | GO:0050764 | 102 | 3 | 18204 | 49 |
HCK,PLCG2,DOCK2 |
2.629e-03 | -5.94 | regulation of cytoskeleton organization | biological process | GO:0051493 | 521 | 6 | 18204 | 49 |
PREX1,CARMIL3,CSF1R,PRKCD,AKAP13,HCK |
2.635e-03 | -5.94 | P2YPURNOCPTR | prints domains | PR01157 | 24 | 2 | 5227 | 17 |
P2RY2,P2RY6 |
2.637e-03 | -5.94 | CREBBP (CREB binding protein) | protein interactions | 1387 | 557 | 6 | 19454 | 49 |
SPI1,PRKCD,STAT6,HIF1A,IRF5,HCK |
2.646e-03 | -5.93 | RGS14_RGS | interpro domains | IPR037881 | 1 | 1 | 18521 | 49 |
RGS14 |
2.646e-03 | -5.93 | SKAP1_SH3 | interpro domains | IPR035765 | 1 | 1 | 18521 | 49 |
SKAP1 |
2.646e-03 | -5.93 | HIF-1_alpha | interpro domains | IPR001321 | 1 | 1 | 18521 | 49 |
HIF1A |
2.646e-03 | -5.93 | MHC_II-assoc_invar_chain | interpro domains | IPR022339 | 1 | 1 | 18521 | 49 |
CD74 |
2.646e-03 | -5.93 | HCK_SH2 | interpro domains | IPR035851 | 1 | 1 | 18521 | 49 |
HCK |
2.646e-03 | -5.93 | RBD2_RGS14 | interpro domains | IPR046993 | 1 | 1 | 18521 | 49 |
RGS14 |
2.646e-03 | -5.93 | VAV3_SH3_2 | interpro domains | IPR035734 | 1 | 1 | 18521 | 49 |
VAV3 |
2.646e-03 | -5.93 | nPKC_delta | interpro domains | IPR034667 | 1 | 1 | 18521 | 49 |
PRKCD |
2.646e-03 | -5.93 | DOCK1_C2 | interpro domains | IPR047026 | 1 | 1 | 18521 | 49 |
DOCK1 |
2.646e-03 | -5.93 | VAV3_SH3_1 | interpro domains | IPR047015 | 1 | 1 | 18521 | 49 |
VAV3 |
2.646e-03 | -5.93 | STAT6_C | interpro domains | IPR028187 | 1 | 1 | 18521 | 49 |
STAT6 |
2.646e-03 | -5.93 | PLCgamma2_SH3 | interpro domains | IPR035723 | 1 | 1 | 18521 | 49 |
PLCG2 |
2.646e-03 | -5.93 | CSF-1_receptor | interpro domains | IPR030658 | 1 | 1 | 18521 | 49 |
CSF1R |
2.646e-03 | -5.93 | MHCII_invariant_trimer_sf | interpro domains | IPR036613 | 1 | 1 | 18521 | 49 |
CD74 |
2.646e-03 | -5.93 | P2Y6_rcpt | interpro domains | IPR001973 | 1 | 1 | 18521 | 49 |
P2RY6 |
2.646e-03 | -5.93 | PKC_delta | interpro domains | IPR027436 | 1 | 1 | 18521 | 49 |
PRKCD |
2.646e-03 | -5.93 | DHR2_DOCK2 | interpro domains | IPR026799 | 1 | 1 | 18521 | 49 |
DOCK2 |
2.646e-03 | -5.93 | FYB_hSH3 | interpro domains | IPR035540 | 1 | 1 | 18521 | 49 |
FYB1 |
2.646e-03 | -5.93 | MHC_II-assoc_invariant_trimer | interpro domains | IPR011988 | 1 | 1 | 18521 | 49 |
CD74 |
2.646e-03 | -5.93 | TBC1D8_PH-GRAM1 | interpro domains | IPR036009 | 1 | 1 | 18521 | 49 |
TBC1D8 |
2.646e-03 | -5.93 | VAV3_SH2 | interpro domains | IPR035881 | 1 | 1 | 18521 | 49 |
VAV3 |
2.646e-03 | -5.93 | RBD1_RGS14 | interpro domains | IPR046992 | 1 | 1 | 18521 | 49 |
RGS14 |
2.646e-03 | -5.93 | P2Y2_rcpt | interpro domains | IPR000356 | 1 | 1 | 18521 | 49 |
P2RY2 |
2.646e-03 | -5.93 | CD74_antigen | interpro domains | IPR043530 | 1 | 1 | 18521 | 49 |
CD74 |
2.646e-03 | -5.93 | TBC1D8_PH-GRAM2 | interpro domains | IPR036016 | 1 | 1 | 18521 | 49 |
TBC1D8 |
2.646e-03 | -5.93 | STAT6_SH2 | interpro domains | IPR035857 | 1 | 1 | 18521 | 49 |
STAT6 |
2.646e-03 | -5.93 | MHC_II-assoc_invar/CLIP_MHC-bd | interpro domains | IPR015386 | 1 | 1 | 18521 | 49 |
CD74 |
2.682e-03 | -5.92 | Signaling events mediated by focal adhesion kinase | Pathway Interaction DB | fak_pathway | 54 | 4 | 2226 | 25 |
DOCK1,TLN1,ELMO1,GIT2 |
2.682e-03 | -5.92 | PDGFR-beta signaling pathway | Pathway Interaction DB | pdgfrbpathway | 54 | 4 | 2226 | 25 |
HIF1A,GAB1,HCK,PRKCD |
2.692e-03 | -5.92 | cellular response to pyrimidine ribonucleotide | biological process | GO:1905835 | 1 | 1 | 18204 | 49 |
P2RY6 |
2.692e-03 | -5.92 | intermediate-density lipoprotein particle clearance | biological process | GO:0071831 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | regulation of cellular response to very-low-density lipoprotein particle stimulus | biological process | GO:1905890 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | positive regulation of glucosylceramide catabolic process | biological process | GO:2000753 | 1 | 1 | 18204 | 49 |
PRKCD |
2.692e-03 | -5.92 | memory T cell proliferation | biological process | GO:0061485 | 1 | 1 | 18204 | 49 |
DOCK8 |
2.692e-03 | -5.92 | response to pyrimidine ribonucleotide | biological process | GO:1905834 | 1 | 1 | 18204 | 49 |
P2RY6 |
2.692e-03 | -5.92 | regulation of heparan sulfate proteoglycan binding | biological process | GO:1905858 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | zygote asymmetric cell division | biological process | GO:0010070 | 1 | 1 | 18204 | 49 |
RGS14 |
2.692e-03 | -5.92 | positive regulation of phospholipid scramblase activity | biological process | GO:1900163 | 1 | 1 | 18204 | 49 |
PRKCD |
2.692e-03 | -5.92 | regulation of lipid transport across blood-brain barrier | biological process | GO:1903000 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | positive regulation of heparan sulfate proteoglycan binding | biological process | GO:1905860 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | regulation of phospholipid scramblase activity | biological process | GO:1900161 | 1 | 1 | 18204 | 49 |
PRKCD |
2.692e-03 | -5.92 | regulation of transport across blood-brain barrier | biological process | GO:0150200 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | macrophage migration inhibitory factor signaling pathway | biological process | GO:0035691 | 1 | 1 | 18204 | 49 |
CD74 |
2.692e-03 | -5.92 | positive regulation of lipid transport across blood-brain barrier | biological process | GO:1903002 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | positive regulation of transport across blood-brain barrier | biological process | GO:0150201 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | cellular response to interleukin-11 | biological process | GO:0071348 | 1 | 1 | 18204 | 49 |
SBNO2 |
2.751e-03 | -5.90 | myoblast fusion | biological process | GO:0007520 | 29 | 2 | 18204 | 49 |
DOCK2,DOCK1 |
2.754e-03 | -5.89 | MHCassoc_trimer | pfam domains | PF08831 | 1 | 1 | 17795 | 49 |
CD74 |
2.754e-03 | -5.89 | STAT6_C | pfam domains | PF14596 | 1 | 1 | 17795 | 49 |
STAT6 |
2.754e-03 | -5.89 | MHC2-interact | pfam domains | PF09307 | 1 | 1 | 17795 | 49 |
CD74 |
2.758e-03 | -5.89 | CSF2RB (colony stimulating factor 2 receptor subunit beta) | protein interactions | 1439 | 31 | 2 | 19454 | 49 |
PTPN6,HCK |
2.829e-03 | -5.87 | JAK1 (Janus kinase 1) | protein interactions | 3716 | 234 | 4 | 19454 | 49 |
PLCG2,STAT6,GAB1,PTPN6 |
2.836e-03 | -5.87 | negative regulation of immune system process | biological process | GO:0002683 | 529 | 6 | 18204 | 49 |
CD74,STAT6,HCK,SPI1,PTPN6,RHBDF2 |
2.848e-03 | -5.86 | adaptive immune response | biological process | GO:0002250 | 363 | 5 | 18204 | 49 |
SKAP1,PRKCD,STAT6,IL6R,CD74 |
2.921e-03 | -5.84 | regulation of cell-substrate adhesion | biological process | GO:0010810 | 221 | 4 | 18204 | 49 |
PREX1,SKAP1,DOCK1,TLN1 |
2.921e-03 | -5.84 | leukocyte mediated immunity | biological process | GO:0002443 | 221 | 4 | 18204 | 49 |
PTPN6,PRKCD,STAT6,CD74 |
2.935e-03 | -5.83 | Phospholipase D signaling pathway | KEGG pathways | ko04072 | 145 | 4 | 7161 | 30 |
PIK3R5,PLCG2,GAB1,ADCY7 |
2.935e-03 | -5.83 | Phospholipase D signaling pathway | KEGG pathways | hsa04072 | 145 | 4 | 7161 | 30 |
GAB1,ADCY7,PIK3R5,PLCG2 |
2.937e-03 | -5.83 | CC2D1B (coiled-coil and C2 domain containing 1B) | protein interactions | 200014 | 32 | 2 | 19454 | 49 |
SKAP1,TLN1 |
2.937e-03 | -5.83 | AAMDC (adipogenesis associated Mth938 domain containing) | protein interactions | 28971 | 32 | 2 | 19454 | 49 |
VAV3,GMIP |
2.971e-03 | -5.82 | regulation of response to biotic stimulus | biological process | GO:0002831 | 534 | 6 | 18204 | 49 |
GSDME,APOE,HCK,PTPN6,PLCG2,SPI1 |
3.080e-03 | -5.78 | CH | prosite domains | PS50021 | 81 | 3 | 12186 | 44 |
PARVG,VAV3,EHBP1L1 |
3.112e-03 | -5.77 | Protein_kinase_ATP_BS | interpro domains | IPR017441 | 377 | 5 | 18521 | 49 |
NRK,CSF1R,HCK,NEK6,PRKCD |
3.113e-03 | -5.77 | cell population proliferation | biological process | GO:0008283 | 726 | 7 | 18204 | 49 |
CSF1R,STAT6,HIF1A,PRKCD,DOCK8,DOCK2,PTPN6 |
3.122e-03 | -5.77 | ELMO3 (engulfment and cell motility 3) | protein interactions | 79767 | 33 | 2 | 19454 | 49 |
DOCK1,ELMO1 |
3.140e-03 | -5.76 | neutrophil activation | biological process | GO:0042119 | 31 | 2 | 18204 | 49 |
PREX1,PRKCD |
3.140e-03 | -5.76 | B cell homeostasis | biological process | GO:0001782 | 31 | 2 | 18204 | 49 |
DOCK10,HIF1A |
3.186e-03 | -5.75 | positive regulation of cellular biosynthetic process | biological process | GO:0031328 | 2652 | 15 | 18204 | 49 |
PLCG2,IRF5,APOE,SBNO2,STAT6,DENND1B,CSF1R,BLNK,SPI1,SKAP1,PRKCD,P2RY6,HIF1A,CD74,IL6R |
3.212e-03 | -5.74 | cell junction | cellular component | GO:0030054 | 2224 | 13 | 19108 | 49 |
SKAP1,APOE,FYB1,GIT2,RGS14,DOCK10,PRKCD,PARVG,HCK,GAB1,TLN1,PTPN6,ARHGAP33 |
3.217e-03 | -5.74 | KRTAP10-8 (keratin associated protein 10-8) | protein interactions | 386681 | 399 | 5 | 19454 | 49 |
HCK,DOCK2,ARHGAP33,NEK6,P2RY6 |
3.228e-03 | -5.74 | transcription coregulator binding | molecular function | GO:0001221 | 114 | 3 | 18094 | 47 |
STAT6,NEK6,HIF1A |
3.248e-03 | -5.73 | MHC class II-associated invariant chain, trimerisation domain | gene3d domains | 1.10.870.10 | 1 | 1 | 14470 | 47 |
CD74 |
3.251e-03 | -5.73 | G alpha (12/13) signalling events | REACTOME pathways | R-HSA-416482 | 88 | 3 | 10285 | 35 |
VAV3,PREX1,AKAP13 |
3.252e-03 | -5.73 | CD74ANTIGEN | prints domains | PR01990 | 1 | 1 | 5227 | 17 |
CD74 |
3.252e-03 | -5.73 | P2Y2PRNOCPTR | prints domains | PR00594 | 1 | 1 | 5227 | 17 |
P2RY2 |
3.252e-03 | -5.73 | HYPOXIAIF1A | prints domains | PR01080 | 1 | 1 | 5227 | 17 |
HIF1A |
3.252e-03 | -5.73 | P2Y6PRNOCPTR | prints domains | PR01068 | 1 | 1 | 5227 | 17 |
P2RY6 |
3.312e-03 | -5.71 | ITGB7 (integrin subunit beta 7) | protein interactions | 3695 | 34 | 2 | 19454 | 49 |
PRKCD,TLN1 |
3.344e-03 | -5.70 | lipopolysaccharide-mediated signaling pathway | biological process | GO:0031663 | 32 | 2 | 18204 | 49 |
PLCG2,HCK |
3.345e-03 | -5.70 | actin cytoskeleton organization | biological process | GO:0030036 | 547 | 6 | 18204 | 49 |
PREX1,ELMO1,DOCK2,TLN1,MYO1F,PARVG |
3.406e-03 | -5.68 | localization within membrane | biological process | GO:0051668 | 549 | 6 | 18204 | 49 |
DENND1B,SKAP1,FYB1,APOE,RHBDF2,DOCK2 |
3.421e-03 | -5.68 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 9 | 16828 | 45 |
HCK,PRKCD,ARHGAP15,GAB1,BLNK,NEK6,CSF1R,DOCK2,SPI1 |
3.421e-03 | -5.68 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 9 | 16828 | 45 |
DOCK2,SPI1,NEK6,CSF1R,BLNK,GAB1,PRKCD,ARHGAP15,HCK |
3.423e-03 | -5.68 | regulation of leukocyte migration | biological process | GO:0002685 | 231 | 4 | 18204 | 49 |
IL6R,CD74,DOCK8,CSF1R |
3.474e-03 | -5.66 | Role of phospholipids in phagocytosis | REACTOME pathways | R-HSA-2029485 | 26 | 2 | 10285 | 35 |
PRKCD,PLCG2 |
3.484e-03 | -5.66 | SYK (spleen associated tyrosine kinase) | protein interactions | 6850 | 248 | 4 | 19454 | 49 |
PLCG2,GAB1,PTPN6,BLNK |
3.484e-03 | -5.66 | MET (MET proto-oncogene, receptor tyrosine kinase) | protein interactions | 4233 | 248 | 4 | 19454 | 49 |
GAB1,HCK,PLCG2,VAV3 |
3.507e-03 | -5.65 | Mbp (myelin basic protein) | protein interactions | 17196 | 35 | 2 | 19454 | 49 |
FYB1,HCK |
3.553e-03 | -5.64 | negative regulation of inflammatory response to antigenic stimulus | biological process | GO:0002862 | 33 | 2 | 18204 | 49 |
HCK,RHBDF2 |
3.553e-03 | -5.64 | mature B cell differentiation | biological process | GO:0002335 | 33 | 2 | 18204 | 49 |
PLCG2,DOCK10 |
3.649e-03 | -5.61 | upper_aerodigestive_tract-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-head_neck-carcinoma-squamous_cell_carcinoma | 9263 | 34 | 16828 | 45 |
PREX1,PIK3R5,PARVG,PTPN6,DOCK2,ADCY7,ARHGAP33,GAB1,SKAP1,ARHGAP15,BLNK,RGS14,MYO1F,DOCK10,IL6R,PRKCD,PLCG2,APOE,CSF1R,GIT2,WDFY4,STAT6,TLN1,HCK,DOCK8,DOCK1,SBNO2,EHBP1L1,HIF1A,IRF5,NEK6,VAV3,AKAP13,SPI1 |
3.721e-03 | -5.59 | inflammatory response | biological process | GO:0006954 | 559 | 6 | 18204 | 49 |
IRF5,BLNK,CSF1R,HIF1A,HCK,IL6R |
3.742e-03 | -5.59 | nef (Nef) | protein interactions | 156110 | 802 | 7 | 19454 | 49 |
ELMO1,CD74,PRKCD,ADCY7,CSF1R,DOCK2,HCK |
3.744e-03 | -5.59 | PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | REACTOME pathways | R-HSA-8849471 | 27 | 2 | 10285 | 35 |
ELMO1,DOCK1 |
3.756e-03 | -5.58 | positive regulation of biosynthetic process | biological process | GO:0009891 | 2697 | 15 | 18204 | 49 |
P2RY6,PRKCD,SKAP1,SPI1,IL6R,CD74,HIF1A,BLNK,CSF1R,SBNO2,DENND1B,STAT6,IRF5,APOE,PLCG2 |
3.769e-03 | -5.58 | regulation of B cell differentiation | biological process | GO:0045577 | 34 | 2 | 18204 | 49 |
PTPN6,SPI1 |
3.783e-03 | -5.58 | G protein-coupled receptor signaling pathway | biological process | GO:0007186 | 1178 | 9 | 18204 | 49 |
PREX1,P2RY2,P2RY6,PIK3R5,APOE,ADCY7,RGS14,PTPN6,AKAP13 |
3.796e-03 | -5.57 | Bacterial invasion of epithelial cells | KEGG pathways | ko05100 | 76 | 3 | 7161 | 30 |
GAB1,ELMO1,DOCK1 |
3.796e-03 | -5.57 | Bacterial invasion of epithelial cells | KEGG pathways | hsa05100 | 76 | 3 | 7161 | 30 |
ELMO1,DOCK1,GAB1 |
3.858e-03 | -5.56 | receptor complex | cellular component | GO:0043235 | 409 | 5 | 19108 | 49 |
IL6R,CD74,CSF1R,SKAP1,PTPN6 |
3.887e-03 | -5.55 | positive regulation of response to external stimulus | biological process | GO:0032103 | 564 | 6 | 18204 | 49 |
PLCG2,CSF1R,SPI1,HCK,IL6R,CD74 |
3.913e-03 | -5.54 | CARD11 (caspase recruitment domain family member 11) | protein interactions | 84433 | 37 | 2 | 19454 | 49 |
FYB1,PRKCD |
3.916e-03 | -5.54 | Interferon gamma signaling | REACTOME pathways | R-HSA-877300 | 94 | 3 | 10285 | 35 |
PRKCD,IRF5,PTPN6 |
3.933e-03 | -5.54 | UQCRH (ubiquinol-cytochrome c reductase hinge protein) | protein interactions | 7388 | 126 | 3 | 19454 | 49 |
GSDME,P2RY6,APOE |
3.933e-03 | -5.54 | haematopoietic_and_lymphoid_tissue-skin-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-skin-lymphoid_neoplasm-follicular_lymphoma | 35 | 2 | 16828 | 45 |
RHBDF2,STAT6 |
3.990e-03 | -5.52 | granulocyte activation | biological process | GO:0036230 | 35 | 2 | 18204 | 49 |
PREX1,PRKCD |
3.990e-03 | -5.52 | positive regulation of myeloid leukocyte cytokine production involved in immune response | biological process | GO:0061081 | 35 | 2 | 18204 | 49 |
CD74,PLCG2 |
4.023e-03 | -5.52 | CaM pathway | REACTOME pathways | R-HSA-111997 | 28 | 2 | 10285 | 35 |
PRKCD,ADCY7 |
4.023e-03 | -5.52 | Calmodulin induced events | REACTOME pathways | R-HSA-111933 | 28 | 2 | 10285 | 35 |
ADCY7,PRKCD |
4.036e-03 | -5.51 | membrane organization | biological process | GO:0061024 | 761 | 7 | 18204 | 49 |
DOCK2,APOE,VAV3,ELMO1,NEK6,PRKCD,DOCK1 |
4.111e-03 | -5.49 | GAB2 (GRB2 associated binding protein 2) | protein interactions | 9846 | 128 | 3 | 19454 | 49 |
PLCG2,PTPN6,GAB1 |
4.123e-03 | -5.49 | STK33 (serine/threonine kinase 33) | protein interactions | 65975 | 38 | 2 | 19454 | 49 |
HCK,TLN1 |
4.127e-03 | -5.49 | pleura | COSMIC cancer mutations | pleura | 4914 | 22 | 16828 | 45 |
ARHGAP15,GAB1,ARHGAP33,RGS14,PTPN6,PIK3R5,PREX1,DOCK1,TLN1,HCK,STAT6,AKAP13,SPI1,VAV3,HIF1A,NEK6,IRF5,PLCG2,PRKCD,IL6R,CSF1R,GIT2 |
4.137e-03 | -5.49 | oesophagus-carcinoma | COSMIC cancer mutations | oesophagus-carcinoma | 4269 | 20 | 16828 | 45 |
AKAP13,ELMO1,GMIP,VAV3,BLNK,ARHGAP33,DOCK1,HCK,TLN1,P2RY2,DOCK8,DOCK2,TBC1D8,RHBDF2,CSF1R,WDFY4,MYO1F,DOCK10,PREX1,PIK3R5 |
4.163e-03 | -5.48 | regulation of leukocyte activation | biological process | GO:0002694 | 572 | 6 | 18204 | 49 |
PTPN6,DOCK8,SPI1,CD74,STAT6,VAV3 |
4.200e-03 | -5.47 | cytoplasm | cellular component | GO:0005737 | 12081 | 40 | 19108 | 49 |
ARHGAP33,PREX1,TLN1,DOCK1,RHBDF2,NEK6,DOCK2,PARVG,IPCEF1,ARHGAP15,RGS14,CD74,IRF5,WDFY4,FYB1,SKAP1,GSDME,AKAP13,HIF1A,PLCG2,DENND1B,GAB1,PTPN6,TBXAS1,GMIP,MYO1F,EHBP1L1,HCK,CARMIL3,PRKCD,DOCK10,STAT6,ELMO1,NRK,PIK3R5,ARHGAP27,VAV3,DOCK8,BLNK,APOE |
4.218e-03 | -5.47 | phagocytosis, engulfment | biological process | GO:0006911 | 36 | 2 | 18204 | 49 |
ELMO1,DOCK1 |
4.234e-03 | -5.46 | EGFR tyrosine kinase inhibitor resistance | KEGG pathways | hsa01521 | 79 | 3 | 7161 | 30 |
IL6R,GAB1,PLCG2 |
4.234e-03 | -5.46 | EGFR tyrosine kinase inhibitor resistance | KEGG pathways | ko01521 | 79 | 3 | 7161 | 30 |
PLCG2,IL6R,GAB1 |
4.234e-03 | -5.46 | positive regulation of protein phosphorylation | biological process | GO:0001934 | 574 | 6 | 18204 | 49 |
CSF1R,IL6R,CD74,PRKCD,PIK3R5,PLCG2 |
4.277e-03 | -5.45 | p75 NTR receptor-mediated signalling | REACTOME pathways | R-HSA-193704 | 97 | 3 | 10285 | 35 |
AKAP13,PREX1,VAV3 |
4.292e-03 | -5.45 | STAT3 (signal transducer and activator of transcription 3) | protein interactions | 6774 | 427 | 5 | 19454 | 49 |
PRKCD,STAT6,HCK,IL6R,HIF1A |
4.299e-03 | -5.45 | regulation of organelle organization | biological process | GO:0033043 | 1201 | 9 | 18204 | 49 |
AKAP13,HCK,HIF1A,TBC1D8,PRKCD,CSF1R,CARMIL3,NEK6,PREX1 |
4.322e-03 | -5.44 | regulation of leukocyte chemotaxis | biological process | GO:0002688 | 122 | 3 | 18204 | 49 |
CSF1R,CD74,IL6R |
4.334e-03 | -5.44 | GPCR downstream signaling | REACTOME pathways | R-HSA-388396 | 974 | 9 | 10285 | 35 |
RGS14,P2RY6,P2RY2,ADCY7,PRKCD,VAV3,PIK3R5,AKAP13,PREX1 |
4.357e-03 | -5.44 | signaling receptor binding | molecular function | GO:0005102 | 1493 | 10 | 18094 | 47 |
TLN1,APOE,VAV3,DOCK2,BLNK,IL6R,P2RY2,HCK,CD74,FYB1 |
4.451e-03 | -5.41 | regulation of macrophage cytokine production | biological process | GO:0010935 | 37 | 2 | 18204 | 49 |
PLCG2,CD74 |
4.523e-03 | -5.40 | positive regulation of cell-substrate adhesion | biological process | GO:0010811 | 124 | 3 | 18204 | 49 |
PREX1,SKAP1,DOCK1 |
4.523e-03 | -5.40 | positive regulation of lipid metabolic process | biological process | GO:0045834 | 124 | 3 | 18204 | 49 |
CD74,PRKCD,APOE |
4.575e-03 | -5.39 | PLD2 (phospholipase D2) | protein interactions | 5338 | 133 | 3 | 19454 | 49 |
PRKCD,SKAP1,HIF1A |
4.610e-03 | -5.38 | Ca-dependent events | REACTOME pathways | R-HSA-111996 | 30 | 2 | 10285 | 35 |
ADCY7,PRKCD |
4.610e-03 | -5.38 | FCERI mediated Ca+2 mobilization | REACTOME pathways | R-HSA-2871809 | 30 | 2 | 10285 | 35 |
VAV3,PLCG2 |
4.626e-03 | -5.38 | mammary gland development | biological process | GO:0030879 | 125 | 3 | 18204 | 49 |
CSF1R,STAT6,HIF1A |
4.691e-03 | -5.36 | unsaturated fatty acid biosynthetic process | biological process | GO:0006636 | 38 | 2 | 18204 | 49 |
TBXAS1,CD74 |
4.852e-03 | -5.33 | cellular process | biological process | GO:0009987 | 14996 | 47 | 18204 | 49 |
SPI1,NEK6,ARHGAP15,DOCK10,DOCK8,ARHGAP33,GMIP,IRF5,ADCY7,FYB1,VAV3,AKAP13,RGS14,PTPN6,TBXAS1,GAB1,CARMIL3,PLCG2,GIT2,SKAP1,CD74,HIF1A,MYO1F,BLNK,IPCEF1,PIK3R5,STAT6,ELMO1,GSDME,CSF1R,WDFY4,P2RY6,PRKCD,P2RY2,DOCK1,IL6R,PREX1,DOCK2,ARHGAP27,SBNO2,DENND1B,HCK,TLN1,PARVG,NRK,RHBDF2,APOE |
4.853e-03 | -5.33 | VEGFA-VEGFR2 Pathway | REACTOME pathways | R-HSA-4420097 | 330 | 5 | 10285 | 35 |
ELMO1,TLN1,PRKCD,DOCK1,VAV3 |
4.869e-03 | -5.32 | NEFL (neurofilament light chain) | protein interactions | 4747 | 136 | 3 | 19454 | 49 |
NEK6,GMIP,SKAP1 |
4.881e-03 | -5.32 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 16 | 16828 | 45 |
PTPN6,ARHGAP27,PREX1,DOCK10,DOCK2,CSF1R,GIT2,WDFY4,GAB1,DOCK1,ARHGAP15,SKAP1,AKAP13,ELMO1,VAV3,BLNK |
4.918e-03 | -5.31 | cell differentiation | biological process | GO:0030154 | 3645 | 18 | 18204 | 49 |
DOCK10,DOCK2,BLNK,PTPN6,AKAP13,PREX1,SPI1,DOCK1,HIF1A,CD74,IL6R,APOE,PLCG2,GSDME,CSF1R,SBNO2,HCK,STAT6 |
4.923e-03 | -5.31 | adrenal_cortical_carcinoma | COSMIC cancer mutations | adrenal_cortical_carcinoma | 2256 | 13 | 16828 | 45 |
CSF1R,WDFY4,ADCY7,DOCK2,PTPN6,RGS14,BLNK,IPCEF1,ELMO1,DOCK8,DOCK1,SKAP1,SBNO2 |
4.929e-03 | -5.31 | positive regulation of protein kinase activity | biological process | GO:0045860 | 256 | 4 | 18204 | 49 |
PIK3R5,CSF1R,IL6R,PRKCD |
4.936e-03 | -5.31 | long-term memory | biological process | GO:0007616 | 39 | 2 | 18204 | 49 |
RGS14,APOE |
4.936e-03 | -5.31 | regulation of T cell apoptotic process | biological process | GO:0070232 | 39 | 2 | 18204 | 49 |
HIF1A,DOCK8 |
4.963e-03 | -5.31 | cellular developmental process | biological process | GO:0048869 | 3648 | 18 | 18204 | 49 |
AKAP13,PTPN6,DOCK2,DOCK10,BLNK,HIF1A,IL6R,CD74,SPI1,DOCK1,PREX1,PLCG2,APOE,STAT6,HCK,SBNO2,CSF1R,GSDME |
5.031e-03 | -5.29 | KIR2DL5A (killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 5A) | protein interactions | 57292 | 2 | 1 | 19454 | 49 |
PTPN6 |
5.031e-03 | -5.29 | Per1 (period circadian clock 1) | protein interactions | 18626 | 2 | 1 | 19454 | 49 |
HIF1A |
5.031e-03 | -5.29 | HIF1A-AS2 (HIF1A antisense RNA 2) | protein interactions | 100750247 | 2 | 1 | 19454 | 49 |
HIF1A |
5.031e-03 | -5.29 | MPIG6B (megakaryocyte and platelet inhibitory receptor G6b) | protein interactions | 80739 | 2 | 1 | 19454 | 49 |
PTPN6 |
5.031e-03 | -5.29 | CUZD1 (CUB and zona pellucida like domains 1) | protein interactions | 50624 | 2 | 1 | 19454 | 49 |
PTPN6 |
5.031e-03 | -5.29 | Siglece (sialic acid binding Ig-like lectin E) | protein interactions | 83382 | 2 | 1 | 19454 | 49 |
PTPN6 |
5.031e-03 | -5.29 | IGHE (immunoglobulin heavy constant epsilon) | protein interactions | 3497 | 2 | 1 | 19454 | 49 |
STAT6 |
5.031e-03 | -5.29 | Arnt (aryl hydrocarbon receptor nuclear translocator) | protein interactions | 11863 | 2 | 1 | 19454 | 49 |
HIF1A |
5.062e-03 | -5.29 | defense response to other organism | biological process | GO:0098542 | 1006 | 8 | 18204 | 49 |
HCK,CD74,IL6R,PRKCD,CSF1R,PTPN6,PLCG2,IRF5 |
5.085e-03 | -5.28 | central_nervous_system-brain-glioma-astrocytoma_Grade_II | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_II | 420 | 5 | 16828 | 45 |
SBNO2,RGS14,WDFY4,PREX1,TLN1 |
5.122e-03 | -5.27 | chylomicron remnant | cellular component | GO:0034360 | 2 | 1 | 19108 | 49 |
APOE |
5.122e-03 | -5.27 | discoidal high-density lipoprotein particle | cellular component | GO:0034365 | 2 | 1 | 19108 | 49 |
APOE |
5.122e-03 | -5.27 | CSF1-CSF1R complex | cellular component | GO:1990682 | 2 | 1 | 19108 | 49 |
CSF1R |
5.122e-03 | -5.27 | macrophage migration inhibitory factor receptor complex | cellular component | GO:0035692 | 2 | 1 | 19108 | 49 |
CD74 |
5.160e-03 | -5.27 | B cell differentiation | biological process | GO:0030183 | 130 | 3 | 18204 | 49 |
BLNK,DOCK10,PLCG2 |
5.187e-03 | -5.26 | prostaglandin metabolic process | biological process | GO:0006693 | 40 | 2 | 18204 | 49 |
TBXAS1,CD74 |
5.188e-03 | -5.26 | G protein-coupled UDP receptor activity | molecular function | GO:0045029 | 2 | 1 | 18094 | 47 |
P2RY6 |
5.188e-03 | -5.26 | interleukin-6 receptor activity | molecular function | GO:0004915 | 2 | 1 | 18094 | 47 |
IL6R |
5.188e-03 | -5.26 | macrophage migration inhibitory factor binding | molecular function | GO:0035718 | 2 | 1 | 18094 | 47 |
CD74 |
5.188e-03 | -5.26 | interleukin-6 binding | molecular function | GO:0019981 | 2 | 1 | 18094 | 47 |
IL6R |
5.188e-03 | -5.26 | macrophage colony-stimulating factor receptor activity | molecular function | GO:0005011 | 2 | 1 | 18094 | 47 |
CSF1R |
5.188e-03 | -5.26 | thromboxane-A synthase activity | molecular function | GO:0004796 | 2 | 1 | 18094 | 47 |
TBXAS1 |
5.241e-03 | -5.25 | Ser-Thr/Tyr_kinase_cat_dom | interpro domains | IPR001245 | 133 | 3 | 18521 | 49 |
HCK,CSF1R,NEK6 |
5.254e-03 | -5.25 | ITGA1 (integrin subunit alpha 1) | protein interactions | 3672 | 43 | 2 | 19454 | 49 |
TLN1,PTPN6 |
5.284e-03 | -5.24 | PIK3R5/6 | interpro domains | IPR019522 | 2 | 1 | 18521 | 49 |
PIK3R5 |
5.284e-03 | -5.24 | SNO | interpro domains | IPR026741 | 2 | 1 | 18521 | 49 |
SBNO2 |
5.284e-03 | -5.24 | SNO_AAA | interpro domains | IPR039187 | 2 | 1 | 18521 | 49 |
SBNO2 |
5.284e-03 | -5.24 | Talin_R4 | interpro domains | IPR049108 | 2 | 1 | 18521 | 49 |
TLN1 |
5.284e-03 | -5.24 | GSDME | interpro domains | IPR042377 | 2 | 1 | 18521 | 49 |
GSDME |
5.284e-03 | -5.24 | PLC-gamma_C-SH2 | interpro domains | IPR035023 | 2 | 1 | 18521 | 49 |
PLCG2 |
5.284e-03 | -5.24 | GIT-like | interpro domains | IPR047161 | 2 | 1 | 18521 | 49 |
GIT2 |
5.284e-03 | -5.24 | GIT1/2_CC | interpro domains | IPR032352 | 2 | 1 | 18521 | 49 |
GIT2 |
5.284e-03 | -5.24 | Tyr_Pase_non-rcpt_typ-6/11 | interpro domains | IPR012152 | 2 | 1 | 18521 | 49 |
PTPN6 |
5.284e-03 | -5.24 | GIT1_C | interpro domains | IPR022018 | 2 | 1 | 18521 | 49 |
GIT2 |
5.284e-03 | -5.24 | Ie/If_SH3 | interpro domains | IPR035507 | 2 | 1 | 18521 | 49 |
MYO1F |
5.284e-03 | -5.24 | Vinculin-bd_dom | interpro domains | IPR015009 | 2 | 1 | 18521 | 49 |
TLN1 |
5.284e-03 | -5.24 | HIF-1_CTAD | interpro domains | IPR014887 | 2 | 1 | 18521 | 49 |
HIF1A |
5.284e-03 | -5.24 | DOCK1_5_SH3 | interpro domains | IPR047025 | 2 | 1 | 18521 | 49 |
DOCK1 |
5.284e-03 | -5.24 | SBNO_Helicase_C_dom | interpro domains | IPR026937 | 2 | 1 | 18521 | 49 |
SBNO2 |
5.284e-03 | -5.24 | Talin1/2-RS | interpro domains | IPR037438 | 2 | 1 | 18521 | 49 |
TLN1 |
5.284e-03 | -5.24 | iRhom1_2_N | interpro domains | IPR022241 | 2 | 1 | 18521 | 49 |
RHBDF2 |
5.284e-03 | -5.24 | Talin_cent_sf | interpro domains | IPR036476 | 2 | 1 | 18521 | 49 |
TLN1 |
5.284e-03 | -5.24 | SKAP_fam | interpro domains | IPR037781 | 2 | 1 | 18521 | 49 |
SKAP1 |
5.284e-03 | -5.24 | PLC-gamma_N-SH2 | interpro domains | IPR035024 | 2 | 1 | 18521 | 49 |
PLCG2 |
5.284e-03 | -5.24 | PLC-gamma | interpro domains | IPR016279 | 2 | 1 | 18521 | 49 |
PLCG2 |
5.284e-03 | -5.24 | Talin_cent | interpro domains | IPR015224 | 2 | 1 | 18521 | 49 |
TLN1 |
5.284e-03 | -5.24 | GIT_SHD | interpro domains | IPR013724 | 2 | 1 | 18521 | 49 |
GIT2 |
5.290e-03 | -5.24 | growth factor binding | molecular function | GO:0019838 | 136 | 3 | 18094 | 47 |
CSF1R,RHBDF2,IL6R |
5.369e-03 | -5.23 | Signaling by VEGF | REACTOME pathways | R-HSA-194138 | 338 | 5 | 10285 | 35 |
PRKCD,DOCK1,VAV3,ELMO1,TLN1 |
5.370e-03 | -5.23 | regulation of cellular component biogenesis | biological process | GO:0044087 | 1016 | 8 | 18204 | 49 |
APOE,TLN1,PLCG2,PREX1,HCK,SKAP1,TBC1D8,PRKCD |
5.376e-03 | -5.23 | positive regulation of lipid transporter activity | biological process | GO:0110113 | 2 | 1 | 18204 | 49 |
PRKCD |
5.376e-03 | -5.23 | hepatic immune response | biological process | GO:0002384 | 2 | 1 | 18204 | 49 |
IL6R |
5.376e-03 | -5.23 | pro-T cell differentiation | biological process | GO:0002572 | 2 | 1 | 18204 | 49 |
SPI1 |
5.376e-03 | -5.23 | negative regulation of neutrophil degranulation | biological process | GO:0043314 | 2 | 1 | 18204 | 49 |
SPI1 |
5.376e-03 | -5.23 | inositol trisphosphate biosynthetic process | biological process | GO:0032959 | 2 | 1 | 18204 | 49 |
PLCG2 |
5.376e-03 | -5.23 | lipid transport involved in lipid storage | biological process | GO:0010877 | 2 | 1 | 18204 | 49 |
APOE |
5.376e-03 | -5.23 | response to interleukin-11 | biological process | GO:0071105 | 2 | 1 | 18204 | 49 |
SBNO2 |
5.376e-03 | -5.23 | regulation of sphingomyelin catabolic process | biological process | GO:2000754 | 2 | 1 | 18204 | 49 |
PRKCD |
5.376e-03 | -5.23 | positive regulation of macrophage migration inhibitory factor signaling pathway | biological process | GO:2000448 | 2 | 1 | 18204 | 49 |
CD74 |
5.376e-03 | -5.23 | positive regulation of sphingomyelin catabolic process | biological process | GO:2000755 | 2 | 1 | 18204 | 49 |
PRKCD |
5.382e-03 | -5.22 | NCAPD3 (non-SMC condensin II complex subunit D3) | protein interactions | 23310 | 141 | 3 | 19454 | 49 |
CD74,SKAP1,P2RY6 |
5.397e-03 | -5.22 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-angioimmunoblastic_T_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-angioimmunoblastic_T_cell_lymphoma | 265 | 4 | 16828 | 45 |
STAT6,HCK,BLNK,PLCG2 |
5.443e-03 | -5.21 | prostanoid metabolic process | biological process | GO:0006692 | 41 | 2 | 18204 | 49 |
TBXAS1,CD74 |
5.460e-03 | -5.21 | regulation of secretion | biological process | GO:0051046 | 605 | 6 | 18204 | 49 |
SPI1,P2RY2,HIF1A,CD74,RHBDF2,APOE |
5.469e-03 | -5.21 | EPO signaling pathway | Pathway Interaction DB | epopathway | 33 | 3 | 2226 | 25 |
PTPN6,GAB1,PLCG2 |
5.496e-03 | -5.20 | ASB9 (ankyrin repeat and SOCS box containing 9) | protein interactions | 140462 | 44 | 2 | 19454 | 49 |
TLN1,PLCG2 |
5.496e-03 | -5.20 | HOXA10 (homeobox A10) | protein interactions | 3206 | 44 | 2 | 19454 | 49 |
PTPN6,SPI1 |
5.497e-03 | -5.20 | regulation of sequestering of calcium ion | biological process | GO:0051282 | 133 | 3 | 18204 | 49 |
PTPN6,PLCG2,P2RY6 |
5.497e-03 | -5.20 | positive regulation of adaptive immune response | biological process | GO:0002821 | 133 | 3 | 18204 | 49 |
SKAP1,STAT6,DENND1B |
5.500e-03 | -5.20 | PI3K_1B_p101 | pfam domains | PF10486 | 2 | 1 | 17795 | 49 |
PIK3R5 |
5.500e-03 | -5.20 | GIT_SHD | pfam domains | PF08518 | 2 | 1 | 17795 | 49 |
GIT2 |
5.500e-03 | -5.20 | iRhom1-2_N | pfam domains | PF12595 | 2 | 1 | 17795 | 49 |
RHBDF2 |
5.500e-03 | -5.20 | Helicase_C_4 | pfam domains | PF13871 | 2 | 1 | 17795 | 49 |
SBNO2 |
5.500e-03 | -5.20 | GIT1_C | pfam domains | PF12205 | 2 | 1 | 17795 | 49 |
GIT2 |
5.500e-03 | -5.20 | HIF-1a_CTAD | pfam domains | PF08778 | 2 | 1 | 17795 | 49 |
HIF1A |
5.500e-03 | -5.20 | Talin_middle | pfam domains | PF09141 | 2 | 1 | 17795 | 49 |
TLN1 |
5.500e-03 | -5.20 | Talin_R4 | pfam domains | PF21692 | 2 | 1 | 17795 | 49 |
TLN1 |
5.500e-03 | -5.20 | PKC_C2 | pfam domains | PF21494 | 2 | 1 | 17795 | 49 |
PRKCD |
5.500e-03 | -5.20 | VBS | pfam domains | PF08913 | 2 | 1 | 17795 | 49 |
TLN1 |
5.500e-03 | -5.20 | AAA_34 | pfam domains | PF13872 | 2 | 1 | 17795 | 49 |
SBNO2 |
5.500e-03 | -5.20 | GIT_CC | pfam domains | PF16559 | 2 | 1 | 17795 | 49 |
GIT2 |
5.564e-03 | -5.19 | response to stress | biological process | GO:0006950 | 3388 | 17 | 18204 | 49 |
RGS14,PTPN6,IPCEF1,BLNK,HIF1A,IL6R,CD74,SPI1,PRKCD,VAV3,TLN1,PLCG2,APOE,IRF5,STAT6,HCK,CSF1R |
5.611e-03 | -5.18 | cytoskeleton organization | biological process | GO:0007010 | 1251 | 9 | 18204 | 49 |
ELMO1,PREX1,NEK6,PARVG,MYO1F,TLN1,RGS14,APOE,DOCK2 |
5.612e-03 | -5.18 | regulation of actin filament polymerization | biological process | GO:0030833 | 134 | 3 | 18204 | 49 |
PRKCD,HCK,PREX1 |
5.646e-03 | -5.18 | phosphatidylinositol binding | molecular function | GO:0035091 | 276 | 4 | 18094 | 47 |
TLN1,DENND1B,ARHGAP33,GSDME |
5.704e-03 | -5.17 | breast-carcinoma-HER-positive_carcinoma | COSMIC cancer mutations | breast-carcinoma-HER-positive_carcinoma | 2025 | 12 | 16828 | 45 |
PIK3R5,P2RY6,PTPN6,PRKCD,PLCG2,CSF1R,STAT6,TLN1,P2RY2,DOCK8,GAB1,VAV3 |
5.704e-03 | -5.17 | HER-positive_carcinoma | COSMIC cancer mutations | HER-positive_carcinoma | 2025 | 12 | 16828 | 45 |
PIK3R5,PRKCD,PLCG2,P2RY6,PTPN6,CSF1R,P2RY2,DOCK8,STAT6,TLN1,GAB1,VAV3 |
5.706e-03 | -5.17 | COPG2 (COPI coat complex subunit gamma 2) | protein interactions | 26958 | 144 | 3 | 19454 | 49 |
RHBDF2,CD74,P2RY6 |
5.713e-03 | -5.16 | regulation of protein serine/threonine kinase activity | biological process | GO:0071900 | 267 | 4 | 18204 | 49 |
PIK3R5,APOE,RGS14,PRKCD |
5.721e-03 | -5.16 | negative regulation of response to external stimulus | biological process | GO:0032102 | 428 | 5 | 18204 | 49 |
HCK,PRKCD,PTPN6,APOE,RHBDF2 |
5.760e-03 | -5.16 | regulation of developmental process | biological process | GO:0050793 | 2540 | 14 | 18204 | 49 |
ARHGAP15,RGS14,PTPN6,PREX1,HIF1A,CD74,IL6R,SPI1,APOE,CSF1R,GAB1,ARHGAP33,HCK,STAT6 |
5.816e-03 | -5.15 | KDR (kinase insert domain receptor) | protein interactions | 3791 | 145 | 3 | 19454 | 49 |
PLCG2,P2RY2,PTPN6 |
5.828e-03 | -5.15 | transcription coactivator binding | molecular function | GO:0001223 | 44 | 2 | 18094 | 47 |
HIF1A,STAT6 |
5.864e-03 | -5.14 | regulation of actin filament organization | biological process | GO:0110053 | 269 | 4 | 18204 | 49 |
HCK,PRKCD,CARMIL3,PREX1 |
5.890e-03 | -5.13 | response to wounding | biological process | GO:0009611 | 431 | 5 | 18204 | 49 |
TLN1,PTPN6,PLCG2,HIF1A,VAV3 |
5.895e-03 | -5.13 | DAG and IP3 signaling | REACTOME pathways | R-HSA-1489509 | 34 | 2 | 10285 | 35 |
ADCY7,PRKCD |
5.941e-03 | -5.13 | regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction | biological process | GO:0051896 | 270 | 4 | 18204 | 49 |
PTPN6,VAV3,PIK3R5,CSF1R |
5.945e-03 | -5.13 | immunological synapse | cellular component | GO:0001772 | 45 | 2 | 19108 | 49 |
SKAP1,VAV3 |
5.952e-03 | -5.12 | actin filament-based process | biological process | GO:0030029 | 616 | 6 | 18204 | 49 |
PREX1,ELMO1,DOCK2,TLN1,PARVG,MYO1F |
5.962e-03 | -5.12 | protein phosphatase binding | molecular function | GO:0019903 | 142 | 3 | 18094 | 47 |
STAT6,CSF1R,SKAP1 |
5.962e-03 | -5.12 | protein tyrosine kinase activity | molecular function | GO:0004713 | 142 | 3 | 18094 | 47 |
HCK,CSF1R,PRKCD |
5.967e-03 | -5.12 | myeloid leukocyte migration | biological process | GO:0097529 | 137 | 3 | 18204 | 49 |
IL6R,PREX1,VAV3 |
5.974e-03 | -5.12 | T-helper cell differentiation | biological process | GO:0042093 | 43 | 2 | 18204 | 49 |
STAT6,IL6R |
5.974e-03 | -5.12 | CD4-positive, alpha-beta T cell differentiation involved in immune response | biological process | GO:0002294 | 43 | 2 | 18204 | 49 |
STAT6,IL6R |
5.974e-03 | -5.12 | positive regulation of substrate adhesion-dependent cell spreading | biological process | GO:1900026 | 43 | 2 | 18204 | 49 |
PREX1,DOCK1 |
5.974e-03 | -5.12 | positive regulation of interleukin-12 production | biological process | GO:0032735 | 43 | 2 | 18204 | 49 |
PLCG2,IRF5 |
5.994e-03 | -5.12 | adenoma | COSMIC cancer mutations | adenoma | 2873 | 15 | 16828 | 45 |
DOCK8,HCK,TLN1,STAT6,SKAP1,HIF1A,IPCEF1,DOCK10,PREX1,PLCG2,APOE,PRKCD,WDFY4,TBC1D8,DOCK2 |
6.089e-03 | -5.10 | non-membrane spanning protein tyrosine kinase activity | molecular function | GO:0004715 | 45 | 2 | 18094 | 47 |
HCK,PRKCD |
6.091e-03 | -5.10 | positive regulation of phosphorylation | biological process | GO:0042327 | 619 | 6 | 18204 | 49 |
PLCG2,PRKCD,CD74,IL6R,PIK3R5,CSF1R |
6.211e-03 | -5.08 | regulation of cell shape | biological process | GO:0008360 | 139 | 3 | 18204 | 49 |
HCK,ARHGAP15,CSF1R |
6.229e-03 | -5.08 | Interleukin-4 and 13 signaling | REACTOME pathways | R-HSA-6785807 | 111 | 3 | 10285 | 35 |
STAT6,HIF1A,IL6R |
6.247e-03 | -5.08 | alpha-beta T cell differentiation involved in immune response | biological process | GO:0002293 | 44 | 2 | 18204 | 49 |
IL6R,STAT6 |
6.247e-03 | -5.08 | alpha-beta T cell activation involved in immune response | biological process | GO:0002287 | 44 | 2 | 18204 | 49 |
IL6R,STAT6 |
6.247e-03 | -5.08 | mammary gland morphogenesis | biological process | GO:0060443 | 44 | 2 | 18204 | 49 |
CSF1R,STAT6 |
6.364e-03 | -5.06 | Downstream signal transduction | REACTOME pathways | R-HSA-186763 | 352 | 5 | 10285 | 35 |
PRKCD,GAB1,TLN1,STAT6,ADCY7 |
6.400e-03 | -5.05 | regulation of localization | biological process | GO:0032879 | 2028 | 12 | 18204 | 49 |
CD74,HIF1A,P2RY6,PRKCD,SPI1,P2RY2,DOCK2,PTPN6,HCK,APOE,RHBDF2,PLCG2 |
6.426e-03 | -5.05 | enzyme-linked receptor protein signaling pathway | biological process | GO:0007167 | 626 | 6 | 18204 | 49 |
RGS14,BLNK,HCK,STAT6,CSF1R,GAB1 |
6.438e-03 | -5.05 | cytokine binding | molecular function | GO:0019955 | 146 | 3 | 18094 | 47 |
CD74,CSF1R,IL6R |
6.461e-03 | -5.04 | positive regulation of chemotaxis | biological process | GO:0050921 | 141 | 3 | 18204 | 49 |
CD74,IL6R,CSF1R |
6.486e-03 | -5.04 | - | gene3d domains | 6.10.250.220 | 2 | 1 | 14470 | 47 |
SKAP1 |
6.500e-03 | -5.04 | PTK2 (protein tyrosine kinase 2) | protein interactions | 5747 | 296 | 4 | 19454 | 49 |
TLN1,DOCK1,HCK,PTPN6 |
6.511e-03 | -5.03 | CYTH2 (cytohesin 2) | protein interactions | 9266 | 48 | 2 | 19454 | 49 |
IPCEF1,DOCK1 |
6.527e-03 | -5.03 | negative regulation of peptidyl-tyrosine phosphorylation | biological process | GO:0050732 | 45 | 2 | 18204 | 49 |
PRKCD,PTPN6 |
6.527e-03 | -5.03 | plasma membrane invagination | biological process | GO:0099024 | 45 | 2 | 18204 | 49 |
DOCK1,ELMO1 |
6.527e-03 | -5.03 | negative regulation of blood coagulation | biological process | GO:0030195 | 45 | 2 | 18204 | 49 |
PRKCD,APOE |
6.527e-03 | -5.03 | positive regulation of B cell proliferation | biological process | GO:0030890 | 45 | 2 | 18204 | 49 |
CD74,VAV3 |
6.588e-03 | -5.02 | positive regulation of small molecule metabolic process | biological process | GO:0062013 | 142 | 3 | 18204 | 49 |
APOE,CD74,P2RY6 |
6.592e-03 | -5.02 | PLC-gamma1 signalling | REACTOME pathways | R-HSA-167021 | 36 | 2 | 10285 | 35 |
ADCY7,PRKCD |
6.592e-03 | -5.02 | EGFR interacts with phospholipase C-gamma | REACTOME pathways | R-HSA-212718 | 36 | 2 | 10285 | 35 |
PRKCD,ADCY7 |
6.645e-03 | -5.01 | Type II diabetes mellitus | WikiPathways | WP1584 | 22 | 2 | 5310 | 30 |
PIK3R5,PRKCD |
6.660e-03 | -5.01 | positive regulation of leukocyte cell-cell adhesion | biological process | GO:1903039 | 279 | 4 | 18204 | 49 |
DOCK8,CD74,PTPN6,SKAP1 |
6.777e-03 | -4.99 | CYTH1 (cytohesin 1) | protein interactions | 9267 | 49 | 2 | 19454 | 49 |
IPCEF1,PRKCD |
6.812e-03 | -4.99 | negative regulation of hemostasis | biological process | GO:1900047 | 46 | 2 | 18204 | 49 |
APOE,PRKCD |
6.903e-03 | -4.98 | positive regulation of cellular metabolic process | biological process | GO:0031325 | 3164 | 16 | 18204 | 49 |
PIK3R5,BLNK,HIF1A,CD74,IL6R,SPI1,SKAP1,P2RY6,PRKCD,PLCG2,APOE,IRF5,STAT6,DENND1B,SBNO2,CSF1R |
6.978e-03 | -4.97 | regulation of innate immune response | biological process | GO:0045088 | 449 | 5 | 18204 | 49 |
HCK,PTPN6,PLCG2,SPI1,APOE |
7.000e-03 | -4.96 | Signaling events mediated by TCPTP | Pathway Interaction DB | tcptp_pathway | 36 | 3 | 2226 | 25 |
CSF1R,GAB1,STAT6 |
7.049e-03 | -4.95 | TRIM15 (tripartite motif containing 15) | protein interactions | 89870 | 50 | 2 | 19454 | 49 |
IRF5,GAB1 |
7.053e-03 | -4.95 | positive regulation of transport | biological process | GO:0051050 | 844 | 7 | 18204 | 49 |
HIF1A,P2RY6,PRKCD,P2RY2,APOE,DOCK2,PLCG2 |
7.092e-03 | -4.95 | ATG16L1 (autophagy related 16 like 1) | protein interactions | 55054 | 1138 | 8 | 19454 | 49 |
DOCK2,ELMO1,GMIP,GIT2,ARHGAP15,PLCG2,AKAP13,TLN1 |
7.103e-03 | -4.95 | regulation of erythrocyte differentiation | biological process | GO:0045646 | 47 | 2 | 18204 | 49 |
SPI1,HIF1A |
7.226e-03 | -4.93 | testis-germ_cell_tumour-seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-seminoma | 648 | 6 | 16828 | 45 |
CSF1R,HCK,NEK6,RHBDF2,PRKCD,ADCY7 |
7.241e-03 | -4.93 | PPP6R1 (protein phosphatase 6 regulatory subunit 1) | protein interactions | 22870 | 157 | 3 | 19454 | 49 |
IRF5,CD74,P2RY6 |
7.246e-03 | -4.93 | leukocyte chemotaxis | biological process | GO:0030595 | 147 | 3 | 18204 | 49 |
IL6R,PREX1,VAV3 |
7.295e-03 | -4.92 | Signaling by the B Cell Receptor (BCR) | REACTOME pathways | R-HSA-983705 | 229 | 4 | 10285 | 35 |
PLCG2,GAB1,PTPN6,BLNK |
7.325e-03 | -4.92 | CD247 (CD247 molecule) | protein interactions | 919 | 51 | 2 | 19454 | 49 |
DOCK2,PTPN6 |
7.346e-03 | -4.91 | regulation of canonical NF-kappaB signal transduction | biological process | GO:0043122 | 287 | 4 | 18204 | 49 |
PLCG2,AKAP13,CD74,NEK6 |
7.382e-03 | -4.91 | regulation of reactive oxygen species metabolic process | biological process | GO:2000377 | 148 | 3 | 18204 | 49 |
PLCG2,PRKCD,HIF1A |
7.399e-03 | -4.91 | icosanoid biosynthetic process | biological process | GO:0046456 | 48 | 2 | 18204 | 49 |
CD74,TBXAS1 |
7.399e-03 | -4.91 | regulation of inflammatory response to antigenic stimulus | biological process | GO:0002861 | 48 | 2 | 18204 | 49 |
HCK,RHBDF2 |
7.399e-03 | -4.91 | T cell differentiation involved in immune response | biological process | GO:0002292 | 48 | 2 | 18204 | 49 |
STAT6,IL6R |
7.475e-03 | -4.90 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 28 | 16828 | 45 |
WDFY4,GIT2,CSF1R,APOE,PRKCD,MYO1F,DOCK10,DENND1B,AKAP13,VAV3,HIF1A,SBNO2,DOCK1,TLN1,STAT6,ADCY7,DOCK2,ARHGAP27,PARVG,PIK3R5,PREX1,IPCEF1,GMIP,ELMO1,BLNK,ARHGAP15,SKAP1,GAB1 |
7.479e-03 | -4.90 | human chr2q36.2 | chromosome location | human chr2q36.2 | 4 | 1 | 26134 | 49 |
DOCK10 |
7.496e-03 | -4.89 | COG6 (component of oligomeric golgi complex 6) | protein interactions | 57511 | 159 | 3 | 19454 | 49 |
DOCK8,NEK6,P2RY6 |
7.538e-03 | -4.89 | Cops5 (COP9 signalosome subunit 5) | protein interactions | 26754 | 3 | 1 | 19454 | 49 |
HIF1A |
7.538e-03 | -4.89 | SIGLEC11 (sialic acid binding Ig like lectin 11) | protein interactions | 114132 | 3 | 1 | 19454 | 49 |
PTPN6 |
7.538e-03 | -4.89 | EPYC (epiphycan) | protein interactions | 1833 | 3 | 1 | 19454 | 49 |
PLCG2 |
7.538e-03 | -4.89 | FAM220A (family with sequence similarity 220 member A) | protein interactions | 84792 | 3 | 1 | 19454 | 49 |
NEK6 |
7.538e-03 | -4.89 | ORF34 (ORF34;ORF36) | protein interactions | 4961504 | 3 | 1 | 19454 | 49 |
HIF1A |
7.538e-03 | -4.89 | Ahr (aryl-hydrocarbon receptor) | protein interactions | 11622 | 3 | 1 | 19454 | 49 |
HIF1A |
7.538e-03 | -4.89 | CX3CR1 (C-X3-C motif chemokine receptor 1) | protein interactions | 1524 | 3 | 1 | 19454 | 49 |
HIF1A |
7.538e-03 | -4.89 | SSX4B (SSX family member 4B) | protein interactions | 548313 | 3 | 1 | 19454 | 49 |
HIF1A |
7.557e-03 | -4.89 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 40 | 16828 | 45 |
ADCY7,DOCK2,TBXAS1,PTPN6,PARVG,CD74,PIK3R5,PREX1,IPCEF1,ELMO1,GMIP,RGS14,BLNK,ARHGAP15,SKAP1,GAB1,ARHGAP33,P2RY2,RHBDF2,TBC1D8,WDFY4,CSF1R,GIT2,PLCG2,PRKCD,DOCK10,MYO1F,DENND1B,SPI1,AKAP13,VAV3,NEK6,IRF5,HIF1A,SBNO2,EHBP1L1,DOCK1,DOCK8,HCK,STAT6 |
7.605e-03 | -4.88 | CEBPE (CCAAT enhancer binding protein epsilon) | protein interactions | 1053 | 52 | 2 | 19454 | 49 |
SPI1,STAT6 |
7.674e-03 | -4.87 | ciliary neurotrophic factor receptor complex | cellular component | GO:0070110 | 3 | 1 | 19108 | 49 |
IL6R |
7.674e-03 | -4.87 | interleukin-6 receptor complex | cellular component | GO:0005896 | 3 | 1 | 19108 | 49 |
IL6R |
7.700e-03 | -4.87 | platelet aggregation | biological process | GO:0070527 | 49 | 2 | 18204 | 49 |
TLN1,PTPN6 |
7.700e-03 | -4.87 | regulation of cell adhesion mediated by integrin | biological process | GO:0033628 | 49 | 2 | 18204 | 49 |
PTPN6,SKAP1 |
7.700e-03 | -4.87 | negative regulation of coagulation | biological process | GO:0050819 | 49 | 2 | 18204 | 49 |
APOE,PRKCD |
7.700e-03 | -4.87 | visual learning | biological process | GO:0008542 | 49 | 2 | 18204 | 49 |
HIF1A,RGS14 |
7.765e-03 | -4.86 | signaling receptor complex adaptor activity | molecular function | GO:0030159 | 51 | 2 | 18094 | 47 |
BLNK,RGS14 |
7.773e-03 | -4.86 | interleukin-11 binding | molecular function | GO:0019970 | 3 | 1 | 18094 | 47 |
IL6R |
7.773e-03 | -4.86 | diacylglycerol-dependent, calcium-independent serine/threonine kinase activity | molecular function | GO:0004699 | 3 | 1 | 18094 | 47 |
PRKCD |
7.773e-03 | -4.86 | interleukin-11 receptor activity | molecular function | GO:0004921 | 3 | 1 | 18094 | 47 |
IL6R |
7.773e-03 | -4.86 | G protein-coupled ADP receptor activity | molecular function | GO:0001621 | 3 | 1 | 18094 | 47 |
P2RY6 |
7.773e-03 | -4.86 | A1 adenosine receptor binding | molecular function | GO:0031686 | 3 | 1 | 18094 | 47 |
P2RY2 |
7.773e-03 | -4.86 | 12-hydroxyheptadecatrienoic acid synthase activity | molecular function | GO:0036134 | 3 | 1 | 18094 | 47 |
TBXAS1 |
7.798e-03 | -4.85 | negative regulation of protein phosphorylation | biological process | GO:0001933 | 292 | 4 | 18204 | 49 |
APOE,RGS14,PTPN6,PRKCD |
7.799e-03 | -4.85 | negative regulation of secretion by cell | biological process | GO:1903531 | 151 | 3 | 18204 | 49 |
APOE,RHBDF2,SPI1 |
7.891e-03 | -4.84 | GNA12 (G protein subunit alpha 12) | protein interactions | 2768 | 53 | 2 | 19454 | 49 |
AKAP13,PRKCD |
7.891e-03 | -4.84 | VAV3 (vav guanine nucleotide exchange factor 3) | protein interactions | 10451 | 53 | 2 | 19454 | 49 |
GAB1,BLNK |
7.916e-03 | -4.84 | Parvin | interpro domains | IPR028433 | 3 | 1 | 18521 | 49 |
PARVG |
7.916e-03 | -4.84 | CARMIL_PH | interpro domains | IPR041245 | 3 | 1 | 18521 | 49 |
CARMIL3 |
7.916e-03 | -4.84 | FYB1/2-like | interpro domains | IPR043443 | 3 | 1 | 18521 | 49 |
FYB1 |
7.916e-03 | -4.84 | PH_Vav | interpro domains | IPR037832 | 3 | 1 | 18521 | 49 |
VAV3 |
7.916e-03 | -4.84 | C2_Dock-C | interpro domains | IPR037808 | 3 | 1 | 18521 | 49 |
DOCK8 |
7.916e-03 | -4.84 | RGS10/12/14-like | interpro domains | IPR046995 | 3 | 1 | 18521 | 49 |
RGS14 |
7.916e-03 | -4.84 | ELMO_ARM | interpro domains | IPR024574 | 3 | 1 | 18521 | 49 |
ELMO1 |
7.916e-03 | -4.84 | HIF_alpha-like | interpro domains | IPR021537 | 3 | 1 | 18521 | 49 |
HIF1A |
7.916e-03 | -4.84 | C2_Dock-D | interpro domains | IPR037809 | 3 | 1 | 18521 | 49 |
DOCK10 |
7.916e-03 | -4.84 | FERM_f0 | interpro domains | IPR032425 | 3 | 1 | 18521 | 49 |
TLN1 |
7.916e-03 | -4.84 | CARMIL_C | interpro domains | IPR031943 | 3 | 1 | 18521 | 49 |
CARMIL3 |
7.916e-03 | -4.84 | RII-bd_1 | interpro domains | IPR018459 | 3 | 1 | 18521 | 49 |
AKAP13 |
7.916e-03 | -4.84 | DENND1A/B/C | interpro domains | IPR040032 | 3 | 1 | 18521 | 49 |
DENND1B |
7.916e-03 | -4.84 | hSH3 | interpro domains | IPR029294 | 3 | 1 | 18521 | 49 |
FYB1 |
7.941e-03 | -4.84 | regulation of actin polymerization or depolymerization | biological process | GO:0008064 | 152 | 3 | 18204 | 49 |
PREX1,HCK,PRKCD |
7.941e-03 | -4.84 | blood vessel diameter maintenance | biological process | GO:0097746 | 152 | 3 | 18204 | 49 |
P2RY2,TBXAS1,APOE |
7.941e-03 | -4.84 | regulation of tube diameter | biological process | GO:0035296 | 152 | 3 | 18204 | 49 |
P2RY2,TBXAS1,APOE |
7.974e-03 | -4.83 | ATP5PO (ATP synthase peripheral stalk subunit OSCP) | protein interactions | 539 | 314 | 4 | 19454 | 49 |
P2RY6,PREX1,APOE,DOCK8 |
8.007e-03 | -4.83 | modulation by host of viral process | biological process | GO:0044788 | 50 | 2 | 18204 | 49 |
CSF1R,APOE |
8.011e-03 | -4.83 | GIT | smart domains | SM00555 | 2 | 1 | 9717 | 39 |
GIT2 |
8.040e-03 | -4.82 | regulation of programmed cell death | biological process | GO:0043067 | 1569 | 10 | 18204 | 49 |
CD74,HCK,HIF1A,PRKCD,CSF1R,GSDME,PLCG2,PTPN6,DOCK8,IRF5 |
8.054e-03 | -4.82 | positive regulation of antifungal innate immune response | biological process | GO:1905036 | 3 | 1 | 18204 | 49 |
SPI1 |
8.054e-03 | -4.82 | positive regulation of chemokine-mediated signaling pathway | biological process | GO:0070101 | 3 | 1 | 18204 | 49 |
HIF1A |
8.054e-03 | -4.82 | leukocyte migration involved in immune response | biological process | GO:0002522 | 3 | 1 | 18204 | 49 |
HCK |
8.054e-03 | -4.82 | adenylate cyclase-activating adrenergic receptor signaling pathway involved in heart process | biological process | GO:0086023 | 3 | 1 | 18204 | 49 |
AKAP13 |
8.054e-03 | -4.82 | myeloid dendritic cell activation involved in immune response | biological process | GO:0002277 | 3 | 1 | 18204 | 49 |
DOCK2 |
8.054e-03 | -4.82 | regulation of myeloid progenitor cell differentiation | biological process | GO:1905453 | 3 | 1 | 18204 | 49 |
SPI1 |
8.054e-03 | -4.82 | follicular B cell differentiation | biological process | GO:0002316 | 3 | 1 | 18204 | 49 |
PLCG2 |
8.054e-03 | -4.82 | membrane raft polarization | biological process | GO:0001766 | 3 | 1 | 18204 | 49 |
DOCK2 |
8.054e-03 | -4.82 | negative regulation of synaptic plasticity | biological process | GO:0031914 | 3 | 1 | 18204 | 49 |
RGS14 |
8.054e-03 | -4.82 | positive regulation of low-density lipoprotein particle receptor catabolic process | biological process | GO:0032805 | 3 | 1 | 18204 | 49 |
APOE |
8.054e-03 | -4.82 | isotype switching to IgE isotypes | biological process | GO:0048289 | 3 | 1 | 18204 | 49 |
STAT6 |
8.054e-03 | -4.82 | neural fold elevation formation | biological process | GO:0021502 | 3 | 1 | 18204 | 49 |
HIF1A |
8.054e-03 | -4.82 | very-low-density lipoprotein particle clearance | biological process | GO:0034447 | 3 | 1 | 18204 | 49 |
APOE |
8.054e-03 | -4.82 | positive regulation of phospholipid catabolic process | biological process | GO:0060697 | 3 | 1 | 18204 | 49 |
PRKCD |
8.054e-03 | -4.82 | endothelial to hematopoietic transition | biological process | GO:0098508 | 3 | 1 | 18204 | 49 |
SPI1 |
8.054e-03 | -4.82 | regulation of macrophage migration inhibitory factor signaling pathway | biological process | GO:2000446 | 3 | 1 | 18204 | 49 |
CD74 |
8.054e-03 | -4.82 | termination of signal transduction | biological process | GO:0023021 | 3 | 1 | 18204 | 49 |
PRKCD |
8.077e-03 | -4.82 | myeloid cell differentiation | biological process | GO:0030099 | 295 | 4 | 18204 | 49 |
CSF1R,SBNO2,SPI1,PTPN6 |
8.077e-03 | -4.82 | regulation of endocytosis | biological process | GO:0030100 | 295 | 4 | 18204 | 49 |
HCK,PLCG2,APOE,DOCK2 |
8.085e-03 | -4.82 | myeloid leukocyte differentiation | biological process | GO:0002573 | 153 | 3 | 18204 | 49 |
CSF1R,SBNO2,SPI1 |
8.085e-03 | -4.82 | regulation of tube size | biological process | GO:0035150 | 153 | 3 | 18204 | 49 |
P2RY2,TBXAS1,APOE |
8.238e-03 | -4.80 | HIF-1 | pfam domains | PF11413 | 3 | 1 | 17795 | 49 |
HIF1A |
8.238e-03 | -4.80 | hSH3 | pfam domains | PF14603 | 3 | 1 | 17795 | 49 |
FYB1 |
8.238e-03 | -4.80 | ELMO_ARM | pfam domains | PF11841 | 3 | 1 | 17795 | 49 |
ELMO1 |
8.238e-03 | -4.80 | Carm_PH | pfam domains | PF17888 | 3 | 1 | 17795 | 49 |
CARMIL3 |
8.238e-03 | -4.80 | FERM_f0 | pfam domains | PF16511 | 3 | 1 | 17795 | 49 |
TLN1 |
8.238e-03 | -4.80 | CARMIL_C | pfam domains | PF16000 | 3 | 1 | 17795 | 49 |
CARMIL3 |
8.238e-03 | -4.80 | RII_binding_1 | pfam domains | PF10522 | 3 | 1 | 17795 | 49 |
AKAP13 |
8.296e-03 | -4.79 | RASA1 (RAS p21 protein activator 1) | protein interactions | 5921 | 165 | 3 | 19454 | 49 |
HCK,CSF1R,GAB1 |
8.320e-03 | -4.79 | regulation of granulocyte chemotaxis | biological process | GO:0071622 | 51 | 2 | 18204 | 49 |
CSF1R,CD74 |
8.328e-03 | -4.79 | upper_leg | COSMIC cancer mutations | upper_leg | 880 | 7 | 16828 | 45 |
DOCK8,ARHGAP15,CSF1R,VAV3,NEK6,DOCK2,ELMO1 |
8.340e-03 | -4.79 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 156 | 3 | 16828 | 45 |
HCK,BLNK,SPI1 |
8.362e-03 | -4.78 | lung-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-adenocarcinoma | 15133 | 45 | 16828 | 45 |
IPCEF1,ELMO1,GMIP,RGS14,BLNK,GAB1,ARHGAP33,ARHGAP15,SKAP1,P2RY2,ADCY7,DOCK2,TBXAS1,PTPN6,CD74,PARVG,ARHGAP27,PREX1,PIK3R5,AKAP13,SPI1,VAV3,IRF5,HIF1A,NEK6,DOCK1,SBNO2,EHBP1L1,TLN1,HCK,STAT6,DOCK8,RHBDF2,TBC1D8,CSF1R,GIT2,WDFY4,P2RY6,APOE,PLCG2,PRKCD,MYO1F,DOCK10,DENND1B,IL6R |
8.362e-03 | -4.78 | Signaling by PDGF | REACTOME pathways | R-HSA-186797 | 376 | 5 | 10285 | 35 |
ADCY7,STAT6,TLN1,PRKCD,GAB1 |
8.377e-03 | -4.78 | regulation of actin filament length | biological process | GO:0030832 | 155 | 3 | 18204 | 49 |
PRKCD,HCK,PREX1 |
8.377e-03 | -4.78 | regulation of G protein-coupled receptor signaling pathway | biological process | GO:0008277 | 155 | 3 | 18204 | 49 |
HIF1A,RGS14,GIT2 |
8.388e-03 | -4.78 | HIF-1 signaling pathway | KEGG pathways | hsa04066 | 101 | 3 | 7161 | 30 |
HIF1A,PLCG2,IL6R |
8.390e-03 | -4.78 | regulation of biological quality | biological process | GO:0065008 | 2936 | 15 | 18204 | 49 |
PLCG2,TLN1,APOE,HCK,CSF1R,ARHGAP33,ARHGAP15,PTPN6,RGS14,TBXAS1,HIF1A,P2RY2,PRKCD,PREX1,VAV3 |
8.477e-03 | -4.77 | DOCK1 (dedicator of cytokinesis 1) | protein interactions | 1793 | 55 | 2 | 19454 | 49 |
IPCEF1,ELMO1 |
8.477e-03 | -4.77 | POLK (DNA polymerase kappa) | protein interactions | 51426 | 55 | 2 | 19454 | 49 |
PARVG,STAT6 |
8.525e-03 | -4.76 | protein autophosphorylation | biological process | GO:0046777 | 156 | 3 | 18204 | 49 |
HCK,NEK6,CSF1R |
8.550e-03 | -4.76 | Prot_kinase_dom | interpro domains | IPR000719 | 480 | 5 | 18521 | 49 |
PRKCD,NEK6,NRK,CSF1R,HCK |
8.573e-03 | -4.76 | TP73 (tumor protein p73) | protein interactions | 7161 | 167 | 3 | 19454 | 49 |
PRKCD,HCK,HIF1A |
8.602e-03 | -4.76 | ACTA1 (actin alpha 1, skeletal muscle) | protein interactions | 58 | 321 | 4 | 19454 | 49 |
HIF1A,PRKCD,TLN1,EHBP1L1 |
8.638e-03 | -4.75 | membrane invagination | biological process | GO:0010324 | 52 | 2 | 18204 | 49 |
DOCK1,ELMO1 |
8.675e-03 | -4.75 | positive regulation of endocytosis | biological process | GO:0045807 | 157 | 3 | 18204 | 49 |
PLCG2,APOE,DOCK2 |
8.713e-03 | -4.74 | KLK10 (kallikrein related peptidase 10) | protein interactions | 5655 | 168 | 3 | 19454 | 49 |
MYO1F,PTPN6,APOE |
8.776e-03 | -4.74 | PIK3CG (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma) | protein interactions | 5294 | 56 | 2 | 19454 | 49 |
GAB1,PIK3R5 |
8.776e-03 | -4.74 | EML3 (EMAP like 3) | protein interactions | 256364 | 56 | 2 | 19454 | 49 |
NEK6,SKAP1 |
8.826e-03 | -4.73 | regulation of blood vessel endothelial cell migration | biological process | GO:0043535 | 158 | 3 | 18204 | 49 |
APOE,GAB1,HIF1A |
8.847e-03 | -4.73 | Focal adhesion | KEGG pathways | ko04510 | 198 | 4 | 7161 | 30 |
TLN1,VAV3,DOCK1,PARVG |
8.847e-03 | -4.73 | Focal adhesion | KEGG pathways | hsa04510 | 198 | 4 | 7161 | 30 |
DOCK1,PARVG,TLN1,VAV3 |
8.962e-03 | -4.71 | regulation of platelet activation | biological process | GO:0010543 | 53 | 2 | 18204 | 49 |
PRKCD,APOE |
9.081e-03 | -4.70 | PTPRC (protein tyrosine phosphatase receptor type C) | protein interactions | 5788 | 57 | 2 | 19454 | 49 |
SKAP1,PTPN6 |
9.081e-03 | -4.70 | DOCK9 (dedicator of cytokinesis 9) | protein interactions | 23348 | 57 | 2 | 19454 | 49 |
DOCK10,DOCK1 |
9.081e-03 | -4.70 | PRKCQ (protein kinase C theta) | protein interactions | 5588 | 57 | 2 | 19454 | 49 |
PRKCD,FYB1 |
9.098e-03 | -4.70 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 17 | 16828 | 45 |
WDFY4,DOCK2,DOCK10,DENND1B,PLCG2,CD74,BLNK,VAV3,HIF1A,ELMO1,AKAP13,HCK,STAT6,ARHGAP15,SKAP1,GAB1,DOCK1 |
9.213e-03 | -4.69 | human chr11q13.4 | chromosome location | human chr11q13.4 | 77 | 2 | 26134 | 49 |
P2RY6,P2RY2 |
9.290e-03 | -4.68 | regulation of alcohol biosynthetic process | biological process | GO:1902930 | 54 | 2 | 18204 | 49 |
APOE,P2RY6 |
9.317e-03 | -4.68 | Signaling by GPCR | REACTOME pathways | R-HSA-372790 | 1299 | 10 | 10285 | 35 |
PRKCD,PIK3R5,VAV3,AKAP13,PREX1,TLN1,RGS14,P2RY6,P2RY2,ADCY7 |
9.390e-03 | -4.67 | KDM3A (lysine demethylase 3A) | protein interactions | 55818 | 58 | 2 | 19454 | 49 |
STAT6,HIF1A |
9.548e-03 | -4.65 | response to bacterium | biological process | GO:0009617 | 681 | 6 | 18204 | 49 |
PLCG2,IRF5,PRKCD,SBNO2,HCK,IL6R |
9.575e-03 | -4.65 | negative regulation of cell adhesion | biological process | GO:0007162 | 310 | 4 | 18204 | 49 |
CD74,SPI1,PTPN6,PRKCD |
9.586e-03 | -4.65 | GYPA (glycophorin A (MNS blood group)) | protein interactions | 2993 | 174 | 3 | 19454 | 49 |
DOCK1,NEK6,GSDME |
9.586e-03 | -4.65 | SURF4 (surfeit 4) | protein interactions | 6836 | 174 | 3 | 19454 | 49 |
P2RY2,P2RY6,DOCK1 |
9.625e-03 | -4.64 | neutrophil chemotaxis | biological process | GO:0030593 | 55 | 2 | 18204 | 49 |
PREX1,VAV3 |
9.625e-03 | -4.64 | CD4-positive, alpha-beta T cell differentiation | biological process | GO:0043367 | 55 | 2 | 18204 | 49 |
IL6R,STAT6 |
9.642e-03 | -4.64 | Proteoglycans in cancer | KEGG pathways | ko05205 | 203 | 4 | 7161 | 30 |
HIF1A,PLCG2,GAB1,PTPN6 |
9.642e-03 | -4.64 | Proteoglycans in cancer | KEGG pathways | hsa05205 | 203 | 4 | 7161 | 30 |
PLCG2,HIF1A,PTPN6,GAB1 |
9.703e-03 | -4.64 | C1_1 | pfam domains | PF00130 | 54 | 2 | 17795 | 49 |
VAV3,PRKCD |
9.713e-03 | -4.63 | - | gene3d domains | 6.10.140.1000 | 3 | 1 | 14470 | 47 |
DENND1B |
9.713e-03 | -4.63 | - | gene3d domains | 6.10.250.810 | 3 | 1 | 14470 | 47 |
ELMO1 |
9.751e-03 | -4.63 | dendritic spine | cellular component | GO:0043197 | 172 | 3 | 19108 | 49 |
RGS14,ARHGAP33,DOCK10 |
9.767e-03 | -4.63 | positive regulation of leukocyte proliferation | biological process | GO:0070665 | 164 | 3 | 18204 | 49 |
CD74,CSF1R,VAV3 |
9.823e-03 | -4.62 | Th17 cell differentiation | KEGG pathways | hsa04659 | 107 | 3 | 7161 | 30 |
STAT6,HIF1A,IL6R |
9.823e-03 | -4.62 | Th17 cell differentiation | KEGG pathways | ko04659 | 107 | 3 | 7161 | 30 |
HIF1A,STAT6,IL6R |
9.871e-03 | -4.62 | cell-cell junction | cellular component | GO:0005911 | 513 | 5 | 19108 | 49 |
PRKCD,SKAP1,GAB1,PTPN6,TLN1 |
9.895e-03 | -4.62 | negative regulation of phosphorylation | biological process | GO:0042326 | 313 | 4 | 18204 | 49 |
APOE,PRKCD,PTPN6,RGS14 |
9.964e-03 | -4.61 | positive regulation of miRNA transcription | biological process | GO:1902895 | 56 | 2 | 18204 | 49 |
HIF1A,SPI1 |
1.000e-02 | -4.60 | positive regulation of response to biotic stimulus | biological process | GO:0002833 | 314 | 4 | 18204 | 49 |
HCK,PLCG2,SPI1,GSDME |
1.004e-02 | -4.60 | Mapk1 (mitogen activated protein kinase 1) | protein interactions | 116590 | 4 | 1 | 19454 | 49 |
HIF1A |
1.004e-02 | -4.60 | Ocln (occludin) | protein interactions | 18260 | 4 | 1 | 19454 | 49 |
PRKCD |
1.004e-02 | -4.60 | CD34 (CD34 molecule) | protein interactions | 947 | 4 | 1 | 19454 | 49 |
PRKCD |
1.004e-02 | -4.60 | H1-10-AS1 (H1-10 antisense RNA 1) | protein interactions | 339942 | 4 | 1 | 19454 | 49 |
PTPN6 |
1.004e-02 | -4.60 | TOP3B (DNA topoisomerase III beta) | protein interactions | 8940 | 1465 | 9 | 19454 | 49 |
ARHGAP33,PREX1,IRF5,ADCY7,TLN1,AKAP13,EHBP1L1,RHBDF2,SBNO2 |
1.006e-02 | -4.60 | neuron spine | cellular component | GO:0044309 | 174 | 3 | 19108 | 49 |
RGS14,ARHGAP33,DOCK10 |
1.007e-02 | -4.60 | Class I PI3K signaling events | Pathway Interaction DB | pi3kcipathway | 41 | 3 | 2226 | 25 |
PLCG2,PREX1,HCK |
1.018e-02 | -4.59 | STAT6-mediated induction of chemokines | REACTOME pathways | R-HSA-3249367 | 3 | 1 | 10285 | 35 |
STAT6 |
1.018e-02 | -4.59 | Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha | REACTOME pathways | R-HSA-1234162 | 3 | 1 | 10285 | 35 |
HIF1A |
1.022e-02 | -4.58 | intermediate-density lipoprotein particle | cellular component | GO:0034363 | 4 | 1 | 19108 | 49 |
APOE |
1.022e-02 | -4.58 | phosphatidylinositol 3-kinase complex, class IB | cellular component | GO:0005944 | 4 | 1 | 19108 | 49 |
PIK3R5 |
1.031e-02 | -4.57 | osteoclast differentiation | biological process | GO:0030316 | 57 | 2 | 18204 | 49 |
SBNO2,CSF1R |
1.031e-02 | -4.57 | visual behavior | biological process | GO:0007632 | 57 | 2 | 18204 | 49 |
HIF1A,RGS14 |
1.035e-02 | -4.57 | FBXL12 (F-box and leucine rich repeat protein 12) | protein interactions | 54850 | 61 | 2 | 19454 | 49 |
APOE,DOCK8 |
1.035e-02 | -4.57 | very-low-density lipoprotein particle receptor binding | molecular function | GO:0070326 | 4 | 1 | 18094 | 47 |
APOE |
1.035e-02 | -4.57 | ciliary neurotrophic factor receptor activity | molecular function | GO:0004897 | 4 | 1 | 18094 | 47 |
IL6R |
1.037e-02 | -4.57 | seminoma | COSMIC cancer mutations | seminoma | 700 | 6 | 16828 | 45 |
ADCY7,PRKCD,RHBDF2,NEK6,CSF1R,HCK |
1.044e-02 | -4.56 | Host Interactions of HIV factors | REACTOME pathways | R-HSA-162909 | 134 | 3 | 10285 | 35 |
DOCK2,HCK,ELMO1 |
1.054e-02 | -4.55 | Gab1-4-like | interpro domains | IPR046355 | 4 | 1 | 18521 | 49 |
GAB1 |
1.054e-02 | -4.55 | Prot_kin_PKC_delta | interpro domains | IPR014376 | 4 | 1 | 18521 | 49 |
PRKCD |
1.054e-02 | -4.55 | ApoA_E | interpro domains | IPR000074 | 4 | 1 | 18521 | 49 |
APOE |
1.054e-02 | -4.55 | ILWEQ_dom | interpro domains | IPR002558 | 4 | 1 | 18521 | 49 |
TLN1 |
1.054e-02 | -4.55 | I/LWEQ_dom_sf | interpro domains | IPR035964 | 4 | 1 | 18521 | 49 |
TLN1 |
1.054e-02 | -4.55 | NT-C2 | interpro domains | IPR019448 | 4 | 1 | 18521 | 49 |
EHBP1L1 |
1.059e-02 | -4.55 | lung-carcinoid-endocrine_tumour | COSMIC cancer mutations | lung-carcinoid-endocrine_tumour | 502 | 5 | 16828 | 45 |
TBC1D8,PRKCD,NEK6,CSF1R,HCK |
1.072e-02 | -4.54 | NMDA glutamate receptor clustering | biological process | GO:0097114 | 4 | 1 | 18204 | 49 |
APOE |
1.072e-02 | -4.54 | positive regulation of inositol trisphosphate biosynthetic process | biological process | GO:0032962 | 4 | 1 | 18204 | 49 |
P2RY6 |
1.072e-02 | -4.54 | regulation of phospholipid efflux | biological process | GO:1902994 | 4 | 1 | 18204 | 49 |
APOE |
1.072e-02 | -4.54 | positive regulation of establishment of T cell polarity | biological process | GO:1903905 | 4 | 1 | 18204 | 49 |
DOCK8 |
1.072e-02 | -4.54 | positive regulation of isotype switching to IgE isotypes | biological process | GO:0048295 | 4 | 1 | 18204 | 49 |
STAT6 |
1.072e-02 | -4.54 | negative regulation of mast cell activation involved in immune response | biological process | GO:0033007 | 4 | 1 | 18204 | 49 |
PTPN6 |
1.072e-02 | -4.54 | B-1 B cell homeostasis | biological process | GO:0001922 | 4 | 1 | 18204 | 49 |
HIF1A |
1.072e-02 | -4.54 | respiratory burst after phagocytosis | biological process | GO:0045728 | 4 | 1 | 18204 | 49 |
HCK |
1.072e-02 | -4.54 | macrophage colony-stimulating factor signaling pathway | biological process | GO:0038145 | 4 | 1 | 18204 | 49 |
CSF1R |
1.072e-02 | -4.54 | response to caloric restriction | biological process | GO:0061771 | 4 | 1 | 18204 | 49 |
APOE |
1.072e-02 | -4.54 | T-helper 1 cell lineage commitment | biological process | GO:0002296 | 4 | 1 | 18204 | 49 |
STAT6 |
1.072e-02 | -4.54 | positive regulation of endodeoxyribonuclease activity | biological process | GO:0032079 | 4 | 1 | 18204 | 49 |
PRKCD |
1.072e-02 | -4.54 | positive regulation of phospholipid efflux | biological process | GO:1902995 | 4 | 1 | 18204 | 49 |
APOE |
1.072e-02 | -4.54 | regulation of inositol trisphosphate biosynthetic process | biological process | GO:0032960 | 4 | 1 | 18204 | 49 |
P2RY6 |
1.072e-02 | -4.54 | regulation of mature B cell apoptotic process | biological process | GO:0002905 | 4 | 1 | 18204 | 49 |
CD74 |
1.072e-02 | -4.54 | negative regulation of mature B cell apoptotic process | biological process | GO:0002906 | 4 | 1 | 18204 | 49 |
CD74 |
1.072e-02 | -4.54 | positive regulation of microglial cell mediated cytotoxicity | biological process | GO:1904151 | 4 | 1 | 18204 | 49 |
SPI1 |
1.072e-02 | -4.54 | positive regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity | biological process | GO:0031587 | 4 | 1 | 18204 | 49 |
P2RY6 |
1.072e-02 | -4.54 | epithelial cell differentiation involved in mammary gland alveolus development | biological process | GO:0061030 | 4 | 1 | 18204 | 49 |
HIF1A |
1.076e-02 | -4.53 | negative regulation of protein kinase activity | biological process | GO:0006469 | 170 | 3 | 18204 | 49 |
APOE,PRKCD,RGS14 |
1.089e-02 | -4.52 | INSR (insulin receptor) | protein interactions | 3643 | 344 | 4 | 19454 | 49 |
PTPN6,GAB1,VAV3,PRKCD |
1.097e-02 | -4.51 | I_LWEQ | pfam domains | PF01608 | 4 | 1 | 17795 | 49 |
TLN1 |
1.097e-02 | -4.51 | NT-C2 | pfam domains | PF10358 | 4 | 1 | 17795 | 49 |
EHBP1L1 |
1.097e-02 | -4.51 | Apolipoprotein | pfam domains | PF01442 | 4 | 1 | 17795 | 49 |
APOE |
1.101e-02 | -4.51 | IFNAR1 (interferon alpha and beta receptor subunit 1) | protein interactions | 3454 | 63 | 2 | 19454 | 49 |
PTPN6,STAT6 |
1.103e-02 | -4.51 | leading edge membrane | cellular component | GO:0031256 | 180 | 3 | 19108 | 49 |
TLN1,PLCG2,DOCK8 |
1.103e-02 | -4.51 | Signaling Pathways in Glioblastoma | WikiPathways | WP2261 | 83 | 3 | 5310 | 30 |
PRKCD,PLCG2,GAB1 |
1.104e-02 | -4.51 | specific granule lumen | cellular component | GO:0035580 | 62 | 2 | 19108 | 49 |
DOCK2,PTPN6 |
1.105e-02 | -4.51 | PLC beta mediated events | REACTOME pathways | R-HSA-112043 | 47 | 2 | 10285 | 35 |
ADCY7,PRKCD |
1.108e-02 | -4.50 | protein phosphorylation | biological process | GO:0006468 | 503 | 5 | 18204 | 49 |
CSF1R,NEK6,HCK,PRKCD,PTPN6 |
1.113e-02 | -4.50 | PROTEIN_KINASE_ATP | prosite domains | PS00107 | 377 | 5 | 12186 | 44 |
HCK,NEK6,NRK,CSF1R,PRKCD |
1.126e-02 | -4.49 | response to inorganic substance | biological process | GO:0010035 | 505 | 5 | 18204 | 49 |
ADCY7,PLCG2,PRKCD,HIF1A,STAT6 |
1.126e-02 | -4.49 | cellular response to organonitrogen compound | biological process | GO:0071417 | 505 | 5 | 18204 | 49 |
GAB1,P2RY6,PRKCD,P2RY2,STAT6 |
1.128e-02 | -4.48 | regulation of smooth muscle cell proliferation | biological process | GO:0048660 | 173 | 3 | 18204 | 49 |
APOE,P2RY6,IL6R |
1.131e-02 | -4.48 | Myometrial Relaxation and Contraction Pathways | WikiPathways | WP289 | 158 | 4 | 5310 | 30 |
ADCY7,PLCG2,PRKCD,RGS14 |
1.134e-02 | -4.48 | LRCH2 (leucine rich repeats and calponin homology domain containing 2) | protein interactions | 57631 | 64 | 2 | 19454 | 49 |
DOCK8,DOCK2 |
1.134e-02 | -4.48 | DGKE (diacylglycerol kinase epsilon) | protein interactions | 8526 | 64 | 2 | 19454 | 49 |
P2RY6,CD74 |
1.137e-02 | -4.48 | positive regulation of cytokine-mediated signaling pathway | biological process | GO:0001961 | 60 | 2 | 18204 | 49 |
HIF1A,CD74 |
1.148e-02 | -4.47 | regulation of lipid metabolic process | biological process | GO:0019216 | 327 | 4 | 18204 | 49 |
PRKCD,PLCG2,CD74,APOE |
1.149e-02 | -4.47 | IL6-mediated signaling events | Pathway Interaction DB | il6_7pathway | 43 | 3 | 2226 | 25 |
IL6R,HCK,PRKCD |
1.151e-02 | -4.46 | G-protein mediated events | REACTOME pathways | R-HSA-112040 | 48 | 2 | 10285 | 35 |
ADCY7,PRKCD |
1.151e-02 | -4.46 | G alpha (z) signalling events | REACTOME pathways | R-HSA-418597 | 48 | 2 | 10285 | 35 |
ADCY7,PRKCD |
1.153e-02 | -4.46 | circulatory system process | biological process | GO:0003013 | 508 | 5 | 18204 | 49 |
TBXAS1,APOE,P2RY2,TBC1D8,AKAP13 |
1.155e-02 | -4.46 | EPHA2 (EPH receptor A2) | protein interactions | 1969 | 350 | 4 | 19454 | 49 |
GAB1,CSF1R,HIF1A,HCK |
1.160e-02 | -4.46 | positive regulation of cell-cell adhesion | biological process | GO:0022409 | 328 | 4 | 18204 | 49 |
DOCK8,CD74,SKAP1,PTPN6 |
1.160e-02 | -4.46 | central_nervous_system-brain-glioma-astrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_III | 1419 | 9 | 16828 | 45 |
WDFY4,VAV3,ELMO1,DOCK2,DOCK10,ARHGAP15,SKAP1,CD74,DOCK1 |
1.168e-02 | -4.45 | ESRRA (estrogen related receptor alpha) | protein interactions | 2101 | 65 | 2 | 19454 | 49 |
HIF1A,PRKCD |
1.174e-02 | -4.44 | bone mineralization | biological process | GO:0030282 | 61 | 2 | 18204 | 49 |
SBNO2,HIF1A |
1.189e-02 | -4.43 | BCAR1 (BCAR1 scaffold protein, Cas family member) | protein interactions | 9564 | 547 | 5 | 19454 | 49 |
FYB1,DOCK2,HCK,DOCK1,TLN1 |
1.196e-02 | -4.43 | regulation of small molecule metabolic process | biological process | GO:0062012 | 331 | 4 | 18204 | 49 |
P2RY6,HIF1A,CD74,APOE |
1.209e-02 | -4.42 | Kinase-like_dom_sf | interpro domains | IPR011009 | 523 | 5 | 18521 | 49 |
PRKCD,NEK6,CSF1R,NRK,HCK |
1.211e-02 | -4.41 | regulation of substrate adhesion-dependent cell spreading | biological process | GO:1900024 | 62 | 2 | 18204 | 49 |
PREX1,DOCK1 |
1.211e-02 | -4.41 | regulation of B cell mediated immunity | biological process | GO:0002712 | 62 | 2 | 18204 | 49 |
PTPN6,STAT6 |
1.211e-02 | -4.41 | regulation of immunoglobulin mediated immune response | biological process | GO:0002889 | 62 | 2 | 18204 | 49 |
PTPN6,STAT6 |
1.211e-02 | -4.41 | macrophage activation | biological process | GO:0042116 | 62 | 2 | 18204 | 49 |
PLCG2,SBNO2 |
1.227e-02 | -4.40 | regulation of vesicle-mediated transport | biological process | GO:0060627 | 516 | 5 | 18204 | 49 |
PLCG2,SPI1,HCK,DOCK2,APOE |
1.237e-02 | -4.39 | regulation of response to wounding | biological process | GO:1903034 | 179 | 3 | 18204 | 49 |
APOE,PRKCD,PTPN6 |
1.246e-02 | -4.39 | peptidyl-amino acid modification | biological process | GO:0018193 | 518 | 5 | 18204 | 49 |
NEK6,CSF1R,PRKCD,PTPN6,HCK |
1.246e-02 | -4.39 | KHDRBS1 (KH RNA binding domain containing, signal transduction associated 1) | protein interactions | 10657 | 358 | 4 | 19454 | 49 |
PLCG2,HCK,PTPN6,DOCK2 |
1.247e-02 | -4.38 | central_nervous_system-brainstem-primitive_neuroectodermal_tumour-medulloblastoma-WNT_subtype | COSMIC cancer mutations | central_nervous_system-brainstem-primitive_neuroectodermal_tumour-medulloblastoma-WNT_subtype | 181 | 3 | 16828 | 45 |
ELMO1,VAV3,WDFY4 |
1.250e-02 | -4.38 | UBE3C (ubiquitin protein ligase E3C) | protein interactions | 9690 | 192 | 3 | 19454 | 49 |
HIF1A,P2RY6,CD74 |
1.253e-02 | -4.38 | NBR2 (neighbor of BRCA1 lncRNA 2) | protein interactions | 10230 | 5 | 1 | 19454 | 49 |
GMIP |
1.253e-02 | -4.38 | VHLL (VHL like) | protein interactions | 391104 | 5 | 1 | 19454 | 49 |
HIF1A |
1.253e-02 | -4.38 | NBPF6 (NBPF member 6) | protein interactions | 653149 | 5 | 1 | 19454 | 49 |
PARVG |
1.253e-02 | -4.38 | LINC01139 (long intergenic non-protein coding RNA 1139) | protein interactions | 339535 | 5 | 1 | 19454 | 49 |
HIF1A |
1.253e-02 | -4.38 | Vhl (von Hippel-Lindau tumor suppressor) | protein interactions | 24874 | 5 | 1 | 19454 | 49 |
HIF1A |
1.253e-02 | -4.38 | SNHG11 (small nucleolar RNA host gene 11) | protein interactions | 128439 | 5 | 1 | 19454 | 49 |
HIF1A |
1.266e-02 | -4.37 | WNT_subtype | COSMIC cancer mutations | WNT_subtype | 182 | 3 | 16828 | 45 |
VAV3,WDFY4,ELMO1 |
1.270e-02 | -4.37 | NS-malignant_melanoma | COSMIC cancer mutations | NS-malignant_melanoma | 3420 | 16 | 16828 | 45 |
TLN1,HCK,P2RY2,GAB1,DOCK1,ARHGAP15,SKAP1,SBNO2,VAV3,AKAP13,DENND1B,PTPN6,PLCG2,CSF1R,WDFY4,DOCK2 |
1.274e-02 | -4.36 | negative regulation of kinase activity | biological process | GO:0033673 | 181 | 3 | 18204 | 49 |
APOE,RGS14,PRKCD |
1.276e-02 | -4.36 | alpha-beta T cell receptor complex | cellular component | GO:0042105 | 5 | 1 | 19108 | 49 |
PTPN6 |
1.277e-02 | -4.36 | negative regulation of programmed cell death | biological process | GO:0043069 | 946 | 7 | 18204 | 49 |
PRKCD,HCK,HIF1A,CD74,CSF1R,PLCG2,DOCK8 |
1.280e-02 | -4.36 | phosphatase binding | molecular function | GO:0019902 | 188 | 3 | 18094 | 47 |
STAT6,SKAP1,CSF1R |
1.281e-02 | -4.36 | multivesicular body | cellular component | GO:0005771 | 67 | 2 | 19108 | 49 |
APOE,CD74 |
1.281e-02 | -4.36 | testis | COSMIC cancer mutations | testis | 733 | 6 | 16828 | 45 |
PRKCD,HCK,RHBDF2,ADCY7,NEK6,CSF1R |
1.285e-02 | -4.35 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 13 | 16828 | 45 |
DOCK10,PREX1,WDFY4,CSF1R,DOCK2,SKAP1,ARHGAP15,DOCK1,GAB1,BLNK,VAV3,ELMO1,AKAP13 |
1.285e-02 | -4.35 | SORT1 (sortilin 1) | protein interactions | 6272 | 194 | 3 | 19454 | 49 |
TBC1D8,P2RY6,TLN1 |
1.287e-02 | -4.35 | regulation of B cell proliferation | biological process | GO:0030888 | 64 | 2 | 18204 | 49 |
VAV3,CD74 |
1.287e-02 | -4.35 | cellular senescence | biological process | GO:0090398 | 64 | 2 | 18204 | 49 |
PRKCD,SPI1 |
1.287e-02 | -4.35 | regulation of interleukin-12 production | biological process | GO:0032655 | 64 | 2 | 18204 | 49 |
IRF5,PLCG2 |
1.292e-02 | -4.35 | Signaling by ERBB2 | REACTOME pathways | R-HSA-1227986 | 51 | 2 | 10285 | 35 |
GAB1,PRKCD |
1.293e-02 | -4.35 | Talin, central domain | gene3d domains | 1.20.1420.10 | 4 | 1 | 14470 | 47 |
TLN1 |
1.293e-02 | -4.35 | plasma membrane signaling receptor complex | cellular component | GO:0098802 | 191 | 3 | 19108 | 49 |
SKAP1,PTPN6,IL6R |
1.293e-02 | -4.35 | regulation of cytokine-mediated signaling pathway | biological process | GO:0001959 | 182 | 3 | 18204 | 49 |
HIF1A,CD74,PTPN6 |
1.294e-02 | -4.35 | PSMD3 (proteasome 26S subunit, non-ATPase 3) | protein interactions | 5709 | 362 | 4 | 19454 | 49 |
PTPN6,P2RY6,PLCG2,CD74 |
1.299e-02 | -4.34 | Interleukin-3, 5 and GM-CSF signaling | REACTOME pathways | R-HSA-512988 | 271 | 4 | 10285 | 35 |
BLNK,HCK,PTPN6,TLN1 |
1.303e-02 | -4.34 | CD2AP (CD2 associated protein) | protein interactions | 23607 | 195 | 3 | 19454 | 49 |
HCK,BLNK,RHBDF2 |
1.304e-02 | -4.34 | SH3_9 | pfam domains | PF14604 | 63 | 2 | 17795 | 49 |
SKAP1,ARHGAP33 |
1.304e-02 | -4.34 | femur | COSMIC cancer mutations | femur | 1197 | 8 | 16828 | 45 |
WDFY4,BLNK,AKAP13,RHBDF2,DOCK10,PREX1,P2RY2,ARHGAP15 |
1.306e-02 | -4.34 | phosphorylation | biological process | GO:0016310 | 729 | 6 | 18204 | 49 |
NRK,HCK,PRKCD,PTPN6,CSF1R,NEK6 |
1.307e-02 | -4.34 | regulation of response to stress | biological process | GO:0080134 | 1431 | 9 | 18204 | 49 |
SPI1,SBNO2,PRKCD,HCK,CD74,RHBDF2,APOE,PTPN6,PLCG2 |
1.310e-02 | -4.34 | EVL (Enah/Vasp-like) | protein interactions | 51466 | 69 | 2 | 19454 | 49 |
FYB1,HCK |
1.310e-02 | -4.34 | anatomical structure morphogenesis | biological process | GO:0009653 | 2225 | 12 | 18204 | 49 |
VAV3,HIF1A,SPI1,DOCK1,DOCK10,DOCK2,PTPN6,GAB1,CSF1R,STAT6,SBNO2,APOE |
1.310e-02 | -4.33 | Neurotrophin signaling pathway | KEGG pathways | ko04722 | 119 | 3 | 7161 | 30 |
GAB1,PLCG2,PRKCD |
1.310e-02 | -4.33 | Neurotrophin signaling pathway | KEGG pathways | hsa04722 | 119 | 3 | 7161 | 30 |
PLCG2,PRKCD,GAB1 |
1.316e-02 | -4.33 | Gasdermin_PUB | interpro domains | IPR041263 | 5 | 1 | 18521 | 49 |
GSDME |
1.316e-02 | -4.33 | Hematopoietin_rcpt_L_F3_CS | interpro domains | IPR003530 | 5 | 1 | 18521 | 49 |
IL6R |
1.321e-02 | -4.33 | BLK (BLK proto-oncogene, Src family tyrosine kinase) | protein interactions | 640 | 196 | 3 | 19454 | 49 |
HCK,GAB1,PLCG2 |
1.325e-02 | -4.32 | T cell differentiation in thymus | biological process | GO:0033077 | 65 | 2 | 18204 | 49 |
DOCK2,CD74 |
1.339e-02 | -4.31 | hypoxia-inducible factor-1alpha signaling pathway | biological process | GO:0097411 | 5 | 1 | 18204 | 49 |
HIF1A |
1.339e-02 | -4.31 | chylomicron remnant clearance | biological process | GO:0034382 | 5 | 1 | 18204 | 49 |
APOE |
1.339e-02 | -4.31 | regulation of mast cell activation involved in immune response | biological process | GO:0033006 | 5 | 1 | 18204 | 49 |
PTPN6 |
1.339e-02 | -4.31 | connective tissue replacement involved in inflammatory response wound healing | biological process | GO:0002248 | 5 | 1 | 18204 | 49 |
HIF1A |
1.339e-02 | -4.31 | negative regulation of filopodium assembly | biological process | GO:0051490 | 5 | 1 | 18204 | 49 |
PRKCD |
1.339e-02 | -4.31 | regulation of microglial cell mediated cytotoxicity | biological process | GO:1904149 | 5 | 1 | 18204 | 49 |
SPI1 |
1.339e-02 | -4.31 | glutamate receptor clustering | biological process | GO:0097688 | 5 | 1 | 18204 | 49 |
APOE |
1.339e-02 | -4.31 | epididymis development | biological process | GO:1905867 | 5 | 1 | 18204 | 49 |
PTPN6 |
1.339e-02 | -4.31 | regulation of glucosylceramide catabolic process | biological process | GO:2000752 | 5 | 1 | 18204 | 49 |
PRKCD |
1.339e-02 | -4.31 | positive regulation of amyloid fibril formation | biological process | GO:1905908 | 5 | 1 | 18204 | 49 |
APOE |
1.339e-02 | -4.31 | negative regulation of adipose tissue development | biological process | GO:1904178 | 5 | 1 | 18204 | 49 |
SPI1 |
1.339e-02 | -4.31 | positive regulation of deoxyribonuclease activity | biological process | GO:0032077 | 5 | 1 | 18204 | 49 |
PRKCD |
1.339e-02 | -4.31 | regulation of antifungal innate immune response | biological process | GO:1905034 | 5 | 1 | 18204 | 49 |
SPI1 |
1.339e-02 | -4.31 | positive regulation of dendritic spine maintenance | biological process | GO:1902952 | 5 | 1 | 18204 | 49 |
APOE |
1.339e-02 | -4.31 | AMPA glutamate receptor clustering | biological process | GO:0097113 | 5 | 1 | 18204 | 49 |
APOE |
1.339e-02 | -4.31 | ciliary neurotrophic factor-mediated signaling pathway | biological process | GO:0070120 | 5 | 1 | 18204 | 49 |
IL6R |
1.339e-02 | -4.31 | regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity | biological process | GO:0031585 | 5 | 1 | 18204 | 49 |
P2RY6 |
1.346e-02 | -4.31 | ITGB3 (integrin subunit beta 3) | protein interactions | 3690 | 70 | 2 | 19454 | 49 |
TLN1,P2RY2 |
1.356e-02 | -4.30 | chondroblastoma | COSMIC cancer mutations | chondroblastoma | 534 | 5 | 16828 | 45 |
VAV3,PREX1,WDFY4,DOCK2,ARHGAP15 |
1.361e-02 | -4.30 | parathyroid-adenoma | COSMIC cancer mutations | parathyroid-adenoma | 187 | 3 | 16828 | 45 |
PLCG2,TBC1D8,PRKCD |
1.364e-02 | -4.29 | positive regulation of tyrosine phosphorylation of STAT protein | biological process | GO:0042531 | 66 | 2 | 18204 | 49 |
CSF1R,IL6R |
1.364e-02 | -4.29 | neutrophil migration | biological process | GO:1990266 | 66 | 2 | 18204 | 49 |
PREX1,VAV3 |
1.364e-02 | -4.29 | homotypic cell-cell adhesion | biological process | GO:0034109 | 66 | 2 | 18204 | 49 |
PTPN6,TLN1 |
1.369e-02 | -4.29 | Gasdermin_C | pfam domains | PF17708 | 5 | 1 | 17795 | 49 |
GSDME |
1.382e-02 | -4.28 | Integrins in angiogenesis | Pathway Interaction DB | avb3_integrin_pathway | 46 | 3 | 2226 | 25 |
TLN1,CSF1R,VAV3 |
1.390e-02 | -4.28 | regulation of lymphocyte mediated immunity | biological process | GO:0002706 | 187 | 3 | 18204 | 49 |
PTPN6,DENND1B,STAT6 |
1.394e-02 | -4.27 | FANCI (FA complementation group I) | protein interactions | 55215 | 200 | 3 | 19454 | 49 |
NEK6,P2RY6,HIF1A |
1.404e-02 | -4.27 | positive regulation of response to cytokine stimulus | biological process | GO:0060760 | 67 | 2 | 18204 | 49 |
CD74,HIF1A |
1.404e-02 | -4.27 | positive regulation of miRNA metabolic process | biological process | GO:2000630 | 67 | 2 | 18204 | 49 |
SPI1,HIF1A |
1.405e-02 | -4.27 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 748 | 6 | 16828 | 45 |
PLCG2,ELMO1,DOCK1,CD74,HCK,STAT6 |
1.405e-02 | -4.27 | anatomical structure formation involved in morphogenesis | biological process | GO:0048646 | 964 | 7 | 18204 | 49 |
GAB1,VAV3,DOCK2,HIF1A,SBNO2,DOCK1,PTPN6 |
1.406e-02 | -4.26 | innate immune response | biological process | GO:0045087 | 741 | 6 | 18204 | 49 |
IRF5,CSF1R,PTPN6,PLCG2,CD74,HCK |
1.420e-02 | -4.25 | FANCL (FA complementation group L) | protein interactions | 55120 | 72 | 2 | 19454 | 49 |
IL6R,DOCK8 |
1.420e-02 | -4.25 | ITGB2 (integrin subunit beta 2) | protein interactions | 3689 | 72 | 2 | 19454 | 49 |
PRKCD,TLN1 |
1.430e-02 | -4.25 | regulation of lipid biosynthetic process | biological process | GO:0046890 | 189 | 3 | 18204 | 49 |
APOE,CD74,PRKCD |
1.430e-02 | -4.25 | regulation of intrinsic apoptotic signaling pathway | biological process | GO:2001242 | 189 | 3 | 18204 | 49 |
CD74,HIF1A,GSDME |
1.437e-02 | -4.24 | I_LWEQ | prosite domains | PS50945 | 4 | 1 | 12186 | 44 |
TLN1 |
1.437e-02 | -4.24 | C2_NT | prosite domains | PS51840 | 4 | 1 | 12186 | 44 |
EHBP1L1 |
1.444e-02 | -4.24 | cellular response to hydrogen peroxide | biological process | GO:0070301 | 68 | 2 | 18204 | 49 |
STAT6,PRKCD |
1.444e-02 | -4.24 | cell-cell recognition | biological process | GO:0009988 | 68 | 2 | 18204 | 49 |
DOCK8,DOCK2 |
1.444e-02 | -4.24 | negative regulation of leukocyte mediated immunity | biological process | GO:0002704 | 68 | 2 | 18204 | 49 |
SPI1,PTPN6 |
1.444e-02 | -4.24 | CD4-positive, alpha-beta T cell activation | biological process | GO:0035710 | 68 | 2 | 18204 | 49 |
STAT6,IL6R |
1.458e-02 | -4.23 | PANK4 (pantothenate kinase 4 (inactive)) | protein interactions | 55229 | 73 | 2 | 19454 | 49 |
GMIP,PTPN6 |
1.466e-02 | -4.22 | CH | pfam domains | PF00307 | 67 | 2 | 17795 | 49 |
EHBP1L1,PARVG |
1.470e-02 | -4.22 | INPPL1 (inositol polyphosphate phosphatase like 1) | protein interactions | 3636 | 204 | 3 | 19454 | 49 |
CSF1R,GAB1,STAT6 |
1.477e-02 | -4.22 | Immunoglobulin | interpro domains | IPR013151 | 70 | 2 | 18521 | 49 |
IL6R,CSF1R |
1.485e-02 | -4.21 | regulation of blood coagulation | biological process | GO:0030193 | 69 | 2 | 18204 | 49 |
PRKCD,APOE |
1.496e-02 | -4.20 | TEC (tec protein tyrosine kinase) | protein interactions | 7006 | 74 | 2 | 19454 | 49 |
GAB1,PLCG2 |
1.496e-02 | -4.20 | NGEF (neuronal guanine nucleotide exchange factor) | protein interactions | 25791 | 74 | 2 | 19454 | 49 |
HCK,PRKCD |
1.498e-02 | -4.20 | response to molecule of bacterial origin | biological process | GO:0002237 | 354 | 4 | 18204 | 49 |
IRF5,PLCG2,SBNO2,HCK |
1.502e-02 | -4.20 | CD300LF (CD300 molecule like family member f) | protein interactions | 146722 | 6 | 1 | 19454 | 49 |
PTPN6 |
1.502e-02 | -4.20 | FXYD7 (FXYD domain containing ion transport regulator 7) | protein interactions | 53822 | 6 | 1 | 19454 | 49 |
APOE |
1.502e-02 | -4.20 | EBNA-2 (nuclear antigen EBNA-2) | protein interactions | 3783761 | 6 | 1 | 19454 | 49 |
SPI1 |
1.502e-02 | -4.20 | SETD9 (SET domain containing 9) | protein interactions | 133383 | 6 | 1 | 19454 | 49 |
PLCG2 |
1.502e-02 | -4.20 | NBPF22P (NBPF member 22, pseudogene) | protein interactions | 285622 | 6 | 1 | 19454 | 49 |
PARVG |
1.502e-02 | -4.20 | LCAT (lecithin-cholesterol acyltransferase) | protein interactions | 3931 | 6 | 1 | 19454 | 49 |
APOE |
1.502e-02 | -4.20 | echA1 (enoyl-CoA hydratase EchA1) | protein interactions | 886723 | 6 | 1 | 19454 | 49 |
PTPN6 |
1.509e-02 | -4.19 | superpathway of inositol phosphate compounds | BIOCYC pathways | HUMAN_PWY-6371 | 66 | 2 | 902 | 3 |
PLCG2,PIK3R5 |
1.526e-02 | -4.18 | positive regulation of reactive oxygen species metabolic process | biological process | GO:2000379 | 70 | 2 | 18204 | 49 |
PLCG2,PRKCD |
1.529e-02 | -4.18 | multivesicular body, internal vesicle | cellular component | GO:0097487 | 6 | 1 | 19108 | 49 |
APOE |
1.533e-02 | -4.18 | regulation of response to cytokine stimulus | biological process | GO:0060759 | 194 | 3 | 18204 | 49 |
PTPN6,CD74,HIF1A |
1.533e-02 | -4.18 | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | biological process | GO:0002822 | 194 | 3 | 18204 | 49 |
PTPN6,DENND1B,STAT6 |
1.537e-02 | -4.18 | lobular_carcinoma | COSMIC cancer mutations | lobular_carcinoma | 763 | 6 | 16828 | 45 |
GMIP,CSF1R,NEK6,WDFY4,PRKCD,HCK |
1.537e-02 | -4.18 | breast-carcinoma-lobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-lobular_carcinoma | 763 | 6 | 16828 | 45 |
GMIP,PRKCD,WDFY4,HCK,CSF1R,NEK6 |
1.547e-02 | -4.17 | PAK2 (p21 (RAC1) activated kinase 2) | protein interactions | 5062 | 208 | 3 | 19454 | 49 |
DOCK2,HCK,GIT2 |
1.548e-02 | -4.17 | Signaling of Hepatocyte Growth Factor Receptor | WikiPathways | WP313 | 34 | 2 | 5310 | 30 |
GAB1,DOCK1 |
1.549e-02 | -4.17 | phosphatidylcholine-sterol O-acyltransferase activator activity | molecular function | GO:0060228 | 6 | 1 | 18094 | 47 |
APOE |
1.549e-02 | -4.17 | NFAT protein binding | molecular function | GO:0051525 | 6 | 1 | 18094 | 47 |
SPI1 |
1.549e-02 | -4.17 | LIM domain binding | molecular function | GO:0030274 | 6 | 1 | 18094 | 47 |
TLN1 |
1.567e-02 | -4.16 | regulation of hemostasis | biological process | GO:1900046 | 71 | 2 | 18204 | 49 |
APOE,PRKCD |
1.567e-02 | -4.16 | lymphocyte homeostasis | biological process | GO:0002260 | 71 | 2 | 18204 | 49 |
HIF1A,DOCK10 |
1.573e-02 | -4.15 | RUNX2 (RUNX family transcription factor 2) | protein interactions | 860 | 76 | 2 | 19454 | 49 |
HIF1A,PRKCD |
1.577e-02 | -4.15 | Adcy_conserved_dom | interpro domains | IPR009398 | 6 | 1 | 18521 | 49 |
ADCY7 |
1.577e-02 | -4.15 | ELMO_dom | interpro domains | IPR006816 | 6 | 1 | 18521 | 49 |
ELMO1 |
1.577e-02 | -4.15 | Gasdermin_pore | interpro domains | IPR040460 | 6 | 1 | 18521 | 49 |
GSDME |
1.577e-02 | -4.15 | CAMSAP-like_CH_dom | interpro domains | IPR022613 | 6 | 1 | 18521 | 49 |
VAV3 |
1.587e-02 | -4.14 | clathrin-coated endocytic vesicle membrane | cellular component | GO:0030669 | 75 | 2 | 19108 | 49 |
CD74,APOE |
1.588e-02 | -4.14 | G Protein Signaling Pathways | WikiPathways | WP35 | 95 | 3 | 5310 | 30 |
ADCY7,AKAP13,PRKCD |
1.592e-02 | -4.14 | cerebellum | COSMIC cancer mutations | cerebellum | 769 | 6 | 16828 | 45 |
SKAP1,ELMO1,DOCK2,WDFY4,STAT6,DOCK10 |
1.592e-02 | -4.14 | ig | pfam domains | PF00047 | 70 | 2 | 17795 | 49 |
IL6R,CSF1R |
1.595e-02 | -4.14 | positive regulation of protein modification process | biological process | GO:0031401 | 762 | 6 | 18204 | 49 |
CSF1R,PIK3R5,CD74,IL6R,PLCG2,PRKCD |
1.595e-02 | -4.14 | cell projection | cellular component | GO:0042995 | 2398 | 12 | 19108 | 49 |
RGS14,APOE,DOCK8,PREX1,TLN1,PLCG2,HIF1A,ARHGAP33,DOCK10,HCK,MYO1F,CARMIL3 |
1.596e-02 | -4.14 | ILWEQ | smart domains | SM00307 | 4 | 1 | 9717 | 39 |
TLN1 |
1.597e-02 | -4.14 | protein localization to plasma membrane | biological process | GO:0072659 | 197 | 3 | 18204 | 49 |
SKAP1,RHBDF2,FYB1 |
1.604e-02 | -4.13 | triglyceride-rich lipoprotein particle clearance | biological process | GO:0071830 | 6 | 1 | 18204 | 49 |
APOE |
1.604e-02 | -4.13 | regulation of phospholipid translocation | biological process | GO:0061091 | 6 | 1 | 18204 | 49 |
PRKCD |
1.604e-02 | -4.13 | negative regulation of protein localization to chromatin | biological process | GO:0120186 | 6 | 1 | 18204 | 49 |
SPI1 |
1.604e-02 | -4.13 | membrane raft distribution | biological process | GO:0031580 | 6 | 1 | 18204 | 49 |
DOCK2 |
1.604e-02 | -4.13 | positive regulation of nuclease activity | biological process | GO:0032075 | 6 | 1 | 18204 | 49 |
PRKCD |
1.604e-02 | -4.13 | regulation of low-density lipoprotein particle receptor catabolic process | biological process | GO:0032803 | 6 | 1 | 18204 | 49 |
APOE |
1.604e-02 | -4.13 | inositol trisphosphate metabolic process | biological process | GO:0032957 | 6 | 1 | 18204 | 49 |
PLCG2 |
1.604e-02 | -4.13 | osteoclast fusion | biological process | GO:0072675 | 6 | 1 | 18204 | 49 |
SBNO2 |
1.604e-02 | -4.13 | oncogene-induced cell senescence | biological process | GO:0090402 | 6 | 1 | 18204 | 49 |
SPI1 |
1.604e-02 | -4.13 | positive regulation of prostaglandin biosynthetic process | biological process | GO:0031394 | 6 | 1 | 18204 | 49 |
CD74 |
1.604e-02 | -4.13 | regulation of defense response to fungus | biological process | GO:1900150 | 6 | 1 | 18204 | 49 |
SPI1 |
1.604e-02 | -4.13 | regulation of lipid transporter activity | biological process | GO:0110112 | 6 | 1 | 18204 | 49 |
PRKCD |
1.604e-02 | -4.13 | interleukin-11-mediated signaling pathway | biological process | GO:0038154 | 6 | 1 | 18204 | 49 |
IL6R |
1.604e-02 | -4.13 | positive regulation of I-kappaB phosphorylation | biological process | GO:1903721 | 6 | 1 | 18204 | 49 |
PLCG2 |
1.604e-02 | -4.13 | elastin metabolic process | biological process | GO:0051541 | 6 | 1 | 18204 | 49 |
HIF1A |
1.604e-02 | -4.13 | positive regulation of mucus secretion | biological process | GO:0070257 | 6 | 1 | 18204 | 49 |
P2RY2 |
1.604e-02 | -4.13 | positive regulation of macrophage proliferation | biological process | GO:0120041 | 6 | 1 | 18204 | 49 |
CSF1R |
1.604e-02 | -4.13 | hemoglobin biosynthetic process | biological process | GO:0042541 | 6 | 1 | 18204 | 49 |
HIF1A |
1.604e-02 | -4.13 | regulation of establishment of T cell polarity | biological process | GO:1903903 | 6 | 1 | 18204 | 49 |
DOCK8 |
1.604e-02 | -4.13 | intestinal epithelial cell maturation | biological process | GO:0060574 | 6 | 1 | 18204 | 49 |
HIF1A |
1.604e-02 | -4.13 | positive regulation of cell-cell adhesion mediated by integrin | biological process | GO:0033634 | 6 | 1 | 18204 | 49 |
SKAP1 |
1.607e-02 | -4.13 | HEATR1 (HEAT repeat containing 1) | protein interactions | 55127 | 211 | 3 | 19454 | 49 |
P2RY2,P2RY6,HIF1A |
1.613e-02 | -4.13 | DYM (dymeclin) | protein interactions | 54808 | 77 | 2 | 19454 | 49 |
P2RY2,P2RY6 |
1.614e-02 | -4.13 | Apolipoprotein | gene3d domains | 1.20.120.20 | 5 | 1 | 14470 | 47 |
APOE |
1.636e-02 | -4.11 | Alpha 6 Beta 4 signaling pathway | WikiPathways | WP244 | 35 | 2 | 5310 | 30 |
GAB1,PRKCD |
1.640e-02 | -4.11 | positive regulation of protein-containing complex assembly | biological process | GO:0031334 | 199 | 3 | 18204 | 49 |
PLCG2,SKAP1,HCK |
1.640e-02 | -4.11 | head_neck | COSMIC cancer mutations | head_neck | 15361 | 45 | 16828 | 45 |
IPCEF1,ELMO1,RGS14,BLNK,SKAP1,GAB1,ARHGAP33,PTPN6,PREX1,SPI1,VAV3,DOCK8,TLN1,PLCG2,P2RY6,IL6R,MYO1F,DENND1B,GMIP,ARHGAP15,P2RY2,ADCY7,DOCK2,TBXAS1,ARHGAP27,PARVG,CD74,PIK3R5,AKAP13,IRF5,HIF1A,NEK6,EHBP1L1,SBNO2,DOCK1,HCK,STAT6,RHBDF2,TBC1D8,WDFY4,GIT2,CSF1R,APOE,PRKCD,DOCK10 |
1.641e-02 | -4.11 | ELMO_CED12 | pfam domains | PF04727 | 6 | 1 | 17795 | 49 |
ELMO1 |
1.641e-02 | -4.11 | Adcy_cons_dom | pfam domains | PF06327 | 6 | 1 | 17795 | 49 |
ADCY7 |
1.641e-02 | -4.11 | Gasdermin | pfam domains | PF04598 | 6 | 1 | 17795 | 49 |
GSDME |
1.641e-02 | -4.11 | CAMSAP_CH | pfam domains | PF11971 | 6 | 1 | 17795 | 49 |
VAV3 |
1.641e-02 | -4.11 | RBD | pfam domains | PF02196 | 6 | 1 | 17795 | 49 |
RGS14 |
1.650e-02 | -4.10 | protein kinase activity | molecular function | GO:0004672 | 577 | 5 | 18094 | 47 |
NEK6,PRKCD,CSF1R,HCK,NRK |
1.652e-02 | -4.10 | negative regulation of wound healing | biological process | GO:0061045 | 73 | 2 | 18204 | 49 |
APOE,PRKCD |
1.652e-02 | -4.10 | positive regulation of phagocytosis | biological process | GO:0050766 | 73 | 2 | 18204 | 49 |
PLCG2,DOCK2 |
1.668e-02 | -4.09 | GNAI3 (G protein subunit alpha i3) | protein interactions | 2773 | 214 | 3 | 19454 | 49 |
RHBDF2,RGS14,GAB1 |
1.668e-02 | -4.09 | NCK1 (NCK adaptor protein 1) | protein interactions | 4690 | 214 | 3 | 19454 | 49 |
BLNK,GAB1,GIT2 |
1.689e-02 | -4.08 | XPO5 (exportin 5) | protein interactions | 57510 | 215 | 3 | 19454 | 49 |
NEK6,P2RY6,HIF1A |
1.690e-02 | -4.08 | MET activates PTPN11 | REACTOME pathways | R-HSA-8865999 | 5 | 1 | 10285 | 35 |
GAB1 |
1.690e-02 | -4.08 | PTK6 Expression | REACTOME pathways | R-HSA-8849473 | 5 | 1 | 10285 | 35 |
HIF1A |
1.693e-02 | -4.08 | IRF4 (interferon regulatory factor 4) | protein interactions | 3662 | 79 | 2 | 19454 | 49 |
STAT6,SPI1 |
1.695e-02 | -4.08 | regulation of coagulation | biological process | GO:0050818 | 74 | 2 | 18204 | 49 |
PRKCD,APOE |
1.706e-02 | -4.07 | regulation of protein polymerization | biological process | GO:0032271 | 202 | 3 | 18204 | 49 |
HCK,PRKCD,PREX1 |
1.710e-02 | -4.07 | HACD3 (3-hydroxyacyl-CoA dehydratase 3) | protein interactions | 51495 | 216 | 3 | 19454 | 49 |
ARHGAP15,NEK6,P2RY6 |
1.714e-02 | -4.07 | positive regulation of macromolecule biosynthetic process | biological process | GO:0010557 | 2592 | 13 | 18204 | 49 |
PLCG2,APOE,BLNK,IRF5,HIF1A,STAT6,DENND1B,CD74,IL6R,SPI1,SKAP1,SBNO2,CSF1R |
1.722e-02 | -4.06 | negative regulation of response to stimulus | biological process | GO:0048585 | 1760 | 10 | 18204 | 49 |
APOE,RHBDF2,PTPN6,RGS14,CD74,HIF1A,HCK,STAT6,PRKCD,SPI1 |
1.729e-02 | -4.06 | Natural killer cell mediated cytotoxicity | KEGG pathways | ko04650 | 132 | 3 | 7161 | 30 |
PTPN6,VAV3,PLCG2 |
1.729e-02 | -4.06 | Natural killer cell mediated cytotoxicity | KEGG pathways | hsa04650 | 132 | 3 | 7161 | 30 |
VAV3,PLCG2,PTPN6 |
1.729e-02 | -4.06 | PRKCA (protein kinase C alpha) | protein interactions | 5578 | 395 | 4 | 19454 | 49 |
PTPN6,PLCG2,AKAP13,PRKCD |
1.732e-02 | -4.06 | adrenal_gland | COSMIC cancer mutations | adrenal_gland | 2628 | 13 | 16828 | 45 |
PTPN6,DOCK1,SKAP1,SBNO2,DOCK8,ADCY7,DOCK2,IPCEF1,ELMO1,CSF1R,RGS14,BLNK,WDFY4 |
1.734e-02 | -4.05 | kidney | COSMIC cancer mutations | kidney | 15380 | 45 | 16828 | 45 |
WDFY4,GIT2,CSF1R,RHBDF2,TBC1D8,IL6R,MYO1F,DOCK10,DENND1B,APOE,PLCG2,PRKCD,P2RY6,VAV3,NEK6,HIF1A,IRF5,SPI1,AKAP13,DOCK8,HCK,TLN1,STAT6,SBNO2,EHBP1L1,DOCK1,TBXAS1,ADCY7,DOCK2,PIK3R5,PREX1,ARHGAP27,PTPN6,CD74,PARVG,RGS14,BLNK,IPCEF1,ELMO1,GMIP,P2RY2,ARHGAP15,SKAP1,GAB1,ARHGAP33 |
1.738e-02 | -4.05 | positive regulation of type I interferon production | biological process | GO:0032481 | 75 | 2 | 18204 | 49 |
IRF5,PLCG2 |
1.738e-02 | -4.05 | negative regulation of protein secretion | biological process | GO:0050709 | 75 | 2 | 18204 | 49 |
APOE,RHBDF2 |
1.750e-02 | -4.05 | LAIR1 (leukocyte associated immunoglobulin like receptor 1) | protein interactions | 3903 | 7 | 1 | 19454 | 49 |
PTPN6 |
1.750e-02 | -4.05 | HGD (homogentisate 1,2-dioxygenase) | protein interactions | 3081 | 7 | 1 | 19454 | 49 |
GIT2 |
1.750e-02 | -4.05 | SIGLEC9 (sialic acid binding Ig like lectin 9) | protein interactions | 27180 | 7 | 1 | 19454 | 49 |
PTPN6 |
1.750e-02 | -4.05 | KCNJ1 (potassium inwardly rectifying channel subfamily J member 1) | protein interactions | 3758 | 7 | 1 | 19454 | 49 |
PRKCD |
1.750e-02 | -4.05 | ERCC6L2 (ERCC excision repair 6 like 2) | protein interactions | 375748 | 7 | 1 | 19454 | 49 |
NEK6 |
1.750e-02 | -4.05 | CDHR3 (cadherin related family member 3) | protein interactions | 222256 | 7 | 1 | 19454 | 49 |
PARVG |
1.750e-02 | -4.05 | NSUN7 (NOP2/Sun RNA methyltransferase family member 7) | protein interactions | 79730 | 7 | 1 | 19454 | 49 |
PTPN6 |
1.750e-02 | -4.05 | DNAI1 (dynein axonemal intermediate chain 1) | protein interactions | 27019 | 7 | 1 | 19454 | 49 |
HIF1A |
1.752e-02 | -4.04 | KRTAP1-1 (keratin associated protein 1-1) | protein interactions | 81851 | 218 | 3 | 19454 | 49 |
P2RY6,HCK,DOCK2 |
1.774e-02 | -4.03 | KRTAP3-3 (keratin associated protein 3-3) | protein interactions | 85293 | 81 | 2 | 19454 | 49 |
P2RY6,DOCK2 |
1.774e-02 | -4.03 | MRS2 (magnesium transporter MRS2) | protein interactions | 57380 | 81 | 2 | 19454 | 49 |
P2RY2,GSDME |
1.782e-02 | -4.03 | alpha-beta T cell differentiation | biological process | GO:0046632 | 76 | 2 | 18204 | 49 |
IL6R,STAT6 |
1.782e-02 | -4.03 | regulation of tyrosine phosphorylation of STAT protein | biological process | GO:0042509 | 76 | 2 | 18204 | 49 |
CSF1R,IL6R |
1.782e-02 | -4.03 | regulation of miRNA transcription | biological process | GO:1902893 | 76 | 2 | 18204 | 49 |
SPI1,HIF1A |
1.782e-02 | -4.03 | myotube differentiation | biological process | GO:0014902 | 76 | 2 | 18204 | 49 |
DOCK2,DOCK1 |
1.793e-02 | -4.02 | HEMATOPO_REC_L_F3 | prosite domains | PS01354 | 5 | 1 | 12186 | 44 |
IL6R |
1.804e-02 | -4.01 | MHC class II protein binding | molecular function | GO:0042289 | 7 | 1 | 18094 | 47 |
CD74 |
1.804e-02 | -4.01 | hydroperoxy icosatetraenoate dehydratase activity | molecular function | GO:0106256 | 7 | 1 | 18094 | 47 |
TBXAS1 |
1.804e-02 | -4.01 | interleukin-6 receptor binding | molecular function | GO:0005138 | 7 | 1 | 18094 | 47 |
IL6R |
1.816e-02 | -4.01 | BLVRA (biliverdin reductase A) | protein interactions | 644 | 82 | 2 | 19454 | 49 |
TLN1,PRKCD |
1.816e-02 | -4.01 | STAT6 (signal transducer and activator of transcription 6) | protein interactions | 6778 | 82 | 2 | 19454 | 49 |
STAT6,PTPN6 |
1.818e-02 | -4.01 | Type II interferon signaling (IFNG) | WikiPathways | WP619 | 37 | 2 | 5310 | 30 |
SPI1,PRKCD |
1.829e-02 | -4.00 | WH_DNA-bd_sf | interpro domains | IPR036390 | 211 | 3 | 18521 | 49 |
SPI1,PREX1,IRF5 |
1.838e-02 | -4.00 | STAT_linker | interpro domains | IPR048988 | 7 | 1 | 18521 | 49 |
STAT6 |
1.838e-02 | -4.00 | Alpha-catenin/vinculin-like_sf | interpro domains | IPR036723 | 7 | 1 | 18521 | 49 |
TLN1 |
1.838e-02 | -4.00 | Interferon_reg_factor-3 | interpro domains | IPR019471 | 7 | 1 | 18521 | 49 |
IRF5 |
1.838e-02 | -4.00 | STAT_N_sf | interpro domains | IPR036535 | 7 | 1 | 18521 | 49 |
STAT6 |
1.838e-02 | -4.00 | STAT_TF_prot_interaction | interpro domains | IPR013799 | 7 | 1 | 18521 | 49 |
STAT6 |
1.838e-02 | -4.00 | GoLoco_motif | interpro domains | IPR003109 | 7 | 1 | 18521 | 49 |
RGS14 |
1.838e-02 | -4.00 | STAT_TF_DNA-bd_N | interpro domains | IPR012345 | 7 | 1 | 18521 | 49 |
STAT6 |
1.838e-02 | -4.00 | RBD_dom | interpro domains | IPR003116 | 7 | 1 | 18521 | 49 |
RGS14 |
1.838e-02 | -4.00 | STAT | interpro domains | IPR001217 | 7 | 1 | 18521 | 49 |
STAT6 |
1.838e-02 | -4.00 | STAT_TF_alpha | interpro domains | IPR013800 | 7 | 1 | 18521 | 49 |
STAT6 |
1.838e-02 | -4.00 | STAT_TF_coiled-coil | interpro domains | IPR015988 | 7 | 1 | 18521 | 49 |
STAT6 |
1.838e-02 | -4.00 | STAT_TF_DNA-bd | interpro domains | IPR013801 | 7 | 1 | 18521 | 49 |
STAT6 |
1.838e-02 | -4.00 | MYSc_Myo1 | interpro domains | IPR036072 | 7 | 1 | 18521 | 49 |
MYO1F |
1.838e-02 | -4.00 | PH_16 | interpro domains | IPR041020 | 7 | 1 | 18521 | 49 |
AKAP13 |
1.843e-02 | -3.99 | Paxillin-dependent events mediated by a4b1 | Pathway Interaction DB | a4b1_paxdep_pathway | 19 | 2 | 2226 | 25 |
TLN1,DOCK1 |
1.843e-02 | -3.99 | cellular response to lipopolysaccharide | biological process | GO:0071222 | 208 | 3 | 18204 | 49 |
SBNO2,PLCG2,HCK |
1.844e-02 | -3.99 | negative regulation of phosphate metabolic process | biological process | GO:0045936 | 377 | 4 | 18204 | 49 |
PRKCD,RGS14,PTPN6,APOE |
1.860e-02 | -3.98 | negative regulation of phosphorus metabolic process | biological process | GO:0010563 | 378 | 4 | 18204 | 49 |
APOE,PRKCD,PTPN6,RGS14 |
1.864e-02 | -3.98 | regulation of apoptotic process | biological process | GO:0042981 | 1518 | 9 | 18204 | 49 |
GSDME,CSF1R,PRKCD,HIF1A,HCK,CD74,IRF5,DOCK8,PTPN6 |
1.866e-02 | -3.98 | positive regulation of canonical NF-kappaB signal transduction | biological process | GO:0043123 | 209 | 3 | 18204 | 49 |
NEK6,CD74,AKAP13 |
1.866e-02 | -3.98 | regulation of chemotaxis | biological process | GO:0050920 | 209 | 3 | 18204 | 49 |
CSF1R,IL6R,CD74 |
1.869e-02 | -3.98 | positive regulation of interleukin-23 production | biological process | GO:0032747 | 7 | 1 | 18204 | 49 |
PLCG2 |
1.869e-02 | -3.98 | macropinocytosis | biological process | GO:0044351 | 7 | 1 | 18204 | 49 |
DOCK2 |
1.869e-02 | -3.98 | wound healing involved in inflammatory response | biological process | GO:0002246 | 7 | 1 | 18204 | 49 |
HIF1A |
1.869e-02 | -3.98 | neural fold formation | biological process | GO:0001842 | 7 | 1 | 18204 | 49 |
HIF1A |
1.869e-02 | -3.98 | positive regulation of dendritic cell antigen processing and presentation | biological process | GO:0002606 | 7 | 1 | 18204 | 49 |
CD74 |
1.869e-02 | -3.98 | interleukin-4-mediated signaling pathway | biological process | GO:0035771 | 7 | 1 | 18204 | 49 |
STAT6 |
1.869e-02 | -3.98 | positive regulation of activation of Janus kinase activity | biological process | GO:0010536 | 7 | 1 | 18204 | 49 |
IL6R |
1.869e-02 | -3.98 | delamination | biological process | GO:0060232 | 7 | 1 | 18204 | 49 |
SPI1 |
1.869e-02 | -3.98 | positive regulation of glomerular mesangial cell proliferation | biological process | GO:0072126 | 7 | 1 | 18204 | 49 |
IL6R |
1.869e-02 | -3.98 | positive regulation of receptor catabolic process | biological process | GO:2000646 | 7 | 1 | 18204 | 49 |
APOE |
1.869e-02 | -3.98 | regulation of mast cell proliferation | biological process | GO:0070666 | 7 | 1 | 18204 | 49 |
STAT6 |
1.869e-02 | -3.98 | positive regulation of sphingolipid biosynthetic process | biological process | GO:0090154 | 7 | 1 | 18204 | 49 |
PRKCD |
1.869e-02 | -3.98 | regulation of macrophage proliferation | biological process | GO:0120040 | 7 | 1 | 18204 | 49 |
CSF1R |
1.869e-02 | -3.98 | positive regulation of ceramide biosynthetic process | biological process | GO:2000304 | 7 | 1 | 18204 | 49 |
PRKCD |
1.869e-02 | -3.98 | very-low-density lipoprotein particle remodeling | biological process | GO:0034372 | 7 | 1 | 18204 | 49 |
APOE |
1.869e-02 | -3.98 | connective tissue replacement | biological process | GO:0097709 | 7 | 1 | 18204 | 49 |
HIF1A |
1.869e-02 | -3.98 | response to yeast | biological process | GO:0001878 | 7 | 1 | 18204 | 49 |
PLCG2 |
1.869e-02 | -3.98 | membrane raft localization | biological process | GO:0051665 | 7 | 1 | 18204 | 49 |
DOCK2 |
1.869e-02 | -3.98 | high-density lipoprotein particle clearance | biological process | GO:0034384 | 7 | 1 | 18204 | 49 |
APOE |
1.869e-02 | -3.98 | regulation of phospholipid catabolic process | biological process | GO:0060696 | 7 | 1 | 18204 | 49 |
PRKCD |
1.869e-02 | -3.98 | TRAIL-activated apoptotic signaling pathway | biological process | GO:0036462 | 7 | 1 | 18204 | 49 |
SPI1 |
1.869e-02 | -3.98 | regulation of isotype switching to IgE isotypes | biological process | GO:0048293 | 7 | 1 | 18204 | 49 |
STAT6 |
1.881e-02 | -3.97 | clathrin-coated vesicle | cellular component | GO:0030136 | 220 | 3 | 19108 | 49 |
APOE,DENND1B,CD74 |
1.900e-02 | -3.96 | PHLDB3 (pleckstrin homology like domain family B member 3) | protein interactions | 653583 | 84 | 2 | 19454 | 49 |
SKAP1,GIT2 |
1.900e-02 | -3.96 | PPARA (peroxisome proliferator activated receptor alpha) | protein interactions | 5465 | 84 | 2 | 19454 | 49 |
PRKCD,AKAP13 |
1.900e-02 | -3.96 | PER1 (period circadian regulator 1) | protein interactions | 5187 | 84 | 2 | 19454 | 49 |
SKAP1,HIF1A |
1.900e-02 | -3.96 | KRTAP3-1 (keratin associated protein 3-1) | protein interactions | 83896 | 84 | 2 | 19454 | 49 |
HCK,DOCK2 |
1.900e-02 | -3.96 | Tyr_kinase_cat_dom | interpro domains | IPR020635 | 80 | 2 | 18521 | 49 |
CSF1R,HCK |
1.904e-02 | -3.96 | RINT1 (RAD50 interactor 1) | protein interactions | 60561 | 225 | 3 | 19454 | 49 |
VAV3,P2RY2,P2RY6 |
1.912e-02 | -3.96 | STAT_alpha | pfam domains | PF01017 | 7 | 1 | 17795 | 49 |
STAT6 |
1.912e-02 | -3.96 | STAT_linker | pfam domains | PF21354 | 7 | 1 | 17795 | 49 |
STAT6 |
1.912e-02 | -3.96 | IRF-3 | pfam domains | PF10401 | 7 | 1 | 17795 | 49 |
IRF5 |
1.912e-02 | -3.96 | STAT_bind | pfam domains | PF02864 | 7 | 1 | 17795 | 49 |
STAT6 |
1.912e-02 | -3.96 | STAT_int | pfam domains | PF02865 | 7 | 1 | 17795 | 49 |
STAT6 |
1.912e-02 | -3.96 | PH_16 | pfam domains | PF17838 | 7 | 1 | 17795 | 49 |
AKAP13 |
1.912e-02 | -3.96 | GoLoco | pfam domains | PF02188 | 7 | 1 | 17795 | 49 |
RGS14 |
1.917e-02 | -3.95 | positive regulation of blood vessel endothelial cell migration | biological process | GO:0043536 | 79 | 2 | 18204 | 49 |
GAB1,HIF1A |
1.933e-02 | -3.95 | I/LWEQ domain | gene3d domains | 1.20.1410.10 | 6 | 1 | 14470 | 47 |
TLN1 |
1.934e-02 | -3.95 | astrocytoma_Grade_III | COSMIC cancer mutations | astrocytoma_Grade_III | 1544 | 9 | 16828 | 45 |
ELMO1,DOCK2,WDFY4,VAV3,SKAP1,ARHGAP15,DOCK1,CD74,DOCK10 |
1.942e-02 | -3.94 | cellular response to nitrogen compound | biological process | GO:1901699 | 580 | 5 | 18204 | 49 |
P2RY2,PRKCD,P2RY6,STAT6,GAB1 |
1.942e-02 | -3.94 | response to virus | biological process | GO:0009615 | 383 | 4 | 18204 | 49 |
HIF1A,WDFY4,GSDME,IRF5 |
1.948e-02 | -3.94 | PRKCD (protein kinase C delta) | protein interactions | 5580 | 227 | 3 | 19454 | 49 |
PRKCD,ADCY7,PTPN6 |
1.959e-02 | -3.93 | regulation of leukocyte cell-cell adhesion | biological process | GO:1903037 | 384 | 4 | 18204 | 49 |
DOCK8,CD74,SKAP1,PTPN6 |
1.961e-02 | -3.93 | negative regulation of transferase activity | biological process | GO:0051348 | 213 | 3 | 18204 | 49 |
RGS14,PRKCD,APOE |
1.963e-02 | -3.93 | regulation of cytokine production involved in inflammatory response | biological process | GO:1900015 | 80 | 2 | 18204 | 49 |
ADCY7,HIF1A |
1.980e-02 | -3.92 | large_intestine-colon | COSMIC cancer mutations | large_intestine-colon | 1291 | 8 | 16828 | 45 |
PREX1,TLN1,PLCG2,ARHGAP27,PTPN6,DOCK1,ADCY7,DOCK2 |
1.993e-02 | -3.92 | PCMT1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase) | protein interactions | 5110 | 229 | 3 | 19454 | 49 |
DOCK8,APOE,AKAP13 |
1.998e-02 | -3.91 | Prkca (protein kinase C, alpha) | protein interactions | 24680 | 8 | 1 | 19454 | 49 |
AKAP13 |
1.998e-02 | -3.91 | HIF3A (hypoxia inducible factor 3 subunit alpha) | protein interactions | 64344 | 8 | 1 | 19454 | 49 |
HIF1A |
1.998e-02 | -3.91 | TREML1 (triggering receptor expressed on myeloid cells like 1) | protein interactions | 340205 | 8 | 1 | 19454 | 49 |
PTPN6 |
1.998e-02 | -3.91 | Marcks (myristoylated alanine rich protein kinase C substrate) | protein interactions | 17118 | 8 | 1 | 19454 | 49 |
PRKCD |
1.998e-02 | -3.91 | LILRB1 (leukocyte immunoglobulin like receptor B1) | protein interactions | 10859 | 8 | 1 | 19454 | 49 |
PTPN6 |
1.998e-02 | -3.91 | SSX4 (SSX family member 4) | protein interactions | 6759 | 8 | 1 | 19454 | 49 |
HIF1A |
1.998e-02 | -3.91 | CD1D (CD1d molecule) | protein interactions | 912 | 8 | 1 | 19454 | 49 |
CD74 |
1.998e-02 | -3.91 | vIRF-3 (vIRF-3) | protein interactions | 4961493 | 8 | 1 | 19454 | 49 |
HIF1A |
2.009e-02 | -3.91 | regulation of amide metabolic process | biological process | GO:0034248 | 81 | 2 | 18204 | 49 |
PRKCD,APOE |
2.021e-02 | -3.90 | skin-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-head_neck-carcinoma-squamous_cell_carcinoma | 14191 | 43 | 16828 | 45 |
PREX1,PTPN6,BLNK,RGS14,ELMO1,IPCEF1,SKAP1,ARHGAP33,GAB1,DENND1B,MYO1F,PLCG2,P2RY6,VAV3,SPI1,DOCK8,TLN1,TBXAS1,DOCK2,ADCY7,PIK3R5,ARHGAP27,PARVG,CD74,GMIP,P2RY2,ARHGAP15,WDFY4,GIT2,CSF1R,TBC1D8,RHBDF2,DOCK10,PRKCD,HIF1A,NEK6,IRF5,AKAP13,STAT6,HCK,EHBP1L1,SBNO2,DOCK1 |
2.025e-02 | -3.90 | PTK6 promotes HIF1A stabilization | REACTOME pathways | R-HSA-8857538 | 6 | 1 | 10285 | 35 |
HIF1A |
2.025e-02 | -3.90 | CD22 mediated BCR regulation | REACTOME pathways | R-HSA-5690714 | 6 | 1 | 10285 | 35 |
PTPN6 |
2.025e-02 | -3.90 | MET activates PI3K/AKT signaling | REACTOME pathways | R-HSA-8851907 | 6 | 1 | 10285 | 35 |
GAB1 |
2.027e-02 | -3.90 | breast-carcinoma-basal_(triple-negative)_carcinoma | COSMIC cancer mutations | breast-carcinoma-basal_(triple-negative)_carcinoma | 2981 | 14 | 16828 | 45 |
TBXAS1,CSF1R,PIK3R5,PLCG2,PRKCD,PTPN6,P2RY6,VAV3,HIF1A,ELMO1,P2RY2,TLN1,STAT6,GAB1 |
2.027e-02 | -3.90 | basal_(triple-negative)_carcinoma | COSMIC cancer mutations | basal_(triple-negative)_carcinoma | 2981 | 14 | 16828 | 45 |
ELMO1,VAV3,HIF1A,GAB1,TLN1,STAT6,P2RY2,TBXAS1,CSF1R,PTPN6,P2RY6,PLCG2,PRKCD,PIK3R5 |
2.031e-02 | -3.90 | apoptotic process | biological process | GO:0006915 | 1038 | 7 | 18204 | 49 |
PRKCD,SPI1,DOCK1,IL6R,HIF1A,NEK6,ELMO1 |
2.034e-02 | -3.90 | regulation of lymphocyte differentiation | biological process | GO:0045619 | 216 | 3 | 18204 | 49 |
SPI1,PTPN6,CD74 |
2.034e-02 | -3.90 | regulation of myeloid cell differentiation | biological process | GO:0045637 | 216 | 3 | 18204 | 49 |
SPI1,CD74,HIF1A |
2.039e-02 | -3.89 | NBPF19 (NBPF member 19) | protein interactions | 101060226 | 231 | 3 | 19454 | 49 |
HCK,DOCK2,P2RY6 |
2.041e-02 | -3.89 | ovary | COSMIC cancer mutations | ovary | 14770 | 44 | 16828 | 45 |
GMIP,ARHGAP15,P2RY2,ADCY7,DOCK2,TBXAS1,ARHGAP27,CD74,PARVG,PIK3R5,AKAP13,HIF1A,NEK6,IRF5,EHBP1L1,SBNO2,DOCK1,HCK,STAT6,RHBDF2,TBC1D8,WDFY4,CSF1R,GIT2,APOE,PRKCD,DOCK10,IPCEF1,ELMO1,RGS14,BLNK,SKAP1,GAB1,ARHGAP33,PTPN6,PREX1,SPI1,VAV3,DOCK8,TLN1,PLCG2,P2RY6,IL6R,MYO1F |
2.044e-02 | -3.89 | RHOJ (ras homolog family member J) | protein interactions | 57381 | 628 | 5 | 19454 | 49 |
DOCK8,TBC1D8,GAB1,DOCK10,GIT2 |
2.056e-02 | -3.88 | granulocyte chemotaxis | biological process | GO:0071621 | 82 | 2 | 18204 | 49 |
PREX1,VAV3 |
2.056e-02 | -3.88 | antioxidant activity | molecular function | GO:0016209 | 85 | 2 | 18094 | 47 |
IPCEF1,APOE |
2.059e-02 | -3.88 | positive regulation of cellular catabolic process | biological process | GO:0031331 | 217 | 3 | 18204 | 49 |
APOE,HIF1A,PRKCD |
2.059e-02 | -3.88 | negative regulation of protein localization | biological process | GO:1903828 | 217 | 3 | 18204 | 49 |
RHBDF2,APOE,SPI1 |
2.060e-02 | -3.88 | transcription regulator activator activity | molecular function | GO:0140537 | 8 | 1 | 18094 | 47 |
HIF1A |
2.060e-02 | -3.88 | adenosine receptor binding | molecular function | GO:0031685 | 8 | 1 | 18094 | 47 |
P2RY2 |
2.060e-02 | -3.88 | CD4 receptor binding | molecular function | GO:0042609 | 8 | 1 | 18094 | 47 |
CD74 |
2.062e-02 | -3.88 | BCR (BCR activator of RhoGEF and GTPase) | protein interactions | 613 | 232 | 3 | 19454 | 49 |
HIF1A,PTPN6,HCK |
2.073e-02 | -3.88 | PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) | protein interactions | 5291 | 88 | 2 | 19454 | 49 |
PRKCD,HCK |
2.079e-02 | -3.87 | Transferase(Phosphotransferase) domain 1 | gene3d domains | 1.10.510.10 | 490 | 5 | 14470 | 47 |
NRK,CSF1R,HCK,NEK6,PRKCD |
2.084e-02 | -3.87 | dendrite | cellular component | GO:0030425 | 620 | 5 | 19108 | 49 |
ARHGAP33,RGS14,APOE,PREX1,DOCK10 |
2.097e-02 | -3.86 | Adcy | interpro domains | IPR030672 | 8 | 1 | 18521 | 49 |
ADCY7 |
2.097e-02 | -3.86 | AC_N | interpro domains | IPR032628 | 8 | 1 | 18521 | 49 |
ADCY7 |
2.097e-02 | -3.86 | Myosin_TH1 | interpro domains | IPR010926 | 8 | 1 | 18521 | 49 |
MYO1F |
2.097e-02 | -3.86 | Tyr_kinase_rcpt_3_CS | interpro domains | IPR001824 | 8 | 1 | 18521 | 49 |
CSF1R |
2.097e-02 | -3.86 | bMERB_dom | interpro domains | IPR022735 | 8 | 1 | 18521 | 49 |
EHBP1L1 |
2.097e-02 | -3.86 | TypeI_recpt_CBD | interpro domains | IPR015321 | 8 | 1 | 18521 | 49 |
IL6R |
2.097e-02 | -3.86 | PH-BEACH_dom | interpro domains | IPR023362 | 8 | 1 | 18521 | 49 |
WDFY4 |
2.110e-02 | -3.86 | dendritic tree | cellular component | GO:0097447 | 622 | 5 | 19108 | 49 |
APOE,PREX1,DOCK10,ARHGAP33,RGS14 |
2.117e-02 | -3.85 | INSRR (insulin receptor related receptor) | protein interactions | 3645 | 89 | 2 | 19454 | 49 |
RHBDF2,PRKCD |
2.120e-02 | -3.85 | haematopoietic_and_lymphoid_tissue-other-normal | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-other-normal | 8 | 1 | 16828 | 45 |
CSF1R |
2.130e-02 | -3.85 | Burkitt_lymphoma | COSMIC cancer mutations | Burkitt_lymphoma | 2119 | 11 | 16828 | 45 |
GAB1,DOCK1,ARHGAP15,SKAP1,VAV3,AKAP13,IPCEF1,GMIP,ELMO1,DOCK10,DOCK2 |
2.130e-02 | -3.85 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | 2119 | 11 | 16828 | 45 |
VAV3,AKAP13,DOCK2,IPCEF1,GMIP,ELMO1,DOCK10,GAB1,DOCK1,ARHGAP15,SKAP1 |
2.134e-02 | -3.85 | intracellular oxygen homeostasis | biological process | GO:0032364 | 8 | 1 | 18204 | 49 |
HIF1A |
2.134e-02 | -3.85 | G protein-coupled receptor signaling pathway involved in heart process | biological process | GO:0086103 | 8 | 1 | 18204 | 49 |
AKAP13 |
2.134e-02 | -3.85 | positive regulation of unsaturated fatty acid biosynthetic process | biological process | GO:2001280 | 8 | 1 | 18204 | 49 |
CD74 |
2.134e-02 | -3.85 | cellular response to macrophage colony-stimulating factor stimulus | biological process | GO:0036006 | 8 | 1 | 18204 | 49 |
CSF1R |
2.134e-02 | -3.85 | multinuclear osteoclast differentiation | biological process | GO:0072674 | 8 | 1 | 18204 | 49 |
SBNO2 |
2.134e-02 | -3.85 | mitotic nuclear membrane disassembly | biological process | GO:0007077 | 8 | 1 | 18204 | 49 |
NEK6 |
2.134e-02 | -3.85 | regulation of I-kappaB phosphorylation | biological process | GO:1903719 | 8 | 1 | 18204 | 49 |
PLCG2 |
2.134e-02 | -3.85 | positive regulation of CoA-transferase activity | biological process | GO:1905920 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | protein import | biological process | GO:0017038 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | regulation of endodeoxyribonuclease activity | biological process | GO:0032071 | 8 | 1 | 18204 | 49 |
PRKCD |
2.134e-02 | -3.85 | regulation of activation of Janus kinase activity | biological process | GO:0010533 | 8 | 1 | 18204 | 49 |
IL6R |
2.134e-02 | -3.85 | regulation of neutrophil degranulation | biological process | GO:0043313 | 8 | 1 | 18204 | 49 |
SPI1 |
2.134e-02 | -3.85 | regulation of Cdc42 protein signal transduction | biological process | GO:0032489 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | triglyceride-rich lipoprotein particle remodeling | biological process | GO:0034370 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | positive regulation of amyloid-beta clearance | biological process | GO:1900223 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | regulation of transforming growth factor beta2 production | biological process | GO:0032909 | 8 | 1 | 18204 | 49 |
HIF1A |
2.138e-02 | -3.85 | nuclear speck | cellular component | GO:0016607 | 414 | 4 | 19108 | 49 |
NEK6,HIF1A,DENND1B,DOCK1 |
2.147e-02 | -3.84 | ELMO | prosite domains | PS51335 | 6 | 1 | 12186 | 44 |
ELMO1 |
2.151e-02 | -3.84 | regulation of release of sequestered calcium ion into cytosol | biological process | GO:0051279 | 84 | 2 | 18204 | 49 |
P2RY6,PTPN6 |
2.152e-02 | -3.84 | astrocytoma_Grade_II | COSMIC cancer mutations | astrocytoma_Grade_II | 601 | 5 | 16828 | 45 |
SBNO2,PREX1,TLN1,RGS14,WDFY4 |
2.159e-02 | -3.84 | cellular response to molecule of bacterial origin | biological process | GO:0071219 | 221 | 3 | 18204 | 49 |
SBNO2,PLCG2,HCK |
2.162e-02 | -3.83 | IPO13 (importin 13) | protein interactions | 9670 | 90 | 2 | 19454 | 49 |
CD74,P2RY6 |
2.165e-02 | -3.83 | regulation of apoptotic signaling pathway | biological process | GO:2001233 | 396 | 4 | 18204 | 49 |
PRKCD,HIF1A,CD74,GSDME |
2.180e-02 | -3.83 | PPP6R3 (protein phosphatase 6 regulatory subunit 3) | protein interactions | 55291 | 237 | 3 | 19454 | 49 |
IRF5,P2RY6,CD74 |
2.182e-02 | -3.82 | Myosin_TH1 | pfam domains | PF06017 | 8 | 1 | 17795 | 49 |
MYO1F |
2.182e-02 | -3.82 | IL6Ra-bind | pfam domains | PF09240 | 8 | 1 | 17795 | 49 |
IL6R |
2.182e-02 | -3.82 | bMERB_dom | pfam domains | PF12130 | 8 | 1 | 17795 | 49 |
EHBP1L1 |
2.182e-02 | -3.82 | AC_N | pfam domains | PF16214 | 8 | 1 | 17795 | 49 |
ADCY7 |
2.207e-02 | -3.81 | KDELR1 (KDEL endoplasmic reticulum protein retention receptor 1) | protein interactions | 10945 | 91 | 2 | 19454 | 49 |
NEK6,P2RY2 |
2.227e-02 | -3.80 | human chr6q25.2 | chromosome location | human chr6q25.2 | 12 | 1 | 26134 | 49 |
IPCEF1 |
2.241e-02 | -3.80 | amyloid-beta binding | molecular function | GO:0001540 | 89 | 2 | 18094 | 47 |
APOE,CD74 |
2.245e-02 | -3.80 | ARHGAP33 (Rho GTPase activating protein 33) | protein interactions | 115703 | 9 | 1 | 19454 | 49 |
NEK6 |
2.245e-02 | -3.80 | ADCY7 (adenylate cyclase 7) | protein interactions | 113 | 9 | 1 | 19454 | 49 |
PRKCD |
2.245e-02 | -3.80 | HLA-DMA (major histocompatibility complex, class II, DM alpha) | protein interactions | 3108 | 9 | 1 | 19454 | 49 |
CD74 |
2.245e-02 | -3.80 | KLRA1P (killer cell lectin like receptor A1, pseudogene) | protein interactions | 10748 | 9 | 1 | 19454 | 49 |
PTPN6 |
2.245e-02 | -3.80 | RWDD3 (RWD domain containing 3) | protein interactions | 25950 | 9 | 1 | 19454 | 49 |
HIF1A |
2.245e-02 | -3.80 | LILRB2 (leukocyte immunoglobulin like receptor B2) | protein interactions | 10288 | 9 | 1 | 19454 | 49 |
PTPN6 |
2.245e-02 | -3.80 | DUX3 (double homeobox 3) | protein interactions | 26582 | 9 | 1 | 19454 | 49 |
PRKCD |
2.245e-02 | -3.80 | LINC02582 (long intergenic non-protein coding RNA 2582) | protein interactions | 100505817 | 9 | 1 | 19454 | 49 |
APOE |
2.245e-02 | -3.80 | CACNA2D3 (calcium voltage-gated channel auxiliary subunit alpha2delta 3) | protein interactions | 55799 | 9 | 1 | 19454 | 49 |
APOE |
2.247e-02 | -3.80 | positive regulation of lipid transport | biological process | GO:0032370 | 86 | 2 | 18204 | 49 |
APOE,PRKCD |
2.252e-02 | -3.79 | STAT transcription factor, all-alpha domain | gene3d domains | 1.20.1050.20 | 7 | 1 | 14470 | 47 |
STAT6 |
2.252e-02 | -3.79 | STAT transcription factor, DNA-binding domain | gene3d domains | 2.60.40.630 | 7 | 1 | 14470 | 47 |
STAT6 |
2.253e-02 | -3.79 | SLC1A5 (solute carrier family 1 member 5) | protein interactions | 6510 | 240 | 3 | 19454 | 49 |
P2RY6,NEK6,RHBDF2 |
2.253e-02 | -3.79 | ARHGEF16 (Rho guanine nucleotide exchange factor 16) | protein interactions | 27237 | 92 | 2 | 19454 | 49 |
ELMO1,PRKCD |
2.262e-02 | -3.79 | striated muscle cell differentiation | biological process | GO:0051146 | 225 | 3 | 18204 | 49 |
DOCK2,DOCK1,AKAP13 |
2.264e-02 | -3.79 | ACTG1 (actin gamma 1) | protein interactions | 71 | 429 | 4 | 19454 | 49 |
ARHGAP27,GSDME,GIT2,APOE |
2.266e-02 | -3.79 | Pathways in cancer | KEGG pathways | hsa05200 | 395 | 5 | 7161 | 30 |
CSF1R,PLCG2,SPI1,HIF1A,ADCY7 |
2.285e-02 | -3.78 | phosphatidylinositol 3-kinase complex, class I | cellular component | GO:0097651 | 9 | 1 | 19108 | 49 |
PIK3R5 |
2.285e-02 | -3.78 | phosphatidylinositol 3-kinase complex, class IA | cellular component | GO:0005943 | 9 | 1 | 19108 | 49 |
PIK3R5 |
2.285e-02 | -3.78 | unconventional myosin complex | cellular component | GO:0016461 | 9 | 1 | 19108 | 49 |
MYO1F |
2.288e-02 | -3.78 | anatomical structure development | biological process | GO:0048856 | 5207 | 21 | 18204 | 49 |
VAV3,PREX1,DOCK1,SPI1,CD74,IL6R,HIF1A,BLNK,DOCK2,DOCK10,AKAP13,PTPN6,GAB1,GSDME,CSF1R,SBNO2,STAT6,HCK,GIT2,APOE,PLCG2 |
2.288e-02 | -3.78 | Focal Adhesion | WikiPathways | WP306 | 195 | 4 | 5310 | 30 |
HCK,TLN1,DOCK1,PIK3R5 |
2.289e-02 | -3.78 | Interferon alpha/beta signaling | REACTOME pathways | R-HSA-909733 | 69 | 2 | 10285 | 35 |
IRF5,PTPN6 |
2.296e-02 | -3.77 | modulation by host of symbiont process | biological process | GO:0051851 | 87 | 2 | 18204 | 49 |
APOE,CSF1R |
2.296e-02 | -3.77 | associative learning | biological process | GO:0008306 | 87 | 2 | 18204 | 49 |
RGS14,HIF1A |
2.313e-02 | -3.77 | C20 prostanoid biosynthesis | BIOCYC pathways | HUMAN_PWY66-374 | 7 | 1 | 902 | 3 |
TBXAS1 |
2.313e-02 | -3.77 | C20 prostanoid biosynthesis | BIOCYC pathways | META_PWY66-374 | 7 | 1 | 902 | 3 |
TBXAS1 |
2.316e-02 | -3.77 | KRT40 (keratin 40) | protein interactions | 125115 | 432 | 4 | 19454 | 49 |
DOCK8,HCK,DOCK2,NEK6 |
2.334e-02 | -3.76 | arm | COSMIC cancer mutations | arm | 1331 | 8 | 16828 | 45 |
CSF1R,MYO1F,STAT6,DOCK8,BLNK,ADCY7,ARHGAP33,PRKCD |
2.341e-02 | -3.75 | cellular response to oxidative stress | biological process | GO:0034599 | 228 | 3 | 18204 | 49 |
STAT6,HIF1A,PRKCD |
2.342e-02 | -3.75 | WH-like_DNA-bd_sf | interpro domains | IPR036388 | 232 | 3 | 18521 | 49 |
PREX1,SPI1,IRF5 |
2.344e-02 | -3.75 | Neurotrophic factor-mediated Trk receptor signaling | Pathway Interaction DB | trkrpathway | 56 | 3 | 2226 | 25 |
DOCK1,GAB1,ELMO1 |
2.345e-02 | -3.75 | ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) | protein interactions | 6098 | 94 | 2 | 19454 | 49 |
VAV3,PTPN6 |
2.345e-02 | -3.75 | GRIN1 (glutamate ionotropic receptor NMDA type subunit 1) | protein interactions | 2902 | 94 | 2 | 19454 | 49 |
ELMO1,DOCK1 |
2.345e-02 | -3.75 | NUAK1 (NUAK family kinase 1) | protein interactions | 9891 | 94 | 2 | 19454 | 49 |
DOCK1,ELMO1 |
2.357e-02 | -3.75 | Interferon_reg_fact_DNA-bd_dom | interpro domains | IPR001346 | 9 | 1 | 18521 | 49 |
IRF5 |
2.357e-02 | -3.75 | BEACH_dom_sf | interpro domains | IPR036372 | 9 | 1 | 18521 | 49 |
WDFY4 |
2.357e-02 | -3.75 | Peptidase_S54_rhomboid_dom | interpro domains | IPR022764 | 9 | 1 | 18521 | 49 |
RHBDF2 |
2.357e-02 | -3.75 | Interferon_reg_fac_CS | interpro domains | IPR019817 | 9 | 1 | 18521 | 49 |
IRF5 |
2.357e-02 | -3.75 | BEACH_dom | interpro domains | IPR000409 | 9 | 1 | 18521 | 49 |
WDFY4 |
2.359e-02 | -3.75 | Activation of NIMA Kinases NEK9, NEK6, NEK7 | REACTOME pathways | R-HSA-2980767 | 7 | 1 | 10285 | 35 |
NEK6 |
2.363e-02 | -3.75 | focal adhesion | cellular component | GO:0005925 | 427 | 4 | 19108 | 49 |
TLN1,PARVG,GIT2,HCK |
2.376e-02 | -3.74 | clathrin-coated endocytic vesicle | cellular component | GO:0045334 | 93 | 2 | 19108 | 49 |
CD74,APOE |
2.381e-02 | -3.74 | cell leading edge | cellular component | GO:0031252 | 428 | 4 | 19108 | 49 |
DOCK8,CARMIL3,PLCG2,TLN1 |
2.397e-02 | -3.73 | sterol catabolic process | biological process | GO:0016127 | 9 | 1 | 18204 | 49 |
APOE |
2.397e-02 | -3.73 | regulation of sarcomere organization | biological process | GO:0060297 | 9 | 1 | 18204 | 49 |
AKAP13 |
2.397e-02 | -3.73 | cellular response to hydroperoxide | biological process | GO:0071447 | 9 | 1 | 18204 | 49 |
PRKCD |
2.397e-02 | -3.73 | iris morphogenesis | biological process | GO:0061072 | 9 | 1 | 18204 | 49 |
HIF1A |
2.397e-02 | -3.73 | establishment of T cell polarity | biological process | GO:0001768 | 9 | 1 | 18204 | 49 |
DOCK2 |
2.397e-02 | -3.73 | transepithelial chloride transport | biological process | GO:0030321 | 9 | 1 | 18204 | 49 |
P2RY6 |
2.397e-02 | -3.73 | marginal zone B cell differentiation | biological process | GO:0002315 | 9 | 1 | 18204 | 49 |
DOCK10 |
2.397e-02 | -3.73 | cholesterol catabolic process | biological process | GO:0006707 | 9 | 1 | 18204 | 49 |
APOE |
2.397e-02 | -3.73 | negative regulation of inflammatory response to wounding | biological process | GO:0106015 | 9 | 1 | 18204 | 49 |
PTPN6 |
2.397e-02 | -3.73 | T-helper 17 cell lineage commitment | biological process | GO:0072540 | 9 | 1 | 18204 | 49 |
IL6R |
2.397e-02 | -3.73 | respiratory burst involved in defense response | biological process | GO:0002679 | 9 | 1 | 18204 | 49 |
HCK |
2.397e-02 | -3.73 | positive regulation of cell proliferation involved in kidney development | biological process | GO:1901724 | 9 | 1 | 18204 | 49 |
IL6R |
2.397e-02 | -3.73 | regulation of mucus secretion | biological process | GO:0070255 | 9 | 1 | 18204 | 49 |
P2RY2 |
2.397e-02 | -3.73 | regulation of protein localization to chromatin | biological process | GO:1905634 | 9 | 1 | 18204 | 49 |
SPI1 |
2.397e-02 | -3.73 | cyclooxygenase pathway | biological process | GO:0019371 | 9 | 1 | 18204 | 49 |
TBXAS1 |
2.397e-02 | -3.73 | positive regulation of hormone biosynthetic process | biological process | GO:0046886 | 9 | 1 | 18204 | 49 |
HIF1A |
2.397e-02 | -3.73 | macrophage proliferation | biological process | GO:0061517 | 9 | 1 | 18204 | 49 |
CSF1R |
2.397e-02 | -3.73 | positive regulation of antigen processing and presentation | biological process | GO:0002579 | 9 | 1 | 18204 | 49 |
CD74 |
2.397e-02 | -3.73 | negative regulation of thymocyte apoptotic process | biological process | GO:0070244 | 9 | 1 | 18204 | 49 |
HIF1A |
2.397e-02 | -3.73 | microglial cell proliferation | biological process | GO:0061518 | 9 | 1 | 18204 | 49 |
CSF1R |
2.397e-02 | -3.73 | positive regulation of T-helper 2 cell cytokine production | biological process | GO:2000553 | 9 | 1 | 18204 | 49 |
DENND1B |
2.397e-02 | -3.73 | glandular epithelial cell maturation | biological process | GO:0002071 | 9 | 1 | 18204 | 49 |
HIF1A |
2.438e-02 | -3.71 | KCTD5 (potassium channel tetramerization domain containing 5) | protein interactions | 54442 | 96 | 2 | 19454 | 49 |
NEK6,GIT2 |
2.438e-02 | -3.71 | RLIM (ring finger protein, LIM domain interacting) | protein interactions | 51132 | 96 | 2 | 19454 | 49 |
STAT6,HIF1A |
2.439e-02 | -3.71 | GBF1 (golgi brefeldin A resistant guanine nucleotide exchange factor 1) | protein interactions | 8729 | 439 | 4 | 19454 | 49 |
TLN1,GSDME,HIF1A,PTPN6 |
2.446e-02 | -3.71 | regulation of Rho protein signal transduction | biological process | GO:0035023 | 90 | 2 | 18204 | 49 |
APOE,AKAP13 |
2.452e-02 | -3.71 | Rhomboid | pfam domains | PF01694 | 9 | 1 | 17795 | 49 |
RHBDF2 |
2.452e-02 | -3.71 | IRF | pfam domains | PF00605 | 9 | 1 | 17795 | 49 |
IRF5 |
2.452e-02 | -3.71 | Beach | pfam domains | PF02138 | 9 | 1 | 17795 | 49 |
WDFY4 |
2.476e-02 | -3.70 | skin-upper_leg-malignant_melanoma | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma | 850 | 6 | 16828 | 45 |
DOCK2,ELMO1,ARHGAP15,NEK6,VAV3,DOCK8 |
2.486e-02 | -3.69 | SOCS3 (suppressor of cytokine signaling 3) | protein interactions | 9021 | 97 | 2 | 19454 | 49 |
GAB1,CSF1R |
2.491e-02 | -3.69 | PGA4 (pepsinogen A4) | protein interactions | 643847 | 10 | 1 | 19454 | 49 |
CD74 |
2.491e-02 | -3.69 | GPLD1 (glycosylphosphatidylinositol specific phospholipase D1) | protein interactions | 2822 | 10 | 1 | 19454 | 49 |
HIF1A |
2.491e-02 | -3.69 | SIGLEC7 (sialic acid binding Ig like lectin 7) | protein interactions | 27036 | 10 | 1 | 19454 | 49 |
PTPN6 |
2.491e-02 | -3.69 | IPCEF1 (interaction protein for cytohesin exchange factors 1) | protein interactions | 26034 | 10 | 1 | 19454 | 49 |
DOCK1 |
2.491e-02 | -3.69 | SIGLEC10 (sialic acid binding Ig like lectin 10) | protein interactions | 89790 | 10 | 1 | 19454 | 49 |
PTPN6 |
2.491e-02 | -3.69 | NRAP (nebulin related anchoring protein) | protein interactions | 4892 | 10 | 1 | 19454 | 49 |
TLN1 |
2.491e-02 | -3.69 | IL11 (interleukin 11) | protein interactions | 3589 | 10 | 1 | 19454 | 49 |
HIF1A |
2.491e-02 | -3.69 | FCER2 (Fc epsilon receptor II) | protein interactions | 2208 | 10 | 1 | 19454 | 49 |
STAT6 |
2.496e-02 | -3.69 | regulation of miRNA metabolic process | biological process | GO:2000628 | 91 | 2 | 18204 | 49 |
SPI1,HIF1A |
2.496e-02 | -3.69 | cellular oxidant detoxification | biological process | GO:0098869 | 91 | 2 | 18204 | 49 |
IPCEF1,APOE |
2.501e-02 | -3.69 | RBD | prosite domains | PS50898 | 7 | 1 | 12186 | 44 |
RGS14 |
2.501e-02 | -3.69 | GOLOCO | prosite domains | PS50877 | 7 | 1 | 12186 | 44 |
RGS14 |
2.534e-02 | -3.68 | Ion Channel and Phorbal Esters Signaling Pathway | SMPDB pathways | SMP0090032 | 5 | 1 | 1369 | 7 |
P2RY2 |
2.546e-02 | -3.67 | cell-substrate junction | cellular component | GO:0030055 | 437 | 4 | 19108 | 49 |
HCK,GIT2,PARVG,TLN1 |
2.548e-02 | -3.67 | positive regulation of transporter activity | biological process | GO:0032411 | 92 | 2 | 18204 | 49 |
PRKCD,P2RY6 |
2.548e-02 | -3.67 | positive regulation of mononuclear cell migration | biological process | GO:0071677 | 92 | 2 | 18204 | 49 |
CSF1R,DOCK8 |
2.555e-02 | -3.67 | DCAF15 (DDB1 and CUL4 associated factor 15) | protein interactions | 90379 | 252 | 3 | 19454 | 49 |
TLN1,EHBP1L1,DOCK2 |
2.555e-02 | -3.67 | PSMD7 (proteasome 26S subunit, non-ATPase 7) | protein interactions | 5713 | 252 | 3 | 19454 | 49 |
PTPN6,PREX1,P2RY6 |
2.559e-02 | -3.67 | regulation of endothelial cell migration | biological process | GO:0010594 | 236 | 3 | 18204 | 49 |
GAB1,APOE,HIF1A |
2.578e-02 | -3.66 | blood circulation | biological process | GO:0008015 | 418 | 4 | 18204 | 49 |
TBXAS1,APOE,P2RY2,TBC1D8 |
2.582e-02 | -3.66 | XPO4 (exportin 4) | protein interactions | 64328 | 99 | 2 | 19454 | 49 |
P2RY6,P2RY2 |
2.582e-02 | -3.66 | FHL5 (four and a half LIM domains 5) | protein interactions | 9457 | 99 | 2 | 19454 | 49 |
NEK6,HCK |
2.587e-02 | -3.65 | regulation of lymphocyte proliferation | biological process | GO:0050670 | 237 | 3 | 18204 | 49 |
VAV3,PTPN6,CD74 |
2.589e-02 | -3.65 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 31 | 16828 | 45 |
RHBDF2,CSF1R,WDFY4,P2RY6,APOE,PLCG2,PRKCD,DOCK10,MYO1F,AKAP13,VAV3,NEK6,IRF5,DOCK1,HCK,TLN1,STAT6,DOCK8,ADCY7,DOCK2,PTPN6,PREX1,PIK3R5,IPCEF1,ELMO1,BLNK,GAB1,ARHGAP33,ARHGAP15,SKAP1,P2RY2 |
2.615e-02 | -3.64 | PAS_fold_3 | interpro domains | IPR013655 | 10 | 1 | 18521 | 49 |
HIF1A |
2.616e-02 | -3.64 | protein localization to cell periphery | biological process | GO:1990778 | 238 | 3 | 18204 | 49 |
FYB1,RHBDF2,SKAP1 |
2.619e-02 | -3.64 | Tyr_kinase_AS | interpro domains | IPR008266 | 95 | 2 | 18521 | 49 |
CSF1R,HCK |
2.621e-02 | -3.64 | bone-femur-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-femur-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 633 | 5 | 16828 | 45 |
DOCK10,PREX1,P2RY2,AKAP13,RHBDF2 |
2.630e-02 | -3.64 | cytokine receptor activity | molecular function | GO:0004896 | 97 | 2 | 18094 | 47 |
CD74,IL6R |
2.630e-02 | -3.64 | PTK6 (protein tyrosine kinase 6) | protein interactions | 5753 | 100 | 2 | 19454 | 49 |
HIF1A,GAB1 |
2.630e-02 | -3.64 | SKAP1 (src kinase associated phosphoprotein 1) | protein interactions | 8631 | 100 | 2 | 19454 | 49 |
SKAP1,FYB1 |
2.630e-02 | -3.64 | MUL1 (mitochondrial E3 ubiquitin protein ligase 1) | protein interactions | 79594 | 100 | 2 | 19454 | 49 |
TBC1D8,GSDME |
2.638e-02 | -3.64 | negative regulation of protein modification process | biological process | GO:0031400 | 421 | 4 | 18204 | 49 |
PRKCD,RGS14,PTPN6,APOE |
2.660e-02 | -3.63 | regulation of behavioral fear response | biological process | GO:2000822 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | negative regulation of sterol biosynthetic process | biological process | GO:0106119 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | endothelial cell chemotaxis | biological process | GO:0035767 | 10 | 1 | 18204 | 49 |
GAB1 |
2.660e-02 | -3.63 | regulation of CoA-transferase activity | biological process | GO:1905918 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | establishment of lymphocyte polarity | biological process | GO:0001767 | 10 | 1 | 18204 | 49 |
DOCK2 |
2.660e-02 | -3.63 | regulation of interleukin-23 production | biological process | GO:0032667 | 10 | 1 | 18204 | 49 |
PLCG2 |
2.660e-02 | -3.63 | high-density lipoprotein particle assembly | biological process | GO:0034380 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | negative regulation of cholesterol biosynthetic process | biological process | GO:0045541 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | negative regulation of mast cell activation | biological process | GO:0033004 | 10 | 1 | 18204 | 49 |
PTPN6 |
2.660e-02 | -3.63 | intracellular monoatomic anion homeostasis | biological process | GO:0030002 | 10 | 1 | 18204 | 49 |
TBXAS1 |
2.660e-02 | -3.63 | regulation of deoxyribonuclease activity | biological process | GO:0032070 | 10 | 1 | 18204 | 49 |
PRKCD |
2.660e-02 | -3.63 | nitric oxide-cGMP-mediated signaling | biological process | GO:0038060 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | negative regulation of glial cell apoptotic process | biological process | GO:0034351 | 10 | 1 | 18204 | 49 |
PRKCD |
2.660e-02 | -3.63 | intracellular chloride ion homeostasis | biological process | GO:0030644 | 10 | 1 | 18204 | 49 |
TBXAS1 |
2.660e-02 | -3.63 | growth hormone receptor signaling pathway via JAK-STAT | biological process | GO:0060397 | 10 | 1 | 18204 | 49 |
STAT6 |
2.660e-02 | -3.63 | integrin activation | biological process | GO:0033622 | 10 | 1 | 18204 | 49 |
TLN1 |
2.660e-02 | -3.63 | cAMP biosynthetic process | biological process | GO:0006171 | 10 | 1 | 18204 | 49 |
ADCY7 |
2.660e-02 | -3.63 | positive regulation of monocyte differentiation | biological process | GO:0045657 | 10 | 1 | 18204 | 49 |
CD74 |
2.660e-02 | -3.63 | hemoglobin metabolic process | biological process | GO:0020027 | 10 | 1 | 18204 | 49 |
HIF1A |
2.678e-02 | -3.62 | Jak-STAT signaling pathway | KEGG pathways | ko04630 | 156 | 3 | 7161 | 30 |
PTPN6,IL6R,STAT6 |
2.678e-02 | -3.62 | Jak-STAT signaling pathway | KEGG pathways | hsa04630 | 156 | 3 | 7161 | 30 |
STAT6,PTPN6,IL6R |
2.679e-02 | -3.62 | FBXO28 (F-box protein 28) | protein interactions | 23219 | 101 | 2 | 19454 | 49 |
GIT2,HIF1A |
2.679e-02 | -3.62 | BMAL1 (basic helix-loop-helix ARNT like 1) | protein interactions | 406 | 101 | 2 | 19454 | 49 |
GIT2,HIF1A |
2.679e-02 | -3.62 | MYO9B (myosin IXB) | protein interactions | 4650 | 101 | 2 | 19454 | 49 |
SKAP1,HIF1A |
2.679e-02 | -3.62 | CLEC4A (C-type lectin domain family 4 member A) | protein interactions | 50856 | 101 | 2 | 19454 | 49 |
PTPN6,RHBDF2 |
2.691e-02 | -3.62 | HuR (ELAVL1) binds and stabilizes mRNA | REACTOME pathways | R-HSA-450520 | 8 | 1 | 10285 | 35 |
PRKCD |
2.696e-02 | -3.61 | germ_cell_tumour | COSMIC cancer mutations | germ_cell_tumour | 867 | 6 | 16828 | 45 |
ADCY7,PRKCD,RHBDF2,NEK6,HCK,CSF1R |
2.706e-02 | -3.61 | G alpha (q) signalling events | REACTOME pathways | R-HSA-416476 | 192 | 3 | 10285 | 35 |
PRKCD,P2RY2,P2RY6 |
2.714e-02 | -3.61 | acute_lymphoblastic_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_leukaemia | 2197 | 11 | 16828 | 45 |
SPI1,BLNK,RGS14,NEK6,GIT2,CSF1R,PRKCD,DOCK1,P2RY2,STAT6,HCK |
2.718e-02 | -3.61 | regulation of hemopoiesis | biological process | GO:1903706 | 425 | 4 | 18204 | 49 |
PTPN6,SPI1,CD74,HIF1A |
2.720e-02 | -3.60 | PAS_3 | pfam domains | PF08447 | 10 | 1 | 17795 | 49 |
HIF1A |
2.728e-02 | -3.60 | FASLG (Fas ligand) | protein interactions | 356 | 102 | 2 | 19454 | 49 |
FYB1,HCK |
2.730e-02 | -3.60 | regulation of mononuclear cell proliferation | biological process | GO:0032944 | 242 | 3 | 18204 | 49 |
PTPN6,CD74,VAV3 |
2.735e-02 | -3.60 | FGFR4 (fibroblast growth factor receptor 4) | protein interactions | 2264 | 455 | 4 | 19454 | 49 |
P2RY6,HIF1A,GAB1,PTPN6 |
2.737e-02 | -3.60 | ADGRG2 (adhesion G protein-coupled receptor G2) | protein interactions | 10149 | 11 | 1 | 19454 | 49 |
GMIP |
2.737e-02 | -3.60 | GHSR (growth hormone secretagogue receptor) | protein interactions | 2693 | 11 | 1 | 19454 | 49 |
P2RY6 |
2.737e-02 | -3.60 | ZNF407 (zinc finger protein 407) | protein interactions | 55628 | 11 | 1 | 19454 | 49 |
STAT6 |
2.737e-02 | -3.60 | FERRY3 (FERRY endosomal RAB5 effector complex subunit 3) | protein interactions | 57102 | 11 | 1 | 19454 | 49 |
IL6R |
2.737e-02 | -3.60 | FMO1 (flavin containing dimethylaniline monoxygenase 1) | protein interactions | 2326 | 11 | 1 | 19454 | 49 |
TLN1 |
2.737e-02 | -3.60 | NYAP1 (neuronal tyrosine phosphorylated phosphoinositide-3-kinase adaptor 1) | protein interactions | 222950 | 11 | 1 | 19454 | 49 |
TLN1 |
2.737e-02 | -3.60 | KLHL32 (kelch like family member 32) | protein interactions | 114792 | 11 | 1 | 19454 | 49 |
PARVG |
2.737e-02 | -3.60 | RGCC (regulator of cell cycle) | protein interactions | 28984 | 11 | 1 | 19454 | 49 |
TLN1 |
2.737e-02 | -3.60 | CYP1A2 (cytochrome P450 family 1 subfamily A member 2) | protein interactions | 1544 | 11 | 1 | 19454 | 49 |
HIF1A |
2.748e-02 | -3.59 | kidney-carcinoma-chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-chromophobe_renal_cell_carcinoma | 430 | 4 | 16828 | 45 |
NEK6,HCK,CSF1R,PRKCD |
2.748e-02 | -3.59 | chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | chromophobe_renal_cell_carcinoma | 430 | 4 | 16828 | 45 |
PRKCD,HCK,CSF1R,NEK6 |
2.752e-02 | -3.59 | plasma membrane bounded cell projection | cellular component | GO:0120025 | 2285 | 11 | 19108 | 49 |
RGS14,APOE,DOCK8,TLN1,PREX1,HIF1A,PLCG2,ARHGAP33,DOCK10,CARMIL3,MYO1F |
2.756e-02 | -3.59 | granulocyte migration | biological process | GO:0097530 | 96 | 2 | 18204 | 49 |
PREX1,VAV3 |
2.769e-02 | -3.59 | ruffle membrane | cellular component | GO:0032587 | 101 | 2 | 19108 | 49 |
TLN1,PLCG2 |
2.777e-02 | -3.58 | human chr14q23.2 | chromosome location | human chr14q23.2 | 15 | 1 | 26134 | 49 |
HIF1A |
2.777e-02 | -3.58 | human chr9p24.3 | chromosome location | human chr9p24.3 | 15 | 1 | 26134 | 49 |
DOCK8 |
2.777e-02 | -3.58 | GoLoco | smart domains | SM00390 | 7 | 1 | 9717 | 39 |
RGS14 |
2.777e-02 | -3.58 | RBD | smart domains | SM00455 | 7 | 1 | 9717 | 39 |
RGS14 |
2.777e-02 | -3.58 | STAT_int | smart domains | SM00964 | 7 | 1 | 9717 | 39 |
STAT6 |
2.777e-02 | -3.58 | IRF-3 | smart domains | SM01243 | 7 | 1 | 9717 | 39 |
IRF5 |
2.778e-02 | -3.58 | PDP1 (pyruvate dehydrogenase phosphatase catalytic subunit 1) | protein interactions | 54704 | 103 | 2 | 19454 | 49 |
HIF1A,PRKCD |
2.809e-02 | -3.57 | IL4-mediated signaling events | Pathway Interaction DB | il4_2pathway | 60 | 3 | 2226 | 25 |
PTPN6,SPI1,STAT6 |
2.810e-02 | -3.57 | leukocyte homeostasis | biological process | GO:0001776 | 97 | 2 | 18204 | 49 |
HIF1A,DOCK10 |
2.821e-02 | -3.57 | nitric-oxide synthase binding | molecular function | GO:0050998 | 11 | 1 | 18094 | 47 |
CD74 |
2.821e-02 | -3.57 | GTPase activating protein binding | molecular function | GO:0032794 | 11 | 1 | 18094 | 47 |
RGS14 |
2.821e-02 | -3.57 | cardiolipin binding | molecular function | GO:1901612 | 11 | 1 | 18094 | 47 |
GSDME |
2.821e-02 | -3.57 | T cell receptor binding | molecular function | GO:0042608 | 11 | 1 | 18094 | 47 |
DOCK2 |
2.821e-02 | -3.57 | STAT family protein binding | molecular function | GO:0097677 | 11 | 1 | 18094 | 47 |
SPI1 |
2.828e-02 | -3.57 | GRK2 (G protein-coupled receptor kinase 2) | protein interactions | 156 | 104 | 2 | 19454 | 49 |
GIT2,PRKCD |
2.832e-02 | -3.56 | IGF1R (insulin like growth factor 1 receptor) | protein interactions | 3480 | 460 | 4 | 19454 | 49 |
VAV3,PRKCD,PTPN6,GAB1 |
2.847e-02 | -3.56 | regulation of cell morphogenesis | biological process | GO:0022604 | 246 | 3 | 18204 | 49 |
ARHGAP15,HCK,CSF1R |
2.847e-02 | -3.56 | response to toxic substance | biological process | GO:0009636 | 246 | 3 | 18204 | 49 |
APOE,IPCEF1,ARHGAP33 |
2.850e-02 | -3.56 | Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway | WikiPathways | WP2203 | 47 | 2 | 5310 | 30 |
STAT6,HCK |
2.851e-02 | -3.56 | PROTEIN_KINASE_DOM | prosite domains | PS50011 | 480 | 5 | 12186 | 44 |
NEK6,HCK,CSF1R,PRKCD,NRK |
2.853e-02 | -3.56 | RECEPTOR_TYR_KIN_III | prosite domains | PS00240 | 8 | 1 | 12186 | 44 |
CSF1R |
2.853e-02 | -3.56 | TH1 | prosite domains | PS51757 | 8 | 1 | 12186 | 44 |
MYO1F |
2.853e-02 | -3.56 | BMERB | prosite domains | PS51848 | 8 | 1 | 12186 | 44 |
EHBP1L1 |
2.853e-02 | -3.56 | PH_BEACH | prosite domains | PS51783 | 8 | 1 | 12186 | 44 |
WDFY4 |
2.863e-02 | -3.55 | response to hydrogen peroxide | biological process | GO:0042542 | 98 | 2 | 18204 | 49 |
STAT6,PRKCD |
2.873e-02 | -3.55 | SM22_calponin | interpro domains | IPR003096 | 11 | 1 | 18521 | 49 |
VAV3 |
2.875e-02 | -3.55 | APP (amyloid beta precursor protein) | protein interactions | 351 | 2342 | 11 | 19454 | 49 |
APOE,P2RY2,HCK,PIK3R5,ARHGAP15,PRKCD,RGS14,CD74,PARVG,AKAP13,SKAP1 |
2.877e-02 | -3.55 | cellular response to biotic stimulus | biological process | GO:0071216 | 247 | 3 | 18204 | 49 |
HCK,PLCG2,SBNO2 |
2.885e-02 | -3.55 | regulation of protein transport | biological process | GO:0051223 | 433 | 4 | 18204 | 49 |
PRKCD,HIF1A,RHBDF2,APOE |
2.886e-02 | -3.55 | BEACH domain | gene3d domains | 1.10.1540.10 | 9 | 1 | 14470 | 47 |
WDFY4 |
2.886e-02 | -3.55 | Nucleotidyltransferases domain 2 | gene3d domains | 1.20.120.330 | 9 | 1 | 14470 | 47 |
GIT2 |
2.892e-02 | -3.54 | INTFRNREGFCT | prints domains | PR00267 | 9 | 1 | 5227 | 17 |
IRF5 |
2.908e-02 | -3.54 | small_intestine | COSMIC cancer mutations | small_intestine | 250 | 3 | 16828 | 45 |
PREX1,CSF1R,ARHGAP33 |
2.913e-02 | -3.54 | Renal cell carcinoma | KEGG pathways | hsa05211 | 64 | 2 | 7161 | 30 |
GAB1,HIF1A |
2.913e-02 | -3.54 | Shigellosis | KEGG pathways | hsa05131 | 64 | 2 | 7161 | 30 |
DOCK1,ELMO1 |
2.913e-02 | -3.54 | Renal cell carcinoma | KEGG pathways | ko05211 | 64 | 2 | 7161 | 30 |
GAB1,HIF1A |
2.917e-02 | -3.53 | activation of GTPase activity | biological process | GO:0090630 | 99 | 2 | 18204 | 49 |
GMIP,TBC1D8 |
2.917e-02 | -3.53 | regulation of signaling receptor activity | biological process | GO:0010469 | 99 | 2 | 18204 | 49 |
PRKCD,HIF1A |
2.922e-02 | -3.53 | regulation of receptor catabolic process | biological process | GO:2000644 | 11 | 1 | 18204 | 49 |
APOE |
2.922e-02 | -3.53 | pinocytosis | biological process | GO:0006907 | 11 | 1 | 18204 | 49 |
DOCK2 |
2.922e-02 | -3.53 | negative regulation of mesenchymal cell apoptotic process | biological process | GO:2001054 | 11 | 1 | 18204 | 49 |
HIF1A |
2.922e-02 | -3.53 | regulation of cell-cell adhesion mediated by integrin | biological process | GO:0033632 | 11 | 1 | 18204 | 49 |
SKAP1 |
2.922e-02 | -3.53 | regulation of dendritic cell antigen processing and presentation | biological process | GO:0002604 | 11 | 1 | 18204 | 49 |
CD74 |
2.922e-02 | -3.53 | CD8-positive, alpha-beta T cell activation | biological process | GO:0036037 | 11 | 1 | 18204 | 49 |
WDFY4 |
2.922e-02 | -3.53 | negative regulation of humoral immune response mediated by circulating immunoglobulin | biological process | GO:0002924 | 11 | 1 | 18204 | 49 |
PTPN6 |
2.922e-02 | -3.53 | pericyte cell differentiation | biological process | GO:1904238 | 11 | 1 | 18204 | 49 |
SPI1 |
2.922e-02 | -3.53 | positive regulation of integrin activation | biological process | GO:0033625 | 11 | 1 | 18204 | 49 |
SKAP1 |
2.922e-02 | -3.53 | negative regulation of cholesterol metabolic process | biological process | GO:0090206 | 11 | 1 | 18204 | 49 |
APOE |
2.922e-02 | -3.53 | regulation of fear response | biological process | GO:1903365 | 11 | 1 | 18204 | 49 |
APOE |
2.922e-02 | -3.53 | negative regulation of platelet aggregation | biological process | GO:0090331 | 11 | 1 | 18204 | 49 |
PRKCD |
2.922e-02 | -3.53 | negative regulation of myeloid leukocyte mediated immunity | biological process | GO:0002887 | 11 | 1 | 18204 | 49 |
SPI1 |
2.922e-02 | -3.53 | positive regulation of chemokine (C-X-C motif) ligand 2 production | biological process | GO:2000343 | 11 | 1 | 18204 | 49 |
CD74 |
2.927e-02 | -3.53 | blood vessel morphogenesis | biological process | GO:0048514 | 435 | 4 | 18204 | 49 |
VAV3,APOE,GAB1,HIF1A |
2.929e-02 | -3.53 | PTN (pleiotrophin) | protein interactions | 5764 | 106 | 2 | 19454 | 49 |
GSDME,NEK6 |
2.935e-02 | -3.53 | stomach-carcinoma | COSMIC cancer mutations | stomach-carcinoma | 439 | 4 | 16828 | 45 |
NEK6,HCK,CSF1R,PRKCD |
2.946e-02 | -3.52 | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | COSMIC cancer mutations | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | 653 | 5 | 16828 | 45 |
DOCK10,STAT6,WDFY4,SKAP1,ELMO1 |
2.951e-02 | -3.52 | PFN1 (profilin 1) | protein interactions | 5216 | 466 | 4 | 19454 | 49 |
DOCK8,AKAP13,DOCK1,GIT2 |
2.963e-02 | -3.52 | SHH_subtype | COSMIC cancer mutations | SHH_subtype | 654 | 5 | 16828 | 45 |
SKAP1,ELMO1,WDFY4,STAT6,DOCK10 |
2.964e-02 | -3.52 | Differentiation Pathway | WikiPathways | WP2848 | 48 | 2 | 5310 | 30 |
CSF1R,IL6R |
2.967e-02 | -3.52 | cellular response to peptide hormone stimulus | biological process | GO:0071375 | 250 | 3 | 18204 | 49 |
STAT6,PRKCD,GAB1 |
2.967e-02 | -3.52 | D-myo-inositol-5-phosphate metabolism | BIOCYC pathways | META_PWY-6367 | 9 | 1 | 902 | 3 |
PLCG2 |
2.970e-02 | -3.52 | intracellular monoatomic ion homeostasis | biological process | GO:0006873 | 437 | 4 | 18204 | 49 |
P2RY2,HIF1A,TBXAS1,APOE |
2.972e-02 | -3.52 | hematopoietic progenitor cell differentiation | biological process | GO:0002244 | 100 | 2 | 18204 | 49 |
SPI1,PTPN6 |
2.972e-02 | -3.52 | positive regulation of smooth muscle cell proliferation | biological process | GO:0048661 | 100 | 2 | 18204 | 49 |
P2RY6,IL6R |
2.980e-02 | -3.51 | RPL39 (ribosomal protein L39) | protein interactions | 6170 | 107 | 2 | 19454 | 49 |
P2RY6,PTPN6 |
2.980e-02 | -3.51 | TPP2 (tripeptidyl peptidase 2) | protein interactions | 7174 | 107 | 2 | 19454 | 49 |
P2RY6,CD74 |
2.982e-02 | -3.51 | NCF4 (neutrophil cytosolic factor 4) | protein interactions | 4689 | 12 | 1 | 19454 | 49 |
PRKCD |
2.982e-02 | -3.51 | TREM2 (triggering receptor expressed on myeloid cells 2) | protein interactions | 54209 | 12 | 1 | 19454 | 49 |
APOE |
2.982e-02 | -3.51 | PTPN20 (protein tyrosine phosphatase non-receptor type 20) | protein interactions | 26095 | 12 | 1 | 19454 | 49 |
PTPN6 |
2.982e-02 | -3.51 | ADGRB3 (adhesion G protein-coupled receptor B3) | protein interactions | 577 | 12 | 1 | 19454 | 49 |
ELMO1 |
2.982e-02 | -3.51 | FBXO8 (F-box protein 8) | protein interactions | 26269 | 12 | 1 | 19454 | 49 |
HIF1A |
2.982e-02 | -3.51 | Cep350 (centrosomal protein 350) | protein interactions | 74081 | 12 | 1 | 19454 | 49 |
TLN1 |
2.982e-02 | -3.51 | SSTR2 (somatostatin receptor 2) | protein interactions | 6752 | 12 | 1 | 19454 | 49 |
PTPN6 |
2.982e-02 | -3.51 | PNMT (phenylethanolamine N-methyltransferase) | protein interactions | 5409 | 12 | 1 | 19454 | 49 |
HCK |
2.982e-02 | -3.51 | ROPN1L (rhophilin associated tail protein 1 like) | protein interactions | 83853 | 12 | 1 | 19454 | 49 |
CD74 |
2.982e-02 | -3.51 | TENM4 (teneurin transmembrane protein 4) | protein interactions | 26011 | 12 | 1 | 19454 | 49 |
DOCK2 |
3.020e-02 | -3.50 | PGRMC2 (progesterone receptor membrane component 2) | protein interactions | 10424 | 269 | 3 | 19454 | 49 |
P2RY6,RHBDF2,CD74 |
3.023e-02 | -3.50 | MAPK1 (ERK2) activation | REACTOME pathways | R-HSA-112411 | 9 | 1 | 10285 | 35 |
IL6R |
3.031e-02 | -3.50 | SLC39A14 (solute carrier family 39 member 14) | protein interactions | 23516 | 108 | 2 | 19454 | 49 |
P2RY6,P2RY2 |
3.034e-02 | -3.50 | Succinate Signalling | SMPDB pathways | SMP0083294 | 6 | 1 | 1369 | 7 |
HIF1A |
3.035e-02 | -3.49 | positive regulation of developmental process | biological process | GO:0051094 | 1385 | 8 | 18204 | 49 |
GAB1,SPI1,IL6R,CD74,HIF1A,STAT6,APOE,RGS14 |
3.043e-02 | -3.49 | Interferon Signaling | REACTOME pathways | R-HSA-913531 | 201 | 3 | 10285 | 35 |
PTPN6,IRF5,PRKCD |
3.074e-02 | -3.48 | vinculin binding | molecular function | GO:0017166 | 12 | 1 | 18094 | 47 |
TLN1 |
3.074e-02 | -3.48 | non-membrane spanning protein tyrosine phosphatase activity | molecular function | GO:0004726 | 12 | 1 | 18094 | 47 |
PTPN6 |
3.074e-02 | -3.48 | MAP-kinase scaffold activity | molecular function | GO:0005078 | 12 | 1 | 18094 | 47 |
AKAP13 |
3.079e-02 | -3.48 | IL-3 Signaling Pathway | WikiPathways | WP286 | 49 | 2 | 5310 | 30 |
PTPN6,HCK |
3.089e-02 | -3.48 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 24 | 16828 | 45 |
WDFY4,CSF1R,TBC1D8,MYO1F,DOCK10,PRKCD,NEK6,HIF1A,VAV3,SPI1,AKAP13,DOCK8,STAT6,HCK,TLN1,SBNO2,DOCK1,DOCK2,PIK3R5,PARVG,GMIP,SKAP1,ARHGAP15,GAB1 |
3.120e-02 | -3.47 | positive regulation of T cell activation | biological process | GO:0050870 | 255 | 3 | 18204 | 49 |
DOCK8,CD74,PTPN6 |
3.135e-02 | -3.46 | TIPRL (TOR signaling pathway regulator) | protein interactions | 261726 | 110 | 2 | 19454 | 49 |
TLN1,RHBDF2 |
3.135e-02 | -3.46 | SLC27A2 (solute carrier family 27 member 2) | protein interactions | 11001 | 110 | 2 | 19454 | 49 |
P2RY6,GSDME |
3.138e-02 | -3.46 | unsaturated fatty acid metabolic process | biological process | GO:0033559 | 103 | 2 | 18204 | 49 |
CD74,TBXAS1 |
3.141e-02 | -3.46 | human chr16q23.3 | chromosome location | human chr16q23.3 | 17 | 1 | 26134 | 49 |
PLCG2 |
3.141e-02 | -3.46 | human chr1q31.3 | chromosome location | human chr1q31.3 | 17 | 1 | 26134 | 49 |
DENND1B |
3.145e-02 | -3.46 | negative regulation of catalytic activity | biological process | GO:0043086 | 445 | 4 | 18204 | 49 |
PRKCD,RGS14,GMIP,APOE |
3.163e-02 | -3.45 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-angioimmunoblastic_T_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-angioimmunoblastic_T_cell_lymphoma | 12 | 1 | 16828 | 45 |
CSF1R |
3.167e-02 | -3.45 | DUF3585 | smart domains | SM01203 | 8 | 1 | 9717 | 39 |
EHBP1L1 |
3.170e-02 | -3.45 | Fc epsilon RI signaling pathway | KEGG pathways | hsa04664 | 67 | 2 | 7161 | 30 |
VAV3,PLCG2 |
3.170e-02 | -3.45 | Fc epsilon RI signaling pathway | KEGG pathways | ko04664 | 67 | 2 | 7161 | 30 |
PLCG2,VAV3 |
3.184e-02 | -3.45 | neurotransmitter-gated ion channel clustering | biological process | GO:0072578 | 12 | 1 | 18204 | 49 |
APOE |
3.184e-02 | -3.45 | regulation of glomerular mesangial cell proliferation | biological process | GO:0072124 | 12 | 1 | 18204 | 49 |
IL6R |
3.184e-02 | -3.45 | response to macrophage colony-stimulating factor | biological process | GO:0036005 | 12 | 1 | 18204 | 49 |
CSF1R |
3.184e-02 | -3.45 | inositol phosphate biosynthetic process | biological process | GO:0032958 | 12 | 1 | 18204 | 49 |
PLCG2 |
3.184e-02 | -3.45 | lymphoid progenitor cell differentiation | biological process | GO:0002320 | 12 | 1 | 18204 | 49 |
SPI1 |
3.184e-02 | -3.45 | insulin secretion involved in cellular response to glucose stimulus | biological process | GO:0035773 | 12 | 1 | 18204 | 49 |
HIF1A |
3.184e-02 | -3.45 | mesenchymal cell apoptotic process | biological process | GO:0097152 | 12 | 1 | 18204 | 49 |
HIF1A |
3.184e-02 | -3.45 | positive regulation of dendritic cell cytokine production | biological process | GO:0002732 | 12 | 1 | 18204 | 49 |
PLCG2 |
3.184e-02 | -3.45 | regulation of chemokine-mediated signaling pathway | biological process | GO:0070099 | 12 | 1 | 18204 | 49 |
HIF1A |
3.184e-02 | -3.45 | regulation of glial cell apoptotic process | biological process | GO:0034350 | 12 | 1 | 18204 | 49 |
PRKCD |
3.184e-02 | -3.45 | nuclear membrane disassembly | biological process | GO:0051081 | 12 | 1 | 18204 | 49 |
NEK6 |
3.184e-02 | -3.45 | regulation of prostaglandin biosynthetic process | biological process | GO:0031392 | 12 | 1 | 18204 | 49 |
CD74 |
3.184e-02 | -3.45 | bone trabecula morphogenesis | biological process | GO:0061430 | 12 | 1 | 18204 | 49 |
SBNO2 |
3.184e-02 | -3.45 | regulation of inflammatory response to wounding | biological process | GO:0106014 | 12 | 1 | 18204 | 49 |
PTPN6 |
3.189e-02 | -3.45 | Signaling events mediated by VEGFR1 and VEGFR2 | Pathway Interaction DB | vegfr1_2_pathway | 63 | 3 | 2226 | 25 |
PTPN6,GAB1,HIF1A |
3.191e-02 | -3.44 | phosphotransferase activity, alcohol group as acceptor | molecular function | GO:0016773 | 686 | 5 | 18094 | 47 |
CSF1R,NEK6,PRKCD,HCK,NRK |
3.195e-02 | -3.44 | regulation of anatomical structure morphogenesis | biological process | GO:0022603 | 894 | 6 | 18204 | 49 |
ARHGAP15,HCK,HIF1A,ARHGAP33,GAB1,CSF1R |
3.195e-02 | -3.44 | defense response to symbiont | biological process | GO:0140546 | 894 | 6 | 18204 | 49 |
IRF5,CSF1R,PTPN6,PLCG2,CD74,HCK |
3.202e-02 | -3.44 | Rhomboid-like | gene3d domains | 1.20.1540.10 | 10 | 1 | 14470 | 47 |
RHBDF2 |
3.204e-02 | -3.44 | IRF_1 | prosite domains | PS00601 | 9 | 1 | 12186 | 44 |
IRF5 |
3.204e-02 | -3.44 | IRF_2 | prosite domains | PS51507 | 9 | 1 | 12186 | 44 |
IRF5 |
3.204e-02 | -3.44 | BEACH | prosite domains | PS50197 | 9 | 1 | 12186 | 44 |
WDFY4 |
3.224e-02 | -3.43 | HMOX2 (heme oxygenase 2) | protein interactions | 3163 | 276 | 3 | 19454 | 49 |
P2RY6,APOE,CD74 |
3.226e-02 | -3.43 | FCRL3 (Fc receptor like 3) | protein interactions | 115352 | 13 | 1 | 19454 | 49 |
PTPN6 |
3.226e-02 | -3.43 | C1orf74 (chromosome 1 open reading frame 74) | protein interactions | 148304 | 13 | 1 | 19454 | 49 |
HCK |
3.226e-02 | -3.43 | IL6 (interleukin 6) | protein interactions | 3569 | 13 | 1 | 19454 | 49 |
IL6R |
3.226e-02 | -3.43 | KCNQ4 (potassium voltage-gated channel subfamily Q member 4) | protein interactions | 9132 | 13 | 1 | 19454 | 49 |
CSF1R |
3.226e-02 | -3.43 | RTL10 (retrotransposon Gag like 10) | protein interactions | 79680 | 13 | 1 | 19454 | 49 |
PLCG2 |
3.226e-02 | -3.43 | EEIG1 (estrogen-induced osteoclastogenesis regulator 1) | protein interactions | 399665 | 13 | 1 | 19454 | 49 |
SKAP1 |
3.226e-02 | -3.43 | MYBPC3 (myosin binding protein C3) | protein interactions | 4607 | 13 | 1 | 19454 | 49 |
BLNK |
3.226e-02 | -3.43 | ANKH (ANKH inorganic pyrophosphate transport regulator) | protein interactions | 56172 | 13 | 1 | 19454 | 49 |
APOE |
3.226e-02 | -3.43 | GABPB2 (GA binding protein transcription factor subunit beta 2) | protein interactions | 126626 | 13 | 1 | 19454 | 49 |
PLCG2 |
3.241e-02 | -3.43 | UBE2V1 (ubiquitin conjugating enzyme E2 V1) | protein interactions | 7335 | 112 | 2 | 19454 | 49 |
RHBDF2,P2RY6 |
3.251e-02 | -3.43 | positive regulation of myeloid cell differentiation | biological process | GO:0045639 | 105 | 2 | 18204 | 49 |
HIF1A,CD74 |
3.251e-02 | -3.43 | gland morphogenesis | biological process | GO:0022612 | 105 | 2 | 18204 | 49 |
STAT6,CSF1R |
3.251e-02 | -3.43 | biomineral tissue development | biological process | GO:0031214 | 105 | 2 | 18204 | 49 |
HIF1A,SBNO2 |
3.251e-02 | -3.43 | cellular response to alcohol | biological process | GO:0097306 | 105 | 2 | 18204 | 49 |
ADCY7,P2RY6 |
3.251e-02 | -3.43 | regulation of postsynapse organization | biological process | GO:0099175 | 105 | 2 | 18204 | 49 |
ARHGAP33,APOE |
3.251e-02 | -3.43 | antigen processing and presentation | biological process | GO:0019882 | 105 | 2 | 18204 | 49 |
CD74,WDFY4 |
3.251e-02 | -3.43 | response to type II interferon | biological process | GO:0034341 | 105 | 2 | 18204 | 49 |
CD74,HCK |
3.256e-02 | -3.42 | dDENN | pfam domains | PF03455 | 12 | 1 | 17795 | 49 |
DENND1B |
3.275e-02 | -3.42 | regulation of plasma membrane bounded cell projection organization | biological process | GO:0120035 | 666 | 5 | 18204 | 49 |
TBC1D8,PRKCD,PREX1,ARHGAP33,APOE |
3.284e-02 | -3.42 | chylomicron | cellular component | GO:0042627 | 13 | 1 | 19108 | 49 |
APOE |
3.294e-02 | -3.41 | LAT (linker for activation of T cells) | protein interactions | 27040 | 113 | 2 | 19454 | 49 |
PLCG2,PTPN6 |
3.294e-02 | -3.41 | CTAG1B (cancer/testis antigen 1B) | protein interactions | 1485 | 113 | 2 | 19454 | 49 |
HCK,GMIP |
3.301e-02 | -3.41 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 17 | 16828 | 45 |
GMIP,ELMO1,SPI1,AKAP13,IRF5,HIF1A,VAV3,EHBP1L1,P2RY2,DOCK8,STAT6,DOCK2,ADCY7,CD74,PIK3R5,DOCK10,PREX1 |
3.309e-02 | -3.41 | ovary-carcinoma-mucinous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-mucinous_carcinoma | 456 | 4 | 16828 | 45 |
CSF1R,HCK,NEK6,PRKCD |
3.315e-02 | -3.41 | Hepatitis C and Hepatocellular Carcinoma | WikiPathways | WP3646 | 51 | 2 | 5310 | 30 |
HIF1A,IL6R |
3.326e-02 | -3.40 | insulin receptor substrate binding | molecular function | GO:0043560 | 13 | 1 | 18094 | 47 |
PRKCD |
3.332e-02 | -3.40 | tube development | biological process | GO:0035295 | 903 | 6 | 18204 | 49 |
HIF1A,CSF1R,GAB1,VAV3,PTPN6,APOE |
3.334e-02 | -3.40 | YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta) | protein interactions | 7529 | 965 | 6 | 19454 | 49 |
AKAP13,PRKCD,GAB1,CD74,P2RY6,DENND1B |
3.340e-02 | -3.40 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 8 | 16828 | 45 |
GMIP,TBC1D8,AKAP13,DOCK2,EHBP1L1,DOCK1,P2RY6,DOCK10 |
3.340e-02 | -3.40 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 8 | 16828 | 45 |
AKAP13,DOCK2,GMIP,TBC1D8,DOCK1,P2RY6,EHBP1L1,DOCK10 |
3.341e-02 | -3.40 | response to alcohol | biological process | GO:0097305 | 262 | 3 | 18204 | 49 |
TBXAS1,ADCY7,P2RY6 |
3.349e-02 | -3.40 | phosphate-containing compound metabolic process | biological process | GO:0006796 | 1681 | 9 | 18204 | 49 |
NEK6,CSF1R,PRKCD,HCK,ADCY7,PIK3R5,PTPN6,PLCG2,NRK |
3.353e-02 | -3.40 | Signaling by FGFR3 fusions in cancer | REACTOME pathways | R-HSA-8853334 | 10 | 1 | 10285 | 35 |
GAB1 |
3.353e-02 | -3.40 | MAPK3 (ERK1) activation | REACTOME pathways | R-HSA-110056 | 10 | 1 | 10285 | 35 |
IL6R |
3.353e-02 | -3.40 | Adenylate cyclase activating pathway | REACTOME pathways | R-HSA-170660 | 10 | 1 | 10285 | 35 |
ADCY7 |
3.353e-02 | -3.40 | MET receptor recycling | REACTOME pathways | R-HSA-8875656 | 10 | 1 | 10285 | 35 |
GAB1 |
3.355e-02 | -3.39 | mucinous_carcinoma | COSMIC cancer mutations | mucinous_carcinoma | 458 | 4 | 16828 | 45 |
PRKCD,HCK,CSF1R,NEK6 |
3.367e-02 | -3.39 | Opioid Signalling | REACTOME pathways | R-HSA-111885 | 85 | 2 | 10285 | 35 |
ADCY7,PRKCD |
3.369e-02 | -3.39 | PRKACA (protein kinase cAMP-activated catalytic subunit alpha) | protein interactions | 5566 | 486 | 4 | 19454 | 49 |
AKAP13,DOCK1,HIF1A,RGS14 |
3.385e-02 | -3.39 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 22 | 16828 | 45 |
DOCK8,STAT6,TLN1,SBNO2,EHBP1L1,DOCK1,VAV3,AKAP13,DOCK10,APOE,PLCG2,WDFY4,CSF1R,TBC1D8,SKAP1,ARHGAP15,GAB1,BLNK,ELMO1,PARVG,PTPN6,DOCK2 |
3.404e-02 | -3.38 | KRT34 (keratin 34) | protein interactions | 3885 | 282 | 3 | 19454 | 49 |
HCK,DOCK2,NEK6 |
3.405e-02 | -3.38 | Signaling by EGFR | REACTOME pathways | R-HSA-177929 | 364 | 4 | 10285 | 35 |
TLN1,ADCY7,GAB1,PRKCD |
3.434e-02 | -3.37 | PRDX3 (peroxiredoxin 3) | protein interactions | 10935 | 283 | 3 | 19454 | 49 |
DOCK8,APOE,NEK6 |
3.439e-02 | -3.37 | regulation of protein secretion | biological process | GO:0050708 | 265 | 3 | 18204 | 49 |
APOE,RHBDF2,HIF1A |
3.443e-02 | -3.37 | positive regulation of cell development | biological process | GO:0010720 | 458 | 4 | 18204 | 49 |
CD74,HIF1A,SPI1,RGS14 |
3.444e-02 | -3.37 | regulation of ceramide biosynthetic process | biological process | GO:2000303 | 13 | 1 | 18204 | 49 |
PRKCD |
3.444e-02 | -3.37 | negative regulation of homotypic cell-cell adhesion | biological process | GO:0034111 | 13 | 1 | 18204 | 49 |
PRKCD |
3.444e-02 | -3.37 | regulation of sphingolipid biosynthetic process | biological process | GO:0090153 | 13 | 1 | 18204 | 49 |
PRKCD |
3.444e-02 | -3.37 | negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway | biological process | GO:1903377 | 13 | 1 | 18204 | 49 |
HIF1A |
3.444e-02 | -3.37 | positive regulation of membrane invagination | biological process | GO:1905155 | 13 | 1 | 18204 | 49 |
PLCG2 |
3.444e-02 | -3.37 | positive regulation of inositol phosphate biosynthetic process | biological process | GO:0060732 | 13 | 1 | 18204 | 49 |
P2RY6 |
3.444e-02 | -3.37 | positive regulation of mitophagy | biological process | GO:1901526 | 13 | 1 | 18204 | 49 |
HIF1A |
3.444e-02 | -3.37 | response to peptidoglycan | biological process | GO:0032494 | 13 | 1 | 18204 | 49 |
IRF5 |
3.444e-02 | -3.37 | regulation of thymocyte apoptotic process | biological process | GO:0070243 | 13 | 1 | 18204 | 49 |
HIF1A |
3.444e-02 | -3.37 | negative regulation of amyloid fibril formation | biological process | GO:1905907 | 13 | 1 | 18204 | 49 |
APOE |
3.444e-02 | -3.37 | membrane disassembly | biological process | GO:0030397 | 13 | 1 | 18204 | 49 |
NEK6 |
3.444e-02 | -3.37 | regulation of dendritic spine maintenance | biological process | GO:1902950 | 13 | 1 | 18204 | 49 |
APOE |
3.444e-02 | -3.37 | T-helper 17 cell differentiation | biological process | GO:0072539 | 13 | 1 | 18204 | 49 |
IL6R |
3.444e-02 | -3.37 | phospholipid efflux | biological process | GO:0033700 | 13 | 1 | 18204 | 49 |
APOE |
3.444e-02 | -3.37 | positive regulation of nitric-oxide synthase activity | biological process | GO:0051000 | 13 | 1 | 18204 | 49 |
HIF1A |
3.444e-02 | -3.37 | negative regulation of leukocyte degranulation | biological process | GO:0043301 | 13 | 1 | 18204 | 49 |
SPI1 |
3.444e-02 | -3.37 | positive regulation of phagocytosis, engulfment | biological process | GO:0060100 | 13 | 1 | 18204 | 49 |
PLCG2 |
3.444e-02 | -3.37 | defense response to tumor cell | biological process | GO:0002357 | 13 | 1 | 18204 | 49 |
SPI1 |
3.444e-02 | -3.37 | type II interferon-mediated signaling pathway | biological process | GO:0060333 | 13 | 1 | 18204 | 49 |
HCK |
3.444e-02 | -3.37 | regulation of T-helper 2 cell cytokine production | biological process | GO:2000551 | 13 | 1 | 18204 | 49 |
DENND1B |
3.456e-02 | -3.36 | LPA receptor mediated events | Pathway Interaction DB | lysophospholipid_pathway | 65 | 3 | 2226 | 25 |
PRKCD,ADCY7,GAB1 |
3.459e-02 | -3.36 | plasma membrane raft | cellular component | GO:0044853 | 114 | 2 | 19108 | 49 |
HCK,SKAP1 |
3.470e-02 | -3.36 | CHAT (choline O-acetyltransferase) | protein interactions | 1103 | 14 | 1 | 19454 | 49 |
PRKCD |
3.470e-02 | -3.36 | Fez2 (fasciculation and elongation protein zeta 2) | protein interactions | 225020 | 14 | 1 | 19454 | 49 |
DENND1B |
3.470e-02 | -3.36 | C9 (complement C9) | protein interactions | 735 | 14 | 1 | 19454 | 49 |
APOE |
3.470e-02 | -3.36 | IFNA8 (interferon alpha 8) | protein interactions | 3445 | 14 | 1 | 19454 | 49 |
APOE |
3.470e-02 | -3.36 | AZIN2 (antizyme inhibitor 2) | protein interactions | 113451 | 14 | 1 | 19454 | 49 |
TLN1 |
3.470e-02 | -3.36 | RHBDF1 (rhomboid 5 homolog 1) | protein interactions | 64285 | 14 | 1 | 19454 | 49 |
HIF1A |
3.470e-02 | -3.36 | CSF3 (colony stimulating factor 3) | protein interactions | 1440 | 14 | 1 | 19454 | 49 |
PARVG |
3.470e-02 | -3.36 | TPSAB1 (tryptase alpha/beta 1) | protein interactions | 7177 | 14 | 1 | 19454 | 49 |
P2RY6 |
3.481e-02 | -3.36 | postsynapse organization | biological process | GO:0099173 | 109 | 2 | 18204 | 49 |
DOCK10,APOE |
3.485e-02 | -3.36 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 17 | 16828 | 45 |
SKAP1,ARHGAP15,DOCK1,GAB1,STAT6,HCK,ELMO1,AKAP13,BLNK,HIF1A,VAV3,PLCG2,CD74,DENND1B,DOCK10,DOCK2,WDFY4 |
3.489e-02 | -3.36 | oesophagus-lower_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-lower_third-carcinoma-squamous_cell_carcinoma | 3507 | 15 | 16828 | 45 |
ADCY7,DOCK2,WDFY4,GIT2,CSF1R,PLCG2,PRKCD,P2RY6,DOCK10,MYO1F,AKAP13,HIF1A,ARHGAP15,ARHGAP33,TLN1 |
3.490e-02 | -3.36 | negative regulation of transport | biological process | GO:0051051 | 460 | 4 | 18204 | 49 |
APOE,RHBDF2,CD74,SPI1 |
3.494e-02 | -3.35 | ovary-carcinoma-endometrioid_carcinoma | COSMIC cancer mutations | ovary-carcinoma-endometrioid_carcinoma | 464 | 4 | 16828 | 45 |
PRKCD,CSF1R,HCK,NEK6 |
3.504e-02 | -3.35 | human chr15q25.3 | chromosome location | human chr15q25.3 | 19 | 1 | 26134 | 49 |
AKAP13 |
3.506e-02 | -3.35 | negative regulation of apoptotic process | biological process | GO:0043066 | 914 | 6 | 18204 | 49 |
DOCK8,PRKCD,CD74,HCK,HIF1A,CSF1R |
3.510e-02 | -3.35 | ETS1 (ETS proto-oncogene 1, transcription factor) | protein interactions | 2113 | 117 | 2 | 19454 | 49 |
STAT6,SPI1 |
3.512e-02 | -3.35 | DNA-binding transcription activator activity | molecular function | GO:0001216 | 478 | 4 | 18094 | 47 |
STAT6,HIF1A,SPI1,IRF5 |
3.521e-02 | -3.35 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 15 | 16828 | 45 |
GMIP,AKAP13,VAV3,ARHGAP33,DOCK1,P2RY2,DOCK8,STAT6,HCK,TBC1D8,WDFY4,GIT2,PARVG,CD74,DOCK10 |
3.521e-02 | -3.35 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 15 | 16828 | 45 |
AKAP13,GMIP,VAV3,DOCK1,ARHGAP33,HCK,STAT6,DOCK8,P2RY2,TBC1D8,GIT2,WDFY4,PARVG,CD74,DOCK10 |
3.522e-02 | -3.35 | response to organonitrogen compound | biological process | GO:0010243 | 915 | 6 | 18204 | 49 |
P2RY6,PRKCD,P2RY2,STAT6,IRF5,GAB1 |
3.523e-02 | -3.35 | SM22CALPONIN | prints domains | PR00888 | 11 | 1 | 5227 | 17 |
VAV3 |
3.537e-02 | -3.34 | protein localization to membrane | biological process | GO:0072657 | 462 | 4 | 18204 | 49 |
SKAP1,APOE,FYB1,RHBDF2 |
3.539e-02 | -3.34 | phospholipase C-activating G protein-coupled receptor signaling pathway | biological process | GO:0007200 | 110 | 2 | 18204 | 49 |
P2RY6,P2RY2 |
3.556e-02 | -3.34 | IRF | smart domains | SM00348 | 9 | 1 | 9717 | 39 |
IRF5 |
3.556e-02 | -3.34 | Beach | smart domains | SM01026 | 9 | 1 | 9717 | 39 |
WDFY4 |
3.558e-02 | -3.34 | PSMD13 (proteasome 26S subunit, non-ATPase 13) | protein interactions | 5719 | 287 | 3 | 19454 | 49 |
PTPN6,PREX1,P2RY6 |
3.577e-02 | -3.33 | oxygen carrier activity | molecular function | GO:0005344 | 14 | 1 | 18094 | 47 |
IPCEF1 |
3.593e-02 | -3.33 | regulation of cell projection organization | biological process | GO:0031344 | 683 | 5 | 18204 | 49 |
ARHGAP33,PREX1,APOE,PRKCD,TBC1D8 |
3.594e-02 | -3.33 | BCR signaling pathway | Pathway Interaction DB | bcr_5pathway | 66 | 3 | 2226 | 25 |
PTPN6,PLCG2,BLNK |
3.598e-02 | -3.32 | positive regulation of lipid localization | biological process | GO:1905954 | 111 | 2 | 18204 | 49 |
PRKCD,APOE |
3.609e-02 | -3.32 | myelodysplastic-myeloproliferative_neoplasm-unclassifiable | COSMIC cancer mutations | myelodysplastic-myeloproliferative_neoplasm-unclassifiable | 112 | 2 | 16828 | 45 |
SPI1,CSF1R |
3.609e-02 | -3.32 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic-myeloproliferative_neoplasm-unclassifiable | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic-myeloproliferative_neoplasm-unclassifiable | 112 | 2 | 16828 | 45 |
SPI1,CSF1R |
3.620e-02 | -3.32 | HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) | protein interactions | 3113 | 119 | 2 | 19454 | 49 |
APOE,CD74 |
3.630e-02 | -3.32 | positive regulation of metabolic process | biological process | GO:0009893 | 3796 | 16 | 18204 | 49 |
PLCG2,IRF5,APOE,SBNO2,STAT6,DENND1B,CSF1R,BLNK,PIK3R5,SPI1,SKAP1,P2RY6,PRKCD,HIF1A,CD74,IL6R |
3.631e-02 | -3.32 | tube morphogenesis | biological process | GO:0035239 | 685 | 5 | 18204 | 49 |
VAV3,GAB1,APOE,CSF1R,HIF1A |
3.642e-02 | -3.31 | Rhomboid-like_sf | interpro domains | IPR035952 | 14 | 1 | 18521 | 49 |
RHBDF2 |
3.645e-02 | -3.31 | Fc epsilon receptor (FCERI) signaling | REACTOME pathways | R-HSA-2454202 | 372 | 4 | 10285 | 35 |
VAV3,GAB1,PLCG2,TLN1 |
3.647e-02 | -3.31 | phosphorus metabolic process | biological process | GO:0006793 | 1707 | 9 | 18204 | 49 |
CSF1R,NEK6,HCK,PRKCD,PIK3R5,ADCY7,NRK,PLCG2,PTPN6 |
3.648e-02 | -3.31 | protein-containing complex binding | molecular function | GO:0044877 | 1772 | 9 | 18094 | 47 |
SPI1,FYB1,CD74,SBNO2,MYO1F,DOCK2,PIK3R5,APOE,TLN1 |
3.657e-02 | -3.31 | extrinsic apoptotic signaling pathway | biological process | GO:0097191 | 112 | 2 | 18204 | 49 |
IL6R,SPI1 |
3.657e-02 | -3.31 | mononuclear cell migration | biological process | GO:0071674 | 112 | 2 | 18204 | 49 |
IL6R,DOCK8 |
3.664e-02 | -3.31 | positive regulation of macromolecule metabolic process | biological process | GO:0010604 | 3485 | 15 | 18204 | 49 |
IRF5,APOE,PLCG2,CSF1R,SBNO2,STAT6,DENND1B,BLNK,PIK3R5,SKAP1,SPI1,PRKCD,HIF1A,IL6R,CD74 |
3.676e-02 | -3.30 | ELP3 (elongator acetyltransferase complex subunit 3) | protein interactions | 55140 | 120 | 2 | 19454 | 49 |
HIF1A,SKAP1 |
3.682e-02 | -3.30 | Signaling by FGFR4 in disease | REACTOME pathways | R-HSA-5655291 | 11 | 1 | 10285 | 35 |
GAB1 |
3.682e-02 | -3.30 | MET activates RAP1 and RAC1 | REACTOME pathways | R-HSA-8875555 | 11 | 1 | 10285 | 35 |
GAB1 |
3.682e-02 | -3.30 | Interleukin-6 signaling | REACTOME pathways | R-HSA-1059683 | 11 | 1 | 10285 | 35 |
IL6R |
3.682e-02 | -3.30 | ErbB Signaling Pathway | WikiPathways | WP673 | 54 | 2 | 5310 | 30 |
PIK3R5,GAB1 |
3.682e-02 | -3.30 | Apoptosis-related network due to altered Notch3 in ovarian cancer | WikiPathways | WP2864 | 54 | 2 | 5310 | 30 |
APOE,VAV3 |
3.683e-02 | -3.30 | GOPC (golgi associated PDZ and coiled-coil motif containing) | protein interactions | 57120 | 291 | 3 | 19454 | 49 |
CSF1R,HCK,RHBDF2 |
3.690e-02 | -3.30 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 26 | 16828 | 45 |
DOCK10,MYO1F,PLCG2,PRKCD,WDFY4,GIT2,CSF1R,RHBDF2,DOCK8,STAT6,SBNO2,DOCK1,VAV3,HIF1A,AKAP13,PIK3R5,PREX1,TBXAS1,ADCY7,DOCK2,ARHGAP15,SKAP1,GAB1,BLNK,IPCEF1,ELMO1 |
3.704e-02 | -3.30 | positive regulation of phospholipid transport | biological process | GO:2001140 | 14 | 1 | 18204 | 49 |
APOE |
3.704e-02 | -3.30 | mammary gland epithelial cell proliferation | biological process | GO:0033598 | 14 | 1 | 18204 | 49 |
STAT6 |
3.704e-02 | -3.30 | positive regulation by symbiont of entry into host | biological process | GO:0075294 | 14 | 1 | 18204 | 49 |
CD74 |
3.704e-02 | -3.30 | regulation of podosome assembly | biological process | GO:0071801 | 14 | 1 | 18204 | 49 |
HCK |
3.704e-02 | -3.30 | T-helper 1 cell differentiation | biological process | GO:0045063 | 14 | 1 | 18204 | 49 |
STAT6 |
3.704e-02 | -3.30 | regulation of unsaturated fatty acid biosynthetic process | biological process | GO:2001279 | 14 | 1 | 18204 | 49 |
CD74 |
3.704e-02 | -3.30 | positive regulation of phospholipid metabolic process | biological process | GO:1903727 | 14 | 1 | 18204 | 49 |
PRKCD |
3.704e-02 | -3.30 | negative regulation of long-term synaptic potentiation | biological process | GO:1900272 | 14 | 1 | 18204 | 49 |
APOE |
3.704e-02 | -3.30 | inflammatory response to wounding | biological process | GO:0090594 | 14 | 1 | 18204 | 49 |
HIF1A |
3.704e-02 | -3.30 | positive regulation of viral entry into host cell | biological process | GO:0046598 | 14 | 1 | 18204 | 49 |
CD74 |
3.704e-02 | -3.30 | regulation of mesenchymal cell apoptotic process | biological process | GO:2001053 | 14 | 1 | 18204 | 49 |
HIF1A |
3.704e-02 | -3.30 | positive regulation of heterotypic cell-cell adhesion | biological process | GO:0034116 | 14 | 1 | 18204 | 49 |
SKAP1 |
3.704e-02 | -3.30 | cellular response to lithium ion | biological process | GO:0071285 | 14 | 1 | 18204 | 49 |
ADCY7 |
3.704e-02 | -3.30 | cellular response to ethanol | biological process | GO:0071361 | 14 | 1 | 18204 | 49 |
ADCY7 |
3.704e-02 | -3.30 | cellular response to purine-containing compound | biological process | GO:0071415 | 14 | 1 | 18204 | 49 |
P2RY6 |
3.704e-02 | -3.30 | alpha-beta T cell proliferation | biological process | GO:0046633 | 14 | 1 | 18204 | 49 |
DOCK2 |
3.706e-02 | -3.30 | vascular process in circulatory system | biological process | GO:0003018 | 273 | 3 | 18204 | 49 |
P2RY2,TBXAS1,APOE |
3.714e-02 | -3.29 | NBEAL1 (neurobeachin like 1) | protein interactions | 65065 | 15 | 1 | 19454 | 49 |
HIF1A |
3.714e-02 | -3.29 | IRF6 (interferon regulatory factor 6) | protein interactions | 3664 | 15 | 1 | 19454 | 49 |
IRF5 |
3.714e-02 | -3.29 | AANAT (aralkylamine N-acetyltransferase) | protein interactions | 15 | 15 | 1 | 19454 | 49 |
P2RY6 |
3.714e-02 | -3.29 | GCK (glucokinase) | protein interactions | 2645 | 15 | 1 | 19454 | 49 |
GMIP |
3.714e-02 | -3.29 | MEP1B (meprin A subunit beta) | protein interactions | 4225 | 15 | 1 | 19454 | 49 |
PRKCD |
3.714e-02 | -3.29 | EBI3 (Epstein-Barr virus induced 3) | protein interactions | 10148 | 15 | 1 | 19454 | 49 |
PRKCD |
3.714e-02 | -3.29 | ADRA2A (adrenoceptor alpha 2A) | protein interactions | 150 | 15 | 1 | 19454 | 49 |
PRKCD |
3.715e-02 | -3.29 | NFKB1 (nuclear factor kappa B subunit 1) | protein interactions | 4790 | 292 | 3 | 19454 | 49 |
SPI1,STAT6,RGS14 |
3.715e-02 | -3.29 | KRTAP10-7 (keratin associated protein 10-7) | protein interactions | 386675 | 292 | 3 | 19454 | 49 |
DOCK2,HCK,P2RY6 |
3.717e-02 | -3.29 | negative regulation of intrinsic apoptotic signaling pathway | biological process | GO:2001243 | 113 | 2 | 18204 | 49 |
HIF1A,CD74 |
3.732e-02 | -3.29 | EIF3J (eukaryotic translation initiation factor 3 subunit J) | protein interactions | 8669 | 121 | 2 | 19454 | 49 |
CD74,P2RY6 |
3.732e-02 | -3.29 | POLR3B (RNA polymerase III subunit B) | protein interactions | 55703 | 121 | 2 | 19454 | 49 |
SKAP1,CD74 |
3.777e-02 | -3.28 | icosanoid metabolic process | biological process | GO:0006690 | 114 | 2 | 18204 | 49 |
CD74,TBXAS1 |
3.780e-02 | -3.28 | low-density lipoprotein particle | cellular component | GO:0034362 | 15 | 1 | 19108 | 49 |
APOE |
3.784e-02 | -3.27 | parathyroid | COSMIC cancer mutations | parathyroid | 476 | 4 | 16828 | 45 |
PLCG2,PRKCD,TBC1D8,DOCK2 |
3.788e-02 | -3.27 | ELK1 (ETS transcription factor ELK1) | protein interactions | 2002 | 122 | 2 | 19454 | 49 |
HIF1A,PLCG2 |
3.808e-02 | -3.27 | IL-4 Signaling Pathway | WikiPathways | WP395 | 55 | 2 | 5310 | 30 |
STAT6,PTPN6 |
3.808e-02 | -3.27 | learning or memory | biological process | GO:0007611 | 276 | 3 | 18204 | 49 |
APOE,RGS14,HIF1A |
3.819e-02 | -3.27 | membrane raft | cellular component | GO:0045121 | 290 | 3 | 19108 | 49 |
SKAP1,PLCG2,HCK |
3.828e-02 | -3.26 | phosphatidylglycerol binding | molecular function | GO:1901611 | 15 | 1 | 18094 | 47 |
GSDME |
3.828e-02 | -3.26 | 1-phosphatidylinositol-3-kinase regulator activity | molecular function | GO:0046935 | 15 | 1 | 18094 | 47 |
PIK3R5 |
3.830e-02 | -3.26 | Alpha-catenin/vinculin-like | gene3d domains | 1.20.120.230 | 12 | 1 | 14470 | 47 |
TLN1 |
3.837e-02 | -3.26 | fatty acid biosynthetic process | biological process | GO:0006633 | 115 | 2 | 18204 | 49 |
TBXAS1,CD74 |
3.843e-02 | -3.26 | RHOU (ras homolog family member U) | protein interactions | 58480 | 507 | 4 | 19454 | 49 |
GAB1,TBC1D8,EHBP1L1,GIT2 |
3.844e-02 | -3.26 | HHV8GK18_gp81 (ORF73) | protein interactions | 4961527 | 123 | 2 | 19454 | 49 |
HIF1A,RGS14 |
3.844e-02 | -3.26 | EIF2B3 (eukaryotic translation initiation factor 2B subunit gamma) | protein interactions | 8891 | 123 | 2 | 19454 | 49 |
P2RY6,CD74 |
3.866e-02 | -3.25 | human chr10q26.2 | chromosome location | human chr10q26.2 | 21 | 1 | 26134 | 49 |
DOCK1 |
3.878e-02 | -3.25 | actin filament organization | biological process | GO:0007015 | 278 | 3 | 18204 | 49 |
MYO1F,ELMO1,PREX1 |
3.885e-02 | -3.25 | membrane microdomain | cellular component | GO:0098857 | 292 | 3 | 19108 | 49 |
SKAP1,HCK,PLCG2 |
3.897e-02 | -3.24 | PLipase_C_Pinositol-sp_Y | interpro domains | IPR001711 | 15 | 1 | 18521 | 49 |
PLCG2 |
3.897e-02 | -3.24 | SMAD-like_dom_sf | interpro domains | IPR017855 | 15 | 1 | 18521 | 49 |
IRF5 |
3.897e-02 | -3.24 | CNH_dom | interpro domains | IPR001180 | 15 | 1 | 18521 | 49 |
NRK |
3.897e-02 | -3.24 | PI-PLC_fam | interpro domains | IPR001192 | 15 | 1 | 18521 | 49 |
PLCG2 |
3.898e-02 | -3.24 | cytoskeleton | cellular component | GO:0005856 | 2412 | 11 | 19108 | 49 |
TLN1,AKAP13,ARHGAP33,PARVG,DOCK2,HCK,MYO1F,NEK6,PIK3R5,RGS14,FYB1 |
3.901e-02 | -3.24 | TNK2 (tyrosine kinase non receptor 2) | protein interactions | 10188 | 124 | 2 | 19454 | 49 |
NEK6,HCK |
3.901e-02 | -3.24 | CEBPB (CCAAT enhancer binding protein beta) | protein interactions | 1051 | 124 | 2 | 19454 | 49 |
SPI1,STAT6 |
3.901e-02 | -3.24 | CEBPA (CCAAT enhancer binding protein alpha) | protein interactions | 1050 | 124 | 2 | 19454 | 49 |
SPI1,HIF1A |
3.901e-02 | -3.24 | RNF5 (ring finger protein 5) | protein interactions | 6048 | 124 | 2 | 19454 | 49 |
HIF1A,P2RY2 |
3.901e-02 | -3.24 | TM9SF3 (transmembrane 9 superfamily member 3) | protein interactions | 56889 | 124 | 2 | 19454 | 49 |
P2RY6,P2RY2 |
3.936e-02 | -3.24 | Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain | gene3d domains | 1.10.10.10 | 232 | 3 | 14470 | 47 |
SPI1,PREX1,IRF5 |
3.941e-02 | -3.23 | TYRKINASE | prints domains | PR00109 | 98 | 2 | 5227 | 17 |
HCK,NEK6 |
3.956e-02 | -3.23 | CYP2C8 (cytochrome P450 family 2 subfamily C member 8) | protein interactions | 1558 | 16 | 1 | 19454 | 49 |
APOE |
3.956e-02 | -3.23 | TAMALIN (trafficking regulator and scaffold protein tamalin) | protein interactions | 160622 | 16 | 1 | 19454 | 49 |
DOCK1 |
3.956e-02 | -3.23 | KCNJ4 (potassium inwardly rectifying channel subfamily J member 4) | protein interactions | 3761 | 16 | 1 | 19454 | 49 |
PRKCD |
3.956e-02 | -3.23 | TNFRSF25 (TNF receptor superfamily member 25) | protein interactions | 8718 | 16 | 1 | 19454 | 49 |
PTPN6 |
3.956e-02 | -3.23 | EPO (erythropoietin) | protein interactions | 2056 | 16 | 1 | 19454 | 49 |
HIF1A |
3.956e-02 | -3.23 | PRICKLE4 (prickle planar cell polarity protein 4) | protein interactions | 29964 | 16 | 1 | 19454 | 49 |
NEK6 |
3.956e-02 | -3.23 | IL1RL2 (interleukin 1 receptor like 2) | protein interactions | 8808 | 16 | 1 | 19454 | 49 |
MYO1F |
3.956e-02 | -3.23 | ZSCAN4 (zinc finger and SCAN domain containing 4) | protein interactions | 201516 | 16 | 1 | 19454 | 49 |
HCK |
3.956e-02 | -3.23 | RASGRP3 (RAS guanyl releasing protein 3) | protein interactions | 25780 | 16 | 1 | 19454 | 49 |
PRKCD |
3.956e-02 | -3.23 | TWIST2 (twist family bHLH transcription factor 2) | protein interactions | 117581 | 16 | 1 | 19454 | 49 |
PLCG2 |
3.959e-02 | -3.23 | cellular detoxification | biological process | GO:1990748 | 117 | 2 | 18204 | 49 |
APOE,IPCEF1 |
3.964e-02 | -3.23 | positive regulation of hormone metabolic process | biological process | GO:0032352 | 15 | 1 | 18204 | 49 |
HIF1A |
3.964e-02 | -3.23 | lipoprotein catabolic process | biological process | GO:0042159 | 15 | 1 | 18204 | 49 |
APOE |
3.964e-02 | -3.23 | negative regulation of B cell mediated immunity | biological process | GO:0002713 | 15 | 1 | 18204 | 49 |
PTPN6 |
3.964e-02 | -3.23 | negative regulation of type 2 immune response | biological process | GO:0002829 | 15 | 1 | 18204 | 49 |
STAT6 |
3.964e-02 | -3.23 | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | biological process | GO:1902166 | 15 | 1 | 18204 | 49 |
CD74 |
3.964e-02 | -3.23 | regulation of phagocytosis, engulfment | biological process | GO:0060099 | 15 | 1 | 18204 | 49 |
PLCG2 |
3.964e-02 | -3.23 | negative regulation of B cell apoptotic process | biological process | GO:0002903 | 15 | 1 | 18204 | 49 |
CD74 |
3.964e-02 | -3.23 | negative regulation of DNA damage response, signal transduction by p53 class mediator | biological process | GO:0043518 | 15 | 1 | 18204 | 49 |
CD74 |
3.964e-02 | -3.23 | positive regulation of cholesterol metabolic process | biological process | GO:0090205 | 15 | 1 | 18204 | 49 |
APOE |
3.964e-02 | -3.23 | oxygen transport | biological process | GO:0015671 | 15 | 1 | 18204 | 49 |
IPCEF1 |
3.964e-02 | -3.23 | columnar/cuboidal epithelial cell maturation | biological process | GO:0002069 | 15 | 1 | 18204 | 49 |
HIF1A |
3.964e-02 | -3.23 | negative regulation of immunoglobulin mediated immune response | biological process | GO:0002890 | 15 | 1 | 18204 | 49 |
PTPN6 |
3.964e-02 | -3.23 | regulation of inositol phosphate biosynthetic process | biological process | GO:0010919 | 15 | 1 | 18204 | 49 |
P2RY6 |
3.964e-02 | -3.23 | regulation of membrane invagination | biological process | GO:1905153 | 15 | 1 | 18204 | 49 |
PLCG2 |
3.975e-02 | -3.23 | PPM1G (protein phosphatase, Mg2+/Mn2+ dependent 1G) | protein interactions | 5496 | 300 | 3 | 19454 | 49 |
P2RY6,STAT6,IRF5 |
4.008e-02 | -3.22 | ARRB1 (arrestin beta 1) | protein interactions | 408 | 301 | 3 | 19454 | 49 |
HIF1A,HCK,NEK6 |
4.009e-02 | -3.22 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | 485 | 4 | 16828 | 45 |
WDFY4,DOCK8,ELMO1,IPCEF1 |
4.009e-02 | -3.22 | medullomyoblastoma | COSMIC cancer mutations | medullomyoblastoma | 485 | 4 | 16828 | 45 |
WDFY4,DOCK8,ELMO1,IPCEF1 |
4.010e-02 | -3.22 | Regulation of gene expression by Hypoxia-inducible Factor | REACTOME pathways | R-HSA-1234158 | 12 | 1 | 10285 | 35 |
HIF1A |
4.010e-02 | -3.22 | PECAM1 interactions | REACTOME pathways | R-HSA-210990 | 12 | 1 | 10285 | 35 |
PTPN6 |
4.010e-02 | -3.22 | Eicosanoids | REACTOME pathways | R-HSA-211979 | 12 | 1 | 10285 | 35 |
TBXAS1 |
4.020e-02 | -3.21 | biological process involved in interaction with symbiont | biological process | GO:0051702 | 118 | 2 | 18204 | 49 |
CSF1R,APOE |
4.041e-02 | -3.21 | TRAF1 (TNF receptor associated factor 1) | protein interactions | 7185 | 302 | 3 | 19454 | 49 |
GIT2,VAV3,TBC1D8 |
4.053e-02 | -3.21 | CNH | pfam domains | PF00780 | 15 | 1 | 17795 | 49 |
NRK |
4.053e-02 | -3.21 | PI-PLC-Y | pfam domains | PF00387 | 15 | 1 | 17795 | 49 |
PLCG2 |
4.061e-02 | -3.20 | testis-germ_cell_tumour-non_seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-non_seminoma | 487 | 4 | 16828 | 45 |
CSF1R,HCK,NEK6,PRKCD |
4.074e-02 | -3.20 | PPIB (peptidylprolyl isomerase B) | protein interactions | 5479 | 303 | 3 | 19454 | 49 |
PREX1,IRF5,DOCK8 |
4.076e-02 | -3.20 | TyrKc | smart domains | SM00219 | 80 | 2 | 9717 | 39 |
CSF1R,HCK |
4.078e-02 | -3.20 | adenylate cyclase activity | molecular function | GO:0004016 | 16 | 1 | 18094 | 47 |
ADCY7 |
4.078e-02 | -3.20 | diacylglycerol-dependent serine/threonine kinase activity | molecular function | GO:0004697 | 16 | 1 | 18094 | 47 |
PRKCD |
4.082e-02 | -3.20 | negative regulation of protein transport | biological process | GO:0051224 | 119 | 2 | 18204 | 49 |
APOE,RHBDF2 |
4.086e-02 | -3.20 | VEGFR1 specific signals | Pathway Interaction DB | vegfr1_pathway | 29 | 2 | 2226 | 25 |
GAB1,HIF1A |
4.108e-02 | -3.19 | SH3KBP1 (SH3 domain containing kinase binding protein 1) | protein interactions | 30011 | 304 | 3 | 19454 | 49 |
ARHGAP27,BLNK,HCK |
4.123e-02 | -3.19 | NGF signalling via TRKA from the plasma membrane | REACTOME pathways | R-HSA-187037 | 387 | 4 | 10285 | 35 |
PRKCD,GAB1,TLN1,ADCY7 |
4.126e-02 | -3.19 | cellular response to chemical stress | biological process | GO:0062197 | 285 | 3 | 18204 | 49 |
PRKCD,HIF1A,STAT6 |
4.132e-02 | -3.19 | TACSTD2 (tumor associated calcium signal transducer 2) | protein interactions | 4070 | 128 | 2 | 19454 | 49 |
GSDME,TBC1D8 |
4.143e-02 | -3.18 | - | gene3d domains | 3.30.450.200 | 13 | 1 | 14470 | 47 |
DENND1B |
4.152e-02 | -3.18 | dDENN_dom | interpro domains | IPR005112 | 16 | 1 | 18521 | 49 |
DENND1B |
4.152e-02 | -3.18 | DENN_C | interpro domains | IPR043153 | 16 | 1 | 18521 | 49 |
DENND1B |
4.152e-02 | -3.18 | uDENN_dom | interpro domains | IPR005113 | 16 | 1 | 18521 | 49 |
DENND1B |
4.173e-02 | -3.18 | cytoskeletal protein binding | molecular function | GO:0008092 | 989 | 6 | 18094 | 47 |
RGS14,APOE,TLN1,NEK6,PARVG,MYO1F |
4.182e-02 | -3.17 | protein tyrosine kinase binding | molecular function | GO:1990782 | 125 | 2 | 18094 | 47 |
PLCG2,BLNK |
4.188e-02 | -3.17 | kinase activity | molecular function | GO:0016301 | 739 | 5 | 18094 | 47 |
PRKCD,CSF1R,NEK6,HCK,NRK |
4.190e-02 | -3.17 | EIF2B4 (eukaryotic translation initiation factor 2B subunit delta) | protein interactions | 8890 | 129 | 2 | 19454 | 49 |
P2RY6,CD74 |
4.190e-02 | -3.17 | PLD1 (phospholipase D1) | protein interactions | 5337 | 129 | 2 | 19454 | 49 |
PLCG2,HIF1A |
4.190e-02 | -3.17 | non_seminoma | COSMIC cancer mutations | non_seminoma | 492 | 4 | 16828 | 45 |
PRKCD,HCK,CSF1R,NEK6 |
4.196e-02 | -3.17 | normal | COSMIC cancer mutations | normal | 16 | 1 | 16828 | 45 |
CSF1R |
4.198e-02 | -3.17 | C16orf92 (chromosome 16 open reading frame 92) | protein interactions | 146378 | 17 | 1 | 19454 | 49 |
APOE |
4.198e-02 | -3.17 | SAT2 (spermidine/spermine N1-acetyltransferase family member 2) | protein interactions | 112483 | 17 | 1 | 19454 | 49 |
HIF1A |
4.198e-02 | -3.17 | RIMBP3C (RIMS binding protein 3C) | protein interactions | 150221 | 17 | 1 | 19454 | 49 |
NEK6 |
4.198e-02 | -3.17 | FAM131C (family with sequence similarity 131 member C) | protein interactions | 348487 | 17 | 1 | 19454 | 49 |
RHBDF2 |
4.198e-02 | -3.17 | SLAMF6 (SLAM family member 6) | protein interactions | 114836 | 17 | 1 | 19454 | 49 |
PTPN6 |
4.198e-02 | -3.17 | CITED2 (Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2) | protein interactions | 10370 | 17 | 1 | 19454 | 49 |
HIF1A |
4.207e-02 | -3.17 | negative regulation of immune effector process | biological process | GO:0002698 | 121 | 2 | 18204 | 49 |
PTPN6,SPI1 |
4.207e-02 | -3.17 | centriolar satellite | cellular component | GO:0034451 | 127 | 2 | 19108 | 49 |
NEK6,PIK3R5 |
4.223e-02 | -3.16 | response to lithium ion | biological process | GO:0010226 | 16 | 1 | 18204 | 49 |
ADCY7 |
4.223e-02 | -3.16 | lactate metabolic process | biological process | GO:0006089 | 16 | 1 | 18204 | 49 |
HIF1A |
4.223e-02 | -3.16 | positive regulation of autophagy of mitochondrion | biological process | GO:1903599 | 16 | 1 | 18204 | 49 |
HIF1A |
4.223e-02 | -3.16 | regulation of cell proliferation involved in kidney development | biological process | GO:1901722 | 16 | 1 | 18204 | 49 |
IL6R |
4.223e-02 | -3.16 | asymmetric cell division | biological process | GO:0008356 | 16 | 1 | 18204 | 49 |
RGS14 |
4.223e-02 | -3.16 | regulation of adipose tissue development | biological process | GO:1904177 | 16 | 1 | 18204 | 49 |
SPI1 |
4.223e-02 | -3.16 | low-density lipoprotein particle remodeling | biological process | GO:0034374 | 16 | 1 | 18204 | 49 |
APOE |
4.223e-02 | -3.16 | locomotory exploration behavior | biological process | GO:0035641 | 16 | 1 | 18204 | 49 |
APOE |
4.223e-02 | -3.16 | intestinal epithelial cell development | biological process | GO:0060576 | 16 | 1 | 18204 | 49 |
HIF1A |
4.223e-02 | -3.16 | positive regulation of immune response to tumor cell | biological process | GO:0002839 | 16 | 1 | 18204 | 49 |
GSDME |
4.223e-02 | -3.16 | positive regulation of B cell differentiation | biological process | GO:0045579 | 16 | 1 | 18204 | 49 |
SPI1 |
4.223e-02 | -3.16 | positive regulation of response to tumor cell | biological process | GO:0002836 | 16 | 1 | 18204 | 49 |
GSDME |
4.223e-02 | -3.16 | cellular response to prostaglandin E stimulus | biological process | GO:0071380 | 16 | 1 | 18204 | 49 |
P2RY6 |
4.223e-02 | -3.16 | positive regulation of membrane protein ectodomain proteolysis | biological process | GO:0051044 | 16 | 1 | 18204 | 49 |
APOE |
4.234e-02 | -3.16 | positive regulation of innate immune response | biological process | GO:0045089 | 288 | 3 | 18204 | 49 |
SPI1,PLCG2,HCK |
4.249e-02 | -3.16 | YIPF5 (Yip1 domain family member 5) | protein interactions | 81555 | 130 | 2 | 19454 | 49 |
P2RY6,P2RY2 |
4.266e-02 | -3.15 | D-myo-inositol (1,4,5)-trisphosphate biosynthesis | BIOCYC pathways | META_PWY-6351 | 13 | 1 | 902 | 3 |
PLCG2 |
4.271e-02 | -3.15 | muscle cell differentiation | biological process | GO:0042692 | 289 | 3 | 18204 | 49 |
DOCK2,DOCK1,AKAP13 |
4.273e-02 | -3.15 | MHC class II protein complex | cellular component | GO:0042613 | 17 | 1 | 19108 | 49 |
CD74 |
4.278e-02 | -3.15 | embryonal | COSMIC cancer mutations | embryonal | 2659 | 12 | 16828 | 45 |
EHBP1L1,APOE,PLCG2,PARVG,DOCK1,PTPN6,DOCK8,DOCK10,ELMO1,AKAP13,WDFY4,VAV3 |
4.278e-02 | -3.15 | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | 2659 | 12 | 16828 | 45 |
APOE,PLCG2,EHBP1L1,PTPN6,DOCK1,PARVG,DOCK8,DOCK10,ELMO1,AKAP13,WDFY4,VAV3 |
4.308e-02 | -3.14 | LGALS7 (galectin 7) | protein interactions | 3963 | 131 | 2 | 19454 | 49 |
DOCK8,GAB1 |
4.308e-02 | -3.14 | NCOA2 (nuclear receptor coactivator 2) | protein interactions | 10499 | 131 | 2 | 19454 | 49 |
HIF1A,STAT6 |
4.318e-02 | -3.14 | uDENN | pfam domains | PF03456 | 16 | 1 | 17795 | 49 |
DENND1B |
4.321e-02 | -3.14 | plasma membrane region | cellular component | GO:0098590 | 1278 | 7 | 19108 | 49 |
P2RY6,IL6R,PLCG2,HCK,DOCK8,TLN1,SKAP1 |
4.327e-02 | -3.14 | transmembrane receptor protein phosphatase activity | molecular function | GO:0019198 | 17 | 1 | 18094 | 47 |
PTPN6 |
4.327e-02 | -3.14 | transmembrane receptor protein tyrosine kinase adaptor activity | molecular function | GO:0005068 | 17 | 1 | 18094 | 47 |
BLNK |
4.327e-02 | -3.14 | GDP-dissociation inhibitor activity | molecular function | GO:0005092 | 17 | 1 | 18094 | 47 |
RGS14 |
4.327e-02 | -3.14 | transmembrane receptor protein tyrosine phosphatase activity | molecular function | GO:0005001 | 17 | 1 | 18094 | 47 |
PTPN6 |
4.337e-02 | -3.14 | FCGR activation | REACTOME pathways | R-HSA-2029481 | 13 | 1 | 10285 | 35 |
HCK |
4.348e-02 | -3.14 | Regulation of CDC42 activity | Pathway Interaction DB | cdc42_reg_pathway | 30 | 2 | 2226 | 25 |
DOCK10,VAV3 |
4.365e-02 | -3.13 | histone deacetylase binding | molecular function | GO:0042826 | 128 | 2 | 18094 | 47 |
SPI1,HIF1A |
4.367e-02 | -3.13 | TXNDC12 (thioredoxin domain containing 12) | protein interactions | 51060 | 132 | 2 | 19454 | 49 |
TLN1,HCK |
4.381e-02 | -3.13 | ACTN1 (actinin alpha 1) | protein interactions | 87 | 312 | 3 | 19454 | 49 |
PTPN6,TLN1,GIT2 |
4.406e-02 | -3.12 | RGS_subdom1/3 | interpro domains | IPR024066 | 17 | 1 | 18521 | 49 |
RGS14 |
4.406e-02 | -3.12 | Thyroglobulin_1 | interpro domains | IPR000716 | 17 | 1 | 18521 | 49 |
CD74 |
4.406e-02 | -3.12 | PLipase_C_PInositol-sp_X_dom | interpro domains | IPR000909 | 17 | 1 | 18521 | 49 |
PLCG2 |
4.406e-02 | -3.12 | A/G_cyclase_CS | interpro domains | IPR018297 | 17 | 1 | 18521 | 49 |
ADCY7 |
4.406e-02 | -3.12 | PAC | interpro domains | IPR001610 | 17 | 1 | 18521 | 49 |
HIF1A |
4.406e-02 | -3.12 | Thyroglobulin_1_sf | interpro domains | IPR036857 | 17 | 1 | 18521 | 49 |
CD74 |
4.406e-02 | -3.12 | cDENN_dom | interpro domains | IPR001194 | 17 | 1 | 18521 | 49 |
DENND1B |
4.440e-02 | -3.11 | DCAF17 (DDB1 and CUL4 associated factor 17) | protein interactions | 80067 | 18 | 1 | 19454 | 49 |
PREX1 |
4.440e-02 | -3.11 | TM4SF20 (transmembrane 4 L six family member 20) | protein interactions | 79853 | 18 | 1 | 19454 | 49 |
CD74 |
4.440e-02 | -3.11 | BEX4 (brain expressed X-linked 4) | protein interactions | 56271 | 18 | 1 | 19454 | 49 |
PRKCD |
4.440e-02 | -3.11 | ZKSCAN7 (zinc finger with KRAB and SCAN domains 7) | protein interactions | 55888 | 18 | 1 | 19454 | 49 |
PLCG2 |
4.440e-02 | -3.11 | Lck (lymphocyte protein tyrosine kinase) | protein interactions | 16818 | 18 | 1 | 19454 | 49 |
APOE |
4.440e-02 | -3.11 | Chmp6 (charged multivesicular body protein 6) | protein interactions | 208092 | 18 | 1 | 19454 | 49 |
PTPN6 |
4.440e-02 | -3.11 | GALM (galactose mutarotase) | protein interactions | 130589 | 18 | 1 | 19454 | 49 |
AKAP13 |
4.461e-02 | -3.11 | regulation of cell-matrix adhesion | biological process | GO:0001952 | 125 | 2 | 18204 | 49 |
TLN1,SKAP1 |
4.461e-02 | -3.11 | memory | biological process | GO:0007613 | 125 | 2 | 18204 | 49 |
RGS14,APOE |
4.481e-02 | -3.11 | reverse cholesterol transport | biological process | GO:0043691 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | positive regulation of vascular permeability | biological process | GO:0043117 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | regulation of dendritic cell cytokine production | biological process | GO:0002730 | 17 | 1 | 18204 | 49 |
PLCG2 |
4.481e-02 | -3.11 | high-density lipoprotein particle remodeling | biological process | GO:0034375 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | monocyte differentiation | biological process | GO:0030224 | 17 | 1 | 18204 | 49 |
CSF1R |
4.481e-02 | -3.11 | regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | biological process | GO:1902165 | 17 | 1 | 18204 | 49 |
CD74 |
4.481e-02 | -3.11 | protein trimerization | biological process | GO:0070206 | 17 | 1 | 18204 | 49 |
CD74 |
4.481e-02 | -3.11 | cellular response to ATP | biological process | GO:0071318 | 17 | 1 | 18204 | 49 |
P2RY2 |
4.481e-02 | -3.11 | fatty acid homeostasis | biological process | GO:0055089 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | regulation of amyloid fibril formation | biological process | GO:1905906 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | cellular response to reactive nitrogen species | biological process | GO:1902170 | 17 | 1 | 18204 | 49 |
STAT6 |
4.481e-02 | -3.11 | axonal transport of mitochondrion | biological process | GO:0019896 | 17 | 1 | 18204 | 49 |
HIF1A |
4.481e-02 | -3.11 | negative regulation of triglyceride metabolic process | biological process | GO:0090209 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | negative regulation of humoral immune response | biological process | GO:0002921 | 17 | 1 | 18204 | 49 |
PTPN6 |
4.481e-02 | -3.11 | response to hepatocyte growth factor | biological process | GO:0035728 | 17 | 1 | 18204 | 49 |
GAB1 |
4.481e-02 | -3.11 | regulation of integrin activation | biological process | GO:0033623 | 17 | 1 | 18204 | 49 |
SKAP1 |
4.481e-02 | -3.11 | regulation of plasma membrane organization | biological process | GO:1903729 | 17 | 1 | 18204 | 49 |
PRKCD |
4.481e-02 | -3.11 | mammary gland epithelial cell differentiation | biological process | GO:0060644 | 17 | 1 | 18204 | 49 |
HIF1A |
4.481e-02 | -3.11 | T-helper 17 type immune response | biological process | GO:0072538 | 17 | 1 | 18204 | 49 |
IL6R |
4.486e-02 | -3.10 | DARS1 (aspartyl-tRNA synthetase 1) | protein interactions | 1615 | 315 | 3 | 19454 | 49 |
PTPN6,TLN1,PRKCD |
4.503e-02 | -3.10 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 2081 | 10 | 16828 | 45 |
BLNK,RGS14,NEK6,GIT2,CSF1R,PRKCD,DOCK1,P2RY2,STAT6,HCK |
4.517e-02 | -3.10 | PROTEIN_KINASE_TYR | prosite domains | PS00109 | 94 | 2 | 12186 | 44 |
HCK,CSF1R |
4.525e-02 | -3.10 | regulation of type I interferon production | biological process | GO:0032479 | 126 | 2 | 18204 | 49 |
PLCG2,IRF5 |
4.525e-02 | -3.10 | response to ethanol | biological process | GO:0045471 | 126 | 2 | 18204 | 49 |
TBXAS1,ADCY7 |
4.547e-02 | -3.09 | JAK3 (Janus kinase 3) | protein interactions | 3718 | 135 | 2 | 19454 | 49 |
PTPN6,STAT6 |
4.556e-02 | -3.09 | HIV Infection | REACTOME pathways | R-HSA-162906 | 236 | 3 | 10285 | 35 |
ELMO1,HCK,DOCK2 |
4.576e-02 | -3.08 | heparan sulfate proteoglycan binding | molecular function | GO:0043395 | 18 | 1 | 18094 | 47 |
APOE |
4.581e-02 | -3.08 | DENN | pfam domains | PF02141 | 17 | 1 | 17795 | 49 |
DENND1B |
4.581e-02 | -3.08 | PI-PLC-X | pfam domains | PF00388 | 17 | 1 | 17795 | 49 |
PLCG2 |
4.581e-02 | -3.08 | Thyroglobulin_1 | pfam domains | PF00086 | 17 | 1 | 17795 | 49 |
CD74 |
4.590e-02 | -3.08 | positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | biological process | GO:0002824 | 127 | 2 | 18204 | 49 |
DENND1B,STAT6 |
4.590e-02 | -3.08 | cellular response to toxic substance | biological process | GO:0097237 | 127 | 2 | 18204 | 49 |
APOE,IPCEF1 |
4.592e-02 | -3.08 | TRIM54 (tripartite motif containing 54) | protein interactions | 57159 | 318 | 3 | 19454 | 49 |
ELMO1,PARVG,NEK6 |
4.606e-02 | -3.08 | CLEC7A (Dectin-1) signaling | REACTOME pathways | R-HSA-5607764 | 101 | 2 | 10285 | 35 |
PRKCD,PLCG2 |
4.608e-02 | -3.08 | PYGB (glycogen phosphorylase B) | protein interactions | 5834 | 136 | 2 | 19454 | 49 |
PRKCD,FYB1 |
4.608e-02 | -3.08 | ITGB5 (integrin subunit beta 5) | protein interactions | 3693 | 136 | 2 | 19454 | 49 |
P2RY2,TLN1 |
4.608e-02 | -3.08 | IRS1 (insulin receptor substrate 1) | protein interactions | 3667 | 136 | 2 | 19454 | 49 |
PRKCD,PLCG2 |
4.608e-02 | -3.08 | ROCK2 (Rho associated coiled-coil containing protein kinase 2) | protein interactions | 9475 | 136 | 2 | 19454 | 49 |
AKAP13,TLN1 |
4.616e-02 | -3.08 | cellular localization | biological process | GO:0051641 | 2660 | 12 | 18204 | 49 |
HCK,HIF1A,CD74,DENND1B,SKAP1,ARHGAP33,RGS14,FYB1,APOE,GIT2,RHBDF2,DOCK2 |
4.616e-02 | -3.08 | EPHA forward signaling | Pathway Interaction DB | epha_fwdpathway | 31 | 2 | 2226 | 25 |
HCK,VAV3 |
4.621e-02 | -3.07 | lung-carcinoid-endocrine_tumour-atypical | COSMIC cancer mutations | lung-carcinoid-endocrine_tumour-atypical | 508 | 4 | 16828 | 45 |
PRKCD,NEK6,CSF1R,HCK |
4.624e-02 | -3.07 | cellular response to hormone stimulus | biological process | GO:0032870 | 504 | 4 | 18204 | 49 |
GAB1,STAT6,P2RY6,PRKCD |
4.627e-02 | -3.07 | GCN1 (GCN1 activator of EIF2AK4) | protein interactions | 10985 | 319 | 3 | 19454 | 49 |
HIF1A,P2RY6,NEK6 |
4.630e-02 | -3.07 | acute_lymphoblastic_T_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_T_cell_leukaemia | 739 | 5 | 16828 | 45 |
CSF1R,PLCG2,PTPN6,DOCK1,DOCK2 |
4.630e-02 | -3.07 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_T_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_T_cell_leukaemia | 739 | 5 | 16828 | 45 |
DOCK1,DOCK2,PTPN6,PLCG2,CSF1R |
4.633e-02 | -3.07 | bone-humerus-other-chondroblastoma | COSMIC cancer mutations | bone-humerus-other-chondroblastoma | 301 | 3 | 16828 | 45 |
WDFY4,DOCK2,ARHGAP15 |
4.641e-02 | -3.07 | negative regulation of multicellular organismal process | biological process | GO:0051241 | 1237 | 7 | 18204 | 49 |
APOE,ADCY7,PTPN6,CD74,HIF1A,PRKCD,SPI1 |
4.655e-02 | -3.07 | regulation of protein binding | biological process | GO:0043393 | 128 | 2 | 18204 | 49 |
APOE,PRKCD |
4.659e-02 | -3.07 | Nucleotide_cyclase | interpro domains | IPR029787 | 18 | 1 | 18521 | 49 |
ADCY7 |
4.659e-02 | -3.07 | A/G_cyclase | interpro domains | IPR001054 | 18 | 1 | 18521 | 49 |
ADCY7 |
4.663e-02 | -3.07 | Regulation of IFNG signaling | REACTOME pathways | R-HSA-877312 | 14 | 1 | 10285 | 35 |
PTPN6 |
4.663e-02 | -3.07 | DCC mediated attractive signaling | REACTOME pathways | R-HSA-418885 | 14 | 1 | 10285 | 35 |
DOCK1 |
4.681e-02 | -3.06 | PDP2 (pyruvate dehydrogenase phosphatase catalytic subunit 2) | protein interactions | 57546 | 19 | 1 | 19454 | 49 |
PRKCD |
4.681e-02 | -3.06 | SLITRK3 (SLIT and NTRK like family member 3) | protein interactions | 22865 | 19 | 1 | 19454 | 49 |
RHBDF2 |
4.681e-02 | -3.06 | PEX2 (peroxisomal biogenesis factor 2) | protein interactions | 5828 | 19 | 1 | 19454 | 49 |
PTPN6 |
4.681e-02 | -3.06 | ZNF197 (zinc finger protein 197) | protein interactions | 10168 | 19 | 1 | 19454 | 49 |
HIF1A |
4.681e-02 | -3.06 | PPRC1 (PPARG related coactivator 1) | protein interactions | 23082 | 19 | 1 | 19454 | 49 |
PRKCD |
4.681e-02 | -3.06 | LTC4S (leukotriene C4 synthase) | protein interactions | 4056 | 19 | 1 | 19454 | 49 |
PRKCD |
4.681e-02 | -3.06 | RCVRN (recoverin) | protein interactions | 5957 | 19 | 1 | 19454 | 49 |
GIT2 |
4.681e-02 | -3.06 | CSF1 (colony stimulating factor 1) | protein interactions | 1435 | 19 | 1 | 19454 | 49 |
CSF1R |
4.715e-02 | -3.05 | intracellular anatomical structure | cellular component | GO:0005622 | 15205 | 44 | 19108 | 49 |
ARHGAP27,VAV3,PIK3R5,GIT2,NRK,APOE,CSF1R,DOCK8,BLNK,PTPN6,GAB1,DENND1B,PLCG2,HIF1A,AKAP13,ELMO1,STAT6,DOCK10,PRKCD,CARMIL3,EHBP1L1,HCK,SPI1,MYO1F,GMIP,TBXAS1,WDFY4,IRF5,CD74,RGS14,ARHGAP15,IPCEF1,SBNO2,GSDME,SKAP1,FYB1,RHBDF2,DOCK1,TLN1,PREX1,ARHGAP33,PARVG,DOCK2,NEK6 |
4.720e-02 | -3.05 | response to organophosphorus | biological process | GO:0046683 | 129 | 2 | 18204 | 49 |
P2RY2,P2RY6 |
4.720e-02 | -3.05 | positive regulation of lymphocyte mediated immunity | biological process | GO:0002708 | 129 | 2 | 18204 | 49 |
STAT6,DENND1B |
4.730e-02 | -3.05 | Regulation of toll-like receptor signaling pathway | WikiPathways | WP1449 | 145 | 3 | 5310 | 30 |
PIK3R5,PTPN6,IRF5 |
4.730e-02 | -3.05 | AKAP12 (A-kinase anchoring protein 12) | protein interactions | 9590 | 138 | 2 | 19454 | 49 |
HCK,RHBDF2 |
4.730e-02 | -3.05 | NCOA1 (nuclear receptor coactivator 1) | protein interactions | 8648 | 138 | 2 | 19454 | 49 |
STAT6,HIF1A |
4.735e-02 | -3.05 | ITGB1 (integrin subunit beta 1) | protein interactions | 3688 | 322 | 3 | 19454 | 49 |
P2RY6,TLN1,RHBDF2 |
4.738e-02 | -3.05 | positive regulation of superoxide anion generation | biological process | GO:0032930 | 18 | 1 | 18204 | 49 |
PRKCD |
4.738e-02 | -3.05 | dendritic spine morphogenesis | biological process | GO:0060997 | 18 | 1 | 18204 | 49 |
DOCK10 |
4.738e-02 | -3.05 | positive regulation of vascular endothelial growth factor receptor signaling pathway | biological process | GO:0030949 | 18 | 1 | 18204 | 49 |
HIF1A |
4.738e-02 | -3.05 | morphogenesis of an epithelial fold | biological process | GO:0060571 | 18 | 1 | 18204 | 49 |
HIF1A |
4.738e-02 | -3.05 | cell-cell junction maintenance | biological process | GO:0045217 | 18 | 1 | 18204 | 49 |
CSF1R |
4.738e-02 | -3.05 | regulation of humoral immune response mediated by circulating immunoglobulin | biological process | GO:0002923 | 18 | 1 | 18204 | 49 |
PTPN6 |
4.738e-02 | -3.05 | positive regulation of neuroinflammatory response | biological process | GO:0150078 | 18 | 1 | 18204 | 49 |
PLCG2 |
4.738e-02 | -3.05 | antifungal innate immune response | biological process | GO:0061760 | 18 | 1 | 18204 | 49 |
PLCG2 |
4.765e-02 | -3.04 | - | gene3d domains | 2.60.200.10 | 15 | 1 | 14470 | 47 |
IRF5 |
4.775e-02 | -3.04 | PHPHLIPASEC | prints domains | PR00390 | 15 | 1 | 5227 | 17 |
PLCG2 |
4.786e-02 | -3.04 | negative regulation of T cell activation | biological process | GO:0050868 | 130 | 2 | 18204 | 49 |
CD74,PTPN6 |
4.789e-02 | -3.04 | Ser/Thr_kinase_AS | interpro domains | IPR008271 | 308 | 3 | 18521 | 49 |
NEK6,NRK,PRKCD |
4.792e-02 | -3.04 | PTPRA (protein tyrosine phosphatase receptor type A) | protein interactions | 5786 | 139 | 2 | 19454 | 49 |
PRKCD,GAB1 |
4.792e-02 | -3.04 | HOMEZ (homeobox and leucine zipper encoding) | protein interactions | 57594 | 139 | 2 | 19454 | 49 |
NEK6,PARVG |
4.792e-02 | -3.04 | MON2 (MON2 homolog, regulator of endosome-to-Golgi trafficking) | protein interactions | 23041 | 139 | 2 | 19454 | 49 |
HIF1A,P2RY6 |
4.812e-02 | -3.03 | positive regulation of protein metabolic process | biological process | GO:0051247 | 1247 | 7 | 18204 | 49 |
IL6R,CD74,PRKCD,CSF1R,PLCG2,APOE,PIK3R5 |
4.817e-02 | -3.03 | atypical | COSMIC cancer mutations | atypical | 515 | 4 | 16828 | 45 |
PRKCD,NEK6,HCK,CSF1R |
4.835e-02 | -3.03 | coated vesicle | cellular component | GO:0030135 | 319 | 3 | 19108 | 49 |
CD74,DENND1B,APOE |
4.844e-02 | -3.03 | Guanylate_cyc | pfam domains | PF00211 | 18 | 1 | 17795 | 49 |
ADCY7 |
4.853e-02 | -3.03 | USP19 (ubiquitin specific peptidase 19) | protein interactions | 10869 | 140 | 2 | 19454 | 49 |
HIF1A,TLN1 |
4.880e-02 | -3.02 | PXN (paxillin) | protein interactions | 5829 | 326 | 3 | 19454 | 49 |
GIT2,TLN1,HCK |
4.884e-02 | -3.02 | clathrin-coated vesicle membrane | cellular component | GO:0030665 | 138 | 2 | 19108 | 49 |
CD74,APOE |
4.887e-02 | -3.02 | ErbB signaling pathway | KEGG pathways | hsa04012 | 85 | 2 | 7161 | 30 |
PLCG2,GAB1 |
4.887e-02 | -3.02 | ErbB signaling pathway | KEGG pathways | ko04012 | 85 | 2 | 7161 | 30 |
GAB1,PLCG2 |
4.889e-02 | -3.02 | negative regulation of molecular function | biological process | GO:0044092 | 744 | 5 | 18204 | 49 |
APOE,SPI1,RGS14,PRKCD,GMIP |
4.891e-02 | -3.02 | Trk receptor signaling mediated by PI3K and PLC-gamma | Pathway Interaction DB | pi3kplctrkpathway | 32 | 2 | 2226 | 25 |
PRKCD,GAB1 |
4.891e-02 | -3.02 | Alpha-synuclein signaling | Pathway Interaction DB | alphasynuclein_pathway | 32 | 2 | 2226 | 25 |
PRKCD,HCK |
4.910e-02 | -3.01 | secretory granule lumen | cellular component | GO:0034774 | 321 | 3 | 19108 | 49 |
PRKCD,DOCK2,PTPN6 |
4.911e-02 | -3.01 | GRAM | interpro domains | IPR004182 | 19 | 1 | 18521 | 49 |
TBC1D8 |
4.911e-02 | -3.01 | PAS_fold | interpro domains | IPR013767 | 19 | 1 | 18521 | 49 |
HIF1A |
4.916e-02 | -3.01 | PELO (pelota mRNA surveillance and ribosome rescue factor) | protein interactions | 53918 | 141 | 2 | 19454 | 49 |
P2RY6,HIF1A |
4.916e-02 | -3.01 | ATP5IF1 (ATP synthase inhibitory factor subunit 1) | protein interactions | 93974 | 141 | 2 | 19454 | 49 |
P2RY6,P2RY2 |
4.921e-02 | -3.01 | ATG9B (autophagy related 9B) | protein interactions | 285973 | 20 | 1 | 19454 | 49 |
TLN1 |
4.921e-02 | -3.01 | SPIB (Spi-B transcription factor) | protein interactions | 6689 | 20 | 1 | 19454 | 49 |
SPI1 |
4.921e-02 | -3.01 | SAXO5 (stabilizer of axonemal microtubules 5) | protein interactions | 374877 | 20 | 1 | 19454 | 49 |
NEK6 |
4.921e-02 | -3.01 | H2BC12L (H2B clustered histone 12 like) | protein interactions | 54145 | 20 | 1 | 19454 | 49 |
PRKCD |
4.921e-02 | -3.01 | IFNG (interferon gamma) | protein interactions | 3458 | 20 | 1 | 19454 | 49 |
STAT6 |
4.922e-02 | -3.01 | skin-axilla-malignant_melanoma | COSMIC cancer mutations | skin-axilla-malignant_melanoma | 133 | 2 | 16828 | 45 |
ELMO1,IPCEF1 |
4.934e-02 | -3.01 | skin-malignant_melanoma | COSMIC cancer mutations | skin-malignant_melanoma | 15741 | 45 | 16828 | 45 |
DOCK10,PRKCD,APOE,CSF1R,GIT2,WDFY4,TBC1D8,RHBDF2,STAT6,HCK,DOCK1,EHBP1L1,SBNO2,NEK6,HIF1A,IRF5,AKAP13,PIK3R5,PARVG,CD74,ARHGAP27,TBXAS1,DOCK2,ADCY7,P2RY2,ARHGAP15,GMIP,DENND1B,MYO1F,IL6R,P2RY6,PLCG2,TLN1,DOCK8,VAV3,SPI1,PREX1,PTPN6,ARHGAP33,GAB1,SKAP1,BLNK,RGS14,ELMO1,IPCEF1 |
4.937e-02 | -3.01 | monoatomic ion homeostasis | biological process | GO:0050801 | 515 | 4 | 18204 | 49 |
P2RY2,HIF1A,TBXAS1,APOE |
4.943e-02 | -3.01 | human chr10q11.23 | chromosome location | human chr10q11.23 | 27 | 1 | 26134 | 49 |
WDFY4 |
4.943e-02 | -3.01 | human chr5p13.1 | chromosome location | human chr5p13.1 | 27 | 1 | 26134 | 49 |
FYB1 |
4.963e-02 | -3.00 | skin-chest-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-chest-carcinoma-squamous_cell_carcinoma | 19 | 1 | 16828 | 45 |
CSF1R |
4.963e-02 | -3.00 | genital | COSMIC cancer mutations | genital | 19 | 1 | 16828 | 45 |
CSF1R |
4.963e-02 | -3.00 | skin-back-other-keratoacanthoma | COSMIC cancer mutations | skin-back-other-keratoacanthoma | 19 | 1 | 16828 | 45 |
CSF1R |
4.963e-02 | -3.00 | skin-upper_leg-other-keratoacanthoma | COSMIC cancer mutations | skin-upper_leg-other-keratoacanthoma | 19 | 1 | 16828 | 45 |
CSF1R |
4.963e-02 | -3.00 | skin-genital-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-genital-carcinoma-squamous_cell_carcinoma | 19 | 1 | 16828 | 45 |
CSF1R |
4.963e-02 | -3.00 | skin-upper_arm-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-upper_arm-carcinoma-squamous_cell_carcinoma | 19 | 1 | 16828 | 45 |
CSF1R |
4.963e-02 | -3.00 | skin-lip-other-keratoacanthoma | COSMIC cancer mutations | skin-lip-other-keratoacanthoma | 19 | 1 | 16828 | 45 |
CSF1R |
4.963e-02 | -3.00 | skin-lower_leg-other-keratoacanthoma | COSMIC cancer mutations | skin-lower_leg-other-keratoacanthoma | 19 | 1 | 16828 | 45 |
CSF1R |
4.963e-02 | -3.00 | skin-chest-other-keratoacanthoma | COSMIC cancer mutations | skin-chest-other-keratoacanthoma | 19 | 1 | 16828 | 45 |
CSF1R |
4.963e-02 | -3.00 | skin-arm-other-keratoacanthoma | COSMIC cancer mutations | skin-arm-other-keratoacanthoma | 19 | 1 | 16828 | 45 |
CSF1R |
4.963e-02 | -3.00 | skin-face-other-keratoacanthoma | COSMIC cancer mutations | skin-face-other-keratoacanthoma | 19 | 1 | 16828 | 45 |
CSF1R |
4.963e-02 | -3.00 | skin-leg-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-leg-carcinoma-squamous_cell_carcinoma | 19 | 1 | 16828 | 45 |
CSF1R |
4.975e-02 | -3.00 | miR-148a/miR-31/FIH1/HIF1α-Notch signaling in glioblastoma | WikiPathways | WP3593 | 9 | 1 | 5310 | 30 |
HIF1A |
4.978e-02 | -3.00 | SACM1L (SAC1 like phosphatidylinositide phosphatase) | protein interactions | 22908 | 142 | 2 | 19454 | 49 |
P2RY6,P2RY2 |
4.983e-02 | -3.00 | PK_Tyr_Ser-Thr | pfam domains | PF07714 | 130 | 2 | 17795 | 49 |
HCK,CSF1R |
4.985e-02 | -3.00 | positive regulation of endothelial cell migration | biological process | GO:0010595 | 133 | 2 | 18204 | 49 |
GAB1,HIF1A |
4.988e-02 | -3.00 | Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | REACTOME pathways | R-HSA-2162123 | 15 | 1 | 10285 | 35 |
TBXAS1 |
4.988e-02 | -3.00 | SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | REACTOME pathways | R-HSA-399955 | 15 | 1 | 10285 | 35 |
TLN1 |
4.988e-02 | -3.00 | Inhibition of adenylate cyclase pathway | REACTOME pathways | R-HSA-997269 | 15 | 1 | 10285 | 35 |
ADCY7 |
4.988e-02 | -3.00 | Adenylate cyclase inhibitory pathway | REACTOME pathways | R-HSA-170670 | 15 | 1 | 10285 | 35 |
ADCY7 |
4.994e-02 | -3.00 | growth factor receptor binding | molecular function | GO:0070851 | 138 | 2 | 18094 | 47 |
IL6R,VAV3 |
4.995e-02 | -3.00 | regulation of protein neddylation | biological process | GO:2000434 | 19 | 1 | 18204 | 49 |
HIF1A |
4.995e-02 | -3.00 | response to hydroperoxide | biological process | GO:0033194 | 19 | 1 | 18204 | 49 |
PRKCD |
4.995e-02 | -3.00 | chloride ion homeostasis | biological process | GO:0055064 | 19 | 1 | 18204 | 49 |
TBXAS1 |
4.995e-02 | -3.00 | positive regulation of macrophage chemotaxis | biological process | GO:0010759 | 19 | 1 | 18204 | 49 |
CSF1R |
4.995e-02 | -3.00 | regulation of B cell apoptotic process | biological process | GO:0002902 | 19 | 1 | 18204 | 49 |
CD74 |
4.995e-02 | -3.00 | adenylate cyclase-activating adrenergic receptor signaling pathway | biological process | GO:0071880 | 19 | 1 | 18204 | 49 |
AKAP13 |
4.995e-02 | -3.00 | negative regulation of alcohol biosynthetic process | biological process | GO:1902931 | 19 | 1 | 18204 | 49 |
APOE |
4.995e-02 | -3.00 | positive regulation of reactive oxygen species biosynthetic process | biological process | GO:1903428 | 19 | 1 | 18204 | 49 |
PLCG2 |
4.995e-02 | -3.00 | regulation of mast cell activation | biological process | GO:0033003 | 19 | 1 | 18204 | 49 |
PTPN6 |
4.995e-02 | -3.00 | regulation of amyloid-beta clearance | biological process | GO:1900221 | 19 | 1 | 18204 | 49 |
APOE |